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Great progress continues to be made in our understanding of stem cell self-renewal and plu‐
ripotency, and the utilization of stem cells for basic and applied applications. This book em‐
bodies recent advances in the biological mechanisms, methods and models of stem cell self-
renewal, reprograming and regeneration, as well as touching on the ethical and moral
dilemmas of embryo donation and adoption. In the first section of this book, ‘Stem Cell Self-
Renewal and Pluripotency’, Agarwal and Zambidis examine the role of the NFκB-STAT3
signaling axis in regulating the induction and maintenance of the pluripotent state. The au‐
thors discuss a novel link between inflammatory pathways and efficient cell reprogram‐
ming, whereby bone marrow stromal-primed human myeloid cell progenitors are
significantly more receptive to reprogramming stimuli than other cell types. Myeloid cells
appear to harbor a unique epigenetic plasticity and are innately equipped to transcriptional‐
ly and epigenetically activate key inflammatory pathways via an interconnected NFκB and
STAT3 signaling machinery. Both pathways act as epigenetic modifiers which promote ESC
pluripotency by inducing an open chromatin state that allows transcription factors to regu‐
late cell fates. The importance of the NuRD complex in ensuring that differentiated cells do
not reactivate pluripotency genes, which might enable tumorigenesis – is also discussed in
this first chapter. The following chapter by Koide examines further the idea that many genes
involved in ESC self-renewal also are involved in cancer cell growth. Considerable evidence
supports the author’s contentions, where self-renewal genes such as Oct 3/4, Sox2, Nanog,
STAT3, Klf4 and Zfp57 are not only required for self-renewal in ESCs, but also are highly
expressed in neoplastic cells. Conversely, there is evidence that oncogenes also are ex‐
pressed in SCs. That several common transcription factors are involved in the regulation of
ESC self-renewal and cancer cell growth raises the intriguing possibility that these common
transcription factors are specifically expressed in cancer stem cells involved in tumor
growth. Moreover, the authors suggest that since ESCs and induced pluripotent stem cells
(iPSCs) have similar gene expression profiles, tumor risk also might be elevated for iPSCs
used for therapeutic purposes. As suggested by Agarwal and Zambidis, preventing cancer‐
ous epigenetic patterns in iPSC via more accurate high-fidelity reprogramming methods
will be the foundation for future clinical applications.
In the next section on ‘Haematopoiesis’, Stefanska and colleagues review how ESCs have
been used to study the development of the haematopoietic system, that is otherwise very
difficult to study in vivo. As the authors write, ‘ESCs have been instrumental in identifying
and characterizing the elusive haemangioblast …. and more recently, this model system has
allowed the merging of two conflicting theories of the origin of blood cells (haemangioblast
and haemogenic endothelium) into a single linear model of development’. In addition, the
precise roles and requirements of many critical regulators of this process have been elucidat‐
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growth. Moreover, the authors suggest that since ESCs and induced pluripotent stem cells
(iPSCs) have similar gene expression profiles, tumor risk also might be elevated for iPSCs
used for therapeutic purposes. As suggested by Agarwal and Zambidis, preventing cancer‐
ous epigenetic patterns in iPSC via more accurate high-fidelity reprogramming methods
will be the foundation for future clinical applications.
In the next section on ‘Haematopoiesis’, Stefanska and colleagues review how ESCs have
been used to study the development of the haematopoietic system, that is otherwise very
difficult to study in vivo. As the authors write, ‘ESCs have been instrumental in identifying
and characterizing the elusive haemangioblast …. and more recently, this model system has
allowed the merging of two conflicting theories of the origin of blood cells (haemangioblast
and haemogenic endothelium) into a single linear model of development’. In addition, the
precise roles and requirements of many critical regulators of this process have been elucidat‐
ed using this model system. This system offers many opportunities to further study cell sig‐
naling pathways that support the development of normal haematopoiesis and
leukaemogenesis. Compared with the murine haematopoietic system, however, little is
known regarding the molecular and cellular regulation of early hematopoiesis in the human
as pointed out in the next review by Chen and colleagues. These researchers have establish‐
ed an efficient method to induce large-scale production of multipotential hematopoietic pro‐
genitor cells by co-culturing hESC/hiPSCs with murine hematopoietic niche-derived stromal
cells. Their review discusses the origin, evolution and the development of both primitive
and definitive hematopoietic waves, especially those derived from hESCs in vitro systems.
They also summarize the cellular and molecular characteristics of cells in primitive and/or
definitive hematopoiesis as well as the critical problems and challenges facing scientists
working in this important area of research. With the advent of these novel hESC/hiPSCs, our
understanding of human haematopoietic development should proceed swiftly.
Major discoveries in the regulation of self-renewal, pluripotency and differentiation are de‐
pendent upon technical developments in the field. In this next section on the ‘Technical Ad‐
vances in the Culture and Use of Induced Pluripotent and Embryonic Stem Cells’, three
research groups present advances and applications of hESCs/iPSCs. Nishishita and collea‐
gues demonstrate a robust, low-cost, stable method for generating and maintaining iPSC
clones from cord blood (CB) cells. This feeder-free and serum-free method that utilizes a
temperature sensitive Sendai virus vector also solves some of the safety concerns related to
tumorigenicity arising from chromosomal integration of exogenous genes and/or infectious
hazards associated with the use of by xenogeneic biological products in the culture system.
The use of CB cells, the youngest somatic cells, is suggested to alleviate concerns regarding
post-natal DNA damage and the ability to cryopreserve CB HSCs long-term in bank confers
a unique advantage to CB cells as a suitable material for generating induced pluripotent
stem (iPSC) cells for future clinical use. In the next chapter, Nag and colleagues review their
development of cell recognizable Fc-chimeric proteins aimed at providing simultaneous
support for cell adhesion, proliferation and differentiation as a highly effective novel class of
defined biomaterials for stem cell applications. These biomaterials have application in re‐
generative medicine and tissue engineering, including feeder-cell free ESC culture, a simpli‐
fied and cost-effective culture system for stem cells, directed differentiation of stem cells,
and on-site stress-free purification of target cells. In the final chapter of this section, Tomiza‐
wa and colleagues describe the development of a hepatocyte selection media that can be
used to select hepatoblast-like cells from ESC and other cells. This clever approach utilizes
differences in arginine and glucose metabolism between SCs and differentiated hepatocytes
to eliminate (induce death of) hiPSCs, for example, and the isolation of differentiated hepa‐
tocytes. This methodology avoids the damage introduced by other selection protocols and is
an important contribution to the development of pure hepatocytes for culture or applied ap‐
plications.
The next two chapters examine ‘New Stem Cell Models’ in two divergent systems. The first,
by Potta and colleagues reviews the potential of using stem cells for evaluating the safety of
drugs. Drug discovery programs often utilize animals to test the efficacy and safety of new
drugs, but the results from such experiments cannot always be extrapolated to humans. This
chapter reviews the development of iPSCs as a novel and cost-effective source of organotyp‐
ic cells for assessing drug toxicity. Kobayashi and colleagues review the use and challenges
of using domestic pigs and the minipig to both derive and utilize SCs.
XII Preface
In the final section on ‘Ethics’, Clark and colleagues remind us of the medical, legal and ethi‐
cal dilemmas associated with embryo donation/adoption. They contend that allowing for
embryo donation/adoption is the only viable option that protects and preserves their human
life. The other viable options: being discarded, destroyed for research, abandoned or kept in
“suspended animation” indefinitely, are unacceptable because they have the potential of
harming or intentionally killing these embryos that deserve special respect. To avoid these
later situations, Clark puts forth a number of recommendations and safeguards involving:
the matching of eggs to be fertilized with those placed in the uterus of the mother, the enact‐
ment of laws at the federal level that regulates Assisted Reproductive Technologies and that
regulates the creation, destruction and exploitation of human embryos, that infertile couples
and individuals willing to take full responsibility for the upbringing of these children
should be encouraged to consider adoption of the presently existing frozen embryos, and
that children who are adopted from frozen embryos have the right to know their genetic
make-up.
The reviews in this book are a reminder of the rapid progress being made in our under‐
standing of stem cell self-renewal and pluripotency, the methodological advances in the cul‐
ture, purification and use of stem cells, and how this basic knowledge and methodological
advances can be utilized for future regenerative medicine, drug screening and other applica‐
tions of medical benefit.
Craig S. Atwood and Sivan Vadakkadath Meethal






ed using this model system. This system offers many opportunities to further study cell sig‐
naling pathways that support the development of normal haematopoiesis and
leukaemogenesis. Compared with the murine haematopoietic system, however, little is
known regarding the molecular and cellular regulation of early hematopoiesis in the human
as pointed out in the next review by Chen and colleagues. These researchers have establish‐
ed an efficient method to induce large-scale production of multipotential hematopoietic pro‐
genitor cells by co-culturing hESC/hiPSCs with murine hematopoietic niche-derived stromal
cells. Their review discusses the origin, evolution and the development of both primitive
and definitive hematopoietic waves, especially those derived from hESCs in vitro systems.
They also summarize the cellular and molecular characteristics of cells in primitive and/or
definitive hematopoiesis as well as the critical problems and challenges facing scientists
working in this important area of research. With the advent of these novel hESC/hiPSCs, our
understanding of human haematopoietic development should proceed swiftly.
Major discoveries in the regulation of self-renewal, pluripotency and differentiation are de‐
pendent upon technical developments in the field. In this next section on the ‘Technical Ad‐
vances in the Culture and Use of Induced Pluripotent and Embryonic Stem Cells’, three
research groups present advances and applications of hESCs/iPSCs. Nishishita and collea‐
gues demonstrate a robust, low-cost, stable method for generating and maintaining iPSC
clones from cord blood (CB) cells. This feeder-free and serum-free method that utilizes a
temperature sensitive Sendai virus vector also solves some of the safety concerns related to
tumorigenicity arising from chromosomal integration of exogenous genes and/or infectious
hazards associated with the use of by xenogeneic biological products in the culture system.
The use of CB cells, the youngest somatic cells, is suggested to alleviate concerns regarding
post-natal DNA damage and the ability to cryopreserve CB HSCs long-term in bank confers
a unique advantage to CB cells as a suitable material for generating induced pluripotent
stem (iPSC) cells for future clinical use. In the next chapter, Nag and colleagues review their
development of cell recognizable Fc-chimeric proteins aimed at providing simultaneous
support for cell adhesion, proliferation and differentiation as a highly effective novel class of
defined biomaterials for stem cell applications. These biomaterials have application in re‐
generative medicine and tissue engineering, including feeder-cell free ESC culture, a simpli‐
fied and cost-effective culture system for stem cells, directed differentiation of stem cells,
and on-site stress-free purification of target cells. In the final chapter of this section, Tomiza‐
wa and colleagues describe the development of a hepatocyte selection media that can be
used to select hepatoblast-like cells from ESC and other cells. This clever approach utilizes
differences in arginine and glucose metabolism between SCs and differentiated hepatocytes
to eliminate (induce death of) hiPSCs, for example, and the isolation of differentiated hepa‐
tocytes. This methodology avoids the damage introduced by other selection protocols and is
an important contribution to the development of pure hepatocytes for culture or applied ap‐
plications.
The next two chapters examine ‘New Stem Cell Models’ in two divergent systems. The first,
by Potta and colleagues reviews the potential of using stem cells for evaluating the safety of
drugs. Drug discovery programs often utilize animals to test the efficacy and safety of new
drugs, but the results from such experiments cannot always be extrapolated to humans. This
chapter reviews the development of iPSCs as a novel and cost-effective source of organotyp‐
ic cells for assessing drug toxicity. Kobayashi and colleagues review the use and challenges
of using domestic pigs and the minipig to both derive and utilize SCs.
PrefaceVIII
In the final section on ‘Ethics’, Clark and colleagues remind us of the medical, legal and ethi‐
cal dilemmas associated with embryo donation/adoption. They contend that allowing for
embryo donation/adoption is the only viable option that protects and preserves their human
life. The other viable options: being discarded, destroyed for research, abandoned or kept in
“suspended animation” indefinitely, are unacceptable because they have the potential of
harming or intentionally killing these embryos that deserve special respect. To avoid these
later situations, Clark puts forth a number of recommendations and safeguards involving:
the matching of eggs to be fertilized with those placed in the uterus of the mother, the enact‐
ment of laws at the federal level that regulates Assisted Reproductive Technologies and that
regulates the creation, destruction and exploitation of human embryos, that infertile couples
and individuals willing to take full responsibility for the upbringing of these children
should be encouraged to consider adoption of the presently existing frozen embryos, and
that children who are adopted from frozen embryos have the right to know their genetic
make-up.
The reviews in this book are a reminder of the rapid progress being made in our under‐
standing of stem cell self-renewal and pluripotency, the methodological advances in the cul‐
ture, purification and use of stem cells, and how this basic knowledge and methodological
advances can be utilized for future regenerative medicine, drug screening and other applica‐
tions of medical benefit.
Craig S. Atwood and Sivan Vadakkadath Meethal







Stem Cell Self-Renewal and Pluripotency
Section 1
Stem Cell Self-Renewal and Pluripotency
Chapter 1
The Role of an NFκB-STAT3 Signaling Axis in Regulating
the Induction and Maintenance of the Pluripotent State
Jasmin Roya Agarwal and Elias T. Zambidis
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57602
1. Introduction
Induced pluripotent stem cells (iPSC) are generated by reprogramming differentiated somatic
cells to a pluripotent cell state that highly resembles embryonic stem cells (ESC) [1]. Fully
reprogrammed iPSC can differentiate into any adult cell type [2-6]. Takahashi and Yamanaka
generated the first iPSC in 2006 by transfecting fibroblasts with four defined factors: SOX2,
OCT4, KLF4, c-MYC (SOKM; also referred to as Yamanaka factors) [7]. The clinical use of iPSC
offers great potential for regenerative medicine as any cell type can be generated from true
pluripotent cells [8-10]. However, human clinical iPSC applications are currently limited by
inefficient methods of reprogramming that often generate incompletely reprogrammed
pluripotent states that harbor potentially cancerous epigenetic signatures, and possess limited
or skewed differentiation capacities [11-13]. Many standard iPSC lines do not fully resemble
pluripotent ESC, and often retain an epigenetic memory of their cell of origin [14, 15]. Such
incompletely reprogrammed iPSC also display limited differentiation potential to all three
germ layers (e.g., endoderm, ectoderm, mesoderm) [16, 17].
To avoid integrating retroviral constructs that may carry mutagenic risks, many non-viral
methods have been described for hiPSC derivation [18,  19].  For example,  one successful
approach  is  to  transiently  express  reprogramming  factors  with  EBNA1-based  episomal
vectors  [20-22].  It  was  initially  intuitive  to  reprogram skin  fibroblasts  due  to  their  easy
accessibility.  However,  standard  episomal  reprogramming  in  fibroblasts  occurs  at  even
lower  efficiencies  (<  0.001-0.1%)  than  reprogramming  with  retroviral  vectors  (0.1%–1%)
[23-25]. Subsequent studies revealed that various cell types possess differential receptive‐
ness for being reprogrammed to pluripotency [26-30]. One highly accessible human donor
source  is  blood,  which  has  been  demonstrated  to  reprogram  with  significantly  greater
efficiency than fibroblasts [4, 20, 31-33].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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The innate immune system possesses highly flexible cell types that are able to adapt quickly
to various pathogens by eliciting defense responses that protect the host [34-36]. Innate
immune cells derived from the myeloid lineage (eg, monocyte-macrophage, dendritic cells,
neutrophils) are able to reactivate some unique features of pluripotent stem cells that may give
them greater flexibility for being reprogrammed to a pluripotent cell state than other differ‐
entiated cells [37]. Additionally, the differentiation state of the cell seems to be of critical
importance for its reprogramming efficiency [38].
Our group established a reprogramming method that solves many of the technical caveats
cited above (Figure 1). We have generated high-fidelity human iPSC (hiPSC) from stromal-
primed (sp) myeloid progenitors [20]. This system can reprogram >50% of episome-expressing
myeloid cells to high-quality hiPSC characterized by minimal retention of hematopoietic-
specific epigenetic memory and a molecular signature that is indistinguishable from bona fide
human ESC (hESC). The use of bone marrow-, peripheral-or cord blood (CB)-derived myeloid
progenitor cells instead of fibroblasts, and a brief priming step on human bone marrow stromal
cells / mesenchymal stem cells (MSC) appeared to be critical for this augmented reprogram‐
ming efficiency. In this system, CD34+ - enriched cord blood cells (CB) are expanded with the
growth factors (GF) FLT3L (FMS-like tyrosine kinase 3 ligand), SCF (stem cell factor) and TPO
(thrombopoietin) for 3 days, subsequently nucleofected with non-integrating episomes
expressing the Yamanaka factors (4F, SOX2, OCT4, KLF4, c-MYC), and then co-cultured on
irradiated MSC for an additional 3 days. Cells are then harvested, and passaged onto MEF
(mouse embryonic fibroblasts), and hiPSC are generated via standard methods and culture
medium. The initial population of enriched CD34+ CB progenitors quickly differentiates to
myeloid and monocytic cells in this system, and reprogrammed cells arise from CD34- myeloid
cells. The first iPSC colonies appear around day 10, and stable mature iPSC colonies can be
established after ~21-25 days. The episomal constructs are partitioned after relatively few cell
divisions (e.g., 2-9 passages) to generate high quality non-integrated hiPSC.
Figure 1. Schema of the stromal-primed myeloid reprogramming protocol for the generation of high quality human
iPSC. 4F: four Yamanaka factors, GF: hematopoietic growth factors.
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A proteomics and bioinformatics analysis of this reprogramming system implicated significant
activation of MSC-induced inflammatory TLR-NFκB and STAT3 signaling [20]. A combination
of cell contact-dependent and soluble factors mediate these effects. A recent study similarly
implicated inflammatory TLR3 signaling as a novel trigger for enhanced fibroblast reprog‐
ramming, albeit at much lesser efficiencies than observed in our myeloid reprogramming
system. TLR3 signaling leads to epigenetic modifications that favor an open chromatin state,
which increases cell plasticity and the induction of pluripotency [39]. Lee et al. termed this
novel link between inflammatory pathways and cell reprogramming ‘Transflammation’ [40].
In this chapter we will discuss hypotheses why inflammation-activated myeloid cells may be
highly receptive to factor-mediated reprogramming. Specifically, we will explore the role of
the NFκB-STAT3 signaling axis in mediating the unique susceptibility of myeloid cells to high-
quality human iPSC derivation.
2. Overview of the canonical and non-canonical NFκB pathway
Multipotent myeloid progenitors are derived from hematopoietic stem cells and differentiate
to monocytes macrophages, dendritic cells, and granulocytes, which elicit the initial innate
immune response toward pathogens [41]. NFκB (nuclear factor kappa-light-chain-enhancer of
activated B cells) is a central transcription factor that regulates these innate immune responses
during microbial infections [42-44]. The NFκB system belongs to a group of early-acting
transcription factors that are present in the cytoplasm in an inactive state but can be quickly
activated by multiple inflammatory stimuli [45, 46].
2.1. The canonical NFκB signaling pathway
The NFκB family consists of 5 members; p65 (RelA), p50 and c-Rel are involved in canonical
signaling, and p52 and RelB are involved in non-canonical signaling. Canonical NFκB
signaling is characterized by activation of the IκB kinase complex (IKK), which contains two
kinases, IKK1/α and IKK2/β along with a non-catalytic subunit called IKKγ (NEMO) [47, 48].
Unstimulated NFκB is sequestered in the cytoplasm by IκBα protein. In contrast, activation of
the IKK complex (e.g., by TLRs) leads to IKKβ-mediated serine phosphorylation of IκBα
triggering its proteasome-mediated degradation and its dissociation from NFκB [49, 50]. This
activates the p65:p50 dimer through p65 phosphorylation and leads to NFκB translocation into
the nucleus where it induces target gene expression. Subsequent acetylation keeps p65 in the
nucleus [51]. This can be reverted by HDAC3 (histone deacetylase 3)-induced deacetylation of
p65, which increases the affinity of NFκB proteins for IκBα and nuclear export [52, 53].
Canonical NFκB signaling is a fast and transient process that regulates complex inflammatory
processes that includes the initial pro-inflammatory phase, the induction of apoptosis, and
even tumorigenesis [54]. It can be activated by toll-like receptors (TLR), which recognize
characteristic pathogenic molecules to activate innate immune responses [55-57].
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2.2. The non-canonical NFκB signaling pathway
Non-canonical NFκB signaling is stimulated via the NFκB-inducing kinase (NIK), which leads
to phosphorylation of the p100 precursor protein and generation of the p52:RelB dimer that
translocates to the nucleus to activate gene transcription. This pathway is uniquely dependent
on steady state levels of NIK expression, which are controlled under normal conditions through
TRAF3-directed ubiquitination and proteasomal degradation. Non-canonical NFκB signaling
is slow but persistent and requires de novo NIK protein synthesis and NIK stabilization [58].
It is activated by receptors that belong to the TNFR (tumor necrosis factor receptor) super‐
family like BAFF (B-cell-activating factor), CD40 or lymphotoxin β-receptor (LTβR) [59-62].
The common feature of these receptors is the possession of a TRAF-binding motif, which
recruits TRAF members (e.g., TRAF2 and TRAF3) during ligand ligation [63, 64]. Receptor
recruitment of TRAF members triggers their degradation, and leads to NIK activation and p100
processing [65]. Additionally, BAFF is an important component of pluripotency-supporting
growth media for the culture of ESC and a regulator of B-cell maturation [66]. It predominantly
activates non-canonical NFκB signaling due to its possession of an atypical TRAF-binding
sequence, which interacts only with TRAF3 but not with TRAF2 [67]. TRAF3 degradation is
sufficient to trigger non-canonical NFκB signaling, whereby activation of the canonical NFκB
pathway requires TRAF2 recruitment [68].
2.3. CD40 stimulates both NFκB pathway components
Another receptor associated with NFκB signaling is CD40, which is expressed on various cell
types including B cells and monocytes. The CD40 receptor interacts with its ligand CD40L,
which is primarily expressed on activated T cells. This signaling is majorly involved in B-cell
activation, dendritic cell maturation, antigen presentation and acts as a co-stimulatory
pathway of T-cells [69]. Upon ligation by CD40L, CD40 targets both the canonical and non-
canonical NFκB pathways via proteolysis of TRAF2 and TRAF3 [70-72]. Non-canonical NFκB
signaling regulates hematopoietic stem cell self-renewal via regulating their interactions with
the microenvironment [73]. The deregulation of non-canonical hematopoietic NFκB signaling
is associated with auto-immunity, inflammation and lymphoid malignancies [58, 74].
2.4. NFκB subunit functions
A third NFκB signaling pathway is activated following response to DNA damage that results
in IκB degradation independent of IKK. This results in dimerization of free NFκB subunits that
are mobilized similarly to canonical NFκB signaling [47]. Unlike RelA, RelB, and c-Rel, the p50
and p52 NFκB subunits do not contain transactivation domains in their C-terminus. Never‐
theless, the p50 and p52 NFκB members play critical roles in modulating the specificity of
NFκB functions and form heterodimers with RelA, RelB, or c-Rel [75]. Cell contact-dependent
signals are crucial during immune responses and can be mediated through NFκB signaling
[76]. This can be augmented by co-stimulatory signals like CD40 or CD28 that directly bind to
NFκB proteins like p65 [77-81].
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3. Functional role of NFκB signaling in stem cells
3.1. Differential roles of canonical and non-canonical NFκB signaling in embryonic stem
cells
TLR activation is not only important for mediating innate immune responses, but also for stem
cell differentiation. For example, hESC are characterized by the expression of pluripotency
genes and markers such as OCT4, NANOG, alkaline phosphatase (AP) and telomerase [82-86].
NFκB signaling has been demonstrated to be crucial for maintaining ESC pluripotency and
viability, and drives lineage-specific differentiation [87, 88]. A balance of canonical and non-
canonical NFκB signaling regulates these opposing functions; non-canonical pathway
signaling maintains hESC pluripotency, and canonical pathway signaling regulates hESC
viability and differentiation [89, 90]. For example, non-canonical NFκB signaling has to be
silenced during cell differentiation, which allows this pathway to act like a switch between
hESC self-renewal and differentiation. RelB positively regulates several key pluripotency
markers and represses lineage markers by direct binding to their regulatory units. RelB down-
regulation reduces the expression of pluripotency genes like SOX2 and induces differentiation-
associated genes like BRACHYURY (mesodermal marker), CDX2 (trophoectodermal marker)
and GATA6 (endodermal marker) [89].
3.2. Canonical NFκB signaling in hematopoietic stem cells
RelB/p52 signaling also positively regulates hematopoietic stem-progenitor cell (HSPC) self-
renewal in response to cytokines (e.g., TPO and SCF) and maintains osteoblast niches and the
bone marrow stromal cell population. It negatively regulates HSPC lineage commitment
through cytokine down-regulation in the bone marrow microenvironment, although it is able
to direct early HSC commitment to the myeloid lineage [73, 91].
Canonical p65 signaling also regulates hematopoietic stem cell functions and lineage commit‐
ment by controlling key factors involved in hematopoietic cell fate [92-94]. Canonical NFκB
signaling is positively regulated by Notch1, which facilitates nuclear retention of NFκB
proteins and promotes self-renewal [95-98]. FGF2 (fibroblast growth factor 2) is important for
hESC self-renewal and preserves the long-term repopulating ability of HSPC through NFκB
activation [99-102]. Deletion of p65, p52 and RelB dramatically decreases HSC differentiation,
function and leads to extramedullary hematopoiesis [103]. NFκB pathway components and
FGF4 are highly expressed in CD34+HSPC from cord blood, where they regulate clonogenicity.
Nuclear p65 can be detected in 90% CB-derived CD34+ cells but only in 50% BM-derived
CD34+ cells [104]. The important role of NFκB in regulating myeloid cell lineage development
has been most potently revealed via genetic deletion of IKKβ, IκBα, and RelB, which resulted
in granulocytosis, splenomegaly and impaired immune responses [73, 103].
3.3. Canonical NFκB signaling during ESC differentiation
Canonical NFκB signaling is very low in the undifferentiated pluripotent state, where it
maintains hESC viability. However, it strongly increases during lineage-specific differentia‐
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tion of pluripotent stem cells. p65 binds to the regulatory regions of similar differentiation
genes as RelB with opposing effects on their activation or silencing. It regulates cell prolifera‐
tion by direct binding to the CYCLIN D1 promoter [89]. There are different levels of inhibiting
canonical NFκB signaling: first, p65 translational repression by the microRNA cluster miR-290
to maintain low p65 protein amounts and second, the inhibition of translated p65 by physical
interaction with NANOG. Similarly, OCT4 expression is reversely correlated with canonical
NFκB signaling [105]. In contrast to most observations in mouse ESC, NFκB probably plays a
more important role in the maintenance of human ESC pluripotency [106]. Finally, active TLRs
are expressed on embryonic, hematopoietic and mesenchymal stem cells (MSC), thus impli‐
cating their roles in a variety of stem cell types [107-110].
4. Role of NFκB signaling during reprogramming to pluripotency
Undifferentiated human iPSC have elevated NFκB activities, which play important roles in
maintaining OCT4 and NANOG expression in pluripotent hiPSC [111]. Innate immune TLR
signaling was recently shown to enhance nuclear reprogramming probably through the
induction of an open chromatin state, and global changes of epigenetic modifiers [39]. This
normally increases cell plasticity in response to a pathogen, but may also enhance the induction
of pluripotency, transdifferentiation and even malignant transformation [112-116].
The EBNA (Epstein-Barr virus nuclear antigen) is a virus-derived protein that is not only a
critical component of episomal reprogramming vectors, where it mediates extra-chromosomal
self-replication, but it is also known to activate several TLRs [117-119]. These include TLR3,
which is known to augment reprogramming efficiencies through the activation of inflamma‐
tory pathways [39, 120]. TLR3 recognizes double-stranded RNA from retroviruses and signals
through TRAF6 and NFκB [121-123]. The TLR3 agonist poly I:C was shown to have the same
effect as retroviral particles in enhancing Yamanaka factor-induced iPSC production. TLR3
causes widespread changes in the expression of epigenetic modifiers and facilitates nuclear
reprogramming by inducing an open chromatin state through down-regulation of histone
deacetylases (HDACs) and H3K4 (histone H3 at lysine 4) trimethylations [38, 39, 124]. These
epigenetic modifications mark transcriptionally active genes, whereas the H3K9me3 (Histone
H3 at lysine 9) modification marks transcriptionally silenced genes [125, 126]. Histone
deacetylation is generally associated with a closed chromatin state and HDAC inhibitors were
shown to enhance nuclear reprogramming [127, 128]. Histone acetylation favors an open
chromatin state, and is maintained by proteins containing histone acetyltransferase (HAT)
domains, such as p300 and CBP [129, 130]. Interestingly, p300/CBP is able to interact with
NFκB [131, 132]. RelB directly interacts with the methyltransferase G9a to mediate gene
silencing of differentiation genes [133]. Epigenetic changes that allow an open chromatin state
are crucial for giving the Yamanaka factors access to promoter regions necessary for the
induction of pluripotency. Epigenetic chromatin modifications by TLRs are normally involved
in the expression of host defense genes during infections [134-136]. This capability can be
deployed to enable nuclear reprogramming as TLR3 was shown to change the methylation
status of the Oct4 and Sox2 promoters. Interestingly, changes in these methylation marks were
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not observed with TLR3 activation alone but only in the presence of the reprogramming
factors. Although TLR3 by itself promotes an open chromatin configuration, the reprogram‐
ming proteins are likely necessary to direct the epigenetic modifiers to the appropriate
promoter sequences [137]. Lee et al. described the potential of inflammatory pathways to
facilitate the induction of pluripotency as ‘transflammation’ [40, 138].
5. Overview of the JAK/STAT pathway
The JAK/STAT pathway (Janus kinase/signal transducer and activator of transcription)
integrates a complex network of exterior signals into the cell, and can be activated by a variety
of ligands and their receptors [139]. These receptors are associated with a JAK tyrosine kinase
at their cytoplasmic domain. The JAK family consists of the four members JAK1, JAK2, JAK3
and TYK2 [140, 141]. Many cytokines and growth factors signal through this pathway to
regulate immune responses, cell proliferation, differentiation and apoptosis [142-146]. Ligand
binding induces the multimerization of gp130 receptor subunits, which brings two JAKs close
to each other inducing trans-phosphorylation. Such activated JAKs phosphorylate their
receptor at the C-terminus and the transcription factor STAT at tyrosine residues. This allows
STAT dimerization and their nuclear translocation to induce target gene transcription. [147,
148] STAT3 acetylation is critical for stable dimer formation and DNA binding [149]. From the
7 mammalian STATs, STAT3 and STAT5 are expressed in many cell types, are activated by a
plethora of cytokines and growth factors, and integrate complex biological signals [150, 151].
The other STAT proteins mainly play specific roles in the immune response to bacterial and
viral infections. STAT3 is an acute phase protein with important functions during immediate
immune reactions [152-154]. STAT3 can be recruited by receptor tyrosine kinases that harbor
a common STAT3 binding motif in their cytoplasmic domain (e.g., GCSF (granulocyte colony-
stimulating factor), LIF (leukemia inhibitory factor), EGF (epidermal growth factor), PDGF
(platelet-derived growth factor), interferons (IFNγ) and interleukins (IL-6, IL-10)) [155-158].
Many cytokines signal through IL-10/STAT3 to achieve an immunosuppressive function or
anti-apoptotic effect [159, 160]. IL-10 is also required during terminal differentiation of
immunoglobulins [161]. STAT3 can be phosphorylated at tyrosine or serine residues. The
phosphorylation site can play distinct roles in the regulation of downstream gene transcription
[162]. Stat3-deficient mice die during early embryogenesis due to Stat3 requirement for the
self-renewal of ESC [163].
Negative feedback regulation of the JAK/STAT circuitry is mediated by the SOCS family of
target genes (suppressors of cytokine signaling) in a way that activated STAT induces SOCS
transcription [164, 165]. SOCS proteins can bind to phosphorylated JAKs as a pseudo-substrate
to inhibit JAK kinase activity and turn off the pathway [166, 167]. SOCS are negative regulators
of the immune response [168, 169]. A small peptide antagonist of SOCS1 was shown to bind
to the activation loop of JAK2 leading to constitutive STAT activation and TLR3 induction.
This boosts the immune system to exert broad antiviral activities [170]. The JAK/STAT pathway
also interacts with many other signaling pathways in a complex manner to regulate cell
homeostasis and immune reactions [149, 171].
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6. Functional role of the JAK/STAT pathway in stem cells
6.1. Stat3 maintains naïve pluripotency in mouse embryonic stem cells
ESC pluripotency is regulated by transcriptional networks that maintain self-renewal and
inhibit differentiation [172-174]. Stat3 and Myc are necessary to maintain mouse ESC (mESC)
self-renewal and bind to many ESC-enriched genes [175]. Their target genes include pluripoten‐
cy-related transcription factors, polycomb group repressive proteins, and histone modifiers
[176, 177]. The transcription factor Stat3 is a key pluripotency factor required for ESC self-
renewal [178, 179]. Mouse ESC require LIF-Stat3 (leukemia inhibitory factor) and Bmp4 (bone
morphogenic protein 4) to remain pluripotent in in vitro cultures, whereas human ESC require
FGF2/MAPK (fibroblast growth factor / mitogen-activated protein kinase) and TGFβ/Activin/
Nodal (transforming growth factor β) [180-183]. Nevertheless, the core circuitry of pluripoten‐
cy is conserved among species and includes OCT4, SOX2 and NANOG [174].
6.2. The LIF-IL6-STAT3 circuitry
LIF belongs to the IL-6 family of cytokines and acts in parallel through the Jak/Stat3 and PI3K/
Akt (Phosphatidylinositide 3-kinase) pathways to maintain Oct4, Sox2 and Nanog expression
via Kruppel-like factor 4 (Klf4) and T-box factor 3 [184, 185]. Lif and IL-6 are necessary for STAT3
phosphorylation mediated by Jak1 [186]. Stat3 phosphorylation positively regulates Klf4 and
Nanog transcripts and facilitates Lif-dependent maintenance of pluripotency in a signaling loop
[106]. Stat3 directly binds to genomic sites of Oct4 and Nanog, regulates the Oct4-Nanog circuitry
and is necessary to maintain the self-renewal and pluripotency of mESC [187-189]. Overexpres‐
sion of Stat3 maintains mESC self-renewal even in the absence of Lif [190]. Withdrawal of LIF
up-regulates the NFκB pathway and results in ESC differentiation as well as STAT3 disrup‐
tion [191-193]. The interleukin 6 (IL-6) response element (IRE) is activated by STAT3, vice versa
IL-6  stimulation leads  to  STAT3 phosphorylation and transactivation of  IRE-  containing
promoters providing a positively regulated STAT3-IL6 loop. STAT3 directly associates with c-
Jun and c-Fos in response to IL-6 [194]. c-Jun and c-Fos are DNA binding proteins and compo‐
nents of the AP-1 (activation protein-1) transcription factor complex [195]. AP-1 can be activated
by TLR2/4, IL-10 or STAT3 to regulate inflammatory responses or drive keratinocyte differen‐
tiation in interplay with STAT3 and c-MYC [196]. Tlr2 also plays an important role in the
maintenance of mESC [107]. STAT3 is important to tune appropriate amounts of AP-1 pro‐
teins required for proper differentiation. DNA binding sites for both AP-1 and STAT3 have been
found in many gene promoters [194, 197]. It is important to note that c-Jun is able to capture or
release the NuRD (nucleosome remodeling and deacetylation) repressor complex, an impor‐
tant epigenetic modulator of gene silencing [198, 199]. STAT3 is able to bind to bivalent histone
modifications enabling a quick switch between the activation of pluripotency genes during ESC
maintenance and their inhibition during cell differentiation [193].
6.3. STAT3 signaling in immune cells
STAT3 also has complex functions during hematopoietic development, immune regulation,
cell growth, and leukemic transformation [200-202]. It is critically important for the survival
and differentiation of lymphocytes and myeloid progenitors [171]. STAT3 signaling can be
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activated in a cell contact-dependent way, which is distinct from its cytokine activation. Co-
cultures of MSC (human mesenchymal stem cells) and APC (antigen-presenting cell) increase
STAT3 signaling in both cell types in a cell contact-dependent way, which mediates the
immune-modulatory effects of MSC to block APC maturation and induce T-cell tolerance
[203]. MSC are high-proliferative non-hematopoietic stem cells with the ability to differentiate
into multiple mesenchymal lineages [204-206]. They accumulate in tumor environments in
response to NFκB signaling and produce cytokines [207]. MSCs are FDA-approved for the
treatment of severe acute GVHD, due to their immunomodulatory properties [208]. STAT3
phosphorylation is induced by cell-cell contacts and inhibited in postconfluent cells that
consequently become apoptotic. Therefore, STAT3 may represent a molecular junction that
allows cell proliferation or growth arrest depending on the state of the cell. Increased STAT3
activity may promote cell survival during cell confluency [209].
6.4. Cell contact-dependent STAT3 signaling during cell transformation
Constitutive STAT3 activation can by itself result in cellular transformation [210-214]. For
example, contact-dependent STAT3 activation is known to play a promoting role in the
interactions between tumor cells and their environment [215-218]. Cell transformation and the
induction of pluripotency may share very similar signaling processes, and it is possible that
STAT3 may represent a common axis [219, 220]. During early tumor development, certain cells
have to acquire stem cell-like features that allow them to self-renew (tumor-initiating cells)
and to produce cell progeny (tumor bulk) [221-224]. These tumor-initiating cells are very
difficult to eradicate during chemotherapies and often re-establish the tumor seen as clinical
relapse [225-227]. Tumor-initiating cells display strong inflammatory gene signatures with
elevated IL6-STAT3-NFκB signaling to sustain their self-renewal [228-231]. A better under‐
standing of the mechanism by which STAT3 and NFκB regulates the acquisition of pluripo‐
tency and self-renewal might also give us crucial insight about tumor development, and may
lead to future novel therapies [171, 232].
7. The role of STAT3 signaling during reprogramming
7.1. STAT3 is a master reprogramming factor
Activation of Stat3 is a limiting factor for the induction of pluripotency, and its over-expression
eliminates the requirement for additional factors to establish pluripotency [233]. These key
properties have positioned Stat3 signaling as one of the master reprogramming factors that
dominantly instructs naïve pluripotency [175]. Elevated Stat3 activity overcomes the pre-iPSC
reprogramming block and enhances the establishment of pluripotency induced by SOKM
[234]. Stat3 and Klf4 co-occupy genomic sites of Oct4, Sox2 and Nanog. Klf4 and c-Myc are
downstream targets of Stat3 signaling and part of the transcriptional network governing
pluripotency. The Stat3 effect is combinatorial with other reprogramming factors, which
implies that additional targets of Stat3 play a pivotal role [235].
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7.2. STAT3 is an epigenetic regulator
Stat3 activation regulates major epigenetic events that induce an open-chromatin state during
late-stage reprogramming to establish pluripotency [236-238]. For example, Stat3 signaling
stimulates DNA methylations to silence lineage commitment genes and facilitates DNA
demethylations to activate pluripotency-related genes [106, 239, 240]. Other chromatin
modifications include histone acetylation and deacetylation, which are catalyzed by enzymes
with histone acetyltransferase (HAT) or histone deacetylase (HDAC) activities. Histone
acetylation is associated with an open chromatin state that allows active gene transcription.
HDAC inhibitors are known to significantly improve the efficiency of iPSC generation by
allowing promoter accessibility [128, 241, 242]. STAT3 suppresses HDAC expression and
repressive chromatin regulators to establish an open-chromatin structure giving full access to
transcriptional machineries. The key pluripotency factor Nanog cooperates with Stat3 to
maintain ESC pluripotency [173]. Interestingly, HDAC inhibitors but not NANOG over-
expression rescues complete reprogramming in the presence of STAT3 inhibition.
Finally, DNA demethylation is regulated in mammalian cells by Tet proteins (tet methylcyto‐
sine dioxygenase), which convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC). Tet1 suppresses ESC differentiation and Tet1 knockdown leads to defects in ESC self-
renewal. Tet1 up-regulation is positively regulated by Stat3 during the late-reprogramming
stage [243-246].
8. Interactions between NFκB and STAT3 signaling
8.1. Synergistic NFκB and STAT3 signaling
The NFκB and STAT3 pathways are closely interconnected in regulating immune responses
[247, 248]. STAT3 activation itself induces further STAT3 phosphorylation. Un-phosphorylat‐
ed STAT3 that accumulates in the cell can bind to un-phosphorylated NFκB in competition
with IκB. The resulting STAT3/NFκB dimer localizes to the nucleus to induce NFκB-dependent
gene expression [249]. STAT3 associates with the p300/CBP (CREB-binding protein) co-
activator enabling its histone acetyltranferase activity to open chromatin structures, which
allows chromatin-modifying proteins to bind the DNA and activate gene transcription. [250,
251] Tyrosine-phosphorylated and acetylated STAT3 additionally binds to the NFκB precursor
protein p100 and induces its processing to p52 by activation of IKKα. STAT3 then binds to the
DNA-binding p52 complex to assist in the activation of target genes [252]. Both, the NFκB and
STAT3 pathway synergize during terminal B-cell differentiation [253]. Phosho-p65/STAT3
dimers and phospho-STAT3/NFκB dimer complexes can bind to κB motifs. Also, phospho-
STAT3 and phosho-p50 interact with each other. Soluble CD40L rapidly activates NFκB p65
and up-regulates IL10 receptors on the cell surface. This renders STAT3 more susceptible to
IL-10 induced phosphorylation [161]. Macrophage activation is regulated by Toll-like recep‐
tors, JAK/STAT signaling and immunoreceptors that signal via ITAM motifs [254, 255]. These
pathways have low activity levels under homeostatic conditions but are strongly activated
during innate immune responses. ITAM-coupled receptors cooperate with TLRs in driving
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NFκB signaling and inflammation during infections, whereas extensive ITAM activation
inhibits JAK/STAT signaling to limit the immune reaction [256, 257]. Pleiotropic cytokines like
interferons and IL-6 regulate the balance of pro-and anti-inflammatory functions by activating
variable levels of STAT1 and STAT3 [258].
8.2. NFκB and STAT3 synergies in stem cells
NFκB and STAT3 are also part of an important stem cell pathway axis [259, 260]. A functional
link between NANOG, NFκB and LIF/STAT3 signaling was shown in the maintenance of
pluripotency [228]. Non-canonical NFκB signaling is activated by STAT3 through activation
of IKKα and p100 processing [58]. Conversely, STAT3 inhibits TLR-induced canonical NFκB
activity probably through up-regulated SOCS3. C-terminal binding of NANOG inhibits the
pro-differentiation activities of canonical NFκB signaling and directly cooperates with STAT3
to maintain ESC pluripotency. NANOG and STAT3 bind to each other and synergistically
activate STAT3-dependent promoters [106, 261].
The STAT3 pathway also interacts with many signaling pathways that are critically involved
in the reprogramming process. For example, STAT3 signaling activates the MYC transcriptome
and signals in loop with LIN28 [229]. LIN28 is expressed in undifferentiated hESC and is able
to enhance the reprogramming efficiency of fibroblasts. It is down-regulated upon ESC
differentiation [262-265]. Proto-oncogene tyrosine-protein kinase Src activation triggers an
inflammatory response mediated by NFκB that directly activates IL6 and Lin28B expression
through a binding site in the first intron. IL6-mediated activation of STAT3 transcription is
necessary for monocyte activation and tumorigenesis. IL6 itself further activates NFκB, thereby
completing a positive NFκB-STAT3-IL6 feedback loop that links inflammation to cell trans‐
formation [229]. Constitutive STAT3 signaling maintains constitutive NFκB activity in tumors
by inhibiting its nuclear export through p65 acetylation, although STAT3 signaling inhibits
NFκB activation during normal immune responses [52].
9. The role of epigenetic regulators during the induction of pluripotency
9.1. The NuRD complex
A panoply of chromatin remodelers play active, regulatory roles during the reprogramming
process [266, 267]. For example, the Mbd3/NuRD complex is an important epigenetic regulator
that restricts the expression of key pluripotency genes [268]. MBD3 (Methyl-CpG-binding
domain protein 3) is part of the NuRD (nucleosome remodeling and deacetylation) repressor
complex, which mediates chromatin remodeling through histone deacetylation via HDAC1/2
and ATPase activities [269-271]. The NuRD complex interacts with methylated DNA to
mediate heterochromatin formation and transcriptional silencing of ESC-specific genes.
Whereas MBD2 recruits NuRD to methylated DNA, MBD3 fails to bind methylated DNA as
it evolved from a methyl-CpG-binding domain to a protein–protein interaction module [272].
Mbd3 antagonizes the establishment of pluripotency and facilitates differentiation [273].
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9.2. MBD3 suppression is a rate-limiting step in factor-mediated reprogramming
Recent evidence suggested that efficient reprogramming may require NuRD complex down-
regulation [274]. The reprogramming factors OCT4, SOX2, KLF4 and MYC bind to MBD3, a
critical component of the NURD complex. In the absence of MBD3, SOKM over-expression
induces pluripotency with almost 100% efficiency [275]. Such reprogramming occurs within
seven days in mouse cells. Once pluripotency is established, MBD3 does not appear to
compromise its maintenance. The MBD3/NuRD repressor complex is probably the predomi‐
nant molecular block that prevents the induction of ground-state pluripotency. Several
reprogramming factors directly interact with the MBD3/NuRD complex to form a potent
negative regulatory complex that restrains pluripotency gene reactivation. Thus, chromatin
de-repression is of critical importance for the conversion of somatic cells into iPSC.
9.3. Bivalent histone modifications
Embryonic stem cells are not only able to maintain their undifferentiated state indefinitely, but
also need to retain their ability to differentiate into various cell types [276]. The co-existence
of these two features requires the combined action of signal transduction pathways, transcrip‐
tion factor networks, and epigenetic regulators [277]. Pluripotent gene expression has to be
maintained in a way that it can be rapidly silenced upon receiving differentiation signals. The
NuRD complex maintains this ESC flexibility by inducing variability in pluripotency factor
expression that results in a low-expressing subpopulation of ESCs primed for differentiation
[268, 278]. The control of gene expression by juxtaposition of antagonistic chromatin regulators
is a common regulatory strategy in ESC, called bivalent histone modification [279, 280].
Individual promoters exhibit trimethylation of two different residues of histone H3: lysine 4
(H3K4me3) and lysine 27 (H3K27me3) [281, 282]. H3K27me3 is a repressive histone modifi‐
cation, whereas H3K4me3 is an activation-associated mark [283]. Both epigenetic markers have
opposing effects and allow quick adjustments between ESC self-renewal and differentiation.
Bivalent genes are generally transcriptionally silent in ESCs but are prone for rapid activation.
MBD3 binding is enriched at bivalent genes characterized by 5hmC modifications. STAT3
binds to bivalent histone modifications and is able to switch between cellular pluripotency and
differentiation [236, 284, 285].
9.4. MBD3 may prevent completion of the reprogramming process
MBD3 plays key roles in the biology of 5-hydroxy-methylcytosine (5hmC) [286]. 5hMC is an
oxidation product of 5-methylcytosine (5mC) [287, 288]. MBD3 silences pluripotency genes
like Oct4 and Nanog through 5-hydroxy-methylation of their promoters. MBD3 binds to 5hmC
in cooperation with Tet1 to regulate 5hmC-marked genes, but does not interact with 5mC.
Mbd3 interaction with 5hmC recruits NuRD to its targets resulting in gene repression.
Knockdown of the MBD3/NuRD complex affects the expression of 5hmC-marked genes [289].
Mbd3 acts upstream of Nanog and may block the transition from partially to fully reprog‐
rammed iPSC by silencing Nanog. Nanog overexpression was dominant over Mbd3 knock‐
down in the induction of efficient reprogramming and is in general sufficient to maintain mESC
pluripotency. Mbd3 depletion facilitates the transcription of Oct4 and Nanog and leads to the
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generation of iPSC and chimeric mice even in the absence of Sox2 or c-Myc [290]. The depletion
of Mbd3/NuRD does not replace Oct4 during iPSC formation as reprogramming did not occur
with Klf4 and c-Myc alone. Mbd3-dependent silencing of pluripotency factors occurs during
ESC differentiation. This involves NuRD-dependent deacetylation of H3K27 required for the
binding of the polycomb repressive complex two. NuRD-dependent silencing of pluripotency
genes prevents the de-differentiation of somatic cells. In the absence of Mbd3, NuRD disas‐
sembles, which lowers this epigenetic barrier and allows the activation of pluripotency genes.
Drug-induced down-regulation of Mbd3/NuRD may greatly improve the efficiency and
fidelity of reprogramming [291].
9.5. STAT3-MBD3 counteractions
Stat3 promotes the expression of self-renewal transcription factors and opposes NURD-
mediated repression of several hundred target genes in ESCs. The opposing functions of Stat3
and NuRD maintain variability in the levels of key self-renewal transcription factors. Stat3,
but not NuRD, is the rate-limiting factor for pluripotency gene expression. Self-renewing ESC
face a barrier that prohibits differentiation. NuRD constrains this barrier within a range that
can be overcome when self-renewal signals are withdrawn [268, 278, 292]. Mbd3/NuRD-
mediated gene silencing is a critical determinant of lineage commitment in embryonic stem
cells and allows cells to exhibit pluripotency and self-renewal. Mbd3-deficient ESC show
Figure 2. The master reprogramming factor STAT3 may overcome an unknown reprogramming block by inducing an
open chromatin formation that facilitates the pluripotency factors SOKM to bind to ESC gene promoters. We hypothe‐
size that upstream inflammatory signals mediated by NFκB signaling may facilitate STAT3 to de-repress the NuRD
complex via c-Jun.
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persistent self-renewal even in the absence of Lif. They are able to undergo the initial steps of
differentiation, but their ability for lineage commitment is severely compromised. They fail to
downregulate undifferentiated cell markers as well as upregulate differentiation markers
[293]. Stat3 has many downstream effectors like the proto-oncogene c-Jun that is part of the
AP-1 complex [194]. The transactivation domain of un-phosphorylated c-Jun recruits Mbd3/
NuRD to AP-1 target genes to mediate gene repression. This repression is relieved by c-Jun N-
terminal phosphorylation or Mbd3 depletion. Upon JNK activation, NuRD dissociates from
c-Jun, which results in de-repression of target gene transcription. Termination of the JNK signal
induces Mbd3/NuRD re-binding to un-phosphorylated c-Jun and cessation of target gene
expression (Figure 2) [199].
10. Conclusions
In this review, we have discussed a potentially novel link between inflammatory pathways
and efficient cell reprogramming. In this context, our group reported that bone marrow
stromal-primed human myeloid cell progenitors are significantly more receptive to reprog‐
ramming stimuli than other cell types [20]. Myeloid cells harbor a unique epigenetic plasticity
that allows them to quickly respond to a plethora of pathogens. They are innately equipped
to transcriptionally and epigenetically activate key inflammatory pathways via an intercon‐
nected NFκB and STAT3 signaling machinery [294]. Both pathways act as epigenetic modifiers
during normal inflammation stimulation, and both are also known to promote ESC pluripo‐
tency by inducing an open chromatin state that allows other transcription factors to regulate
cell fates [236]. This epigenetic remodeling may prove crucial for efficient reprogramming, as
well as the generation of high quality iPSC that resemble ESC without excessive epigenetic
memory of their cell of origin [295].
Moreover, Stat3 is a master reprogramming factor that is able to dominantly instruct pluripo‐
tency, yet is also inherently interconnected with inflammatory signaling cascades (Figure 2).
It binds to bivalent histone modifications, and allows rapid transitions between pluripotency
and differentiation [193]. The NFκB pathway acts in synergy with downstream STAT3
signaling, whereby non-canonical NFκB signaling maintains pluripotency through epigenetic
silencing of differentiation genes and canonical NFκB signaling promotes cell differentiation
[296]. Finally, recent evidence suggests that strong chromatin repression by the NuRD complex
is a key rate-limiting factor during reprogramming to pluripotency. This important complex
may normally function to ensure that differentiated cells do not reactivate pluripotency genes,
which might enable tumorigenesis [268]. We propose the hypothesis that NuRD complex
silencing might be more easily achieved through the activation of inflammatory pathways in
receptive cells such as those from the myeloid lineage.
It remains to be elucidated how all these processes are inter-regulated. It will be especially
important to link reprogramming efficiency with the resulting quality of the pluripotent state
achieved in hiPSC. We hypothesize that epigenetic plasticity in inflammatory cells that
normally allows chromatin accessibility to the transcriptional machinery, could be manipu‐
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lated to facilitate a complete erasure of the donor epigenetic memory during factor-mediated
reprogramming. Additionally, preventing cancerous epigenetic patterns in iPSC via more
accurate high-fidelity reprogramming methods will be the foundation for future clinical
applications [13]. Finally, the basic understanding of pluripotency induction may also give us
a better understanding of how tumor-initiating cells arise and how they can be eradicated to
prevent tumor relapse, thus potentially opening a new era of cancer treatments.
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1. Introduction
Stem cells possess two main attributes, namely, a self-renewal capacity and multipotency. Self-
renewal refers to the ability of a cell to replicate itself without differentiating or losing
multipotency. Multipotency is the ability to differentiate into more than one cell lineage. Recent
studies have revealed that there are several types of stem cells. For example, neural stem cells
can differentiate into neurons, astrocytes, and oligodendrocytes, while hematopoietic stem
cells can differentiate into all types of blood cells. Embryonic stem (ES) cells were originally
established from the inner cell mass (ICM) of mouse blastocysts [1, 2]. As the ICM gives rise
to the embryo, ES cells can differentiate into most cell types in the body and are therefore
pluripotent. The successful establishment of human pluripotent cells, namely, human ES cells
and human induced pluripotent (iPS) cells, opens up the possibility of using these cells in
regenerative medicine [3-5]. However, several issues remain to be resolved. One such issue is
unanticipated tumor formation by transplanted pluripotent cells, which seems to be associated
with the self-renewal capacity of these cells.
The self-renewal of mouse ES cells [6, 7] can be maintained by the presence of leukemia
inhibitory factor (LIF) in the culture medium. LIF binds to LIF receptor (LIFR) and induces
formation of gp130/LIFR heterodimers, leading to activation of the downstream transcription
factor signal transducer and activator of transcription (STAT)-3. The LIF/STAT3 pathway plays
a critical role in ES cell self-renewal by upregulating several self-renewal genes [8]. The
expression of a set of self-renewal genes is also regulated by networks of important transcrip‐
tion factors, including Oct3/4, Sox2, and Nanog [9].
Cancer is one of the most feared diseases throughout the world. Approximately 10 million
people die from cancer every year and the number of cancer patients is increasing. This disease
is characterized by loss of cellular growth control, which is induced by genome alterations,
such as DNA sequence changes, copy number aberrations, chromosomal rearrangements, and
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modifications in DNA methylation. Recent studies have provided evidence that tumor tissue
contains a small subset of stem-like cells called cancer stem cells. Cancer stem cells have stem
cell-like attributes, namely, self-renewal and differentiation, which enables them to produce
tumors by self-renewing and giving rise to differentiated progeny. The concept of cancer stem
cells first arose from studies of leukemia stem cells [10] and subsequently of solid tumors [11,
12]. Given that cancer stem cells play a prominent role in cancer cell growth, it may be
reasonable to expect similarities between ES cells and cancer cells.
Indeed, ES cells are similar to cancer cells in several respects. When injected into immunode‐
ficient mice, ES cells and cancer cells can produce benign and malignant tumors, respectively.
Both cell types have a rapid cell cycle, which results in fast proliferation. Telomerase activity
is very high in both cell types, which allows them to proliferate indefinitely. Both cell types
contain a “side population of cells” with a high drug efflux capacity, which gives rise to their
drug-resistance phenotype. In addition, several signal transduction pathways seem to be used
in both ES cell self-renewal and cancer cell growth. For example, the STAT3 pathway, which
plays a central role in ES cell self-renewal, is activated in several types of cancer cells. On the
other hand, the Wnt/β-catenin pathway, whose activation is associated with tumorigenesis in
many tissues, is involved in ES cell self-renewal. Moreover, poorly differentiated tumors
preferentially overexpress genes that are normally enriched in ES cells [13].
The similarities between ES cells and cancer cells raise the possibility that certain molecules
that are involved in ES cell self-renewal play important roles in cancer cell growth, while
certain oncogenes play critical roles in ES cell self-renewal (Fig. 1). In this chapter, I will provide
examples of such molecules and describe their roles in ES cell self-renewal and tumorigenesis.
Figure 1. Similarity between ES cells and cancer cells.
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2. ES cell self-renewal genes that are involved in cancer cell growth
2.1. Oct3/4
Oct3/4 was originally isolated by three groups [14-16].  Since Oct1 and Oct2 had already
been identified, two groups named this protein Oct3, while the other group named it Oct4.
Therefore,  I  will  use the term “Oct3/4” to describe this protein.  Oct3/4 is a transcription
factor belonging to the POU family and is encoded by the pou5f1 gene. The Oct3/4 protein
contains three domains,  namely,  the N-terminal,  POU, and C-terminal  domains.  The N-
and C-terminal domains are transactivation domains with redundant functions, while the
POU domain is  a bipartite DNA-binding domain consisting of the POU-specific  domain
and the POU homeodomain. In mouse development, deficiency of this transcription factor
results in loss of the ICM [17]. In agreement with this, conditional knockout of this gene
in ES cells results in their differentiation into trophectoderm cells [18], indicating that Oct3/4
is a central player in the self-renewal of ES cells. Furthermore, the recent finding that Oct3/4
is one of the four factors required for the production of iPS cells indicates the importance
of Oct3/4 for the acquisition of pluripotency [19].
Not only suppression, but also overexpression of Oct3/4 induces ES cell differentiation [18],
suggesting that the activity of Oct3/4 needs to be sustained at the correct level to main‐
tain ES cell self-renewal. Oct3/4 expression in ES cells is positively and negatively regulat‐
ed by multiple factors. The upstream region of the pou5f1 gene contains proximal and distal
enhancers, which regulate stem cell-specific expression of Oct3/4 [20]. An orphan nuclear
receptor Lrh1 (also known as Nr5a2) binds to the proximal enhancer to maintain Oct3/4
expression [21],  whereas Oct3/4 and Sox2 associate with the distal enhancer to stimulate
Oct3/4  expression [22].  Negative regulators  of  Oct3/4  expression include Gcnf,  Coup-tfs,
and  Cdx2,  whose  expression  are  induced  upon  ES  cell  differentiation.  In  addition  to
regulation of Oct3/4 expression, the transcriptional activity of Oct3/4 protein is regulated
by Oct3/4-binding proteins. For example, it  is well-established that Sox2 is a co-factor of
Oct3/4. β-catenin binds to Oct3/4 and functions as a co-activator that enhances the transcrip‐
tional activity of Oct3/4 [23]. The orphan nuclear receptor Dax1 also binds to Oct3/4, but
acts as a negative regulator by interfering with the binding of Oct3/4 to DNA [24].
In adult human tissues, expression of Oct3/4 is restricted to germline cells and is very low
in other tissues. By contrast, Oct3/4 is expressed in several types of human cancers, including
prostate,  breast,  oral,  bladder,  and  seminoma  [25],  suggesting  the  importance  of  this
transcription factor in cancer development. Moreover, Oct3/4 is highly expressed in cancer
stem-like cells in breast cancer, lung cancer, and bone sarcoma [26-28]. In lung cancer, Oct3/4
maintains the properties of cancer stem-like cells [28].  In agreement with these findings,
high expression of Oct3/4 significantly correlates with poor overall survival of nasopharyng‐
eal carcinoma patients [29].
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Sox2 is a transcription factor that belongs to the SRY-related HMG-box protein (Sox) family.
The Sox2 protein contains one HMG box, as well as a transactivation domain in its C-terminus.
Expression of Sox2 in ES cells is mainly regulated by Oct3/4 and Sox2 itself. In addition,
microRNAs (miRNAs) are involved in the control of Sox2 expression. For example, miR-9
binds to the 3’-untranslated region of Sox2 mRNA and represses Sox2 expression [30]. In
addition to regulation at the transcriptional level, the activity of Sox2 protein is regulated by
post-translational modifications. Mouse Sox2 protein can be sumoylated at Lys-247, which
impairs its binding to the Fgf4 enhancer [31]. Additionally, acetylation of Lys-75 by p300/CBP
promotes the nuclear export of Sox2 [32]. Akt directly interacts with Sox2 to phosphorylate
Thr-118, leading to stabilization of the Sox2 protein [33].
Sox2-deficient mouse embryos die shortly after implantation [34], indicating that Sox2 is
required for early development. In ES cells, Sox2 usually cooperates with Oct3/4 to regulate
the expression of several self-renewal factors, including Nanog, and disruption of the sox2 gene
results in the differentiation of ES cells into trophectoderm-like cells [35]. In addition, Sox2
regulates expression of histone acetyltransferases, including Tip60 and Elp3, and forms a
positive feedback loop with the polycomb group protein Eed to control the levels of histone
acetylation and methylation [36]. Similar to Oct3/4, Sox2 is one of the four factors required for
iPS cell production [19].
Besides its pivotal role in maintaining ES cell self-renewal, Sox2 is closely associated with many
types of cancer [37]. The Sox2 gene is located at chromosome 3q26, a region that is frequently
amplified in carcinomas. Amplification of the Sox2 gene has been observed in human squa‐
mous cell carcinomas of the lung and esophagus [38]. Sox2 is involved in the tumorigenesis of
several types of tumors, such as lung, breast, skin, prostate, ovarian, and sinonasal. For
example, Sox2 is expressed in early-stage breast tumors, and high Sox2 expression is associated
with large tumor size [39, 40]. Sox2 expression in breast cancer enhances cancer stem cell-like
properties [40]. Sox2 is also reportedly involved in regulation of cancer stem-like cells in
ovarian carcinoma [41].
2.3. Nanog
Nanog was originally identified as a gene whose overexpression can bypass the LIF require‐
ment of mouse ES cells for self-renewal [42, 43]. Nanog protein can be ubiquitinated at its PEST
domain, resulting in its degradation through the proteasome pathway in ES cells [44].
Phosphorylation of Nanog prevents this ubiquitination, thereby increasing the stability of
Nanog [45].
Although Nanog-deficient ES cells expand at a slower rate than wild-type cells,  they can
self-renew and retain expression of Oct3/4 and Sox2 [46]. These observations suggest that
Nanog is involved in the growth of ES cells,  but is  dispensable for ES cell  self-renewal.
Human Nanog is a reprogramming factor that can produce human iPS cells [5]. In murine
cells, mouse Nanog accelerates reprogramming and promotes the transition of pre-iPS cells
into mature iPS cells [47].
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models44
Normally, Nanog is expressed at early embryonic stages and in germline stem cells, but not
in adult tissues. However, Nanog is expressed at high levels in several types of cancers,
including breast, cervical, oral and kidney [48]. Nanog is also highly expressed in germ cell
tumors [49], which are characterized by the gain of the short arm of chromosome 12, at which
the Nanog gene is located. In addition, several reports have suggested that Nanog is involved
in the epithelial-mesenchymal transition and metastasis. For example, Nanog stimulates cell
migration and invasion in ovarian cancer through downregulation of E-cadherin and Foxj1 [50].
Nanog expression is higher in hepatocellular carcinoma cell lines that are highly metastatic
than in those that are lowly metastatic, and the Nodal/Smad3 pathway plays an important role
in the Nanog-stimulated epithelial-mesenchymal transition [51]. More importantly, Nanog
overexpression is associated with poor prognosis in some types of cancer, such as colorectal,
ovarian, and breast [48]
Nanog has 11 highly homologous pseudogenes in human cells. Of these, NanogP8 encodes a
full-length protein with only one amino acid difference from Nanog, and is involved in
tumorigenesis [52, 53]. It was recently shown that NanogP8 can function as a reprogramming
factor, with similar activity to Nanog [54].
2.4. STAT3
STAT3 is a downstream transcription factor of gp130, and is therefore activated by several
cytokines, including interleukin (IL)-6, IL-11, and LIF. This transcription factor was initially
identified as APRF (acute phase response factor), an inducible DNA-binding protein that binds
to the IL-6 response element within the promoters of genes that encode hepatic acute phase
proteins [55]. Human and mouse STAT3 proteins both have 770 amino acid residues and are
highly homologous to each other (only three amino acid differences). In addition to the DNA-
binding domain, STAT3 protein contains a SH2 domain, which facilitates dimer formation
upon phosphorylation by upstream kinases including JAK2. STAT3 protein is usually in an
inactive form and is localized in the cytoplasm. Upon cytokine stimulation, STAT3 is tyrosine-
phosphorylated by activated JAKs. Thereafter, the phosphorylated STAT3 protein forms a
homodimer or a heterodimer and translocates into the nucleus, where it stimulates the
transcription of its target genes. In mouse development, STAT3 activity is detected during
early post-implantation development [56] and Stat3-deficient mice die prior to gastrulation
[57], suggesting that STAT3 plays an important role in early embryogenesis.
STAT3 plays an indispensable role in the self-renewal of mouse ES cells, and deficiency of
STAT3 leads to the differentiation of these cells. By contrast, human ES cells do not require
STAT3 activation for their self-renewal. This discrepancy in the requirement for STAT3 is most
likely due to differences between mouse and human ES cells, as mouse ES cells are derived
from the ICM, whereas human ES cells are derived from the epiblast. Extensive studies have
identified many self-renewal factors that are downstream of STAT3 signaling, such as
transcription factors, epigenetic regulators, and oncogenes [8].
Although the STAT3 protein is normally only activated in response to signals that control cell
growth, overactivation of STAT3 protein has been observed in several types of cancer,
including breast, prostate, and pancreas, as well as leukemia and lymphoma [58]. Indeed,
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STAT3 is constitutively activated in nearly 70% of tumors. Because of the high frequency of its
overactivation, STAT3 is considered to be a valuable target for anti-cancer therapy.
2.5. Krüppel-like factor (Klf) 4
Klfs are a family of transcription factors that play important roles in many fundamental
biological processes. They were named “Krüppel-like” owing to their strong homology with
the Drosophila  gene product Krüppel,  which is involved in segmentation of the develop‐
ing embryo. Klf family proteins contain three C2H2-type zinc fingers that bind DNA. Klf4
was independently cloned by two groups and named “gut-enriched KLF” and “epithelial
zinc finger” owing to its high expression in the intestine and skin epithelium, respective‐
ly [59, 60]. However, it was later discovered that this transcription factor is expressed in
several other tissues, such as lung, testis, and thymus. In addition to a C-terminal DNA-
binding domain consisting of zinc fingers, Klf4 protein contains an activation domain in its
N-terminus and a repressive domain in its  central  region.  Probably owing to this  struc‐
ture, Klf4 is a bi-functional transcription factor that can either activate or repress transcrip‐
tion of its target genes. Similar to Oct3/4 and Sox2, Klf4 is one of the four factors that induce
reprogramming of murine cells [19].
Klf4 is highly expressed in self-renewing ES cells, but not in differentiated ES cells. Klf4
regulates self-renewal-specific expression of Lefty1, in cooperation with Oct3/4 and Sox2 [61].
Klf4 is also involved in Oct3/4 expression [62]. Overexpression of Klf4 results in the inhibition
of ES cell differentiation, possibly through upregulation of Nanog [63, 64]. In addition, there is
a marked overlap between genes that are regulated by Nanog and those that are regulated by
Klf4. These observations suggest the importance of Klf4 in ES cell self-renewal. However,
Klf4-null mice have no detectable defects during embryogenesis [65]. Furthermore, a recent
study reported that the function of Klf4 in ES cell self-renewal is partially redundant because
combined knockdown of Klf4, Klf2, and Klf5, but not any one gene individually, results in
spontaneous ES cell differentiation [62], suggesting that Klf4 is dispensable for ES cell self-
renewal.
In cancer cells, Klf4 acts as a tumor suppressor or an oncogene, possibly owing to its bi-
functionality. Whether Klf4 acts as a tumor suppressor or an oncogene likely depends on the
tumor type. For example, Klf4 functions as a tumor suppressor in the intestinal and gastric
epithelium, and expression of Klf4 is downregulated in human colorectal and gastric carcino‐
mas [66, 67]. On the other hand, overexpression of Klf4 in the skin results in squamous
epithelial dysplasia, eventually leading to squamous cell carcinoma [68, 69]. A high expression
level of Klf4 significantly correlates with a poor prognosis in hepatocellular carcinoma [70].
2.6. Zinc-finger protein (Zfp)-57
Zfp57 is a transcription factor that was originally identified as an undifferentiated cell-specific
gene in F9 embryonal carcinoma cells [71]. Mouse Zfp57 protein contains one Kruppel-
associated box (KRAB) domain and five zinc fingers, while human Zfp57 protein has one
KRAB domain and seven zinc fingers. In adult mouse, Zfp57 is highly expressed in testis and
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brain [71, 72]. Loss of the zygotic function of Zfp57 leads to partial lethality, while eliminating
both the maternal and zygotic functions of Zfp57 results in complete embryonic lethality [73].
Through its KRAB domain, Zfp57 interacts with KRAB-associated protein 1 (Kap1), a scaffold
protein for heterochromatin-inducing factors, and thus participates in genome imprinting by
recruiting Kap1 to multiple imprinting control regions [73, 74]. Mutations in the Zfp57 gene
cause transient neonatal diabetes mellitus type 1 [75]. Zfp57 is a downstream molecule of
STAT3 and Oct3/4 in ES cells, and is therefore specifically expressed in self-renewing ES cells
[76]. Zfp57 deficiency has no effect on the self-renewal or growth in ES cells, suggesting that
this transcription factor is dispensable for ES cell self-renewal.
Based on our prediction that a molecule expressed in self-renewing ES cells may play an
important role in cancer cell growth, we recently screened several ES cell-specific transcription
factors for their tumor-promoting activity, and found that Zfp57 can promote anchorage-
independent growth of human fibrosarcoma HT1080 cells [77]. Zfp57 overexpression enhan‐
ces, while its knockdown suppresses, HT1080 tumor formation in nude mice. Zfp57 regulates
the expression of insulin-like growth factor 2, which plays a critical role in Zfp57-induced
anchorage-independent growth and tumor formation. Furthermore, overexpression of Zfp57
causes anchorage-independent growth of the mouse immortal fibroblast cell line NIH3T3, and
immunohistochemical analysis revealed the overexpression of Zfp57 in several cancers,
including pancreatic, gastric, breast, colon, and esophageal. These results suggest that Zfp57
is an oncogene in some types of cancer. Moreover, we also found that Zfp57 is involved in
anchorage-independent growth of ES cells and that Zfp57-null ES cells form smaller teratomas
than the parental ES cells in immunodeficient mice, suggesting the importance of Zfp57 in
teratoma formation by ES cells.
3. Oncogenes that are involved in ES cell self-renewal
3.1. β-catenin
The importance of the Wnt pathway in tumorigenesis was recognized by identification of
adenomatous polyposis coli (APC) mutations in familial adenomatous polyposis [78, 79]. In
Wnt signaling, the Apc protein functions as a negative regulator and is involved in degradation
of β-catenin, the mammalian homologue of Drosophila Armadillo. β-catenin contains multiple
armadillo repeats in its central region and a transcriptional activator domain in its C-terminal
region. Human and mouse β-catenin proteins both have 781 amino acid residues and are
almost identical to each other (only one amino acid difference). β-catenin acts as a transcrip‐
tional co-activator and an adaptor protein for intracellular adhesion. In epithelial tissues, β-
catenin interacts with cadherins and α-catenin, and regulates epithelial cell growth and
intracellular adhesion. By contrast, in Wnt signaling, β-catenin is a major transcriptional
modulator and plays a crucial role in embryogenesis. In the absence of Wnt signaling, Apc
forms a complex with β-catenin and Axin. This leads to phosphorylation of β-catenin by
glycogen synthase kinase (GSK)-3β, which triggers degradation of β-catenin. When Wnt binds
to its receptor Frizzled, Disheveled is hyper-phosphorylated, which results in release of
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STAT3 is constitutively activated in nearly 70% of tumors. Because of the high frequency of its
overactivation, STAT3 is considered to be a valuable target for anti-cancer therapy.
2.5. Krüppel-like factor (Klf) 4
Klfs are a family of transcription factors that play important roles in many fundamental
biological processes. They were named “Krüppel-like” owing to their strong homology with
the Drosophila  gene product Krüppel,  which is involved in segmentation of the develop‐
ing embryo. Klf family proteins contain three C2H2-type zinc fingers that bind DNA. Klf4
was independently cloned by two groups and named “gut-enriched KLF” and “epithelial
zinc finger” owing to its high expression in the intestine and skin epithelium, respective‐
ly [59, 60]. However, it was later discovered that this transcription factor is expressed in
several other tissues, such as lung, testis, and thymus. In addition to a C-terminal DNA-
binding domain consisting of zinc fingers, Klf4 protein contains an activation domain in its
N-terminus and a repressive domain in its  central  region.  Probably owing to this  struc‐
ture, Klf4 is a bi-functional transcription factor that can either activate or repress transcrip‐
tion of its target genes. Similar to Oct3/4 and Sox2, Klf4 is one of the four factors that induce
reprogramming of murine cells [19].
Klf4 is highly expressed in self-renewing ES cells, but not in differentiated ES cells. Klf4
regulates self-renewal-specific expression of Lefty1, in cooperation with Oct3/4 and Sox2 [61].
Klf4 is also involved in Oct3/4 expression [62]. Overexpression of Klf4 results in the inhibition
of ES cell differentiation, possibly through upregulation of Nanog [63, 64]. In addition, there is
a marked overlap between genes that are regulated by Nanog and those that are regulated by
Klf4. These observations suggest the importance of Klf4 in ES cell self-renewal. However,
Klf4-null mice have no detectable defects during embryogenesis [65]. Furthermore, a recent
study reported that the function of Klf4 in ES cell self-renewal is partially redundant because
combined knockdown of Klf4, Klf2, and Klf5, but not any one gene individually, results in
spontaneous ES cell differentiation [62], suggesting that Klf4 is dispensable for ES cell self-
renewal.
In cancer cells, Klf4 acts as a tumor suppressor or an oncogene, possibly owing to its bi-
functionality. Whether Klf4 acts as a tumor suppressor or an oncogene likely depends on the
tumor type. For example, Klf4 functions as a tumor suppressor in the intestinal and gastric
epithelium, and expression of Klf4 is downregulated in human colorectal and gastric carcino‐
mas [66, 67]. On the other hand, overexpression of Klf4 in the skin results in squamous
epithelial dysplasia, eventually leading to squamous cell carcinoma [68, 69]. A high expression
level of Klf4 significantly correlates with a poor prognosis in hepatocellular carcinoma [70].
2.6. Zinc-finger protein (Zfp)-57
Zfp57 is a transcription factor that was originally identified as an undifferentiated cell-specific
gene in F9 embryonal carcinoma cells [71]. Mouse Zfp57 protein contains one Kruppel-
associated box (KRAB) domain and five zinc fingers, while human Zfp57 protein has one
KRAB domain and seven zinc fingers. In adult mouse, Zfp57 is highly expressed in testis and
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brain [71, 72]. Loss of the zygotic function of Zfp57 leads to partial lethality, while eliminating
both the maternal and zygotic functions of Zfp57 results in complete embryonic lethality [73].
Through its KRAB domain, Zfp57 interacts with KRAB-associated protein 1 (Kap1), a scaffold
protein for heterochromatin-inducing factors, and thus participates in genome imprinting by
recruiting Kap1 to multiple imprinting control regions [73, 74]. Mutations in the Zfp57 gene
cause transient neonatal diabetes mellitus type 1 [75]. Zfp57 is a downstream molecule of
STAT3 and Oct3/4 in ES cells, and is therefore specifically expressed in self-renewing ES cells
[76]. Zfp57 deficiency has no effect on the self-renewal or growth in ES cells, suggesting that
this transcription factor is dispensable for ES cell self-renewal.
Based on our prediction that a molecule expressed in self-renewing ES cells may play an
important role in cancer cell growth, we recently screened several ES cell-specific transcription
factors for their tumor-promoting activity, and found that Zfp57 can promote anchorage-
independent growth of human fibrosarcoma HT1080 cells [77]. Zfp57 overexpression enhan‐
ces, while its knockdown suppresses, HT1080 tumor formation in nude mice. Zfp57 regulates
the expression of insulin-like growth factor 2, which plays a critical role in Zfp57-induced
anchorage-independent growth and tumor formation. Furthermore, overexpression of Zfp57
causes anchorage-independent growth of the mouse immortal fibroblast cell line NIH3T3, and
immunohistochemical analysis revealed the overexpression of Zfp57 in several cancers,
including pancreatic, gastric, breast, colon, and esophageal. These results suggest that Zfp57
is an oncogene in some types of cancer. Moreover, we also found that Zfp57 is involved in
anchorage-independent growth of ES cells and that Zfp57-null ES cells form smaller teratomas
than the parental ES cells in immunodeficient mice, suggesting the importance of Zfp57 in
teratoma formation by ES cells.
3. Oncogenes that are involved in ES cell self-renewal
3.1. β-catenin
The importance of the Wnt pathway in tumorigenesis was recognized by identification of
adenomatous polyposis coli (APC) mutations in familial adenomatous polyposis [78, 79]. In
Wnt signaling, the Apc protein functions as a negative regulator and is involved in degradation
of β-catenin, the mammalian homologue of Drosophila Armadillo. β-catenin contains multiple
armadillo repeats in its central region and a transcriptional activator domain in its C-terminal
region. Human and mouse β-catenin proteins both have 781 amino acid residues and are
almost identical to each other (only one amino acid difference). β-catenin acts as a transcrip‐
tional co-activator and an adaptor protein for intracellular adhesion. In epithelial tissues, β-
catenin interacts with cadherins and α-catenin, and regulates epithelial cell growth and
intracellular adhesion. By contrast, in Wnt signaling, β-catenin is a major transcriptional
modulator and plays a crucial role in embryogenesis. In the absence of Wnt signaling, Apc
forms a complex with β-catenin and Axin. This leads to phosphorylation of β-catenin by
glycogen synthase kinase (GSK)-3β, which triggers degradation of β-catenin. When Wnt binds
to its receptor Frizzled, Disheveled is hyper-phosphorylated, which results in release of
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GSK3β from the β-catenin degradation complex and prevents phosphorylation of β-catenin
by GSK3β. Unphosphorylated β-catenin translocates into the nucleus, where it forms a
complex with Tcf/Lef and functions as a transcriptional co-activator.
In human cancers, such as colon cancer, the β-catenin/Tcf/Lef complex positively regulates the
expression of a variety of cancer-associated genes, including cyclin D, Tert, and c-Myc, to
promote tumorigenesis. Apc mutation leads to stabilization and accumulation of β-catenin in
nuclei. However, in some cancers, mutation of β-catenin itself renders this protein unable to
be phosphorylated, resulting in its stabilization.
Accumulated evidence suggests that Wnt/β-catenin signaling contributes to the maintenance
of ES cell self-renewal. For example, Apc-null ES cells show severe differentiation defects [80].
Undifferentiated ES cells can be maintained in a self-renewing state by using conditioned
medium from Wnt3a-expressing cells [81]. Furthermore, enforced expression of an activated
form of β-catenin maintains the self-renewal of ES cells, even in the absence of LIF [23, 82].
Expression of γ-catenin, which has a similar structure to β-catenin, partially sustains the self-
renewal of ES cells in the absence of LIF [23]. β-catenin binds to Oct3/4 to enhance its tran‐
scriptional activity in ES cells, leading to upregulation of Nanog, a target gene of Oct3/4 [23].
The Wnt/β-catenin pathway upregulates expression of STAT3, and this signaling converges
with that of LIF [83]. Similarly, Wnt and LIF work in synergy to maintain the pluripotency of
mouse ES cells [84]. On the other hand, the self-renewal of ES cells can be maintained without
β-catenin [85]. Taken together, these results suggest that β-catenin promotes, but is dispensa‐
ble, for ES cell self-renewal. Moreover, it was recently shown that ES cells lacking Wnt signaling
resemble epiblast stem cells in terms of their morphology and gene expression [86, 87]. This
suggests that Wnt/β-catenin signaling prevents the transition of ES cells from a naïve to a
primed pluripotent state. In addition, β-catenin regulates Tert expression in ES cells [88], as is
the case in cancer cells.
3.2. Gli
The zinc-finger transcription factor Gli is a central player in the Hedgehog (Hh)-mediated
signaling pathway, which plays a critical role during embryogenesis. Gli belongs to the Klf
family and has three isoforms in mammals, namely, Gli1, Gli2, and Gli3. Gli1 and Gli2 usually
act as transcription activators, while Gli3 is a transcription suppressor. All Gli proteins have
a DNA-binding domain consisting of C2-H2 class zinc fingers. In addition, Gli1 and Gli2
contain a C-terminal transactivation domain, while Gli2 and Gli3 have an N-terminal repres‐
sion domain. Hh family proteins, namely, Sonic Hh, Indian Hh, and Desert Hh, function as
ligands of the transmembrane receptor Ptch1. In the absence of a Hh ligand, Ptch1 inhibits the
activity of the G-protein coupled receptor-like protein Smo, resulting in formation of a complex
of Gli2 and Gli3 with the inhibitory protein Sufu. This results in cleavage of Gli2 and Gli3 into
their repressor forms, which translocate into the nucleus. By contrast, binding of Hh ligands
to Ptch1 results in the release and activation of Smo, leading to activation and nuclear trans‐
location of Gli2, which results in transactivation of target genes, including Gli1.
Gli1 was originally identified as an amplified gene in a human glioma cell line [89]. It was
recently shown that Hh/Gli signaling regulates the self-renewal of glioma stem cells, as well
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as their expression of stemness genes, including Oct3/4 and Sox2 [90]. Gli1 forms a positive
feedback loop with Nanog, and the Nanog/Gli1 signaling axis is indispensable for regulation
of glioma stem cells [91]. In Ewing sarcoma, expression of Gli1 is regulated in an Hh-inde‐
pendent manner: EWS-FLI, an oncogenic transcription factor that is produced by chromosomal
translocation, directly upregulates Gli1 expression to promote tumor growth [92, 93].
Gli1 and Gli2 are both highly expressed in undifferentiated ES cells, while Gli3 expression level
is low [94]. Gli1 and Gli2 are downstream molecules of Oct3/4 and Nanog, and their expression
is downregulated upon differentiation. When Gli1 and Gli2 are suppressed by a dominant-
negative mutant of Gli2, expression of the self-renewal marker Sox2 decreases, whereas that
of the differentiation markers Gata4 and Cdx2 increases, suggesting the importance of Gli
activity for ES cell self-renewal. However, expression of this dominant-negative Gli2 mutant
does not affect expression of the self-renewal markers Oct3/4 and Nanog. These findings
suggest that Gli activity is involved in repressing ES cell differentiation, but is dispensable for
ES cell self-renewal. In addition, Gli is involved in ES cell growth [94, 95].
3.3. Akt
The serine/threonine protein kinase Akt was independently identified by three different
groups. Two groups identified this kinase as being homologous to protein kinase C and protein
kinase A, giving rise to the names “protein kinase B” and “RAC-PK” (related to the A and C
kinases) [96, 97]. The other group identified this kinase as the cellular counterpart of the
oncogene v-akt of the acutely transforming retrovirus AKT8 that is found in a rodent T-cell
lymphoma [98]. Here, I will describe this protein as “Akt”. Akt has three isoforms, namely,
Akt1, Akt2, and Akt3. Each Akt family member has an N-terminal pleckstrin homology
domain, a short α-helical linker, and a C-terminal kinase domain. Akt is directly downstream
of phosphatidylinositol-3-OH kinase, and is a key player in the regulation of cell growth and
survival.
As expected from its identification as a counterpart of a viral oncogene, Akt plays an important
role in human malignancy [99, 100]. Several studies have identified amplification of the Akt
gene in human cancers. Amplification of Akt1 was detected in a human gastric cancer [101].
Amplification and overexpression of Akt2 were detected in ovarian and pancreatic cancers.
Artificial activation of Akt1 or Akt2 can transform NIH3T3 cells [102, 103], and Akt2 anti-sense
RNA inhibits the tumorigenic phenotype of pancreatic carcinoma cell lines [104]. Furthermore,
Akt1 kinase activity is often increased in prostate and breast cancers and is associated with a
poor prognosis [102].
A constitutively activated Akt mutant can maintain the undifferentiated phenotype of mouse
ES cells, even in the absence of LIF, although the mechanism underlying Akt-mediated
maintenance of ES cell self-renewal is unclear [105]. Bechard and Dalton demonstrated that
Akt phosphorylates, and thereby inactivates, GSK3β in ES cells, suggesting that Akt maintains
ES cell self-renewal by inactivating GSK3β and thus stimulating activation of β-catenin [106].
By contrast, Watanabe et al. did not observe the accumulation of β-catenin in nuclei or
activation of the transcriptional activity of β-catenin in mouse ES cells [105]. Another possible
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GSK3β from the β-catenin degradation complex and prevents phosphorylation of β-catenin
by GSK3β. Unphosphorylated β-catenin translocates into the nucleus, where it forms a
complex with Tcf/Lef and functions as a transcriptional co-activator.
In human cancers, such as colon cancer, the β-catenin/Tcf/Lef complex positively regulates the
expression of a variety of cancer-associated genes, including cyclin D, Tert, and c-Myc, to
promote tumorigenesis. Apc mutation leads to stabilization and accumulation of β-catenin in
nuclei. However, in some cancers, mutation of β-catenin itself renders this protein unable to
be phosphorylated, resulting in its stabilization.
Accumulated evidence suggests that Wnt/β-catenin signaling contributes to the maintenance
of ES cell self-renewal. For example, Apc-null ES cells show severe differentiation defects [80].
Undifferentiated ES cells can be maintained in a self-renewing state by using conditioned
medium from Wnt3a-expressing cells [81]. Furthermore, enforced expression of an activated
form of β-catenin maintains the self-renewal of ES cells, even in the absence of LIF [23, 82].
Expression of γ-catenin, which has a similar structure to β-catenin, partially sustains the self-
renewal of ES cells in the absence of LIF [23]. β-catenin binds to Oct3/4 to enhance its tran‐
scriptional activity in ES cells, leading to upregulation of Nanog, a target gene of Oct3/4 [23].
The Wnt/β-catenin pathway upregulates expression of STAT3, and this signaling converges
with that of LIF [83]. Similarly, Wnt and LIF work in synergy to maintain the pluripotency of
mouse ES cells [84]. On the other hand, the self-renewal of ES cells can be maintained without
β-catenin [85]. Taken together, these results suggest that β-catenin promotes, but is dispensa‐
ble, for ES cell self-renewal. Moreover, it was recently shown that ES cells lacking Wnt signaling
resemble epiblast stem cells in terms of their morphology and gene expression [86, 87]. This
suggests that Wnt/β-catenin signaling prevents the transition of ES cells from a naïve to a
primed pluripotent state. In addition, β-catenin regulates Tert expression in ES cells [88], as is
the case in cancer cells.
3.2. Gli
The zinc-finger transcription factor Gli is a central player in the Hedgehog (Hh)-mediated
signaling pathway, which plays a critical role during embryogenesis. Gli belongs to the Klf
family and has three isoforms in mammals, namely, Gli1, Gli2, and Gli3. Gli1 and Gli2 usually
act as transcription activators, while Gli3 is a transcription suppressor. All Gli proteins have
a DNA-binding domain consisting of C2-H2 class zinc fingers. In addition, Gli1 and Gli2
contain a C-terminal transactivation domain, while Gli2 and Gli3 have an N-terminal repres‐
sion domain. Hh family proteins, namely, Sonic Hh, Indian Hh, and Desert Hh, function as
ligands of the transmembrane receptor Ptch1. In the absence of a Hh ligand, Ptch1 inhibits the
activity of the G-protein coupled receptor-like protein Smo, resulting in formation of a complex
of Gli2 and Gli3 with the inhibitory protein Sufu. This results in cleavage of Gli2 and Gli3 into
their repressor forms, which translocate into the nucleus. By contrast, binding of Hh ligands
to Ptch1 results in the release and activation of Smo, leading to activation and nuclear trans‐
location of Gli2, which results in transactivation of target genes, including Gli1.
Gli1 was originally identified as an amplified gene in a human glioma cell line [89]. It was
recently shown that Hh/Gli signaling regulates the self-renewal of glioma stem cells, as well
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as their expression of stemness genes, including Oct3/4 and Sox2 [90]. Gli1 forms a positive
feedback loop with Nanog, and the Nanog/Gli1 signaling axis is indispensable for regulation
of glioma stem cells [91]. In Ewing sarcoma, expression of Gli1 is regulated in an Hh-inde‐
pendent manner: EWS-FLI, an oncogenic transcription factor that is produced by chromosomal
translocation, directly upregulates Gli1 expression to promote tumor growth [92, 93].
Gli1 and Gli2 are both highly expressed in undifferentiated ES cells, while Gli3 expression level
is low [94]. Gli1 and Gli2 are downstream molecules of Oct3/4 and Nanog, and their expression
is downregulated upon differentiation. When Gli1 and Gli2 are suppressed by a dominant-
negative mutant of Gli2, expression of the self-renewal marker Sox2 decreases, whereas that
of the differentiation markers Gata4 and Cdx2 increases, suggesting the importance of Gli
activity for ES cell self-renewal. However, expression of this dominant-negative Gli2 mutant
does not affect expression of the self-renewal markers Oct3/4 and Nanog. These findings
suggest that Gli activity is involved in repressing ES cell differentiation, but is dispensable for
ES cell self-renewal. In addition, Gli is involved in ES cell growth [94, 95].
3.3. Akt
The serine/threonine protein kinase Akt was independently identified by three different
groups. Two groups identified this kinase as being homologous to protein kinase C and protein
kinase A, giving rise to the names “protein kinase B” and “RAC-PK” (related to the A and C
kinases) [96, 97]. The other group identified this kinase as the cellular counterpart of the
oncogene v-akt of the acutely transforming retrovirus AKT8 that is found in a rodent T-cell
lymphoma [98]. Here, I will describe this protein as “Akt”. Akt has three isoforms, namely,
Akt1, Akt2, and Akt3. Each Akt family member has an N-terminal pleckstrin homology
domain, a short α-helical linker, and a C-terminal kinase domain. Akt is directly downstream
of phosphatidylinositol-3-OH kinase, and is a key player in the regulation of cell growth and
survival.
As expected from its identification as a counterpart of a viral oncogene, Akt plays an important
role in human malignancy [99, 100]. Several studies have identified amplification of the Akt
gene in human cancers. Amplification of Akt1 was detected in a human gastric cancer [101].
Amplification and overexpression of Akt2 were detected in ovarian and pancreatic cancers.
Artificial activation of Akt1 or Akt2 can transform NIH3T3 cells [102, 103], and Akt2 anti-sense
RNA inhibits the tumorigenic phenotype of pancreatic carcinoma cell lines [104]. Furthermore,
Akt1 kinase activity is often increased in prostate and breast cancers and is associated with a
poor prognosis [102].
A constitutively activated Akt mutant can maintain the undifferentiated phenotype of mouse
ES cells, even in the absence of LIF, although the mechanism underlying Akt-mediated
maintenance of ES cell self-renewal is unclear [105]. Bechard and Dalton demonstrated that
Akt phosphorylates, and thereby inactivates, GSK3β in ES cells, suggesting that Akt maintains
ES cell self-renewal by inactivating GSK3β and thus stimulating activation of β-catenin [106].
By contrast, Watanabe et al. did not observe the accumulation of β-catenin in nuclei or
activation of the transcriptional activity of β-catenin in mouse ES cells [105]. Another possible
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mechanism is that Akt induces expression of Tbx3, which in turn stimulates expression of
Nanog to maintain ES cell self-renewal [107].
3.4. c-Myc
c-Myc is a cellular counterpart of the v-myc gene, which was isolated from the avian retrovirus
MC29 [108], and belongs to a family of helix-loop-helix/leucine zipper transcription factors. c-
Myc forms a complex with Max, which results in the increased stability of c-Myc protein [109].
Phosphorylation of Thr-62 by Erk also stabilizes c-Myc, while phosphorylation of Thr-58 by
GSK3β reduces the stability of c-Myc [110]. c-Myc regulates expression of its target genes
through binding to E-box sequences and recruiting histone acetyltransferases. Under normal
conditions, when cells are stimulated by an internal or external growth-promoting signal, the
level of c-Myc rapidly and transiently increases to induce cell proliferation, and the level of c-
Myc subsequently returns to a low level in quiescent cells.
It is well-established that many, if not most, human tumors have elevated levels of c-Myc
owing to gene amplification and translocation [111, 112]. Gene amplification of c-Myc has been
reported in several cancers, including breast, ovarian, and colon. A common human translo‐
cation involving c-Myc is t(8;14), which is critical for the development of Burkitt's lymphoma.
Although c-Myc was one of the four factors originally identified as being required for iPS cell
production [19], generation of iPS cells without this transcription factor has been reported
[113], suggesting that c-Myc is dispensable for cell reprogramming.
During the self-renewal of ES cells, levels of c-Myc are elevated [114]. By contrast, upon LIF
withdrawal, the level of c-Myc mRNA decreases and c-Myc protein is phosphorylated on
Thr-58 by GSK3β, which triggers degradation of c-Myc. Expression of a stable c-Myc mutant,
in which the Thr-58 residue is mutated to alanine, allows ES cells to self-renew in the absence
of LIF. By contrast, expression of a dominant-negative form of c-Myc inhibits the self-renewal
of ES cells and induces their differentiation. These findings suggest that c-Myc is critically
involved in maintaining the self-renewal of ES cells. Moreover, analysis of Max-null ES cells
revealed that the function of c-Myc/Max in ES cell self-renewal seems to be largely independent
of the Oct3/4, Sox2, and Nanog regulatory networks [115].
4. Future prospective
As I have described here, several common transcription factors are involved in the regulation
of ES cell self-renewal and cancer cell growth (Fig. 2). This raises several intriguing possibilities.
Considering that these common transcription factors are stem cell-specific and are involved
in tumor growth, it is possible that they are specifically expressed in cancer stem cells and play
important roles in the growth of these cells. Therefore, it is possible that these factors are good
markers of cancer stem cells. If so, it might be possible to utilize these factors to isolate cancer
stem cells, which will help to advance cancer stem cell research. Furthermore, identification
of small compounds that specifically inhibit the functions of these factors may lead to the
development of new anti-cancer drugs that can selectively kill cancer stem cells.
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Since ES cells and iPS cells have similar gene expression profiles, it is likely that these common
transcription factors are also expressed in iPS cells. Considering the transforming potential of
these factors, it is possible that their high expression in iPS cells increases the risk of tumor
formation during cell therapy using iPS-derived cells. Indeed, we have already found that
Zfp57-null ES cells are significantly less able to form tumors than wild-type ES cells.
In this way, understanding the roles of putative oncogenes in ES cells will not only help to
elucidate the molecular basis underlying the similarity between ES cells and cancers cells, but
will also help to develop a novel method that can be used in cancer therapy and regenerative
medicine.
Figure 2. Transcription factor network that regulates ES cell self-renewal. Considering the similarities between ES cells
and cancer cells, at least a part of this network may be used for growth regulation in cancer cells.
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mechanism is that Akt induces expression of Tbx3, which in turn stimulates expression of
Nanog to maintain ES cell self-renewal [107].
3.4. c-Myc
c-Myc is a cellular counterpart of the v-myc gene, which was isolated from the avian retrovirus
MC29 [108], and belongs to a family of helix-loop-helix/leucine zipper transcription factors. c-
Myc forms a complex with Max, which results in the increased stability of c-Myc protein [109].
Phosphorylation of Thr-62 by Erk also stabilizes c-Myc, while phosphorylation of Thr-58 by
GSK3β reduces the stability of c-Myc [110]. c-Myc regulates expression of its target genes
through binding to E-box sequences and recruiting histone acetyltransferases. Under normal
conditions, when cells are stimulated by an internal or external growth-promoting signal, the
level of c-Myc rapidly and transiently increases to induce cell proliferation, and the level of c-
Myc subsequently returns to a low level in quiescent cells.
It is well-established that many, if not most, human tumors have elevated levels of c-Myc
owing to gene amplification and translocation [111, 112]. Gene amplification of c-Myc has been
reported in several cancers, including breast, ovarian, and colon. A common human translo‐
cation involving c-Myc is t(8;14), which is critical for the development of Burkitt's lymphoma.
Although c-Myc was one of the four factors originally identified as being required for iPS cell
production [19], generation of iPS cells without this transcription factor has been reported
[113], suggesting that c-Myc is dispensable for cell reprogramming.
During the self-renewal of ES cells, levels of c-Myc are elevated [114]. By contrast, upon LIF
withdrawal, the level of c-Myc mRNA decreases and c-Myc protein is phosphorylated on
Thr-58 by GSK3β, which triggers degradation of c-Myc. Expression of a stable c-Myc mutant,
in which the Thr-58 residue is mutated to alanine, allows ES cells to self-renew in the absence
of LIF. By contrast, expression of a dominant-negative form of c-Myc inhibits the self-renewal
of ES cells and induces their differentiation. These findings suggest that c-Myc is critically
involved in maintaining the self-renewal of ES cells. Moreover, analysis of Max-null ES cells
revealed that the function of c-Myc/Max in ES cell self-renewal seems to be largely independent
of the Oct3/4, Sox2, and Nanog regulatory networks [115].
4. Future prospective
As I have described here, several common transcription factors are involved in the regulation
of ES cell self-renewal and cancer cell growth (Fig. 2). This raises several intriguing possibilities.
Considering that these common transcription factors are stem cell-specific and are involved
in tumor growth, it is possible that they are specifically expressed in cancer stem cells and play
important roles in the growth of these cells. Therefore, it is possible that these factors are good
markers of cancer stem cells. If so, it might be possible to utilize these factors to isolate cancer
stem cells, which will help to advance cancer stem cell research. Furthermore, identification
of small compounds that specifically inhibit the functions of these factors may lead to the
development of new anti-cancer drugs that can selectively kill cancer stem cells.
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Since ES cells and iPS cells have similar gene expression profiles, it is likely that these common
transcription factors are also expressed in iPS cells. Considering the transforming potential of
these factors, it is possible that their high expression in iPS cells increases the risk of tumor
formation during cell therapy using iPS-derived cells. Indeed, we have already found that
Zfp57-null ES cells are significantly less able to form tumors than wild-type ES cells.
In this way, understanding the roles of putative oncogenes in ES cells will not only help to
elucidate the molecular basis underlying the similarity between ES cells and cancers cells, but
will also help to develop a novel method that can be used in cancer therapy and regenerative
medicine.
Figure 2. Transcription factor network that regulates ES cell self-renewal. Considering the similarities between ES cells
and cancer cells, at least a part of this network may be used for growth regulation in cancer cells.
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1. Introduction
Haematopoiesis, the process of generation of blood cells, is one of the most extensively studied
developmental systems. The whole spectrum of blood cells produced in mammalian organ‐
isms includes primitive erythrocytes and definitive haematopoietic cells such as myeloid,
lymphoid, definitive erythroid and haematopoietic stem cells (HSCs).
Haematopoiesis takes place in several locations during ontogeny and in adult life. The
embryonic origin of blood cells has been studied for more than a century. However, studies
on haematopoiesis in vivo are challenging as embryos, and in particular mammalian embryos,
are extremely small and difficult to access at these very early stages of development. Moreover,
the number of cells per embryo is limited and all the successive developmental events take
place very fast. Therefore different approaches have been developed to facilitate these studies
in vitro and one of them involves the use of embryonic stem (ES) cell in vitro differentiation. In
this chapter, we will highlight some recent results on studies of the development of the
haematopoietic system obtained in particular using the in vitro differentiation of murine ES
cells. We will also present the methods we routinely use in our laboratory to work with wild
type or genetically modified murine ES cells.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Early haematopoietic development
2.1. How can embryonic stem cells be used to study early embryonic haematopoiesis?
Studying haematopoiesis in the mouse embryo in vivo remains challenging, in particular at the
very early stages of development when the embryo is small, difficult to access and the number
of cells is limited. One of the alternative approaches is the in vitro differentiation of ES cells
which are defined as pluripotent cells, able to give rise to three primary germ cell layers
(endoderm, mesoderm and ectoderm) [1]. ES cells are isolated from the inner cell mass of the
blastocyst and under appropriate conditions can be maintained undifferentiated in culture [2]
or alternatively allowed to differentiate. By scaling up cultures of differentiated ES cells, it is
relatively easy to access large number of cells that would be unattainable in vivo. ES cells
represent a unique tool to study the molecular and cellular mechanisms of normal haemato‐
poietic development, or the perturbations of these mechanisms leading to pathogenesis. In
addition, with the advent of human ES cells, and induced human pluripotent stem (iPS) cells,
the differentiation of these stem cells toward haematopoiesis could represent an exciting
approach to generate cell populations to treat haematological disorders.
2.2. Sites of haematopoietic development
In 1920, the embryologist Florence Sabin observed that endothelial and haematopoietic cells
were closely located in the yolk sac of avian embryo [3]. These structures, later called “blood
islands”, were thought to be derived from mesodermal cells undergoing differentiation
towards endothelial and haematopoietic lineages [4]. In the mouse embryo, the first blood cells
were shown to emerge around day E7.5 in the extra-embryonic yolk sac, within the blood
islands [5]. These first haematopoietic cells are primitive erythrocytes that transport large
amounts of oxygen required to support the rapidly growing embryo. In the final days of
gestation, their number decreases rapidly as other haematopoietic cells overtake their function.
For a long time, the yolk sac was thought to generate only primitive erythrocytes. However,
detailed studies indicated that other cell lineages such as definitive erythroid progenitors, mast
cells and bipotential granulocyte/macrophage progenitors are also generated in the murine
yolk sac before circulation [6]. By day E8.5, circulation in the mouse embryo is established and
the newly formed blood vessels connect the extra-embryonic yolk sac to intra-embryonic
tissues. From that time onward, other haematopoietic tissues within the embryo proper
become actively involved in haematopoiesis. In 1994, a seminal study by Muller and co-
workers demonstrated that at day 10 p.c. (post coitus), the aorta-gonad-mesonephros (AGM)
region contains long term repopulating haematopoietic stem cells (HSCs)-the foundation of
the blood system in adult organisms [7]. The AGM region is an intra-embryonic site that will
later develop into major internal organs. Following the discovery of these first HSCs in the
AGM region it was important to distinguish whether these cells were generated in this region
or emigrated from other embryonic locations through the blood circulation. The work of
Medvinsky and Dzierzak established that definitive HSCs, capable of long term multilineage
haematopoietic reconstitution emerge but also expand within the AGM region [8]. More
recently, the placenta, both in mouse and human was reported to contain HSCs [9, 10],
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although whether these HSCs are de novo generated within the placenta remains unknown.
During adult life, the main site of haematopoiesis is the bone marrow, where HSCs are found.
The capacity of HSCs present in the bone marrow to rebuild the whole haematopoietic
hierarchy in recipient organism is routinely used by clinicians to treat many blood-related
diseases through bone marrow transplantations.
2.3. Haemangioblast and haemogenic endothelium – Is there a connection?
The search for the cellular origin of blood cells started nearly 100 years ago, when Sabin
noticed that endothelial and haematopoietic lineages are located in close proximity within
the blood islands,  suggesting the existence of  a  common precursor  called a  haemangio‐
blast  [3].  Few years  later,  in  1924 Alexander  Maximow observed that  the  blood islands
represent mesodermal masses that differentiated towards endothelial and haematopoietic
cells [4]. In vitro experiments based on embryonic stem (ES) cell differentiation were the first
experiments  providing  substantial  data  supporting  the  existence  of  the  haemangioblast
[11-13]. First, Choi and co-workers identified a precursor called blast colony forming cell
(BL-CFC),  expressing FLK1 – the VEGR receptor  2,  that  upon culture gave rise  to  blast
colonies containing precursors for both endothelial and haematopoietic cells [11]. These BL-
CFCs were further shown to express the Brachyury (T) gene as well as the Scl (Stem Cell
Leukaemia) transcription factor [12, 13]. Later, studies on mouse embryos demonstrated the
existence of  the hemangioblast  in vivo  and indicated that it  is  found prominently in the
posterior primitive streak [14]. It probably migrates from there to the yolk sac where the
generation  of  blood,  endothelial  and  vascular  smooth  muscle  cells  take  place  [14].  The
existence of haemangioblast was also more recently documented in human with human ES
cells [15] and in vivo in zebrafish [16].
Another concept of development proposes that a mature endothelial cell with haematopoietic
potential, a haemogenic endothelium, give rise to blood cells. Several in vitro studies demon‐
strated that endothelial cells have the potential to generate blood cell lineages [17, 18]. In these
studies, the authors isolated cells expressing both FLK1 and the endothelial marker VE-
Cadherin and observed that these cells were able of de novo production of blood cells, marked
by the expression of CD45. The generation of blood cells from endothelial progenitors was also
demonstrated in vivo by Jaffredo and collaborators [19]. These authors specifically labelled
endothelial cells in the avian embryo and observed that haematopoietic cells are later generated
from these fluorescent endothelial progenitors.
More recently, a study by Lancrin and colleagues merged the haemangioblast and haemogenic
endothelium theories into one linear model of development, in which the haemogenic
endothelium is an intermediate stage during the generation of blood progenitors from the
haemangioblast [20]. The presence of a haemogenic endothelium cell population was estab‐
lished both in vitro during ES cell differentiation as well as in vivo, in E7.5 mouse embryos
[20-22]. In 2010, the generation of blood cells by haemogenic endothelium was directly
visualised in embryos. This endothelial to haematopoietic transition (EHT) was observed both
during murine [23] and zebrafish embryogenesis [24-26]. A schematic representation of the
successive stages of haematopoietic commitment is presented in Figure 1.
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Figure 1. The process of generation of blood cells from the haemangioblast through a transient haemogenic endo‐
thelium cell population. Specific markers for each cell population are depicted. This figure has been adapted from
[27].
2.4. Primitive erythrocytes – First blood cells in the embryo
Primitive erythrocytes, the first blood cells that emerge during embryogenesis in mammals,
are large and nucleated. Their main function is to transport large quantities of oxygen to
support the rapid growth of the embryo. It has been shown that these cells firstly appear in
vivo in the yolk sac’s blood islands around day E7.5 [28]. Although it was initially thought that
these cells were nucleated, more recent studies have indicated that their nuclei are lost during
the final days of mammalian gestation [29]. Studying primitive erythropoiesis remains
challenging for several reasons; not only is the murine embryo around day 7 of gestation
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extremely small and difficult to access, but also there are no specific cell surface markers to
specifically label this cell population. Therefore, transgenic mouse models were developed to
directly address this later limitation.
Two mouse models used the expression of the same haemoglobin – ε-globin, as a reporter
to track primitive erythropoiesis during ontogeny. In the first model [30], the authors coupled
the ε-globin promoter to the KGFP (jellyfish-derived) fluorescent protein. With this new tool,
they were able to isolate circulating primitive erythrocytes at  different  stages of  murine
embryogenesis  and  also  to  define  the  cell  surface  markers  expressed  by  these  cells  be‐
tween day E9.5 and E12.5 such as TER119, CD71, CD24, CD55 or CD147 [30]. In a second
model,  the  fluorescent  reporter  used  was  a  H2B-EGFP  fusion  protein  [31].  This  model
allowed study of the complex process of maturation of primitive erythrocytes within the
foetal  liver  [31].  More  recently,  the  same  group  monitored  the  emergence  of  primitive
erythrocytes at the very early stages of development in vivo, starting from day E6.75 and
defined key pathways governing the emergence of this cellular lineage [32]. Other studies
have more  directly  examined the  cell  signalling  pathways  supporting the  emergence  of
primitive erythrocytes using both in vivo mouse models, as well as in vitro using the ES cell
differentiation approach. In 2008, the importance of Wnt signalling for the emergence of
primitive erythrocytes from FLK1 positive mesoderm was demonstrated [33]. Later, Cheng
and co-workers expanded those findings and showed that not only the activation of Wnt
pathway is crucial, but also the inhibition of Notch signalling is important for the emer‐
gence of primitive erythrocytes from FLK1 positive cells [34].
2.5. In vivo studies of the first haematopoietic stem cells (HSCs) – the foundation of the
adult blood system
There are several definitive haematopoietic lineages generated during embryogenesis such as
myeloid, lymphoid, definitive erythroid and haematopoietic stem cells. HSCs are the founda‐
tion of the blood system in the adult organism as these cells can differentiate towards all
definitive haematopoietic cells.
HSCs arise first in the AGM, they possess the ability to self renew and, upon transplantation,
they provide multilineage haematopoietic reconstitution [35]. Various studies, spanning
several decades, aimed to characterise HSCs. In 1993, Huang and Auerbach reported that at
E9.0 the murine yolk sac contains HSCs [36]. These cells, however, were unable to provide
long-term multilineage haematopoietic reconstitution. A few months later, Muller and co-
workers demonstrated that at day E10.5 the AGM region of the mouse contains fully functional
HSCs – able to provide long-term haematopoietic reconstitution [7]. These findings were then
expanded and HSCs were shown to emerge and expand within the anterior part of the AGM
region [8]. It was also observed that definitive HSCs are present in the placenta, both in mouse
[9, 37, 38] and human [10]. Interestingly, more recently mouse embryonic head tissues were
shown to contain HSCs [39].
Several research groups investigated the cellular origin of haematopoietic stem cells in vivo.
Zovein and co-workers (2008) demonstrated that HSCs emerge from the endothelium by
performing lineage tracing experiment to specifically label either the endothelium or mesen‐
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thelium cell population. Specific markers for each cell population are depicted. This figure has been adapted from
[27].
2.4. Primitive erythrocytes – First blood cells in the embryo
Primitive erythrocytes, the first blood cells that emerge during embryogenesis in mammals,
are large and nucleated. Their main function is to transport large quantities of oxygen to
support the rapid growth of the embryo. It has been shown that these cells firstly appear in
vivo in the yolk sac’s blood islands around day E7.5 [28]. Although it was initially thought that
these cells were nucleated, more recent studies have indicated that their nuclei are lost during
the final days of mammalian gestation [29]. Studying primitive erythropoiesis remains
challenging for several reasons; not only is the murine embryo around day 7 of gestation
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extremely small and difficult to access, but also there are no specific cell surface markers to
specifically label this cell population. Therefore, transgenic mouse models were developed to
directly address this later limitation.
Two mouse models used the expression of the same haemoglobin – ε-globin, as a reporter
to track primitive erythropoiesis during ontogeny. In the first model [30], the authors coupled
the ε-globin promoter to the KGFP (jellyfish-derived) fluorescent protein. With this new tool,
they were able to isolate circulating primitive erythrocytes at  different  stages of  murine
embryogenesis  and  also  to  define  the  cell  surface  markers  expressed  by  these  cells  be‐
tween day E9.5 and E12.5 such as TER119, CD71, CD24, CD55 or CD147 [30]. In a second
model,  the  fluorescent  reporter  used  was  a  H2B-EGFP  fusion  protein  [31].  This  model
allowed study of the complex process of maturation of primitive erythrocytes within the
foetal  liver  [31].  More  recently,  the  same  group  monitored  the  emergence  of  primitive
erythrocytes at the very early stages of development in vivo, starting from day E6.75 and
defined key pathways governing the emergence of this cellular lineage [32]. Other studies
have more  directly  examined the  cell  signalling  pathways  supporting the  emergence  of
primitive erythrocytes using both in vivo mouse models, as well as in vitro using the ES cell
differentiation approach. In 2008, the importance of Wnt signalling for the emergence of
primitive erythrocytes from FLK1 positive mesoderm was demonstrated [33]. Later, Cheng
and co-workers expanded those findings and showed that not only the activation of Wnt
pathway is crucial, but also the inhibition of Notch signalling is important for the emer‐
gence of primitive erythrocytes from FLK1 positive cells [34].
2.5. In vivo studies of the first haematopoietic stem cells (HSCs) – the foundation of the
adult blood system
There are several definitive haematopoietic lineages generated during embryogenesis such as
myeloid, lymphoid, definitive erythroid and haematopoietic stem cells. HSCs are the founda‐
tion of the blood system in the adult organism as these cells can differentiate towards all
definitive haematopoietic cells.
HSCs arise first in the AGM, they possess the ability to self renew and, upon transplantation,
they provide multilineage haematopoietic reconstitution [35]. Various studies, spanning
several decades, aimed to characterise HSCs. In 1993, Huang and Auerbach reported that at
E9.0 the murine yolk sac contains HSCs [36]. These cells, however, were unable to provide
long-term multilineage haematopoietic reconstitution. A few months later, Muller and co-
workers demonstrated that at day E10.5 the AGM region of the mouse contains fully functional
HSCs – able to provide long-term haematopoietic reconstitution [7]. These findings were then
expanded and HSCs were shown to emerge and expand within the anterior part of the AGM
region [8]. It was also observed that definitive HSCs are present in the placenta, both in mouse
[9, 37, 38] and human [10]. Interestingly, more recently mouse embryonic head tissues were
shown to contain HSCs [39].
Several research groups investigated the cellular origin of haematopoietic stem cells in vivo.
Zovein and co-workers (2008) demonstrated that HSCs emerge from the endothelium by
performing lineage tracing experiment to specifically label either the endothelium or mesen‐
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chyme [21]. Furthermore, the emergence of putative haematopoietic cells from haemogenic
endothelium has been visualised in the mouse embryonic aorta [23]. Similar results were
obtained in zebrafish [24-26]. However whether these blood cells display any long-term
repopulation activity remains to be directly assessed.
2.6. Molecular regulation of early embryonic haematopoiesis
Specific transcription factors regulate the developmental potential of different cells and
progenitors during blood formation. In this section, we will discuss the role and function of a
restricted set of these players.
One of the first genes implicated in mesoderm leading to blood development is the Brachyu‐
ry gene. This transcription factor belongs to the T-box gene family [40] and is expressed by all
nascent mesodermal cells [41]. Its expression is detected in murine embryo as early as E6.5 [42]
and its deletion results in serious developmental defects and lethality by midgestation [42,
43]. In 2003, Fehling and co-workers generated a transgenic ES cell line in which GFP was
targeted to the Brachyury locus. Further differentiation of this ES cell line allowed them to
isolate mesodermal cells. The authors demonstrated that when combined with FLK1 (Fetal
Liver Kinase 1) it was possible to separate three distinct populations corresponding to pre-
mesoderm (negative for both FLK1 and Brachyury), mesodermal (positive for Brachyury only)
and finally haemangioblastic, positive for both FLK1 and Brachyury, populations [13].
Flk1 encodes the receptor 2 for vascular endothelial growth factor (VEGF-R2) [44]. This gene
is expressed by intra-and extra-embryonic mesoderm and later by endothelial cells in the
vasculature [45, 46]. In 1995, Shalaby and colleagues demonstrated that in Flk1 deficient
embryos blood vessels and blood islands are not formed and that hardly any haematopoietic
progenitors are present in these embryos [47]. As a result, Flk1 deletion is embryonic lethal
and embryos die between day E8.5 and E9.5 [47]. A few years later, they also determined, by
evaluating the contribution of Flk1 deficient ES cells to chimaeric mice, that the expression of
Flk1 is crucial for the migration of mesodermal progenitors from the intra-embryonic locations
to the yolk sac [44]. This finding was later confirmed using in vitro differentiation of ES cells.
In 1998 Choi and co-workers demonstrated that during ES cell differentiation, Flk1 expression
marks the blast colony-forming cell (BL-CFC) [11]. Later, it was shown that although Flk1
deficient ES cells are able to give rise to endothelial and haematopoietic lineages upon in
vitro differentiation, they generate reduced number of blast colonies [48]. To date FLK1
remains, with Brachyury, the best marker of haemangioblast.
Etv2, a transcription factor of the Ets family, is another important regulator of haematopoietic
specification. Murine embryos deficient for the expression of Etv2 were shown to die at around
E10.5 and to lack blood cells and vessels [49]. More recently, it was shown that Etv2 is not
required for the specification of primitive mesoderm, but is indispensable in the commitment
of FLK1-positive mesoderm towards haematopoietic and endothelial programmes [50]. Using
a transgenic Etv2 ES cell line and mouse line it was shown that the expression of Etv2 marks
the endothelium and in particular haemogenic endothelial cell population [51]. In the absence
of this transcription factor, both in vivo and in vitro, no haemogenic endothelium was observed
[51]. Furthermore, it was demonstrated using a Cre-mediated deletion of Etv2, that this
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transcription factor is acting at the Flk1 stage and that re-introduction of the Scl transcription
factor in Etv2-deficient ES cells can fully rescue the haematopoietic potential of these cells [52].
The transcription factor Scl (Stem Cell Leukaemia Factor) was originally identified due to its
involvement in chromosomal translocation in T-cell leukaemias [53] and was later demon‐
strated by both in vitro and in vivo studies to play a significant role during embryonic blood
development. Murine embryos lacking this transcription factor do not develop neither
primitive nor definitive haematopoietic cells and die by E9.5 [54, 55]. In addition, Scl-/-ES cells
do not generate blast colonies (Robertson et al., 2000) or any haematopoietic cells [56]. Blast
colony forming cells (BL-CFCs) were shown to express Scl during in vitro ES cell differentiation
[12]. More recently it was demonstrated that Scl is critical for the generation of the haemogenic
endothelium [20].
SOX7, with SOX17 and SOX18, form the F-subgroup of SRY-related (HMG-box) family of
transcription factors [57]. During embryonic development SOX7 transcripts are detected in
various tissues such as brain, heart, lung, kidney and spleen [58]. SOX7 and SOX18 knock‐
downs performed in zebrafish and Xenopus embryos revealed critical roles of these transcrip‐
tion factors in cardiogenesis and vasculogenesis [59-61]. Recently, Wat and colleagues
developed a mouse model lacking the expression of Sox7 that is embryonic lethal at E10.5 due
to cardiovascular abnormalities [62]. SOX7 was recently shown to be also implicated in early
stages of blood development. SOX7 expression is upregulated at the haemangioblast stage and
transiently expressed in the first CD41 – positive blood progenitors emerging from the FLK1-
positive haemangioblasts [63]. Its enforced expression in haematopoietic progenitors, marked
by the expression of CD41, results in the arrest of haematopoietic differentiation of these cells,
a property shared by Sox18 but not Sox17 [64]. Recently, it was also reported that SOX7 is
expressed at the haemogenic endothelium stage, where it regulates the expression of the
endothelial marker VE-Cadherin [65].
The transcription factor RUNX1, encoded by the Runx1/AML1 gene is considered a master
regulator of definitive haematopoiesis. Indeed Runx1 deficient embryos completely lack
definitive haematopoietic cells [66]. The deletion of Runx1 gene is embryonic lethal by E11.5
and E12.5 of gestation, and these embryos present multiple haemorrhages [67]. Runx1 was also
shown to be critical in vitro. Runx1-/-ES cells generate only a few blast colonies and these are
restricted to primitive haematopoietic programme [68]. Furthermore the kinetic of the
development of the haematopoietic system has been shown to be dependent of a gene dosage
effect of Runx1 [69]. Finally, Runx1 is essential for the formation of haematopoietic progenitors
from the haemogenic endothelium [20, 70, 71]. This critical role of RUNX1 in the endothelial
to haematopoietic transition has spurred efforts to identify and characterize its direct tran‐
scriptional targets [72-74].
Although, numerous molecular regulators of haematopoietic specification have been identi‐
fied, it is likely that many others remain to be discovered. In addition, the events they regulate
and how they interact to orchestrate blood development remain largely unknown. The specific
requirement for several of these regulators is depicted in Figure 2.
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Flk1 is crucial for the migration of mesodermal progenitors from the intra-embryonic locations
to the yolk sac [44]. This finding was later confirmed using in vitro differentiation of ES cells.
In 1998 Choi and co-workers demonstrated that during ES cell differentiation, Flk1 expression
marks the blast colony-forming cell (BL-CFC) [11]. Later, it was shown that although Flk1
deficient ES cells are able to give rise to endothelial and haematopoietic lineages upon in
vitro differentiation, they generate reduced number of blast colonies [48]. To date FLK1
remains, with Brachyury, the best marker of haemangioblast.
Etv2, a transcription factor of the Ets family, is another important regulator of haematopoietic
specification. Murine embryos deficient for the expression of Etv2 were shown to die at around
E10.5 and to lack blood cells and vessels [49]. More recently, it was shown that Etv2 is not
required for the specification of primitive mesoderm, but is indispensable in the commitment
of FLK1-positive mesoderm towards haematopoietic and endothelial programmes [50]. Using
a transgenic Etv2 ES cell line and mouse line it was shown that the expression of Etv2 marks
the endothelium and in particular haemogenic endothelial cell population [51]. In the absence
of this transcription factor, both in vivo and in vitro, no haemogenic endothelium was observed
[51]. Furthermore, it was demonstrated using a Cre-mediated deletion of Etv2, that this
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transcription factors [57]. During embryonic development SOX7 transcripts are detected in
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tion factors in cardiogenesis and vasculogenesis [59-61]. Recently, Wat and colleagues
developed a mouse model lacking the expression of Sox7 that is embryonic lethal at E10.5 due
to cardiovascular abnormalities [62]. SOX7 was recently shown to be also implicated in early
stages of blood development. SOX7 expression is upregulated at the haemangioblast stage and
transiently expressed in the first CD41 – positive blood progenitors emerging from the FLK1-
positive haemangioblasts [63]. Its enforced expression in haematopoietic progenitors, marked
by the expression of CD41, results in the arrest of haematopoietic differentiation of these cells,
a property shared by Sox18 but not Sox17 [64]. Recently, it was also reported that SOX7 is
expressed at the haemogenic endothelium stage, where it regulates the expression of the
endothelial marker VE-Cadherin [65].
The transcription factor RUNX1, encoded by the Runx1/AML1 gene is considered a master
regulator of definitive haematopoiesis. Indeed Runx1 deficient embryos completely lack
definitive haematopoietic cells [66]. The deletion of Runx1 gene is embryonic lethal by E11.5
and E12.5 of gestation, and these embryos present multiple haemorrhages [67]. Runx1 was also
shown to be critical in vitro. Runx1-/-ES cells generate only a few blast colonies and these are
restricted to primitive haematopoietic programme [68]. Furthermore the kinetic of the
development of the haematopoietic system has been shown to be dependent of a gene dosage
effect of Runx1 [69]. Finally, Runx1 is essential for the formation of haematopoietic progenitors
from the haemogenic endothelium [20, 70, 71]. This critical role of RUNX1 in the endothelial
to haematopoietic transition has spurred efforts to identify and characterize its direct tran‐
scriptional targets [72-74].
Although, numerous molecular regulators of haematopoietic specification have been identi‐
fied, it is likely that many others remain to be discovered. In addition, the events they regulate
and how they interact to orchestrate blood development remain largely unknown. The specific
requirement for several of these regulators is depicted in Figure 2.
Embryonic Stem Cell Differentiation – A Model System to Study Embryonic Haematopoiesis
http://dx.doi.org/10.5772/57607
71
Figure 2. Molecular regulation of early embryonic haematopoiesis. The stages of blood development where the
function of the different genes is critical are indicated.
3. Methods and procols to study haematopoitic development during es cell
differentiation
ES cell differentiation provides a relatively easy and accessible system to study early embry‐
onic haematopoiesis. Using well-defined protocols, it is possible to effectively study the events
happening in vivo using this in vitro approach. This experimental system was shown to
recapitulate the early in vivo events of development of the haematopoietic system.
3.1. Mouse embryonic fibroblasts (MEFs)
There are several methods to keep ES cells undifferentiated. One of them consists of growing
ES cells on mouse embryonic fibroblasts (MEFs). Before working with ES cells, it is recom‐
mended to prepare a good stock of MEFs to be used as feeder cell layer. For that, wild type
ICR or DR4 (resistant to four drugs) [75] MEFs are harvested from E14.5 embryos and cultured
in Iscove’s modified Dulbecco medium (IMDM, Lonza) supplemented with 50 µg/ml penicil‐
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lin-streptomicin (Gibco), 2mM L-Glutamine, 10% of FCS (PAA Laboratories) and 1,5x10-4
monothioglycerol (MTG, Sigma) under low oxygen conditions. When amplified, MEFs are
harvested (TrypLE, Invitrogen) and irradiated at 30Gy to stop the cells proliferation. The cells
should be frozen at around 1 million cells per ml of IMDM supplemented with 50% FCS and
10% of dimethyl sulfoxide (DMSO). Cells should be stored at-80 0C. Thawed MEFs should be
replated in one six-well plate previously coated with gelatine and let to adhere to the plastic
wells overnight. Upon microscopic examination, MEFs should cover the entire surface of the
cell-culture dish and be ready to be seeded with ES cells.
3.2. ES cell culture
ES cells are cultured on irradiated MEFs in a media constituted of Dulbeco’s modified Eagle
Medium (DMEM, Gibco) supplemented with 50 µg/ml penicillin-streptomycin, 2mM L-
Glutamine, 15% FCS (PAA Laboratories), 2% Leukaemia Inhibitory Factor (LIF) (conditioned
medium from LIF-generating cell line, see [76]) or 50 units of recombinant ESGRO LIF/ml
(Millipore) and 1,5x104 MTG (Sigma). Leukaemia inhibitory factor (LIF) – is a cytokine
inhibiting differentiation. ES cells, when cultured on MEFs feeder cell layer in the presence of
LIF remain undifferentiated. Upon microscopic observation they form tightly associated
clusters of cells that are bright and shiny in appearance (Fig. 3A).
3.3. Generation of embryoid bodies
Embryoid bodies (EBs) are three-dimensional structures spontaneously generated by ES cells
during differentiation. They contain precursors for the three primary germ layers ectoderm,
endoderm and mesoderm. Two passages on gelatine are performed to remove the MEFs that
would hamper ES cells differentiation. The first passage is performed in DMEM-ES media
(described above), whereas for the second passage DMEM is replaced with IMDM. The ES
cells are then harvested by trypsinisation and seeded into liquid cultures in non-tissue culture
Petri dishes (Sterilin) in differentiation medium containing: IMDM supplemented with 15%
FCS serum selected for differentiation (PAA Laboratories), 2mM L-Glutamine, 180 µg/ml
transferring (Roche), 25 µg/ml Ascorbic Acid (AA, Sigma) and 4,6x10-4 MTG. The density of
cell seeding should be adjusted in function of the day at which the cultures will be harvested,
varying from 1,5x104 cells/ml (for day 4-6) up to 3,0 x 104 cells/ml (for days 2.5-3.5). 10-20ml of
“Differentiation medium” should be used per one Petri dish.
By performing two passages on gelatine and removing feeder cell layer and LIF, ES cells
become primed for differentiation and formation of three-dimensional embryoid bodies in
liquid culture (Figure 3B). Early EBs contain precursors for the three primary germ layers. By
day 7, hemoglobinisation can be observed as red areas present within the EBs (Figure 3C). This
system is versatile and allows to access and study in details several subsequent stages of blood
development such as the emergence of haemangioblast, production of blast colonies and the
development of primitive and definitive blood precursors (Figure 4).
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Figure 2. Molecular regulation of early embryonic haematopoiesis. The stages of blood development where the
function of the different genes is critical are indicated.
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differentiation
ES cell differentiation provides a relatively easy and accessible system to study early embry‐
onic haematopoiesis. Using well-defined protocols, it is possible to effectively study the events
happening in vivo using this in vitro approach. This experimental system was shown to
recapitulate the early in vivo events of development of the haematopoietic system.
3.1. Mouse embryonic fibroblasts (MEFs)
There are several methods to keep ES cells undifferentiated. One of them consists of growing
ES cells on mouse embryonic fibroblasts (MEFs). Before working with ES cells, it is recom‐
mended to prepare a good stock of MEFs to be used as feeder cell layer. For that, wild type
ICR or DR4 (resistant to four drugs) [75] MEFs are harvested from E14.5 embryos and cultured
in Iscove’s modified Dulbecco medium (IMDM, Lonza) supplemented with 50 µg/ml penicil‐
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models72
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should be frozen at around 1 million cells per ml of IMDM supplemented with 50% FCS and
10% of dimethyl sulfoxide (DMSO). Cells should be stored at-80 0C. Thawed MEFs should be
replated in one six-well plate previously coated with gelatine and let to adhere to the plastic
wells overnight. Upon microscopic examination, MEFs should cover the entire surface of the
cell-culture dish and be ready to be seeded with ES cells.
3.2. ES cell culture
ES cells are cultured on irradiated MEFs in a media constituted of Dulbeco’s modified Eagle
Medium (DMEM, Gibco) supplemented with 50 µg/ml penicillin-streptomycin, 2mM L-
Glutamine, 15% FCS (PAA Laboratories), 2% Leukaemia Inhibitory Factor (LIF) (conditioned
medium from LIF-generating cell line, see [76]) or 50 units of recombinant ESGRO LIF/ml
(Millipore) and 1,5x104 MTG (Sigma). Leukaemia inhibitory factor (LIF) – is a cytokine
inhibiting differentiation. ES cells, when cultured on MEFs feeder cell layer in the presence of
LIF remain undifferentiated. Upon microscopic observation they form tightly associated
clusters of cells that are bright and shiny in appearance (Fig. 3A).
3.3. Generation of embryoid bodies
Embryoid bodies (EBs) are three-dimensional structures spontaneously generated by ES cells
during differentiation. They contain precursors for the three primary germ layers ectoderm,
endoderm and mesoderm. Two passages on gelatine are performed to remove the MEFs that
would hamper ES cells differentiation. The first passage is performed in DMEM-ES media
(described above), whereas for the second passage DMEM is replaced with IMDM. The ES
cells are then harvested by trypsinisation and seeded into liquid cultures in non-tissue culture
Petri dishes (Sterilin) in differentiation medium containing: IMDM supplemented with 15%
FCS serum selected for differentiation (PAA Laboratories), 2mM L-Glutamine, 180 µg/ml
transferring (Roche), 25 µg/ml Ascorbic Acid (AA, Sigma) and 4,6x10-4 MTG. The density of
cell seeding should be adjusted in function of the day at which the cultures will be harvested,
varying from 1,5x104 cells/ml (for day 4-6) up to 3,0 x 104 cells/ml (for days 2.5-3.5). 10-20ml of
“Differentiation medium” should be used per one Petri dish.
By performing two passages on gelatine and removing feeder cell layer and LIF, ES cells
become primed for differentiation and formation of three-dimensional embryoid bodies in
liquid culture (Figure 3B). Early EBs contain precursors for the three primary germ layers. By
day 7, hemoglobinisation can be observed as red areas present within the EBs (Figure 3C). This
system is versatile and allows to access and study in details several subsequent stages of blood
development such as the emergence of haemangioblast, production of blast colonies and the
development of primitive and definitive blood precursors (Figure 4).
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Figure 3. Morphology of ES cells and embryoid bodies (EBs). A) Typical appearance of ES cell in culture. Cells form
bright, shiny adherent colonies and are cultured on a layer of MEFs feeder cell layer. B) Typical appearance of EBs in
culture. These three-dimensional structures are formed during ES cell differentiation and contain precursors for three
primary germ cell layers. C) Embryoid bodies at day 7 of differentiation containing haemoglobin (indicated with aster‐
isks). Scale bar 300µm.
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Figure 4. The ES/EB differentiation system. Upon differentiation of ES cells, three-dimensional structures, called em‐
bryoid bodies (EBs) are formed. Sorting EBs at day 2.5-3.5 for the expression of FLK1 enrich for BL-CFC, the in vitro
equivalent of the haemangioblast. Upon culture, the BL-CFCs generate blast colonies that contain precursors for hae‐
matopoietic, endothelial and vascular smooth muscle cells. Day 4-6 EBs contain haematopoietic progenitors that can
give rise to various primitive and definitive haematopoietic colonies.
3.4. Blast colonies
There are two alternative approaches to study the development of blast colonies; liquid culture
on gelatine or semi-solid culture in methylcellulose. Liquid culture on gelatine facilitates
harvesting of the cells for flow cytometry analysis or time-lapse imaging techniques. Alterna‐
tively, the semi-solid culture is a clonogenic assay allowing the growth of of individual blast
colonies and their quantification. Individual blast colonies can then further be isolated and
their haematopoietic potential assessed. To perform blast colony culture, EBs are harvested
between day 2.5 and 3.5 and the cells are enriched for haemangioblast by sorting for the
expression of FLK1, the receptor 2 for VEGF. Isolated FLK1 positive cells are then replated on
gelatinised cell culture plates at the density of 8,5 x 104 cell/10cm2 in a medium containing
IMDM supplemented with 10% FCS, 2mM L-Glutamine mM, 180 µg/ml transferrin, 25 µg/ml
ascorbic acid, 4.6 x 10-4 M MTG, 15% endothelial cell line-D4T conditioned medium [11], 10
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matopoietic, endothelial and vascular smooth muscle cells. Day 4-6 EBs contain haematopoietic progenitors that can
give rise to various primitive and definitive haematopoietic colonies.
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harvesting of the cells for flow cytometry analysis or time-lapse imaging techniques. Alterna‐
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colonies and their quantification. Individual blast colonies can then further be isolated and
their haematopoietic potential assessed. To perform blast colony culture, EBs are harvested
between day 2.5 and 3.5 and the cells are enriched for haemangioblast by sorting for the
expression of FLK1, the receptor 2 for VEGF. Isolated FLK1 positive cells are then replated on
gelatinised cell culture plates at the density of 8,5 x 104 cell/10cm2 in a medium containing
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ng/ml interleukin 6 (IL-6) (Peprotech) and 5 ng/ml vascular endothelial growth factor (VEGF,
Peprotech). For semi-solid cultures, FLK1 positive cells are seeded in 35 mm x 10 mm (BD
Falcon) dishes at a density of 1.5 x 104 cells/ml in IMDM medium supplemented with 10% FCS,
2mM L-Glutamine mM, 180 µg/ml transferrin, 25 µg/ml ascorbic acid, 4.6 x 10-4 M MTG, 15%
endothelial cell line-D4T conditioned medium [11], 10 ng/ml interleukin 6 (IL-6) (Peprotech)
and 5 ng/ml vascular endothelial growth factor (VEGF, Peprotech). The medium is additionally
supplemented with 10 g/L methylcellulose (dissolved in IMDM, Alfa-Aesar). Blast colonies
are scored 3-4 days after replating. Plating 3.0 x 104 cells per 1 ml of semi-solid medium should
result in the formation of around 300-400 of blast colonies.
Sorting EBs between day 2.5 and 3.5 for the expression of FLK1 enrich for blast colony forming
cell (BL-CFCs) [11, 13]. During the formation of blast colonies, several distinct morphological
stages can be observed. First, there is the formation of tight clusters of adherent cells and later,
single round cells emerging from these tight clusters. These cells then proliferate (Figure 5A).
Alongside these morphological changes, there is first an upregulation of endothelial markers,
such as TIE2 and VE-Cadherin during the formation of the tight clusters. Later the expression
of these endothelial markers is gradually downregulated whereas the expression of haema‐
topoietic markers (such as CD41 and then CD45) is upregulated (Figure 5B). This correlates
with the emergence of round floating–haematopoietic-cells.
Figure 5. The development of the blast colony during four days of differentiation. A) Microscopic image showing
representative blast colonies. Scale bar 100µm. B) Schematic representation of the different cell surface markers ex‐
pressed on cells during blast colony differentiation.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models76
It was recently shown that the haemangioblast progenitor can also generate vascular smooth
muscle cells in addition to endothelial and haematopoietic cells [14, 77, 78]. Accordingly,
Yamashita and co-workers also established that FLK1 positive cells can differentiate towards
endothelial and mural cells [78]. Smooth muscle cells appear, under the microscope as large
flat adherent cells. These cells express smooth muscle specific genes such as smooth muscle
actin α, transgelin, calponin, and smooth muscle myosin heavy chain [79]. A typical immuno-
staining of α-smooth muscle actin is presented in figure 6A. We have recently analysed in more
detail the generation of smooth muscle cells and showed that these cells are largely generated
independently from the haemogenic endothelium [80].
Figure 6. The differentiation of ES cells towards smooth muscle cells. Representative image of smooth muscle
cells stained with SMAα-Cy3 antibody. These cells also carry a transgenic BAC containing H2B-VENUS cDNA under the
control of the α-smooth muscle actin transcriptional regulatory elements. Scale bar 100µm.
3.5. Culture of haemogenic endothelium
During blast colony development in vitro, tight clusters of adherent cells that represent
haemogenic endothelium are observed after around two days. This population of cells
corresponds to an intermediate stage in the formation of blood cells from the haemangioblast.
It was recently shown that these cells express TIE2 and VE-cadherin (markers of endothelial
cells), c-KIT (expressed by both haematopoietic and endothelial cells) and are negative for
CD41 (first haematopoietic marker) expression [20]. To isolate haemogenic endothelium, cells
in day 2 liquid blast cultures are harvested and FACS sorted for the expression of these markers
[20]. It is also possible to isolate a more advanced haemogenic endothelium cell population,
positive for the expression of CD41 [70]. The cells are next plated onto gelatin-coated plates at
a density of 1.2 x 105 cells/cm2 in IMDM medium supplemented with 10% FCS, 2 mM L-
Glutamine, 180 µg/ml transferrin, 25 µg/ml ascorbic acid, 4.6 x 10-4 M MTG, 10 ng/ml Oncos‐
tatin M (R&D Systems) and 1 ng/ml bFGF (Peprotech). Cells are grown in standard culture
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are scored 3-4 days after replating. Plating 3.0 x 104 cells per 1 ml of semi-solid medium should
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single round cells emerging from these tight clusters. These cells then proliferate (Figure 5A).
Alongside these morphological changes, there is first an upregulation of endothelial markers,
such as TIE2 and VE-Cadherin during the formation of the tight clusters. Later the expression
of these endothelial markers is gradually downregulated whereas the expression of haema‐
topoietic markers (such as CD41 and then CD45) is upregulated (Figure 5B). This correlates
with the emergence of round floating–haematopoietic-cells.
Figure 5. The development of the blast colony during four days of differentiation. A) Microscopic image showing
representative blast colonies. Scale bar 100µm. B) Schematic representation of the different cell surface markers ex‐
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positive for the expression of CD41 [70]. The cells are next plated onto gelatin-coated plates at
a density of 1.2 x 105 cells/cm2 in IMDM medium supplemented with 10% FCS, 2 mM L-
Glutamine, 180 µg/ml transferrin, 25 µg/ml ascorbic acid, 4.6 x 10-4 M MTG, 10 ng/ml Oncos‐
tatin M (R&D Systems) and 1 ng/ml bFGF (Peprotech). Cells are grown in standard culture
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conditions. Upon culture, at least 1-2% of these cells generate primitive and definitive haema‐
topoietic cells [20]. During this process, the haemogenic endothelial cell population (TIE2+,c-
KIT+,CD41-) cells gradually acquire the expression of CD41. The cells then progress further
and lose their expression of endothelial markers.
3.6. Haematopoietic colonies assays
To evaluate the presence of haematopoietic colonies, EBs should be harvested at day 4,5 or 6
and trypsinised. Cells from the EBs can be then directly used or alternatively sorted for the
expression of a marker of haematopoietic progenitors, such as for example CD41. Approxi‐
mately 3.0 x 104 unsorted cells should be plated in 35 mm x 10 mm (BD Falcon) dishes in 1 ml
of semisolid medium containing IMDM, 15% plasma derived serum (PDS) (Antech), 10%
protein free hybridoma medium (PFHM, Gibco), 2mM L-Glutamine, 180 µg/ml transferrin, 25
µg/ml ascorbic acid, 4.6 x 10-4 M MTG and cytokines such as: 1% c-KIT ligand supernatant,
1% interleukin 3 supernatant (IL-3) (see [76]), 1µg/ml GM-CSF, 1% thrombopoietin condi‐
tioned media, 10 ng/ml IL-6 (Peprotech), 10 ng/ml macrophage colony stimulating factor (M-
CSF), 5 ng/ml IL-11 (R&D Systems) and 4 U/ml of Erythropoietin (Ortho-Biotech) and 10 g/L
methylcellulose (dissolved in IMDM, Alfa-Aesar). Haematopoietic colonies are assessed and
scored based on their morphology. Primitive erythroid colonies are scored at day 5, whereas
definitive haematopoietic colonies are usually enumerated 8 days after replating. Morphologic
landmarks are used to distinguish the different types of haematopoietic colonies. Haemato‐
poietic progenitors can also be cultured in liquid conditions to allow easier access of the cells
for subsequent flow cytometry analysis or cytospin assays. For that cells should be seeded at
a density of 2.0 x 106 /ml in ultra low-adherence tissue culture plates (Costar) in the haemato‐
poietic medium described above with methylcellulose being replaced with IDMD medium.
The onset of emergence of primitive erythroid cells is observed within EBs by day 4 of
differentiation [81]. Definitive erythroid and macrophage precursors appear shortly after and
are followed by mast cells and multilineage precursors [81]. Primitive colonies appear around
day 4 of culture. These colonies are round, compact and bright red in colour. By day 6-7 of
culture, morphologically distinguishable definitive haematopoietic colonies are detected
(Figure 7).
4. Conclusions and future directions
In this chapter, we have reviewed recent progress in our understanding of the development
of the haematopoietic system. We have emphasized the critical role that the use of ES cells, in
particular murine ES cells, has played in these recent advances. ES cells have been instrumental
to identify and characterise the elusive haemangioblast. More recently, this model system
allowed the merging of the two conflicting theories of the origin of blood cells (haemangioblast
and haemogenic endothelium) in a single linear model of development. In addition the precise
roles and requirements of many critical regulators of this process have been to a large extent
elucidated using this approach.
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Although only very succinctly discussed in this chapter, this system is also very amenable to
examination of the cell signalling pathways that support the development of normal haema‐
topoiesis [33, 34, 82-84]. Interestingly these pathways are also implicated in leukaemogenesis
[85, 86]. Finally with the advent of novel human ES cells or human iPS cells [87], that recapit‐
ulate better the ground state and are easier to work with, and development of new methods
facilitating genome editing [88-92], this experimental system is very likely to be instrumental
for delivering new advances in our understanding of human haematopoietic development,
that is otherwise very difficult to study in vivo.
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Figure 7. Examples of haematopoietic colonies obtained during ES cell differentiation A) Primitive erythroid colony –
red in colour, compact and relatively small. B) Definitive myeloid colony – bigger in size, white and looser cells. C)
Mixed haematopoietic colony. Scale bar 50µm.
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1. Introduction
It is well believed that human embryonic stem cells (hESCs [1]) and induced pluripotent stem
cells (hiPSCs [2]) are of great potential use for tissue substitutes (for example, blood cells) and
to cure various congenital disorders. In mammals, hematopoiesis has already been precisely
described in murine system but not yet in human. Early development of hematopoietic system
can be well defined by a series of waves from primitive hematopoiesis (early embryogenesis)
to definitive ones (late fetal stages). In vitro induction of undifferentiated hESC to functionally
mature blood cells may mimic the early hematopoietic development during human embryonic
and fetal stages. It also provides an ideal model to uncover molecular and cellular mechanisms
controlling early development of human hematopoiesis. On the other hand, functionally
matured blood cells derived from hESC/hiPSCs are expected to be widely used for clinical
cellular therapies. Although almost all kinds of the mature blood cells can be generated from
hESCs, there still lacks solid evidence for the generation of reconstituting hematopoietic stem
cells (HSCs) from hESC or hiPSC. So far until now, in vitro hESC-derived blood cells possess
phenotypical maturity and partial functions while still more or less share embryonic/fetal
characteristics, differing greatly from their adult counterparts. This indicated that in vitro
culture systems are not perfect enough to exert full mature activities. Lack of knowledge about
the molecular and cellular regulations in human early hematopoiesis has handicapped the
development of research on hESC/hiPSC-derived hematopoiesis.
Having been focusing on basic and clinical research on hESC/hiPSC-derived functionally
mature blood cells for long, our group has established an efficient method to induce large-scale
production of multipotential hematopoietic progenitor cells by coculturing hESC/hiPSCs with
murine hematopoietic niche-derived stromal cells [3-6]. By this method, large quantity of
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
[92] Wei, C., et al., TALEN or Cas9-rapid, efficient and specific choices for genome modi‐
fications. J Genet Genomics, 2013. 40(6): p. 281-9.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models86
Chapter 4
Human Embryonic Stem Cell-Derived Primitive and
Definitive Hematopoiesis
Bo Chen, Bin Mao, Shu Huang, Ya Zhou,
Kohichiro Tsuji and Feng Ma
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/58628
1. Introduction
It is well believed that human embryonic stem cells (hESCs [1]) and induced pluripotent stem
cells (hiPSCs [2]) are of great potential use for tissue substitutes (for example, blood cells) and
to cure various congenital disorders. In mammals, hematopoiesis has already been precisely
described in murine system but not yet in human. Early development of hematopoietic system
can be well defined by a series of waves from primitive hematopoiesis (early embryogenesis)
to definitive ones (late fetal stages). In vitro induction of undifferentiated hESC to functionally
mature blood cells may mimic the early hematopoietic development during human embryonic
and fetal stages. It also provides an ideal model to uncover molecular and cellular mechanisms
controlling early development of human hematopoiesis. On the other hand, functionally
matured blood cells derived from hESC/hiPSCs are expected to be widely used for clinical
cellular therapies. Although almost all kinds of the mature blood cells can be generated from
hESCs, there still lacks solid evidence for the generation of reconstituting hematopoietic stem
cells (HSCs) from hESC or hiPSC. So far until now, in vitro hESC-derived blood cells possess
phenotypical maturity and partial functions while still more or less share embryonic/fetal
characteristics, differing greatly from their adult counterparts. This indicated that in vitro
culture systems are not perfect enough to exert full mature activities. Lack of knowledge about
the molecular and cellular regulations in human early hematopoiesis has handicapped the
development of research on hESC/hiPSC-derived hematopoiesis.
Having been focusing on basic and clinical research on hESC/hiPSC-derived functionally
mature blood cells for long, our group has established an efficient method to induce large-scale
production of multipotential hematopoietic progenitor cells by coculturing hESC/hiPSCs with
murine hematopoietic niche-derived stromal cells [3-6]. By this method, large quantity of
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
matured erythrocytes and other functional blood cells could be harvested. In this chapter we
will discuss the latest progress in this research field along with our recent discoveries. We will
emphasize on the origin, evolution and the development of both primitive and definitive
hematopoietic waves, especially those derived from hESCs in vitro systems. The critical
problems need to be solved and the research prospects of this field will also be addressed at
the end of the chapter.
2. The primitive and definitive waves of hematopoiesis in mammals
2.1. Anatomical sites of hematopoiesis at different developmental stages
Hematopoiesis takes place in some discrete anatomical niches that change temporally and
spatially in mammals. Its maturation along with developing ontogeny is a successive event
initiated from yolk sac (YS) and then to intra-embryonic sites. The classical opinion believes
that para-aortic splanchnopleura (P-Sp)/aorta-gonad-mesonephros (AGM) ought to be the sole
location for the emergence of intra-embryonic hematopoiesis, where the earliest HSCs exist.
During midgestation, these HSCs move to fetal liver (FL), a predominant hematopoietic place
until birth [7, 8]. Hematopoietic precursors seed the bone marrow (BM) in late gestation, where
maintaining the principal site of HSC activity lifelong. However, a recent discovery provided
solid proof that before HSCs enter the circulation, the embryonic day (E) 10.5–11.5 mouse head
is an unappreciated site for HSC emergence within the developing embryo independent to the
AGM region [9].
Yolk Sac. The first wave of blood cell generation begins at embryonic day E7.0 at YS and is
termed primitive hematopoiesis, producing large erythroblasts that express embryonic
hemoglobins [10, 11]. The second wave, termed definitive hematopoiesis, produces smaller
erythroblasts that express adult hemoglobins and various other blood cells [12]. Long-term
repopulating HSCs (LTR-HSC) appear only in the second wave [13].
The murine YS is a bilayer organ composed of extra-embryonic mesoderm cells apposing to
visceral endoderm cells. Its mesoderm layer produces the first blood cells within blood islands
[14, 15]. Between E8.0 and E9.0, the outer layer’s cells of the blood island in YS differentiate
into endothelial cells and form a spindle shape while the vast majority of the inner cells
gradually lose their intercellular attachments along with their differentiation into primitive
erythroblasts [16].
The research of Yoder’s group support that the YS not only acts as the sole site of primitive
erythropoiesis but also possibly serves as the first source of definitive hematopoietic progen‐
itors during embryonic development [15,17]. The result of BFU-E assay indicated that follow‐
ing the early wave of primitive erythropoiesis, definitive erythroid progenitors appear at 1-7
somite pairs (E8.25) and solely exist within the YS. After that the definitive erythroid (according
to the CFU-E assay), mast cell and bipotential granulocyte/macrophage progenitors develop
in the YS [18]. Another proof comes from Ncx1-/- embryo, which could not initiate a heartbeat
on embryonic day E8.25 while development continued through E10. There is similar amount
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of primitive erythroid progenitors and definitive HPCs in YS of Ncx1-/- and WT mice through
E9.5, while the P-Sp region in Ncx1-/- mice lacks primitive erythroblasts and definitive
hematopoietic progenitor cells (HPCs) from E8.25 to E9.5 [17]. So it is reasonable to believe
that primitive erythroblasts and nearly all definitive HPCs seeded the fetal liver after E9.5 are
generated from the YS between E7.0-E9.5 and are re-distributed into the embryo proper via
the systemic circulation [17]. The definitive hematopoiesis may originate from primitive
hematopoiesis during embryonic development and migrating HSCs come from the murine
YS, which seed the liver and initiate hematopoiesis on 10.0 day postcoitus (dpc). But whether
YS cells isolated before day 11.0 dpc possess any long-term repopulating HSC activity remains
controversy. Yoder et al proved that donor day 9.0 dpc YS cells could establish long-term
hematopoietic system in conditioned newborns, but not in adult recipients [19]. When these
early YS cells were co-cultured for 4 days with AGM-S3, an AGM region-derived stromal cell
line, they obtained such capacity of reconstitution [20]. All the evidence so far agree that YS
itself couldn’t provide long-term repopulating HSC activity while the hematopoietic cells
originate from YS could own this activity through proper “education” by definitive hemato‐
poiesis niches or the stromal cell line derived from them [20, 21].
AGM. Following the onset of circulation at E8.5, hematopoietic progenitors rapidly move
within the embryo. Determining the anatomical origins of definitive hematopoiesis is a
complicated and controversial topic. It is now widely recognized that main source of definitive
hematopoiesis originates from the AGM region [8]. Using irradiated adult mice as the
recipients, Müller et al reported that LTR-HSC first appeared in the AGM region at 10 dpc and
expanded in 11 dpc AGM region [13]. Medvinsky et al then demonstrated that, at day 10 in
gestation, hematopoietic stem cells initiate autonomously and exclusively within the AGM
region under in vitro organ culture condition [8]. All these findings suggested that the AGM
region at 10 to 11 dpc provides a microenvironment suitable for generation of LTR-HSC. Xu
et al obtained a stromal cell line derived from the AGM region of 10.5 dpc mouse embryo
(AGM-S3) that could support the growth and proliferation of hematopoietic progenitor/stem
cells from adult mouse bone marrow and human cord blood without additional cytokines [21].
The same research group found that no definitive hematopoiesis-derived colony-forming cells
were generated from YS and P-Sp cells at 8.5 dpc before co-cultured with AGM-S3 cells.
However after 4-day co-culture of 8.5 dpc YS and P-Sp cells with AGM-S3, spleen colony-
forming cells and HSCs capable of reconstituting definitive hematopoiesis in adult mice
simultaneously appeared [20]. It is proposed that precursors that had the potential to generate
definitive HSCs appear in both extra-embryonic (YS) and intra-embryonic (P-Sp) region, the
latter providing microenvironment to support the definitive hematopoiesis from both
precursors.
Fetal liver and bone marrow. At 9 dpc, the liver rudiment begins to form an evagination of
gut into the septum transversum. The liver does not generate hematopoietic cells de novo but
is instead colonized at late E9 by hematopoietic cells generated in other tissues [22; 23]. The
first erythroblasts are visible in the liver at 9 dpc. From 10 dpc onwards, the erythroid lineage
begins to develop definitive characteristics. Myeloid CFU-Cs appears in the fetal liver at 9 dpc
and macrophages and B cells are present at 10-11 dpc [24]. Although most of these differenti‐
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matured erythrocytes and other functional blood cells could be harvested. In this chapter we
will discuss the latest progress in this research field along with our recent discoveries. We will
emphasize on the origin, evolution and the development of both primitive and definitive
hematopoietic waves, especially those derived from hESCs in vitro systems. The critical
problems need to be solved and the research prospects of this field will also be addressed at
the end of the chapter.
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The research of Yoder’s group support that the YS not only acts as the sole site of primitive
erythropoiesis but also possibly serves as the first source of definitive hematopoietic progen‐
itors during embryonic development [15,17]. The result of BFU-E assay indicated that follow‐
ing the early wave of primitive erythropoiesis, definitive erythroid progenitors appear at 1-7
somite pairs (E8.25) and solely exist within the YS. After that the definitive erythroid (according
to the CFU-E assay), mast cell and bipotential granulocyte/macrophage progenitors develop
in the YS [18]. Another proof comes from Ncx1-/- embryo, which could not initiate a heartbeat
on embryonic day E8.25 while development continued through E10. There is similar amount
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itself couldn’t provide long-term repopulating HSC activity while the hematopoietic cells
originate from YS could own this activity through proper “education” by definitive hemato‐
poiesis niches or the stromal cell line derived from them [20, 21].
AGM. Following the onset of circulation at E8.5, hematopoietic progenitors rapidly move
within the embryo. Determining the anatomical origins of definitive hematopoiesis is a
complicated and controversial topic. It is now widely recognized that main source of definitive
hematopoiesis originates from the AGM region [8]. Using irradiated adult mice as the
recipients, Müller et al reported that LTR-HSC first appeared in the AGM region at 10 dpc and
expanded in 11 dpc AGM region [13]. Medvinsky et al then demonstrated that, at day 10 in
gestation, hematopoietic stem cells initiate autonomously and exclusively within the AGM
region under in vitro organ culture condition [8]. All these findings suggested that the AGM
region at 10 to 11 dpc provides a microenvironment suitable for generation of LTR-HSC. Xu
et al obtained a stromal cell line derived from the AGM region of 10.5 dpc mouse embryo
(AGM-S3) that could support the growth and proliferation of hematopoietic progenitor/stem
cells from adult mouse bone marrow and human cord blood without additional cytokines [21].
The same research group found that no definitive hematopoiesis-derived colony-forming cells
were generated from YS and P-Sp cells at 8.5 dpc before co-cultured with AGM-S3 cells.
However after 4-day co-culture of 8.5 dpc YS and P-Sp cells with AGM-S3, spleen colony-
forming cells and HSCs capable of reconstituting definitive hematopoiesis in adult mice
simultaneously appeared [20]. It is proposed that precursors that had the potential to generate
definitive HSCs appear in both extra-embryonic (YS) and intra-embryonic (P-Sp) region, the
latter providing microenvironment to support the definitive hematopoiesis from both
precursors.
Fetal liver and bone marrow. At 9 dpc, the liver rudiment begins to form an evagination of
gut into the septum transversum. The liver does not generate hematopoietic cells de novo but
is instead colonized at late E9 by hematopoietic cells generated in other tissues [22; 23]. The
first erythroblasts are visible in the liver at 9 dpc. From 10 dpc onwards, the erythroid lineage
begins to develop definitive characteristics. Myeloid CFU-Cs appears in the fetal liver at 9 dpc
and macrophages and B cells are present at 10-11 dpc [24]. Although most of these differenti‐
Human Embryonic Stem Cell-Derived Primitive and Definitive Hematopoiesis
http://dx.doi.org/10.5772/58628
89
ated cell types are found early in liver development, the more immature cell types, such as the
CFU-S progenitor and the LTR-HSC [7, 25], can be detected only beginning at 11 dpc. Since
the liver rudiment is colonized by exogenous blood cells [26]HSCs must arise elsewhere.
Previous study on mouse embryo supported that HSCs able to engraft adult mice were present
in the liver beginning at E11–E12 [27-29]. These fetal liver–derived HSCs expressed CD34, c-
kit, AA4.1, and Sca-1 surface markers, and were thought to migrate to the fetal BM after E15
[30], the latter providing a continuous supply of mature blood cells for the lifespan (Figure 1).
Figure 1. Primitive and definitive hematopoiesis
2.2. Characterization of the progenies derived from primitive and definitive hematopoiesis
The embryonic and fetal erythrocytes only come from primitive hematopoiesis wave while
definitive HSCs and T lymphocytes only come from definitive hematopoiesis wave [31]. We
will summarize the cellular and molecular characteristics of these cells in primitive and/or
definitive hematopoiesis.
2.2.1. Erythrocytes
The erythroid cells within the blood islands of YS are known as primitive or embryonic
erythrocytes, specially named as EryP. Differing from the ones found in the FL and adult BM,
these YS primitive erythrocytes are typically large in size, nucleated and express embryonic
pattren of hemoglobins [32, 33]. The development of primitive erythroid lineage is so transient
that its progenitors reach top number in the developing YS at E8.25 and soon become unde‐
tectable at E9.0. They would never occur in the late stage of embryonic development [18, 33].
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Following the early wave of primitive erythropoiesis and before the generation of adult-
repopulating HSCs, a transient erythromyeloid wave of definitive hematopoietic progenitors
(erythroid/myeloid progenitors [EMPs]) emerges in the YS. This YS-derived definitive wave
begins E8.25 and colonizes the liver by E10.5. All maturation stage of erythroid precursors and
the first definitive erythrocytes could be observed in the liver and circulation at E11.5 [34].
Initially, the development and differentiation of both primitive and definitive erythroid
precursor cells depend on growth factor signaling [35],while the later committed erythroid
progenitor is different [18, 36].
After HSC expansion in the fetal liver between E12.5 and E16.5, the definitive erythroid
progenitors are exponentially increased, which produce massive number of definitive
erythroid precursors exclusively expressing adult globins [37, 38]. Thus, HSCs that colonize
the fetal liver are commonly described as the origin of “definitive” hematopoiesis in the
mammalian embryo.
2.2.2. Macrophage
Another mature hematopoietic cells present in the early YS are macrophages. Progenitor
cells of functional macrophages were first found in YS of the mouse between day 7 and 8
of gestation. Pro-monocytes and macrophages were firstly identified in the 10-day YS and
11-day  FL,  indicating  that  the  primitive  macrophage  progenitors  are  “proximal”  to  the
promonocyte on the pathway of sequential macrophage maturation [39]. The observation
that they mature rapidly, bypassing the monocyte stage of development, and express lower
level of certain genes than later stage macrophages suggests that they could represent a
unique population [40, 41].
However, the distinction of primitive macrophages is not as clear as the primitive erythroid
lineage, since it is unknown if the molecular events leading to their development differ
significantly from other types of macrophages. Because that is a close relationship between
microphages and the maturation of erythroid cells, the special developmental trait of micro‐
phages probably is the adaptation for the primitive erythrogenesis process [12, 18]
2.2.3. Mast cells
In fetal stages, a large number of MC precursors could be found in murine YS and fetal blood,
indicating a strong wave of MC development taking place in early embryo [42, 43]. But little
is known about human MC development during the embryonic and fetal stages. The human
and non-human primates MCs could be generated from ES cells when co-cultured with mouse
AGM or OP9 (a fetal bone cell line from M-CSF knockout mouse) cells [4, 44], providing
important information about human MC development in early embryonic stage.
In humans, two types of MCs have been identified based on their neutral protease composi‐
tions [45]. Connective tissue-type MCs (CT-MCs)mainly located in skin and sub-mucosal area
and express tryptase, chymase, MC carboxypeptidase, and cathepsin G in their secretory
granules. Mucosal-type MCs (M-MCs) that locates in alveolar wall and small intestinal mucosa
express only tryptase. The non-human primate ESC-derived MCs are similar to CT-MC in
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that its progenitors reach top number in the developing YS at E8.25 and soon become unde‐
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In fetal stages, a large number of MC precursors could be found in murine YS and fetal blood,
indicating a strong wave of MC development taking place in early embryo [42, 43]. But little
is known about human MC development during the embryonic and fetal stages. The human
and non-human primates MCs could be generated from ES cells when co-cultured with mouse
AGM or OP9 (a fetal bone cell line from M-CSF knockout mouse) cells [4, 44], providing
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phenotype and functionally identical to human skin counterparts, indicating that a different
pathway may occur in early development for this two type of MCs. [4].
2.2.4. Lymphocytes
It is ambiguous to obtain common opinion about the origin site and time of lymphocytes
during embryonic development. Some researchers persist that lymphoid precursors could
be detected in the YS (extraembryo) prior to the embryo,  which is  as early as Day 8 of
gestation [46,  47].  The opposite  opinion believe that  lymphoid precursors  appear  in  the
embryo proper before the YS [48]. Other researchers believe that they appear in both sites
at the same developmental stage [49, 50]. The clonal assays of Godin et al. suggested that
this  controversy  might  be  due  to  difference  in  the  experimental  condition among these
groups to favor lymphoid potential but not lymphoid commitment [51]. If the latter as a
standard, the early fetal liver was the first place to produce committed lymphoid precur‐
sors [52]. Different to myelopoiesis, lymphogenesis has no primitive wave and is specifical‐
ly derived from definitive hematopoiesis.
2.2.5. LTR-HSC
The definitive hematopoiesis is defined by LT-HSCs that could reconstitute the hematopoiet‐
ic system in irradiated adult mouse. The primitive hematopoiesis could not support such
a reconstitution in adult mouse but only in fetal ones [8]. The primitive hematopoiesis has
too simple and incomplete hematopoietic hierarchy compared with definitive hematopoie‐
sis  and could not  be  detected of  the  complete  activity  of  LT-HSC [24].  The mechanism
controlling  developmental  difference  between  two  waves  of  hematopoiesis  has  been
obviously observed, but whether “primitive” HSC exists is still a controversial topic [53].
Some researches support the opinion that LT-HSC also originates from YS. Only after the
“education” on AGM, these YS LT-HSC progenitors become the functional LT-HSCs, for
the hematopoietic  cell  isolated from E9.5  YS could reconstitute  hematopoietic  system in
irradiated adult mouse after 4 days co-cultured with mAGM-S3 cells [20]. Immediately after
primitive hematopoiesis at YS, the definitive hematopoietic progenitors could be detected
by generating CFU-GM and BFU-E, indicating that HSCs probably originate from YS and
finally mature at AGM region [18]. But other groups persist that LT-HSC has no relation
to YS and was produced de novo from AGM [54].
2.3. Molecular mechanisms controlling the transition from primitive to definitive
hematopoiesis
Recently, findings from different gene targeting experiments have demonstrated that the
primitive and definitive hematopoietic lineages develop from a common precursor by distinct
molecular programs, and that the respective cell populations are regulated by different growth
factors. Though the controversy still exists about their origins, the YS-derived cell population
that only have primitive hematopoiesis potential could obtain definitive hematopoiesis
potential by the “education” on mAGM cells in vitro [20]. The YS cell grafted to fetal liver or
fetal marrow could also obtain LT-HSC activity [19, 55]. This provides strong evidences to
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support that the primitive hematopoietic progenitor cells could transfer to definitive ones in
the microenvironment of fetus definitive hematopoiesis origin, such as mouse AGM, fetal liver
and fetal marrow. It is obvious that molecular signals released by definitive hematopoiesis
niche cells play a key role in such “education”.
Because the component of hemoglobin provides clear trace to describe the developmental
stages of red blood or its precursor that distinguish the primitive from definitive hemato‐
poiesis, the erythropoiesis serves as an ideal model to research both waves of hematopoie‐
sis.  It  also provides clue to dissect  their  molecular switch mechanism, which is  also the
main object in our discussion about the molecular regulation of both primitive and definitive
hematopoiesis.
In situ studies of the early embryo have demonstrated that genes known to play a role in
the onset of hematopoietic development (e. g., GATA-2,scl/tal-1, rbtn2) are expressed prior
to the appearance of the blood islands [56]. This suggests that the molecular program that
leads to hematopoietic commitment begins shortly after gastrulation at approximate Day
7.0  of  gestation.  Under  the  control  of  tal-1,  rbtn2,  GATA-2,  and  GATA-1  that  was  ex‐
pressed  orderly,  primitive  mammalian  erythropoiesis  takes  place  in  a  subpopulation  of
extra-embryonic mesoderm cells during gastrulation. Though these transcriptional factors
were also expressed in other region of embryo in the same stage (tal-1 and rbtn2 also in
posterior  embryonic  mesoderm  and  GATA-1  and  GATA-2  expression  also  in  extra-
embryonic  tissues  of  ectodermal  origin),  their  expression  pattern  in  extra-embryonic
mesoderm  cells  still  play  a  key  role  in  understanding  the  molecular  mechanism  of
hematopoietic commitments [56].
By gene-targeting studies on transcription factors essential for development of all hemato‐
poietic lineages, the key control genes for primitive and/or definitive hematopoiesis (such as
Gata1, Gata2, AML1, C-myb, EKLF, rbtn2) were well analyzed.
GATA gene family. GATA1 expression is highly restricted in erythroid cells, megakaryocytic
cells, eosinophils, dendritic cells, and MCs of hematopoietic cell [57]. It is essential for red blood
cell (RBC) development because GATA-1-/- mice will die between E10.5–E11.5 in mid-
gestation by anemia [58]. In such mutated embryo, only primitive erythroid cells could be
found in the peripheral blood, which are arrested at a proerythroblast stage and express βH1,
α and ζ-globin transcripts, then die by apoptosis [59]. Matured definitive erythroid cells were
completely absent in GATA-1-/- mice [60-62]. GATA-2, another important member of GATA
family, was expressed in many other multi-lineage progenitors and HSCs [63] and also plays
important role in proliferation, survival and differentiation of early hematopoietic cells,
though the result of its functional mutation is relatively mild compared with GATA-1 [59].
At the late stage of erythrocyte development the “GATA switch” is the key molecular mech‐
anism for erythroid differentiation companied by down-regulating GATA2 and up-regulating
GATA1 expression. This is the process that GATA-1 occupies the GATA binding site on the
upstream element of GATA2 gene and represses the expression of the latter [64]. In general,
after terminal erythroid differentiation start, GATA1 directly opens the expression of erythroid
lineage-affiliated genes such as β-globin, Alas2, and Gata1 itself while at the same time
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phenotype and functionally identical to human skin counterparts, indicating that a different
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that only have primitive hematopoiesis potential could obtain definitive hematopoiesis
potential by the “education” on mAGM cells in vitro [20]. The YS cell grafted to fetal liver or
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were also expressed in other region of embryo in the same stage (tal-1 and rbtn2 also in
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hematopoietic commitments [56].
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GATA gene family. GATA1 expression is highly restricted in erythroid cells, megakaryocytic
cells, eosinophils, dendritic cells, and MCs of hematopoietic cell [57]. It is essential for red blood
cell (RBC) development because GATA-1-/- mice will die between E10.5–E11.5 in mid-
gestation by anemia [58]. In such mutated embryo, only primitive erythroid cells could be
found in the peripheral blood, which are arrested at a proerythroblast stage and express βH1,
α and ζ-globin transcripts, then die by apoptosis [59]. Matured definitive erythroid cells were
completely absent in GATA-1-/- mice [60-62]. GATA-2, another important member of GATA
family, was expressed in many other multi-lineage progenitors and HSCs [63] and also plays
important role in proliferation, survival and differentiation of early hematopoietic cells,
though the result of its functional mutation is relatively mild compared with GATA-1 [59].
At the late stage of erythrocyte development the “GATA switch” is the key molecular mech‐
anism for erythroid differentiation companied by down-regulating GATA2 and up-regulating
GATA1 expression. This is the process that GATA-1 occupies the GATA binding site on the
upstream element of GATA2 gene and represses the expression of the latter [64]. In general,
after terminal erythroid differentiation start, GATA1 directly opens the expression of erythroid
lineage-affiliated genes such as β-globin, Alas2, and Gata1 itself while at the same time
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represses Gata2, c-Kit, c-Myb, and c-Myc, responding for the proliferation of progenitors in
earlier stages of hematopoiesis [65].
AML1/Runx1. Homozygous mutations of AML1/Runx1 did not interfere normal morpho‐
genesis and YS-derived erythropoiesis, but completely inhibit FL hematopoiesis, leading to
the death of embryo around E12.5. The same mutation in ES cells do not influence their
differentiation potential into primitive erythroid cells in vitro while stop occurence of any
definitive myeloid or erythroid progenitors in both the YS and FL after injected to blastocysts
to produce chimeric animals. Above proofs support the key role of AML1 and AML1-regulated
target genes to all lineages in definitive hematopoiesis [10, 66]
c-Myb. c-Myb is highly expressed in immature hematopoietic cells and its expression is down-
regulated as they become more differentiated [67, 68]. c-Myb controls self-renewal and
differentiation of adult HSCs and its disruption seriously depletes the HSC pool and inhibits
the definitive hematopoiesis [69].
EKLF. EKLF is zero or very weakly expressed in hematopoietic stem cells and multipoten‐
tial myeloid progenitors, while arise since more matured stages and play a role all the time
later for RBC differentiation. Its expression is up-regulated when myoloid and erythriod
progenitors were committed to the erythroid lineage while down-regulated when differen‐
tiate  toward  megakaryopoiesis  [70].  During  the  global  expansion  of  erythroid  gene
expression  in  primitive  and definitive  lineages,  EKLF also  plays  a  direct  role  in  globin
switching. EKLF is weakly expressed during embryonic and fetal development, which led
to a low expression of adult β-globin, Bcl11a and a high one of γ-globin. While in adults,
EKLF is highly expressed in definitive RBCs that results in high levels of adult β-globin
and Bcl11a expression, and represses γ-globin expression [71]. Finally, EKLF stop the cell
cycle of RBCs at the terminal maturation [72]. EKLF/KLF1 mutations will change the RBC
phenotypes or even lead to disease. [73, 74]
Rbtn2. Rbtn2 is a nuclear protein expressed in erythroid lineage in vivo, which is essential for
erythroid development in mice. The homozygous mutation of rbtn2 inhibits YS erythropoiesis
and leads to embryonic lethality around E10.5. YS tissue from homozygous mutant mice and
double-mutant ES cells could not process erythroid development in in vitro differentiation
system, showing a key role for Rbtn2 in erythroid differentiation, which is high related to
GATA-1 [75]
EPO/EPOR. Erythropoietin is a glycoprotein produced primarily by kidney and is the
principal factor to regulate RBC production, mainly functioning on erythroid progenitors
within the FL and adult BM [76]. The erythroid progenitors before BFU-E stage and RBC after
late basophilic erythroblast stage are not responsive to EPO. Proliferation in CFU-E stage could
highly responsive to EPO and this response is very transient. The affinity between erythro‐
poietin and its receptor (EPO-R) and their concentration decide strength of such response
during the erythropoiesis. EPO-R signaling pathway is necessary for both primitive and
definitive erythropoiesis [77, 78].
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3. hESC-derived primitive and definitive hematopoietic cells
The first hESC line was established by Thomson’s group in 1998 [1] and then the first hiPSC
line by Yamanaka’s group in 2007 [2]. Both cells provide possibility to uncover various normal
or diseased mechanisms in early human development. By in vitro differentiation system,
factors controlling the primitive and definitive hematopoiesis could be investigated in detail
using the method of embryoid body (EB) forming [79], or co-culture with hematopoietic niche-
derived stromal cell lines [3-6, 80, 81]. Among them, method of EBs could obtain large quantity
of blood cells that were not well matured, mimicking the primitive hematopoietic cells [82,
83]. Then, co-culture with OP9 cells was applied to promote the differentiation based on EB
method and large-scale production of mature erythrocytes with some definitive properties
could be obtained [84, 85]. Although OP9 co-culture system could obtain robust growth of
matured blood cells, it is clearly not a natural process and could not be used as proper model
to elucidate the natural mechanism controlling early human hematopoiesis. The stromal cells
isolated from early hematopoietic niches, such as AGM region, FL and late-stage fetal BM,
should be more reasonable candidates to support the in vitro differentiation of hESC/hiPSC-
derived hematopoietic stem/progenitor cells. The Lako’s group compared the differences
among several in vitro differentiation systems based on stromal cell co-culture and optimized
their culture conditions. Their result suggested that AGM-derived cell line was most proper
for the hematopoiesis differentiation of ESC. [86]
Based on in vitro differentiation systems, researchers tried to make clear the details of early
human hematopoiesis using hESCs as a model. Keller’s group found two distinct types of
hemangioblasts during hESCs differentiation culture, one could give rise to primitive eryth‐
roid, macrophages and endothelial cells, while the other one generated only primitive
erythroid and endothelial cells [87]. Their work provided the first evidence to prove the
existence of hemangioblasts derived from hESCs in vitro. The follow-up work showed that
under the control of growth factors and hematopoietic cytokines the hematopoiesis and
myelopoiesis will happen during the later stage; and common bi-potent progenitor capable of
generating erythroid and megakaryocytic cells could be observed, mimicking the process in
vivo [88, 89]. Through the analysis of hemoglobin components, an erythroid maturation could
be observed by the ratio of β-globin expression during hESC differentiation culture, which
seems a maturation switch but not lineage switch [90]. Above researches indicated that the in
vitro hESC differentiation system could reflect the in vivo hematopoietic process during the
early human embryonic development.
Slukvin’s group applied PO9 co-culture system to explore the detail pathway from hESCs to
definitive hematopoiesis. They firstly characterized a population of differentiating hemato‐
poietic cells defined by the expression of CD43, which is distinct to endothelial and mesen‐
chymal cells. Then they defined the erythro-megakaryocytic progenitors
(CD34+CD43+CD235a+CD41a+/-CD45-) and multi-potent lymphohematopoietic progenitors
(CD34+CD43+CD235a-CD41a-CD45-) in later stage, which replicated the beginning of
definitive hematopoiesis in some degree [91, 92]. The human myelomonocytic cells could also
be generated from expansion and differentiation of pluripotent stem cell-derived lin-
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CD34+CD43+CD45+ progenitors. All the defined population above could be detected during
the in vitro differentiation for different hESCs or hiPSCs lines [92].
By different culture conditions, nearly all of the blood lineages could be obtained from hESCs
according to the experience from murine ESC protocols, which pave the way to the clinic
application [93]. Jame’s group also identified a wave of hemogenic endothelial development
during the transition from endothelial to hematopoietic cell [94], reflecting the classic property
of definitive hematopoiesis. Their result showed that the definitive hematopoiesis could be
researched in vitro differentiation system and most progenitor population could be obtained
in such a system.
Although research on the early development of human hematopoiesis using human embryo
is rigorously restricted by ethics, so far accumulated data have clearly demonstrated that in
vitro hESC-derived hematopoiesis is more or less similar to the events happening in murine
fetal development (Figure 2). Thus, research on hESC-hematopoiesis should contribute greatly
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3.1. hESC-derived erythrocytes
Research on hESC-derived erythrocytes is one of the hot points because of the fact that
development of erythrocytes shows distinct trait between primitive and definitive waves.
More important is that the matured RBCs have no nucleus, which could avoid the exogenous
gene interference when clinically applied to treat patients. Much labor has been donated to
optimize the method of in vitro differentiation of RBCs from hESCs. For example, Lu’s group
firstly use EBs formation and then co-culture with OP9 to obtain a high yield of erythrocytes
with some efficiency of enucleation. However, these erythrocytes were still immature because
only 16% of these hESC-derived erythrocytes expressed β-globin [84]. Similar work has been
done by several other groups using OP9 system [95, 96]
In our laboratory, we have recently established efficient blood cell-yeilding systems by co-
culture of hESC/hiPSCs with murine AGM and FL stromal cells (Figure 3). In the co-culture,
undifferentiated hESC/hiPSC colonies grow up and differentiate firstly to a mesoderm-like
structure, then to hematopoietic progenitor cells on days 10 to 14. In the second suspension
culture, these hESC/hiPSC-derived hematopoietic progenitors are further induced to some
specific blood cell lineages, such as erythrocytes, mast cells, and eosinophils, etc. [3]. By a clone-
tracing method, we gained concrete results that hESC-derived erythrocytes kept continuously
progressing toward maturation over a time course. The expression of β-globin vs ε-globin
showed a typical switching pattern, mimicking the normal development of human erythro‐
cytes. On day 12 of the co-culture with murine FL-derived stromal cells, hESC-derived
erythrocytes (BFU-E) express β-globin at about 60%, but up-regulated to almost 100% with
additional 6 days of culture. These matured hESC-derived erythrocytes can undergo enuclea‐
tion and release oxygen [5].
Our results showed that the in vitro differentiation from hESCs to matured hematopoietic cells
is a progressive process if proper co-culture condition provided. Functionally matured blood
cells similar to those from the definitive hematopoiesis could be obtained in large-scale
production by this method.
3.2. hESC-derived HSCs
The most challenging task for research on hESC/hiPSC-derived hematopoiesis is to obtain the
real HSC from in vitro differentiation system [97]. Although hESC/hiPSC-derived hemato‐
poietic cells that could be engrafted in immune compromised mice have been reported [86,
98-102], effort to obtain real HSCs from hESCs has largely been done in vain during past years.
In most experiments, the engraftment rate was very low and mostly restricted to the myeloid
lineage, and it was ambiguous if these engrafed cells were derived from real HSCs. The co-
culture with S17 could induce hESCs to HSC-like properties with low capacity of RBC potential
[103]. If a modified cell line generated from mAGM (AM20.1B4) was used the RBC activity of
HSC will be increased much [86]. But these hESC-derived HSC-like cells could not repopulate
in NOD-SCID mice, representing they were not true definitive HSCs that satisfy the functional
definition.
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A recent report showed that when co-cultured with OP9-DL1 cells, the hESC-derived hema‐
topoietic progenitor cells that formed endothelium-lined cell clumps could be induced into T-
lineage cells [104]. These hESC-derived T cells expressed sequential surface markers from T-
lymphoid progenitors (CD34+CD7+) to matured T cells (double positive CD4+CD8+and finally
maturedCD3+CD1-CD27+). The T-lineage cell production provided concrete evidence that
hESC-derived hematopoiesis endowed with definitive property. The functional matured
hESC-derived NK cells could also be generated by sequential co-culture on different feeder
cells [105, 106]. But the detail of HMC molecular and globulin class-switching during this
process has still not been elucidated.
3.4. Hemangioblasts
The blood islands region in YS consists of clusters of primitive erythroblasts surrounded by
mature endothelial cells. The close development relationship between hematopoietic and
endothelial cells in such a region indicated that these lineages ought to share a common
progenitor named as the hemangioblast [16, 33, 107]. This concept was provided nearly one
century ago [108,109] while it has been circumstantially supported by the latest molecular
genetic and embryological proofs [110-114]. More direct evidence came from the in vitro
Figure 3. Co-culture of hESC/hiPSCs with murine AGM or FL stromal cells
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differentiation system based on ESCs. Some differentiation models identified a progenitor with
properties of the hemangioblast [115, 116], indicating that the primitive hematopoiesis derived
from ESCs should pass through a hemangioblast stage. Further studies showed that these
hemangioblasts might have more potential than hematopoietic and endothelial cells, such as
smooth muscle [117, 118].
hESC-derived hemangioblasts have also been identified in differentiation cultures [87]. These
hESC-derived hemangioblasts were defined by the expression of KDR and could generate
clonal cells sharing both hematopoietic and vascular potential. There were two distinct types
of hESC-derived hemangioblasts: one gave rise to primitive erythroid cells, macrophages, and
endothelial cells and the other generated only the primitive erythroid population and endo‐
thelial cells. This finding provided evidence that hESC-derived hematopoiesis mimicked the
normal development pattern of human earliest stage of hematopoietic commitment.
3.5. Hemogenic endothelium
Different to hemangioblasts from YS, the concept of “hemogenic endothelial” come from the
research of AGM, which is in the ventral wall of the aorta and buds off HSCs [13]. The molecular
control of hemogenic endothelium is different to that of hemangioblasts. For example, Runx1
was indispensable for the hematopoiesis originated from hemogenic endothelia, but not
hemangioblasts [119, 120]. And the hemogenic endothelium did not originate from heman‐
gioblasts but presumptive mesoangioblasts, which could express endothelial-specific genes
and ultimately express HSC-associated markers [121]. Since hemogenic endothelium is closely
related to definitive hematopoiesis and has been regarded as the necessary stage for generation
of HSCs, the details of its potential and developmental process to produce HSCs should be
finely elucidated [122-125].
In some in vitro differentiation systems, hESC-derived CD34+ hemogenic progenitor cells
could also be detected with the endothelium potential [3, 126]. In an OP-9 co-culture system,
hESC-derived hemogenic endothelium progenitors (HEPs) were identified pinpoint by VE-
cadherin+CD73-CD235a/CD43- intermediate phenotype, which arise at the post primitive
streak stage of differentiation directly from a hematovascular mesodermal precursor (KDR
+APLNR+PDGFRalow/-). These HEPs differ from non-HEPs (VE-cadherin+CD73+) and early
hematopoietic cells (VEcadherin+CD235a+CD41a−) [124]. This subtle finding may provide clue
to facilitate generation of HSCs from hESCs (Figure 4).
3.6. Switching mechanisms controlling primitive hematopoiesis to definitive one
The origin of two waves of hematopoiesis was distinct in the sight of embryogenesis by the
research for Xenopus [127], mice [128] and human [54]. However, the reciprocal transplant test
in Xenopus embryo proved that the hematopoietic progenitor cell in VBI(corresponding to YS)
and DLP(corresponding to AGM) could change their potential according to microenvironment
of the graft site [129]. Similarly, blast-like cells derived from murine ESCs could differentiate
to both primitive and definitive lineages [130]. In our study by a clonal tracing method, hESC-
derived erythrocytes showed the primitive properties at the early stage and progressively
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differentiation system based on ESCs. Some differentiation models identified a progenitor with
properties of the hemangioblast [115, 116], indicating that the primitive hematopoiesis derived
from ESCs should pass through a hemangioblast stage. Further studies showed that these
hemangioblasts might have more potential than hematopoietic and endothelial cells, such as
smooth muscle [117, 118].
hESC-derived hemangioblasts have also been identified in differentiation cultures [87]. These
hESC-derived hemangioblasts were defined by the expression of KDR and could generate
clonal cells sharing both hematopoietic and vascular potential. There were two distinct types
of hESC-derived hemangioblasts: one gave rise to primitive erythroid cells, macrophages, and
endothelial cells and the other generated only the primitive erythroid population and endo‐
thelial cells. This finding provided evidence that hESC-derived hematopoiesis mimicked the
normal development pattern of human earliest stage of hematopoietic commitment.
3.5. Hemogenic endothelium
Different to hemangioblasts from YS, the concept of “hemogenic endothelial” come from the
research of AGM, which is in the ventral wall of the aorta and buds off HSCs [13]. The molecular
control of hemogenic endothelium is different to that of hemangioblasts. For example, Runx1
was indispensable for the hematopoiesis originated from hemogenic endothelia, but not
hemangioblasts [119, 120]. And the hemogenic endothelium did not originate from heman‐
gioblasts but presumptive mesoangioblasts, which could express endothelial-specific genes
and ultimately express HSC-associated markers [121]. Since hemogenic endothelium is closely
related to definitive hematopoiesis and has been regarded as the necessary stage for generation
of HSCs, the details of its potential and developmental process to produce HSCs should be
finely elucidated [122-125].
In some in vitro differentiation systems, hESC-derived CD34+ hemogenic progenitor cells
could also be detected with the endothelium potential [3, 126]. In an OP-9 co-culture system,
hESC-derived hemogenic endothelium progenitors (HEPs) were identified pinpoint by VE-
cadherin+CD73-CD235a/CD43- intermediate phenotype, which arise at the post primitive
streak stage of differentiation directly from a hematovascular mesodermal precursor (KDR
+APLNR+PDGFRalow/-). These HEPs differ from non-HEPs (VE-cadherin+CD73+) and early
hematopoietic cells (VEcadherin+CD235a+CD41a−) [124]. This subtle finding may provide clue
to facilitate generation of HSCs from hESCs (Figure 4).
3.6. Switching mechanisms controlling primitive hematopoiesis to definitive one
The origin of two waves of hematopoiesis was distinct in the sight of embryogenesis by the
research for Xenopus [127], mice [128] and human [54]. However, the reciprocal transplant test
in Xenopus embryo proved that the hematopoietic progenitor cell in VBI(corresponding to YS)
and DLP(corresponding to AGM) could change their potential according to microenvironment
of the graft site [129]. Similarly, blast-like cells derived from murine ESCs could differentiate
to both primitive and definitive lineages [130]. In our study by a clonal tracing method, hESC-
derived erythrocytes showed the primitive properties at the early stage and progressively
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turned to be definitive ones along with co-culture on FL cells [5], indicating that there exists a
possible switching mechanism controlling the conversion.
However, the molecular mechanism controlling such a switch remains unclear so far. The
switch observed in process of hESC-derived hematopoiesis probably is caused by the influence
or induction of the definitive hematopoietic niche-derived stromal cells (AGM, FL). The
cellular and molecular signals, including the growth factors and adhesion proteins expressed
by feeder cells and growth factors added in medium ought to play a key role to activate the
switch controlling the definitive hematopoiesis (such as Hedgehog, Notch1 and BMP signal
pathways). Among them, HoxB4 had been identified as the key factor to promote such a switch
[131]. Many key factors expressed in primitive and/or definitive erythrogenesis could also be
tracked in ESC-derived hematopoiesis [94, 132]. Since the hemoglobin switch of erythrocyte
could be used as the indicator of premitive and definitive hematopoiesis, the erythrogenesis-
related factors, such as GATA1, GATA2, AML1, SCL, EKLF, ought to be changed their
Figure 4. Development of hemangioblasts and hemogenic endothelia from pluripotent stem cells
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expression profile during such a switch. A thorough transcriptome analysis by deep sequenc‐
ing or gene chip should be useful tools to detect hESC-derived hematopoietic switch.
4. Concluding remarks and future perspectives
The in vitro production of functionally matured blood cells from hESC/hiPSCs has provided
an excellent model for both basic research and clinical applications. hESC/hiPSC-derived RBCs
are highly fancied because of their unlimited use as the substitute for blood transfusion, not
to mention the the utilization of hESC/hiPSC-derived HSCs in transplantation. On the other
hand, hiPSCs can provide patient-tailored models for analyzing the pathogenesis of malignant
blood diseases and thus develop individual treatment by molecular corrections. Innate
immune-related cells differentiated from hESC/hiPSCs will also help us to reveal the initial
establishment of human immune system, and to explore drug screening system and cell
therapy model for deficiencies of innate immunity.
However, before the successful application of hESC-derived cellular therapy, there are still
many problems needed to be solved. The molecular mechanisms controlling both primitive
and definitive hematopoiesis should be clarified at first. The HSC-like cells and functional
matured blood cells derived from hESC / hiPSC in vitro must also be proven their activities in
vivo. Besides, more efficient culture system free from xenobiotics must be optimized.
In order to realize above aims, the following efforts need to be done to promote the research
in this field:
1. The latest molecular biological technology and other new technique tool should be applied
in the future research.
Currently, Tetracycline (tc) and Tet repressor (TetR) system (tet-on and off) is one of the most
matured and widely applied regulatory systems [133] in organisms ranging from bacteria to
mammals. The technique by Transcription activator-like effector nucleases (TALENs [135,
136]) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) systems [136, 137] have also been developed. These methods let us be able to
do molecular manipulation in genomic scale(named “genome edit”) by unlimited times
against single cell line without obvious influence to the cell characteristic, thus provide an ideal
model to investigate the development events in hESC-derived hematopoiesis.
2. A highly efficient animal-source-free 3D culture system should be developed to search
for the generation of hESC-derived HSCs.
A big problem that hampers the progress in research on hESC-derived hematopoiesis is a lack
of a proper culture system that fully mimics the microenvironment of early development of
human hematopoiesis. An ideal culture model should be completely free of any animal source
substitutes and to great extent imitate a live structure as done in vivo circumstances. Since
HSCs develop in a complicated niche composed of various cell types (endothelial cells,
osteoblasts, mesenchymal cells, etc. ), a 3D culture model mixed by several hematopoietic niche
cells should benefit the efficiency of generating true HSCs from hESCs.
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Currently, Tetracycline (tc) and Tet repressor (TetR) system (tet-on and off) is one of the most
matured and widely applied regulatory systems [133] in organisms ranging from bacteria to
mammals. The technique by Transcription activator-like effector nucleases (TALENs [135,
136]) and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) systems [136, 137] have also been developed. These methods let us be able to
do molecular manipulation in genomic scale(named “genome edit”) by unlimited times
against single cell line without obvious influence to the cell characteristic, thus provide an ideal
model to investigate the development events in hESC-derived hematopoiesis.
2. A highly efficient animal-source-free 3D culture system should be developed to search
for the generation of hESC-derived HSCs.
A big problem that hampers the progress in research on hESC-derived hematopoiesis is a lack
of a proper culture system that fully mimics the microenvironment of early development of
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3. The new concept and theory should be introduced to conduct the research of hESC-
derived hematopoiesis.
According to the recent researches by Deng and other group [138, 139], the pluripotency of
stem cells is only the balance between several transcription factor groups controlling layer
lineage differentiation. Their finding denied the existence of special pluripotent factors and
showed that maintenance of ESC/iPSCs may be only because that all the way to any differen‐
tiation direction has been blocked by mutually antagonistic lineage specifiers [140]. Such
concept may also help us to uncover the controlling balance by some specifiers in early
hematopoiesis, especially for those controlling primitive and definitive ones. Since we always
try to obtain more definitive blood cells for clinic application, to discover the key factor leading
to definitive hematopoiesis is a challenging task to do. Moreover, how to define and describe
the essence of HSCs at molecular level is also an issue need to be re-addressed.
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1. Introduction
Cord blood (CB) cells are commonly used for the treatment of leukemia and inherited
metabolic diseases. To date, more than 20,000 bone marrow transplants have been performed
on children and adults with cord blood cells, and There are more than 450,000 HLA-defined
CB collections stored frozen cryoperserved form in more than 50 units public CB banks and
more than 2,000 CB transplants are being performed world-wide per year. CB cells are the
youngest somatic cells and in theory have no post natal DNA damage such as caused by UV
or chemical irritant exposure. Therefore, our previous study thought that use to the ability to
cryopreserve CB HSC long-term in bank, which conferring a unique advantage to CB cell as a
suitable material for generating induced pluripotent stem (iPSC) cells for future clinical use.[1]
iPSC should be generated with methods that do not require integration of exogenous DNA,
thereby reducing the chance of tumorigenicity caused by random chromosomal insertion of
exogenous genes. Several non-integrating reprogramming methods using EBNA based-
plasmids vector [2, 3, 4, 5], piggy-back transposons [6, 7], human artificial chromosome vectors
[8], small peptides [9, 10], mRNA [11] and proteins [12] have been reported. Among the vectors
employed for these experiments, the Sendai virus (SeV) vector (that lacks a DNA phase) is
recognized as a potent reagent for reprogramming of somatic cells [13-15]. However, complete
elimination of the SeV construct carrying reprogramming factors is a key issue to assure three
germ layer differentiation of individual cells. The presence of residual reprogramming factors
in transfected cells could impede differentiation and contribute to formation of tumors after
implantation. Therefore, the possible presence of the SeV construct should be checked at a
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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single cell level (not at a cell clump level) utilizing single cell cloning techniques in the naïve
state [16-18]. Recently, feeder-free culture systems utilizing Laminin 511, LM-E8s or Matrigel
have been reported for the maintenance of established iPSCs or ES cells [19-23]. The generation
of iPSCs from fibroblasts on vitronectin-coated dishes and maintenance of iPSCs in chemically
defined medium on vitronectin-coated dishes has been reported [23]. These studies were to
characterize as substrates that support hESCs in a sustainable undifferentiated state under a
xeno-free and chemical defined culture condition [20, 23]. On the other hands, multiple matrix
proteins, such as laminin, vitronectin fibronectin and synthetic polymer surfaces support
hESC/iPSC growth and maintenance. Most of these materials are too expensive for large-scale
usage. Because, recombinants vitronectin is relatively easy to over-express and purify, we
tested vitronectin in two feeder-free ES/iPS mediums. (mTeSR-1 and ReproFF2).
In this chapter, we describe the generation of iPSC clones from cord blood cells (CBCs) in
feeder-free thought naïve conditions using temperature sensitive SeV vector. Additional,
human naïve iPSC culturing methods using feeder-free systems and we introduce to low-cost
and stable and easy maintenance culturing methods of hESC/iPSC.
2. Experimental procedures, materials and methods
2.1. Cord blood
CD34+CBCscan be procured from Riken Bio Resource center (Riken BRC, Ibaraki, Japan) or
other commercial suppliers. Alternatively CD34+CBCscan be obtained from fresh cord blood
using a mononuclear cells isolation kit (Lymphoprep TM, Cosmo Bio Co., Japan), and a human
CD34 Micro Bead kit (Miltenyi Biotec, 130-046-702) or Auto Macs columns (Miltenyi Biotec,
Germany) in accordance with the manufacturer’s instruction. CD34+CBCs were cultured in the
density of 1.0 x 105 cells in two mL of hematopoietic culture medium [serum-free X-Vivo10
containing 50 ng/mL IL-6 (Peprotech, London, UK), 50 ng/mL sIL-6R (Peprotech) 50 ng/mL
SCF (Peprotech), 10 ng/mL TPO (Peprotech), and 20 ng /mL Flt3/4 ligand (R&D System,
Bostone, USA)] for one day prior to viral infection [23].
2.2. Preparation of coated dish for feeder-free generating iPS cells
PronectinFplus® coated-dish for reprogramming of CBCs is prepared as follows: One mg/mL
stock solution PronectinFplus® (hereafter, Pronectin F, Sanyo Chemical Industries, Japan) was
prepared by adding one mL of 37 oC deionized water to lyophilized Pronectin F. Ten ug/mL
of Pronectin F working solution was prepared by diluting the stock solution with phosphate
buffered saline (PBS). The culture dish (BD Life Science, Canada) was covered completely with
Pronectin F and left overnight at room temperature. The coating solution was then removed
by aspiration., and then dish was rinsed twice with PBS.
To make vitonectin-coated culture dish, the vitronectin-N (VTN-N) (Life Technology,USA) is
used for a six-well plate. Dilute thawed VTN-N with 1xPBS (Life Technology,USA). in
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accordance with the manufacturer’s instruction. Keep coated wells in culture medium at 37oC,
5% CO2 during passaging procedure until cells are ready to be re-plated.
2.3. Sendai virus infection and reprogramming
Temperature-sensitive Sendai virus vector constructs inserting four reprogramming factors
(SeV18+HS-OCT3/4/TS⊿F, SeV18+HS-SOX2/TS⊿F, SeV18+HS-KLF4/TS⊿F, SeV(HNL)c-MYC/
TS15⊿F, SeV18+GFP/TS⊿F) were supplied by DNAVEC Corp. 1.0 x 104 CD34+CBCs were
transferred to one well of a 96-well plate in 180 µL of hematopoietic cell culture medium with
20 µL of viral supernatant containing 20 M.O.I. each of SeV constructs at 5% CO2, 37 oC. The
medium was changed to fresh medium in the following days (15-18 hours after infection).
Infected cells were cultured another three days in hematopoietic culture medium in 96-well
plates, after which 1 x 104 infected CBC were seeded on a Pronectin F-coated 6-well dish in
primate ES cell medium ReproFF2 supplemented with 5 ng/mL bFGF (ReproCELL Inc,
RCHEMD006B, JAPAN) to generate ES cell-like colonies under 20% O2, 37 oC conditions. The
amount of SeV constructs in the transfected cells was reduced by incubation cells at 5% CO2,
38 oC for three days.
2.4. Cell culture in naïve state
After heat treatment, three hundred cells were resuspened in 100ml of naïve cell culture
medium (see below). The cells were seeded in ten well of 96-well plate (100µl/well) pre-coated
with Pronectin F. Approximately single cell in every three wells was seed in a 96-well plate.
The presence of a single cell per individual well was verified by microscopic observation (phase
contrast Olympus CKX31) in the same manner as single cell cloning. These cells were cultured
at 37 oC in 5% O2, 5% CO2 condition in naïve cell culture medium to form dome-shape colonies.
50 mL of naïve ES/iPS cell culture medium was prepared by mixing 24 mL DMEM/F-12
medium (Invitrogen, 11320, Osaka), 24 mL Neurobasal medium (Invitrogen, 21103), 0.5 mL
x100 nonessential amino acids (Invitrogen, 11140), 1 mL B27 supplement (Invitrogen;
17504044), and 0.5 mL N2 supplement (Invitrogen; 17502048). The medium also contained final
concentrations of 0.5 mg/mL BSA Fraction V (Sigma, A8412, Nebraska), penicillin-streptomy‐
cin (final x 1, Nacalai, Kyoto), 1 mM glutamine (Nacalai), 0.1 mM β-mercaptoethanol (Invi‐
trogen 21985), 1 µM PD0325901 (Stemgent, 04-0006, Cambridge), 3 µM CHIR99021 (Stemgent,
04-0004), 10 µM Forskolin (Sigma, F6886) and 20 ng/mL of recombinant human LIF (Millipore;
LIF1005, Billerica).
2.5. Gene chip analysis
Total RNAs from several established iPSCs lines (prime [1st, 2nd] and naïve), khES-1 (Riken
BRC) and CD34+CBCs (Riken BRC) were purified with an RNeasy Mini kit (QIAGEN),
amplified Ovation Pico WTA System (Takara cat#3300–12), labeled with an Encore Biotin
Module (Takara catalog number 4200–12) and then hybridized with a human Gene Chip (U133
plus 2.0 Array Affymetrix).
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single cell level (not at a cell clump level) utilizing single cell cloning techniques in the naïve
state [16-18]. Recently, feeder-free culture systems utilizing Laminin 511, LM-E8s or Matrigel
have been reported for the maintenance of established iPSCs or ES cells [19-23]. The generation
of iPSCs from fibroblasts on vitronectin-coated dishes and maintenance of iPSCs in chemically
defined medium on vitronectin-coated dishes has been reported [23]. These studies were to
characterize as substrates that support hESCs in a sustainable undifferentiated state under a
xeno-free and chemical defined culture condition [20, 23]. On the other hands, multiple matrix
proteins, such as laminin, vitronectin fibronectin and synthetic polymer surfaces support
hESC/iPSC growth and maintenance. Most of these materials are too expensive for large-scale
usage. Because, recombinants vitronectin is relatively easy to over-express and purify, we
tested vitronectin in two feeder-free ES/iPS mediums. (mTeSR-1 and ReproFF2).
In this chapter, we describe the generation of iPSC clones from cord blood cells (CBCs) in
feeder-free thought naïve conditions using temperature sensitive SeV vector. Additional,
human naïve iPSC culturing methods using feeder-free systems and we introduce to low-cost
and stable and easy maintenance culturing methods of hESC/iPSC.
2. Experimental procedures, materials and methods
2.1. Cord blood
CD34+CBCscan be procured from Riken Bio Resource center (Riken BRC, Ibaraki, Japan) or
other commercial suppliers. Alternatively CD34+CBCscan be obtained from fresh cord blood
using a mononuclear cells isolation kit (Lymphoprep TM, Cosmo Bio Co., Japan), and a human
CD34 Micro Bead kit (Miltenyi Biotec, 130-046-702) or Auto Macs columns (Miltenyi Biotec,
Germany) in accordance with the manufacturer’s instruction. CD34+CBCs were cultured in the
density of 1.0 x 105 cells in two mL of hematopoietic culture medium [serum-free X-Vivo10
containing 50 ng/mL IL-6 (Peprotech, London, UK), 50 ng/mL sIL-6R (Peprotech) 50 ng/mL
SCF (Peprotech), 10 ng/mL TPO (Peprotech), and 20 ng /mL Flt3/4 ligand (R&D System,
Bostone, USA)] for one day prior to viral infection [23].
2.2. Preparation of coated dish for feeder-free generating iPS cells
PronectinFplus® coated-dish for reprogramming of CBCs is prepared as follows: One mg/mL
stock solution PronectinFplus® (hereafter, Pronectin F, Sanyo Chemical Industries, Japan) was
prepared by adding one mL of 37 oC deionized water to lyophilized Pronectin F. Ten ug/mL
of Pronectin F working solution was prepared by diluting the stock solution with phosphate
buffered saline (PBS). The culture dish (BD Life Science, Canada) was covered completely with
Pronectin F and left overnight at room temperature. The coating solution was then removed
by aspiration., and then dish was rinsed twice with PBS.
To make vitonectin-coated culture dish, the vitronectin-N (VTN-N) (Life Technology,USA) is
used for a six-well plate. Dilute thawed VTN-N with 1xPBS (Life Technology,USA). in
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accordance with the manufacturer’s instruction. Keep coated wells in culture medium at 37oC,
5% CO2 during passaging procedure until cells are ready to be re-plated.
2.3. Sendai virus infection and reprogramming
Temperature-sensitive Sendai virus vector constructs inserting four reprogramming factors
(SeV18+HS-OCT3/4/TS⊿F, SeV18+HS-SOX2/TS⊿F, SeV18+HS-KLF4/TS⊿F, SeV(HNL)c-MYC/
TS15⊿F, SeV18+GFP/TS⊿F) were supplied by DNAVEC Corp. 1.0 x 104 CD34+CBCs were
transferred to one well of a 96-well plate in 180 µL of hematopoietic cell culture medium with
20 µL of viral supernatant containing 20 M.O.I. each of SeV constructs at 5% CO2, 37 oC. The
medium was changed to fresh medium in the following days (15-18 hours after infection).
Infected cells were cultured another three days in hematopoietic culture medium in 96-well
plates, after which 1 x 104 infected CBC were seeded on a Pronectin F-coated 6-well dish in
primate ES cell medium ReproFF2 supplemented with 5 ng/mL bFGF (ReproCELL Inc,
RCHEMD006B, JAPAN) to generate ES cell-like colonies under 20% O2, 37 oC conditions. The
amount of SeV constructs in the transfected cells was reduced by incubation cells at 5% CO2,
38 oC for three days.
2.4. Cell culture in naïve state
After heat treatment, three hundred cells were resuspened in 100ml of naïve cell culture
medium (see below). The cells were seeded in ten well of 96-well plate (100µl/well) pre-coated
with Pronectin F. Approximately single cell in every three wells was seed in a 96-well plate.
The presence of a single cell per individual well was verified by microscopic observation (phase
contrast Olympus CKX31) in the same manner as single cell cloning. These cells were cultured
at 37 oC in 5% O2, 5% CO2 condition in naïve cell culture medium to form dome-shape colonies.
50 mL of naïve ES/iPS cell culture medium was prepared by mixing 24 mL DMEM/F-12
medium (Invitrogen, 11320, Osaka), 24 mL Neurobasal medium (Invitrogen, 21103), 0.5 mL
x100 nonessential amino acids (Invitrogen, 11140), 1 mL B27 supplement (Invitrogen;
17504044), and 0.5 mL N2 supplement (Invitrogen; 17502048). The medium also contained final
concentrations of 0.5 mg/mL BSA Fraction V (Sigma, A8412, Nebraska), penicillin-streptomy‐
cin (final x 1, Nacalai, Kyoto), 1 mM glutamine (Nacalai), 0.1 mM β-mercaptoethanol (Invi‐
trogen 21985), 1 µM PD0325901 (Stemgent, 04-0006, Cambridge), 3 µM CHIR99021 (Stemgent,
04-0004), 10 µM Forskolin (Sigma, F6886) and 20 ng/mL of recombinant human LIF (Millipore;
LIF1005, Billerica).
2.5. Gene chip analysis
Total RNAs from several established iPSCs lines (prime [1st, 2nd] and naïve), khES-1 (Riken
BRC) and CD34+CBCs (Riken BRC) were purified with an RNeasy Mini kit (QIAGEN),
amplified Ovation Pico WTA System (Takara cat#3300–12), labeled with an Encore Biotin
Module (Takara catalog number 4200–12) and then hybridized with a human Gene Chip (U133
plus 2.0 Array Affymetrix).




After the iPS cells have reached the 80% of confluence, it must be harvested and fixed to make
a cytogenetic suspension. iPS cells are growth arrested and accumulated in metaphase or
prometaphase by inhibiting tubulin polymerization and thus preventing the formation of the
mitotic spindle using colcemid (Sigma, #D7385). Following exposure to colcemid, iPS cells are
treated with a hypotonic solution to enhance the dispersion of chromosomes and fixed with
carnoy fixative (Methanol: Acetic Acid=3:1). Once fixed, the cytogenetic preparation can be
stored in cell pellets, under fixative conditions and 20oC for several months. Fixed cells are
spread on slides and air-dried, to be finally banded for the correct identification of chromo‐
somes.
3. Results
3.1. Selection of coating materials for feeder-free generating iPS cells
Using gene chip approach, we investigated the levels of adhesion molecule expression on (i)
CD34+CBCs, (ii) the resulting iPSC cells and (iii) naïve iPSC on SNL (SNL76/7, ECACC)
cultured in naïve cell medium. We identified several molecules that were expressed by
CD34+CBCs and by the resulting primed and naïve iPSCs cultured on feeder cell SNL (Table
1). These data prompted us to use their ligands to anchor CBCs to dishes for reprogramming
in a feeder-free system. In this context, fibronectin or a relevant material, which has an-Arg-
Gly-Asp-(RGD) motif that can bind to the integrin α5/β1 dimmer expressed on CBCs, was
selected as a candidate for a coating material for the generation of iPSCs.
Mean and standard deviation of signal values for the expression of indicated genes from three independent experiments.
Table 1. Gene chip analysis of adhesion molecules on CD34+cells, and primed and naive iPSCs cultured on SNL.
From the point of view of quality control and reagent tracking, synthetic peptides expressing
the RGD motif are preferable to natural ligands. Thus, Pronectin F which mimics the peptide
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structure of fibronectin, was chosen and tested for reprogramming CBCs. Pronectin F was
synthesized by fusing two amino acid motifs, RGD and (GAGAGS)9 in tandem to produce a-
RGD-(GAGAGS)9-RGD-(GAGAGS)9-RGD-(GAGAGS)9-RGD-polypeptide. This polypeptide
has thirteen RGD motifs and is folded at the RGD sequence. Thus, the RGD motif is effectively
exposed at the limbs of the peptide bundle, facilitating its potent binding affinity to the integrin
α5/β1 dimer.
3.2. Generation of iPS cells on synthetic peptide (Pronectin F®)
Protocol for generating iPSC on feeder less condition is shown in Figure 1.
Figure 1. Protocol for generation of iPSCs from CD34+CBCs on Pronectin F-coated dishes with temperature sensitive
SeV vectors. P: passage.
Human ES cell-like colonies (first prime state) were picked up at day 24 and cultured on
Pronectin F-coated dishes. The colonies were subjected to heat treatment (38oC, three days) at
passage three (P3). Colonies emerged from single cells in Pronectin F-coated 96-well plates
under naïve conditions at P4, dome-shaped colonies at P5 under naïve conditions, ES cell-like
colonies (second primed) cultured under primed culture conditions at P6,P7.
The medium was changed every other day for transformed adherent cell stage (day 1-12).
However, during day 13-17, primate ES medium was changed every day. The reprogramming
process was monitored by checking the morphology of the transfected cells. CD34+cells
infected with SeV constructs were cultured in serum-free hematopoietic cell culture, as shown
in Figure 2 (day1). Some cells attached to Pronectin F-coated dishes by day four in Figure 2
(day 4). Cobble stone-like cell colonies emerged at day nine and cell clumps with round and
small cells emerged inside the colonies at day 13 on Pronectin F-coated dishes (Figure 2, day
9, day 13). Cell clumps within cobble stone-like colonies grew (Figure 2, day 17) and finally
human ES cell-like colonies emerged (Figure 2, day 24) on Pronectin F-coated dishes which
were then picked up for serial passage. Fifteen to twenty-two dish-shape human ES cell-like
colonies were picked out of 10,000 CD34+CBCs seeded on Pronectin F-coated dish in primate
ES medium. Colonies were picked approximately three weeks after viral infection. Cells from
individual colonies were transferred to a Pronectin F-coated 48-well plate to select passage-
able ES cell-like colonies capable of passage.




After the iPS cells have reached the 80% of confluence, it must be harvested and fixed to make
a cytogenetic suspension. iPS cells are growth arrested and accumulated in metaphase or
prometaphase by inhibiting tubulin polymerization and thus preventing the formation of the
mitotic spindle using colcemid (Sigma, #D7385). Following exposure to colcemid, iPS cells are
treated with a hypotonic solution to enhance the dispersion of chromosomes and fixed with
carnoy fixative (Methanol: Acetic Acid=3:1). Once fixed, the cytogenetic preparation can be
stored in cell pellets, under fixative conditions and 20oC for several months. Fixed cells are
spread on slides and air-dried, to be finally banded for the correct identification of chromo‐
somes.
3. Results
3.1. Selection of coating materials for feeder-free generating iPS cells
Using gene chip approach, we investigated the levels of adhesion molecule expression on (i)
CD34+CBCs, (ii) the resulting iPSC cells and (iii) naïve iPSC on SNL (SNL76/7, ECACC)
cultured in naïve cell medium. We identified several molecules that were expressed by
CD34+CBCs and by the resulting primed and naïve iPSCs cultured on feeder cell SNL (Table
1). These data prompted us to use their ligands to anchor CBCs to dishes for reprogramming
in a feeder-free system. In this context, fibronectin or a relevant material, which has an-Arg-
Gly-Asp-(RGD) motif that can bind to the integrin α5/β1 dimmer expressed on CBCs, was
selected as a candidate for a coating material for the generation of iPSCs.
Mean and standard deviation of signal values for the expression of indicated genes from three independent experiments.
Table 1. Gene chip analysis of adhesion molecules on CD34+cells, and primed and naive iPSCs cultured on SNL.
From the point of view of quality control and reagent tracking, synthetic peptides expressing
the RGD motif are preferable to natural ligands. Thus, Pronectin F which mimics the peptide
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structure of fibronectin, was chosen and tested for reprogramming CBCs. Pronectin F was
synthesized by fusing two amino acid motifs, RGD and (GAGAGS)9 in tandem to produce a-
RGD-(GAGAGS)9-RGD-(GAGAGS)9-RGD-(GAGAGS)9-RGD-polypeptide. This polypeptide
has thirteen RGD motifs and is folded at the RGD sequence. Thus, the RGD motif is effectively
exposed at the limbs of the peptide bundle, facilitating its potent binding affinity to the integrin
α5/β1 dimer.
3.2. Generation of iPS cells on synthetic peptide (Pronectin F®)
Protocol for generating iPSC on feeder less condition is shown in Figure 1.
Figure 1. Protocol for generation of iPSCs from CD34+CBCs on Pronectin F-coated dishes with temperature sensitive
SeV vectors. P: passage.
Human ES cell-like colonies (first prime state) were picked up at day 24 and cultured on
Pronectin F-coated dishes. The colonies were subjected to heat treatment (38oC, three days) at
passage three (P3). Colonies emerged from single cells in Pronectin F-coated 96-well plates
under naïve conditions at P4, dome-shaped colonies at P5 under naïve conditions, ES cell-like
colonies (second primed) cultured under primed culture conditions at P6,P7.
The medium was changed every other day for transformed adherent cell stage (day 1-12).
However, during day 13-17, primate ES medium was changed every day. The reprogramming
process was monitored by checking the morphology of the transfected cells. CD34+cells
infected with SeV constructs were cultured in serum-free hematopoietic cell culture, as shown
in Figure 2 (day1). Some cells attached to Pronectin F-coated dishes by day four in Figure 2
(day 4). Cobble stone-like cell colonies emerged at day nine and cell clumps with round and
small cells emerged inside the colonies at day 13 on Pronectin F-coated dishes (Figure 2, day
9, day 13). Cell clumps within cobble stone-like colonies grew (Figure 2, day 17) and finally
human ES cell-like colonies emerged (Figure 2, day 24) on Pronectin F-coated dishes which
were then picked up for serial passage. Fifteen to twenty-two dish-shape human ES cell-like
colonies were picked out of 10,000 CD34+CBCs seeded on Pronectin F-coated dish in primate
ES medium. Colonies were picked approximately three weeks after viral infection. Cells from
individual colonies were transferred to a Pronectin F-coated 48-well plate to select passage-
able ES cell-like colonies capable of passage.
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Figure 2. Phase contrast light microscopic observation of cells during reprogramming. Images captured on a Pronec‐
tin F-coated dish on days 1, 4, 9, 13, 17 and 24. day 1; Infected CD34+CBCs with Sendai virus seed on Pronectin F®-
coated dish. day 4; Infected CD34+CBCs were attachment and little spread on Pronectin F-coated dish. day 9: Infected
CD34+CBCs expansion on Pronectin F-coated dish. day 13; Infected CD34+CBCs expansion with colony-like state. day
17; generation of small ES-like colony around spreading apart of infected CD34+CBCs. day 24; Human ES cell-like colo‐
nies emerged on Pronectin F-coated dishes.
Human ES cell-like colonies (first primed state) were picked up at day 24 and cultured on
Pronectin F-coated dishes. The colonies were subjected to heat treatment (38 oC, three days) at
passage three (P3) to reduce the SeV constructs (Figure 3).
Figure 3. Expression of SeV in reprogrammed cell clone before and after heat treatment.
Expression of SeV in ES cell-like colonies before heat treatment at passage three (SeV at P3)
and after heat treatment and single cell cloning at passage.
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Reprogrammed cell clone before single cell cloning in the naïve state was named PF (Pronectin
F –coated Feeder-less clones). The level of SeV protein expression was determined by immu‐
nostaining with SeV HN antibody (polyclonal-rabbit, gift to DNAVEC Corp., Ibaraki).
Then, single cells from dish-shaped (first primed) primate ES cell-like colonies at passage three
were seeded on a Pronectin F-coated 96 well plate at approximately one cell per three wells
and cultured in naïve medium under hypoxic conditions (5% O2, 5% CO2 at 37o C). After five
or six days, dome-shaped mouse ES cell like-colonies were collected and expanded on
Pronectin F-coated dishes. Next, cell clumps were transferred to primate ES medium under
20% O2 again to culture them in the primed state in Figure 4.
Figure 4. Generation of reprogrammed cell clone from a single cell via the naïve state.
Light microscopic image and ALP staining at P3 are shown in upper and lower panels,
respectively. Colonies emerged from single cells in Pronectin F-coated 96-well plates under
naïve condition at P4, dome-shaped colonies at P5 under naïve condition, ES cell-like colonies
(second primed) cultured under primed culture condition at P6 or long-term passaged clone
at P45 are shown. And, the colonies were subjected to heat treatment (38°C, three days).
Colonies emerged from single cells in Pronectin F-coated 96-well plates under naïve conditions
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Figure 2. Phase contrast light microscopic observation of cells during reprogramming. Images captured on a Pronec‐
tin F-coated dish on days 1, 4, 9, 13, 17 and 24. day 1; Infected CD34+CBCs with Sendai virus seed on Pronectin F®-
coated dish. day 4; Infected CD34+CBCs were attachment and little spread on Pronectin F-coated dish. day 9: Infected
CD34+CBCs expansion on Pronectin F-coated dish. day 13; Infected CD34+CBCs expansion with colony-like state. day
17; generation of small ES-like colony around spreading apart of infected CD34+CBCs. day 24; Human ES cell-like colo‐
nies emerged on Pronectin F-coated dishes.
Human ES cell-like colonies (first primed state) were picked up at day 24 and cultured on
Pronectin F-coated dishes. The colonies were subjected to heat treatment (38 oC, three days) at
passage three (P3) to reduce the SeV constructs (Figure 3).
Figure 3. Expression of SeV in reprogrammed cell clone before and after heat treatment.
Expression of SeV in ES cell-like colonies before heat treatment at passage three (SeV at P3)
and after heat treatment and single cell cloning at passage.
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Reprogrammed cell clone before single cell cloning in the naïve state was named PF (Pronectin
F –coated Feeder-less clones). The level of SeV protein expression was determined by immu‐
nostaining with SeV HN antibody (polyclonal-rabbit, gift to DNAVEC Corp., Ibaraki).
Then, single cells from dish-shaped (first primed) primate ES cell-like colonies at passage three
were seeded on a Pronectin F-coated 96 well plate at approximately one cell per three wells
and cultured in naïve medium under hypoxic conditions (5% O2, 5% CO2 at 37o C). After five
or six days, dome-shaped mouse ES cell like-colonies were collected and expanded on
Pronectin F-coated dishes. Next, cell clumps were transferred to primate ES medium under
20% O2 again to culture them in the primed state in Figure 4.
Figure 4. Generation of reprogrammed cell clone from a single cell via the naïve state.
Light microscopic image and ALP staining at P3 are shown in upper and lower panels,
respectively. Colonies emerged from single cells in Pronectin F-coated 96-well plates under
naïve condition at P4, dome-shaped colonies at P5 under naïve condition, ES cell-like colonies
(second primed) cultured under primed culture condition at P6 or long-term passaged clone
at P45 are shown. And, the colonies were subjected to heat treatment (38°C, three days).
Colonies emerged from single cells in Pronectin F-coated 96-well plates under naïve conditions
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at P4, dome-shaped colonies at P5 under naïve conditions, ES cell-like colonies (second
primed).
Long-term passaged clone (PFX#9) at P45 is shown. After single cell cloning in the naïve state,
picked up cell clones were named as PFX (Pronection F-coated Feeder-free iPSC derived from
female (XX) cord blood cell. We used female cord blood cells (XX) to check the status of being
in the naïve stage manifested by reactivation of X-chomosome inhibition. Culturing cells in
the naïve state was useful for a single cell cloning in limited dilution, but we fail to support
cell culture in the naïve stage robustly for more than five passages. Therefore cells were kept
culturing in the primed condition (20% O2, the ES cell medium containing bFGF) after single
cell cloning in the naïve state for further appraisal and passages.
Whether dome–shape cells cultured in the naïve condition (Figure 4, P5) was indeed in the
naïve state or not a reactivation of X-chromosome inhibition was determined by gene chip
analysis (Table 2.) and RT-PCR (Figure 5) with each states (prime [1st, 2nd] and naïve).
Table 2. Xist gene expression analysis by gene chip for X-chromosome activite / inactivite states using four different
probes.
Naïve PFXs were cultured in the naïve state and 2nd primed PFs were cultured in the naïve
state. PF #13 1st prime and khES-1 1st primed were cultured in the primed state (without being
in the naïve state). PF #13 and PFXs are female (XX) in origin, while human ES cell line khES01
is male in (XY) origin.
Figure 5. Expression of Xist genes in naïve and prime state iPS cell determined by RT-PCR.
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RT-PCR determination of naïve state in iPSC colony, second primed colonies 1; PFX#2 or 3;
PFX#9, naïve state colonies before each second prime state colonies (2; PFX#2 naïve, 4; PFX#9
naïve). Values were normalized using the housekeeping gene GAPDH.
3.3. Maintenance and characterization of reprogrammed cells
3.3.1. Maintenance of reprogrammed cells established in feeder free condition
Once established on a Pronectin-coated dish, reprogrammed cell colonies can be maintained
either in a Pronectin F-, Laminin-or Matrigels-coated dish for serial passage. 100-200 cell
clumps (50-100 µm diameters) were seeded on 100mm dish or in six wells of a 6-well plate and
cultured until colonies reach 70-80% confluence. The split ratio was routinely 1:3. This is a
protocol for passage via cell clump, not via single cell suspension.
It is possible to conduct cell passaging via single cell suspension in serum-free media (mTeSR1,
TeSR2 and ReproFF) in the primed condition with the use of Rock inhibitor (Y-27632, Stemgent,
#2514).
Figure 6. Photograph of forming cell colony from single iPS cell suspension on Matrigel.
As shown in Figure 6, it is notable that single cells migrate towards one another three to thirty-
six hrs after passage to form cell clumps. This is a single cell passage, not a single cell cloning
process. We failed to generate colonies from single cell in the primed state. That is a rationale
for using naïve culture for single cell subcloning purpose. It is convenient to use singe cell
suspension for passage. However, morphology of cell colony via single cell passage in longer
period (P20 or over) is not uniform and is no longer round. We have not accumulated enough
data how relevant this even is, but from a daily practical point of view, we perform cell
passaging via cell clumps.
3.3.2. Characterization of reprogrammed cells by Reverse transcriptase polymerase chain reaction (RT-
PCR)
The expression of pluripotecy related genes were determined by RT-PCR. Total RNA was
purified with an RNeasy Plus Micro kit (QIAGEN 74034), according to the manufacturer’s
instructions, and One µg of total RNA was used for reverse transcription reactions with
PrimeScript RT reagent kit (TAKARA, Japan). Result is shown in Figure 7. Primer sequences
used for PCR are shown in Table 3.
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at P4, dome-shaped colonies at P5 under naïve conditions, ES cell-like colonies (second
primed).
Long-term passaged clone (PFX#9) at P45 is shown. After single cell cloning in the naïve state,
picked up cell clones were named as PFX (Pronection F-coated Feeder-free iPSC derived from
female (XX) cord blood cell. We used female cord blood cells (XX) to check the status of being
in the naïve stage manifested by reactivation of X-chomosome inhibition. Culturing cells in
the naïve state was useful for a single cell cloning in limited dilution, but we fail to support
cell culture in the naïve stage robustly for more than five passages. Therefore cells were kept
culturing in the primed condition (20% O2, the ES cell medium containing bFGF) after single
cell cloning in the naïve state for further appraisal and passages.
Whether dome–shape cells cultured in the naïve condition (Figure 4, P5) was indeed in the
naïve state or not a reactivation of X-chromosome inhibition was determined by gene chip
analysis (Table 2.) and RT-PCR (Figure 5) with each states (prime [1st, 2nd] and naïve).
Table 2. Xist gene expression analysis by gene chip for X-chromosome activite / inactivite states using four different
probes.
Naïve PFXs were cultured in the naïve state and 2nd primed PFs were cultured in the naïve
state. PF #13 1st prime and khES-1 1st primed were cultured in the primed state (without being
in the naïve state). PF #13 and PFXs are female (XX) in origin, while human ES cell line khES01
is male in (XY) origin.
Figure 5. Expression of Xist genes in naïve and prime state iPS cell determined by RT-PCR.
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RT-PCR determination of naïve state in iPSC colony, second primed colonies 1; PFX#2 or 3;
PFX#9, naïve state colonies before each second prime state colonies (2; PFX#2 naïve, 4; PFX#9
naïve). Values were normalized using the housekeeping gene GAPDH.
3.3. Maintenance and characterization of reprogrammed cells
3.3.1. Maintenance of reprogrammed cells established in feeder free condition
Once established on a Pronectin-coated dish, reprogrammed cell colonies can be maintained
either in a Pronectin F-, Laminin-or Matrigels-coated dish for serial passage. 100-200 cell
clumps (50-100 µm diameters) were seeded on 100mm dish or in six wells of a 6-well plate and
cultured until colonies reach 70-80% confluence. The split ratio was routinely 1:3. This is a
protocol for passage via cell clump, not via single cell suspension.
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TeSR2 and ReproFF) in the primed condition with the use of Rock inhibitor (Y-27632, Stemgent,
#2514).
Figure 6. Photograph of forming cell colony from single iPS cell suspension on Matrigel.
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six hrs after passage to form cell clumps. This is a single cell passage, not a single cell cloning
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data how relevant this even is, but from a daily practical point of view, we perform cell
passaging via cell clumps.
3.3.2. Characterization of reprogrammed cells by Reverse transcriptase polymerase chain reaction (RT-
PCR)
The expression of pluripotecy related genes were determined by RT-PCR. Total RNA was
purified with an RNeasy Plus Micro kit (QIAGEN 74034), according to the manufacturer’s
instructions, and One µg of total RNA was used for reverse transcription reactions with
PrimeScript RT reagent kit (TAKARA, Japan). Result is shown in Figure 7. Primer sequences
used for PCR are shown in Table 3.
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Figure 7. Expression of endogenous pluripotency related genes in reprogrammed cell determined by RT-PCR.
Primers Size(bp)
hOCT3/4-F1165 GAC AGG GGG AGG GGA GGA GCT AGG Undifferentiated ES cell
(endo)
144
hOCT3/4-R1283 CTT CCC TCC AAC CAG TTG CCC CAA AC
hSOX2-F1430 GGG AAA TGG GAG GGG TGC AAA AGA GG undifferentiated ES cell
(endo)
151
hSOX2-R1555 TTG CGT GAG TGT GGA TGG GAT TGG TG
hMYC-F253 GCG TCC TGG GAA GGG AGA TCC GGA GC undifferentiated ES cell
(endo)
328
hMYC-R555 TTG AGG GGC ATC GTC GCG GGA GGC TG
hKLF4-F1128 ACG ATC GTG GCC CCG GAA AAG GAC C undifferentiated ES cell
(endo)
397
hKLF4-R1826 TGA TTG TAG TGC TTT CTG GCT GGG CTC C
DPPA4-F GGAGCCGCCTGCCCTGGAAAATTC
undifferentiated ES cell 408
DPPA4-R TTT TTC CTG ATA TTC TAT TCC CAT
hTERT-F3292 CCT GCT CAA GCT GAC TCG ACA CCG TG
undifferentiated ES cell 445
hTERT-R3737 GGA AAA GCT GGC CCT GGG GTG GAG C
REX1-F CAG ATC CTA AAC AGC TCG CAG AAT
undifferentiated ES cell 306
REX1-R GCG TAC GCA AAT TAA AGT CCA GA
NANOG-F CAG CCC CGA TTC TTC CAC CAG TCC C
undifferentiated ES cell 391




hGAPDH F AAC AGC CTC AAG ATC ATC AGC
control 337
hGAPDH R TTG GCA GGT TTT TCT AGA CGG
Table 3. List of genes and the primers used for RT-PCR.
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3.3.3. Evaluation for remaining SeV construct
The remaining SeV construct after heat treatment and single cell cloning was determined by




PF#7 before HT PF#9 before HT CD34+ 201B7 PFX#7 (P8) PFX#9 (P8)
SeV 193736 19719 26850 6511 3997 5414 1135
Table 4. Quantitative RT-PCR determination of residual SeV viral genomes.
Quantitative RT-PCR determination of residual SeV viral genomes in CD34+CBCs three days
after SeV infection (CD34 infected), first primed colony iPS#7 or iPS#9 before heat treatment
at P2 (PF#7 before HT, PF#9 before HT), non-infected CD34+CBCs (CD34) or iPSC clone
generated by retrovirus (201B7), established clones at P9 (PFX#7) or (PFX#9). Values were
normalized using the housekeeping gene GAPDH.
The residual SeV viral genome was determined by qRT-PCR analysis for selection of non-
integration and non-virus of established iPSC lines.
3.3.4. Characterization of reprogrammed cells by Immunohistological staining
ES cell like-colonies were stained with the Leukocyte Alkaline Phosphatase kit (VECTOR,
Burlingame, CA, SK-5300) in accordance with the manufacturer’s instructions. For immuno‐
chemical staining, these cells were fixed with 4% paraformaldehyde followed by staining with
antibodies against Oct3/4 (1:100 sc-5279; Santa Cruz, Biotechnology USA), Nanog (1:500,
RCAB0003P; Reprocell, Tokyo, Japan), SSEA-3 (1:200 MAB4303; Millipore), SSEA-4 (1:200,
MAB4304, Millipore). Photomicrographs were taken with a fluorescent microscope (Olympus
BX51, IX71, Tokyo) and a light microscope (Olympus CKX31).
ES cell-like clone PFX#9 at P8 was stained with antibodies against Nanog, Oct3/4, SSEA-3, or
SSEA-4 as indicated. Alexa 594-and Alexa 488-conjugated secondary antibodies (red and
green, respectively) were used to visualize the staining.
3.3.5. Characterization of reprogrammed cells by gene chip analysis and karyotyping
Total RNAs from several established iPSCs lines, ESCs lines (Riken BRC) and CD34+CBCs
(Riken BRC) were purified with an RNeasy Plus Mini kit (QIAGEN 74136), amplified Ovation
Pico WTA System (Takara cat#3300-12), labeled with an Encore Biotin Module (Takara catalog
number 4200-12) and then hybridized with a human Gene Chip (U133 plus 2.0 Array Affy‐
metrix) according to the manufacturer’s instructions (Figure 9). Karyotyping G-band method
of iPSCs is shown in Figure 10. The amount of metaphases obtained is sometimes inadequate
for chromosome analysis, thus it is always necessary to keep growing the PFX#9 iPS cells. As
shown in Figure 10, PFX#9 iPS cell on VTN-N was normal karyotypic cell.
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Figure 9. Gene expression comparison between the mean (mean) expression of clustered pluripotent stem cell.
[PFX#9(iPSC from CBC with Yamanaka 4factors-heat treat Sendai virus without feeder) and HSC of Cord Blood
(CD34+CBC)] and gene expression of PFX#9, or that of khES-1, (iPSC from CBC with Yamanaka 4 factors-Sendai Virus
on feeder) ((left panel)]. R2: dicision coefficient
Figure 8. Characterization of established iPSC PFX#9 clones. Expression of pluripotency-related molecules in reprog‐
rammed cell clones.
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Figure 10. G-band karyotype analyses. PFX#9 (P45)
3.3.6. In vitro differentiation potentials of reprogrammed cells
The three germ layers differentiation potential of reprogrammed cells was tested via embryo
body (EB) formation. Established ES cell-like clones were transferred to six-well, ultralow
attachment plates (Corning) and cultured in DMEM/F12 containing 20% knockout serum
replacement (KSR, Invitrogen) 2 mM L-glutamine, 1% NEAA, 0.1 mM 2-ME and 0.5% penicillin
and streptomycin or ReproFF medium without bFGF to form EB. The medium was changed
every other day. The resulting EBs were transferred to gelatin-coated plates for 16 days.
Differentiation to ectodermal, mesodermal, or endodermal tissue was confirmed by detection
of molecules related to three germ layers lineage differentiation such as α-feto-protein
(endoderm), βIII-tubulin (ectoderm), GFAP (ectoderm), or Vimentin (mesoderm) with
antibody against α-feto-protein (1:100 dilution MAB1368; R&D Systems), βIII-tublin (1:200
T4026; Sigma), GFAP(1:50 sc-6170 santa cruz biotechnology) or Vimentin (1:100 sc-5565; Santa
Cruz Biotechnology) respectively. Antibodies were visualized with Alexa Fluor 488 goat anti-
mouse (1:1,000; Invitrogen), Alexa Fluor 594 rabbit anti-mouse (1:1,000; Invitrogen), and Alexa
Fluor 594 goat anti-rabbit (1:1,000; Invitrogen). Nuclei were stained with DAPI (1:1,000; Sigma)
as shown in Figure 11.
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Figure 11. In vivo differentiation potential of established clones. Phase contrast images of neuron-like (top left) and
retinal pigmented epithelium (RPE) differentiation (top middle) of established clone PFX#7. Cells were fixed and
stained with antibodies against AFP, βIII-tubulin, GFAP and vimentin to identify specific cell lineages [18].
3.3.7. In vivo differentiation potential of reprogrammed cells by Teratoma formation assay
Reprogrammed cell lines should demonstrate differentiation potential reflecting three germ
layers, in vivo as well as in vitro. To this end, one million iPSCs were injected beneath the
testicular capsule of NOD-SCID mice (SLC Japan) to determine the ability of the transplanted
cells to form teratomas containing cells of all three germ layers. Tumor formation was observed
approximately four weeks after cell transplantation. Tumor tissues were fixed with 4%
formalin, sectioned, and stained with hematoxylin and eosin (Figure 12).
3.3.8. Preservation of Feeder-free iPS cells
Human ES/iPS clones generated and maintained in a feeder-free system could be frozen in cell
clumps using DMSO-free, chemically defined and serum-free freezing medium, CryoStemTM
Freezing Medium (Stemgent), and could be cultured again on a Pronectin F-coated dish after
thawing. Approximately 10-20% of the colony number scored before cryopreservation in
CryoStemTM emerged after thawing.
3.3.9. Long-term, Low-cost and Stable maintenance of undifferentiated human induced pluripotent stem
cells in feeder-free condition
Vitronectin provides a completely defined culture system for the maintenance of hiPSC under
feeder-free conditions such as ReproFF2 medium (Figure 13, Figure 14, Table 5). This system
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allows complete control over the culture environment, resulting in more consistent cell
populations and reproducible results in clinical applications.
Figure 13. Maintenance of iPS cells (PFX#9) on recombinant vitronectin (VTN-N, Life Technology) in ReproFF2 medi‐
um.
Figure 12. Teratoma with cystic structure. It was derived from iPSCs (PFX #9) implanted in the testicular capsule of a
NOD-SCID mouse. It was stained with hematoxylin and eosin for histological observation.
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Figure 14. Expression of endogenous pluripotency related genes in iPSC (PFX#9) on VTN-N determined by qRT-PCR.
Following, the PFX#9 cells cultured with VTN-N was the gene expression of pluripotency
markers comparable iPS cells cultured on Matrigel or on SNL in Figure 12. It was found that
only a recombinant vitronectin (VTN-N) can be maintained in culture for long-term feeder free
conditions.
Primers Size(bp)
hOCT3/4-F GAA ACC CAC ACT GCA GCA GA undifferentiated
ES cell
103
hOCT3/4-R TCG CTT GCC CTT CTG GCG
hSOX2-F GGG AAA TGG GAG GGG TGC AAA AGA GG undifferentiated
ES cell
151
hSOX2-R TTG CGT GAG TGT GGA TGG GAT TGG TG
hMYC-F CGT CTC CAC ACA TCA GCA CAA undifferentiated
ES cell
68
hMYC-R TCT TGG CAG CAG GAT AGT CCT T
hKLF4-F CGC TCC ATT ACC AAG AGC TCA T undifferentiated
ES cell
77
hKLF4-R CGA TCG TCT TCC CCT CTT TG
hTERT-F CGT ACA GGT TTC ACG CAT GTG undifferentiated
ES cell
82
hTERT-R ATG ACG CGC AGG AAA AAT GT
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Primers Size(bp)
REX1-F TGC AGG CGG AAA TAG AAC CT undifferentiated
ES cell
64
REX1-R TCA TAG CAC ACA TAG CCA TCA CAT
NANOG-F CTC AGC TAC AAA CAG GTG AAG AC undifferentiated
ES cell
153
NANOG-R TCC CTG GTG GTA GGA AGA GTA AA
hGAPDH-F CCA CTC CTC CAC CTT TGA CG
control 114
hGAPDH-R ATG AGG TCC ACC ACC CTG TT
Table 5. List of primers used for quantitative real-time PCR (qRT-PCR)
4. Conclusion
In this chapter we have shown the method for generating iPSC from non-cultured CD34+cord
blood cells using feeder-free conditions. The established cell clones were characterized at a
single cell level. This robust iPSC generation method will solve some of the safety concerns
related to tumorigenicity ariseing from chromosomal integration of exogenous genes and/or
infection hazards associated with the use of by xenogeneic biological products in the culture
system. These methods will contribute to future application of iPSCs-derived cell therapy.
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1. Introduction
‘Stem cell’ – the term was first coined by Russian histologist Alexander Maksimov in 1908 to
herald the existence of special cells those have capacity to generate blood cell. Stem cells are
the core materials of regenerative medicine and tissue engineering. Although there are
multiple types of stem cells available based on their origin and functionality; however,
scientifically they can be classified into four well-defined classes– (1) embryonic stem cell
(ESC), (2) adult stem cells (ASC) for example, muscle satellite cells are muscle-specific adult
stem cell, (3) induced pluripotent stem cell (iPSC), and (4) pathological stem cells (PSC) for
example, cancer stem cells (CSC) [1]. Out of these 4 types, ESC and ASCs are true physiological
stem cells, iPSCs are engineered stem cells and PSCs are conditional stem cells. Among them,
ESC and iPSC are being considered true pluripotent stem cells, which have the capacity for
unlimited self-renewal and differentiation into all the specialized cell types of the body.
Therefore these cells have been considered the most favorable cells for using in regenerative
medicine and tissue engineering [2,3,4,5,6,7,8].
Stem cells need a special environment for their survival, maintenance and growth. During the
early stage of establishing the culture methodologies for stem cells, it was realized that they
need support from other cells for example, mouse embryonic fibroblast (MEF). Co-culture
methodology with gamma-irradiated MEF cells used as feeder-cells and enriched culture
media with fetal bovine serum (FBS) were successfully utilized for establishing in vitro stem
cell culture [9,10]. However, using a second non-related cell type (although growth restricted)
is not suitable for differentiation studies – particularly, for 3D cell culture. Later, the MEF layer
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Chapter 6
Cadherin-Fc Chimeric Protein-Based Biomaterials:
Advancing Stem Cell Technology and Regenerative
Medicine Towards Application
Kakon Nag, Nihad Adnan, Koichi Kutsuzawa and
Toshihiro Akaike
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/58287
1. Introduction
‘Stem cell’ – the term was first coined by Russian histologist Alexander Maksimov in 1908 to
herald the existence of special cells those have capacity to generate blood cell. Stem cells are
the core materials of regenerative medicine and tissue engineering. Although there are
multiple types of stem cells available based on their origin and functionality; however,
scientifically they can be classified into four well-defined classes– (1) embryonic stem cell
(ESC), (2) adult stem cells (ASC) for example, muscle satellite cells are muscle-specific adult
stem cell, (3) induced pluripotent stem cell (iPSC), and (4) pathological stem cells (PSC) for
example, cancer stem cells (CSC) [1]. Out of these 4 types, ESC and ASCs are true physiological
stem cells, iPSCs are engineered stem cells and PSCs are conditional stem cells. Among them,
ESC and iPSC are being considered true pluripotent stem cells, which have the capacity for
unlimited self-renewal and differentiation into all the specialized cell types of the body.
Therefore these cells have been considered the most favorable cells for using in regenerative
medicine and tissue engineering [2,3,4,5,6,7,8].
Stem cells need a special environment for their survival, maintenance and growth. During the
early stage of establishing the culture methodologies for stem cells, it was realized that they
need support from other cells for example, mouse embryonic fibroblast (MEF). Co-culture
methodology with gamma-irradiated MEF cells used as feeder-cells and enriched culture
media with fetal bovine serum (FBS) were successfully utilized for establishing in vitro stem
cell culture [9,10]. However, using a second non-related cell type (although growth restricted)
is not suitable for differentiation studies – particularly, for 3D cell culture. Later, the MEF layer
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
was successfully removed from the culture system by introducing MEF-conditioned media
(MEF-CM) that has made the protocol more suitable for experimentation targeting regenera‐
tive medicine but not up to the desired standard due to the presence of xenogeneic agents in
the system [11,12,13]. MEF-CM is enriched cell culture media with MEF-secreted molecules
that functions as a depot for the necessary cytokines for the healthy maintenance of stem cells.
However MEF-CM alone were not adequate to upkeep ESC and iPSC survival and growth
thereby suggesting that MEF cells are not only providing necessary nutrients and cytokines,
in addition they are also backing as physicochemical supports through the ECM to these cells.
However, technically it remains elusive to point out the essential factors, required to maintain
stem cell culture, present in the MEF-CM due to the inconsistency in expression and secretion
of biological factors between experiments and batches. Moreover, it has been shown that not
only proliferation of these cells but the secretion of necessary biomolecules and deposition of
ECM components were also directly related to the gamma-irradiation [11,12,13]. Such factors
directly influence properties of stem cells in culture, and instigate restriction for application
of relevant protocols for regenerative medicine and tissue engineering. Therefore suitable cell-
recognizable biomaterials are highly desired to overcome the dependency of cell-based basal
supports for stem cell culture.
Matrigel was one of the first biomaterials that was effectively applied as plate-coating materials
for in vitro culture of human ESC and iPSC with the aid of MEF-CM as culture medium [14,15].
This was a significant advancement in stem cell technology to make stem cells free from
undesirable feeder-layer cells. Matrigel is a product from decellularization of Engelberth-
Holm-Swarm (EHS) mouse sarcoma cells, and a cocktail of laminin, collagen IV, entactin,
heparin sulfate proteoglycans, and known and unknown growth factors with variable
compositions [16,17,18,19]. It closely resembles the embryonic basement membrane in
consistency and activity as well as providing a biologically functional complex [17,19].
However, Matrigel is not a defined material with high purity and incorporated with substantial
lot to lot variation in constituents both in qualitative and quantitative measures. It has also
been reported contaminated with Lactate Dehydrogenage Elevating Virus, and has raised
additional concerns for safe application of this material in stem cell culture [20]. Such kinds of
issues are strongly demanding a more defined culture condition under good manufacturing
practice (GMP) for safe application of stem cell protocols or methodologies if the ultimate
objective is to employ stem cells in regenerative medicine or tissue engineering.
The individual components of Matrigel provide specific functional queues to ESCs and iPSCs.
For example, ESC exhibits normal growth when cultured on laminin-coated plate, which was
not observed on either fibronectin- or collagen IV-coated surface [21,22,23,24]. It was also
reported that specific laminin isoforms have distinctive effects on stem cells; for instance,
laminin-111, -332, -511 support adhesion and proliferation of stem cells but isoforms -211 and
-411 of laminin do not [22]. The information suggested that designing a defined matrix for stem
cell culture requires special biomaterials that can deliver concurrent supports for cell adhesion,
proliferation and differentiation. In fact, effective stem cell culture condition with high
pluripotency was occasionally achieved in spite of introducing several synthetic and semi‐
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synthetic biomaterials alone or as a blend as cell-culture substrate, and therefore, designing
such a biomaterial remains a challenging but ultimately rewarding task.
Pioneering work from our laboratory introduced Fc-chimeric protein in stem cell technology
approximately a decade ago, and over the years we and others have established multiple Fc-
chimeric proteins as significantly favorable cell-recognizable biomaterials in stem cell tech‐
nology. These works with varieties of Fc-chimeric proteins spanning from ECM component
protein [for example, E-cadherin (ECad)] to cytokine [for example, hepatocyte growth factor
(HGF)] have shown tremendous potential to overcome the major barriers in stem cell tech‐
nology, namely defined condition for stem cell culture, selective differentiation to the target
lineages, convenient purification of the desired cells etc., for the application of stem cell
technology targeting to regenerative medicine. In this article we will focus on ECad-Fc and
NCad-Fc chimeric proteins as novel cell-recognizable biomaterials in stem cell technology
towards application in regenerative medicine.
2. Rationale for using protein as biomaterials
An ideal chemically defined xenogeneic-agent free stem cell culture system might be consists
of chemically known matrix for plate coating that would provide structural basal support to
the stem cells and defined media that is supplemented with highly pure recombinant proteins
as functional cytokines. The system should essentially be free from serum or feeder-cells or
any other animal products. Even though it is very demanding however, designing and
preparing a completely defined stem cell culture system is highly challenging. One worthwhile
goal is to design a defined plate-coating material that can successfully replace Matrigel. Since
stem cells are essentially dependent on cell-cell or cell-surface interaction for survival, which
are mainly mediated by extracellular matrix protein (ECM), a cell-recognizable biomaterial
should preferably mimic ECM protein(s).
Such kind of biomaterials can either be employed as a scaffolding molecule that may provide
structural support of the growing cells, or as functional effector molecules that can target
cellular signal recognition machineries like cell surface receptors or channels to trigger or
maintain signaling cascades necessary for survival, proliferation, and differentiation of
experimental cells [25]. To act as an artificial ECM the biomaterial under consideration should
mimic the physicochemical and biological properties of native components of ECM to facilitate
targeted functionalities of cell for example, adhesion, proliferation, differentiation, etc [26].
Similarly, the candidate effector molecules should have physicochemical signature of the
comparable native molecules for recognition as functional substrate to endogenous receptors
or channels of experimental cells. Synthetic biomaterials have limitations for providing perfect
biochemical structural motif for effective recognition by the cellular recognition machineries
to execute necessary cellular function, and therefore are generally not efficient enough for
practical applications for in vivo condition. Moreover, many of these synthetic biomaterials are
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not biologically compatible at a desired level and may generate pathophysiological compli‐
cations in the long term in the body.
Proteins are native elements of cells and natural ECM scaffolds [27] and therefore recombinant
proteins could be one of the best candidates to design superior biomaterial for application in
regenerative medicine and tissue engineering. Recent progress in biochemistry, molecular
biology, bioinformatics, and engineering provides the prospect of expressing and purifying
desired recombinant protein with high yield (g/L is achievable) in large scale [28], which can
eventually be applied (directly or with modification) as novel, simplified, and bio-active
macromolecules in regenerative medicine and tissue engineering [29,30,31]. Such proteins can
be generated from a genetic template by natural cellular read-out process namely,
DNA>RNA>protein that ensures excellent uniformity and reproducibility of the designed
biomaterial depending on cellular conditions, where the production is executed. The native
biological production process confirms high degree of reproducibility, which is not realistic
by traditional chemosynthetic or mechanosynthetic processes. On the contrary, protein science
has its own negative issues for example, highly efficient expression system for the desired
protein, convenient purification of the target protein, proper folding of the purified protein,
stability of the functional protein, mode of application of experimental protein etc. Chimeric
protein technology has long been considered one of the potential methodologies to overcome
many of these issues including higher productivity, better stability, and efficient purification
of a target protein for bulk scale. Fc-chimeric protein is one such engineered protein that was
introduced in 1989, and has been showing great promise for comparatively convenient
production efficiency of chimeric protein with functional integrity and long-term stability, and
therefore successful applcation in diverse fields of biomedical sciences [32,33,34]. An illustra‐
tion of Fc-chimeric protein is shown in Fig. 1 with ECad-Fc as a model.
Figure 1. Schematics of Fc-chimeric protein, and its molecular function. (A) Functional domain of target protein is
fused as N-terminal with the Fc domain of IgG. ECad is shown here as an example. (B) Plasma-membrane localized
ECad dimer can interact with apposing ECad dimer and form high affinity binding that makes cell-cell and cell-surface
adhesion.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models140
3. Cadherins in cell biology
The cadherins is a large family of single transmembrane proteins with more than 100 members.
Out of these we will be focusing on epithelial cadherin (ECad) and neural cadherin (NCad) in
this report. They are the member of classical cadherin family, and both of them are glycosylated
in their extracellular domain. They have the ability to function as adhesion molecules for the
relevant protein-expressing cells. Generally cadherin forms homophilic dimer, and the dimeric
forms of cadherins take part in Ca+2-dependent coupling from apposing cells that mediates
cell-cell adhesion. These single transmembrane-domain plasma membrane-resident proteins
are not only necessary for cell-cell adhesion but also involved in indispensible signaling
cascades, which are critical for the development-to-homeostasis-to-demise of cells and
organisms.
The extracellular N terminal region of ECad consists of 5 structural domains, which are the
signature motifs for ECad and are responsible for the homophilic binding between two
neighboring as well as apposing molecules, while the C-terminal intracellular region of ECad
interacts with several intracellular proteins such as β-catenin/Armadillo and p-120 catenin
[35,36,37]. The p-120 catenin is associated with the targeted transport and stabilization of the
adhesion complexes on the plasma membrane. Beside, β-catenin interacts with α-catenin,
which in turn initiates actin filament formation via interaction with formin at the adherens
junction [38,39,40,41,42]. However, how cadherin-catenin complexes are connected with
cytoskeletal components e.g., actin is not clearly known.
ECad has been shown linked with many early-to-late developmental and differentiation
processes in vivo and in vitro systems including ESCs, MSCs, iPSCs, and whole embryo
[43,44,45,46,47]. ECad knock out mouse was reported embryonic lethal [48,49], which is a direct
evidence of its critical importance in stem cell biology and regenerative medicine. Our lab first
envisioned the application of ECad as a novel cell-recognizable biomaterial little over a decade
ago while Nagaoka et al. endeavored to improve the differentiation and maturation efficiency
of hepatocyte in an in vitro system [50]. The idea was conceived from the fact that Fc domain
of IgG can bind directionally with an appropriate surface via hydrophobic interaction, and the
fused protein stretches out directionally to offer interaction with a suitable partner [51]. At that
period, several reports suggested that ECad is indispensable for tissue morphogenesis, and is
also required for maintenance of matured tissues. Awata et al. showed that ECad-mediated
cell-cell interaction is necessary for hepatocytes to maintain their differentiated phenotypes by
forming 3D spheroid structure, or multi-layer cell aggregates [52]. Further it was reported that
high cell density culture of fetal liver cells [53,54], which most likely is an ECad-dependent
characteristics, enhanced hepatocyte maturation in culture. These findings suggested that cell-
cell interaction may directly influence hepatocyte maturation as well as maintenance of
differentiated phenotypes. There was, however, no substantial information regarding the role
of ECad in the relevant processes, and to reveal the answer it was essential to have a suitable
tool or methodology that can expedite cell-cell interaction analysis in a controlled manner.
ECad-Fc was designed and deployed as a novel biomaterial in the regenerative medicine field
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fused as N-terminal with the Fc domain of IgG. ECad is shown here as an example. (B) Plasma-membrane localized
ECad dimer can interact with apposing ECad dimer and form high affinity binding that makes cell-cell and cell-surface
adhesion.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models140
3. Cadherins in cell biology
The cadherins is a large family of single transmembrane proteins with more than 100 members.
Out of these we will be focusing on epithelial cadherin (ECad) and neural cadherin (NCad) in
this report. They are the member of classical cadherin family, and both of them are glycosylated
in their extracellular domain. They have the ability to function as adhesion molecules for the
relevant protein-expressing cells. Generally cadherin forms homophilic dimer, and the dimeric
forms of cadherins take part in Ca+2-dependent coupling from apposing cells that mediates
cell-cell adhesion. These single transmembrane-domain plasma membrane-resident proteins
are not only necessary for cell-cell adhesion but also involved in indispensible signaling
cascades, which are critical for the development-to-homeostasis-to-demise of cells and
organisms.
The extracellular N terminal region of ECad consists of 5 structural domains, which are the
signature motifs for ECad and are responsible for the homophilic binding between two
neighboring as well as apposing molecules, while the C-terminal intracellular region of ECad
interacts with several intracellular proteins such as β-catenin/Armadillo and p-120 catenin
[35,36,37]. The p-120 catenin is associated with the targeted transport and stabilization of the
adhesion complexes on the plasma membrane. Beside, β-catenin interacts with α-catenin,
which in turn initiates actin filament formation via interaction with formin at the adherens
junction [38,39,40,41,42]. However, how cadherin-catenin complexes are connected with
cytoskeletal components e.g., actin is not clearly known.
ECad has been shown linked with many early-to-late developmental and differentiation
processes in vivo and in vitro systems including ESCs, MSCs, iPSCs, and whole embryo
[43,44,45,46,47]. ECad knock out mouse was reported embryonic lethal [48,49], which is a direct
evidence of its critical importance in stem cell biology and regenerative medicine. Our lab first
envisioned the application of ECad as a novel cell-recognizable biomaterial little over a decade
ago while Nagaoka et al. endeavored to improve the differentiation and maturation efficiency
of hepatocyte in an in vitro system [50]. The idea was conceived from the fact that Fc domain
of IgG can bind directionally with an appropriate surface via hydrophobic interaction, and the
fused protein stretches out directionally to offer interaction with a suitable partner [51]. At that
period, several reports suggested that ECad is indispensable for tissue morphogenesis, and is
also required for maintenance of matured tissues. Awata et al. showed that ECad-mediated
cell-cell interaction is necessary for hepatocytes to maintain their differentiated phenotypes by
forming 3D spheroid structure, or multi-layer cell aggregates [52]. Further it was reported that
high cell density culture of fetal liver cells [53,54], which most likely is an ECad-dependent
characteristics, enhanced hepatocyte maturation in culture. These findings suggested that cell-
cell interaction may directly influence hepatocyte maturation as well as maintenance of
differentiated phenotypes. There was, however, no substantial information regarding the role
of ECad in the relevant processes, and to reveal the answer it was essential to have a suitable
tool or methodology that can expedite cell-cell interaction analysis in a controlled manner.
ECad-Fc was designed and deployed as a novel biomaterial in the regenerative medicine field
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to address this issue; after a decade, it has been proven to be a suitable material for stem cell
technology and regenerative medicine.
4. ECad-Fc as a cell-recognizable biomaterial
As a biomaterial, ECad-Fc was first applied as plate-coating materials for hepatocyte differ‐
entiation experiments [50]. It was observed that differentiated hepatocytes can efficiently
adhere with the cell culture plate coated with ECad-Fc. The adhered cells demonstrated
comparable molecular characteristics e.g., low DNA synthesizing activity and maintenance of
tryptophan oxygenase (TO) expression like those of spheroid-form hepatocytes. As well, the
hepatocyte cultured on ECad-Fc-coated plate supported the differentiation of hepatocytes in
culture. These results suggested important roles of ECad-Fc matrix for the maintenance of
differentiating hepatocytes. This was the first report of ECad-mediated matrix dependability,
as a biomaterial, for any cell type in regenerative medicine. After a while, Nagaoka et al.
published the landmark report regarding the application of ECad-Fc cell-cooking plate (since
target cell can be obtained on such type of biomaterial-coated plate without additional cell
purification method therefore named so) as a defined matrix for successful maintenance of
murine stem cells without any feeder layer in 2006 [55]. This report signified the alluring
potential of ECad-Fc as a biomaterial for practical application in stem cell technology and
regenerative medicine.
Xenogeneic-agent free stem cell culture method is extremely critical if the objective of the
relevant protocol is to apply the relevant products in regenerative medicine. Since MEF secrets
many unidentified molecules, which are potential xenogeneic elements for human subject
therefore feeder-cell-based early methodologies are not considerable for applying in regener‐
ative medicine. Matrigel is also produced from mouse carcinoma tissue and ill-defined
therefore causing serious known and unknown hazards of xenogeneic contamination in
experimentations. An immunogenic sialic acid (NeuGc) has been identified in a co-culture
experiment for human ESCs applying MEF and animal derivatives as serum replacement
[24,56]. This is specifically worrying as such kind of non-human sialic acid can initiate
immunogenic processes in human triggering complete graft rejection and consequential
complexities. Non-human animal-derived products also can be a possible cause for myco‐
plasma contamination, which can directly infect the cells in culture and either damage them
totally or can change their properties, and thereby directly or indirectly initiate complicacies
for regenerative medicine protocols. Human feeder-cells and serum have been recommended
for culturing human ESCs to evade xenogeneic compound in experimental system for
regenerative medicine. However, this is associated with a high risk of microbial contamination,
for example retroviral components, and hence are not as suitable for in vivo application.
Therefore it is a prime importance to establish completely defined human stem cell culture
system for safe application of relevant products in regenerative medicine.
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5. ECad-Fc is a unique defined matrix for ESC and MSC
The study of Nagaoka et al. [55] revealed that murine ESCs can maintain their pluripotency on
ECad-Fc-coated surface for extended culture periods (Fig. 2). Cells cultured on such type of
substratum were later successfully used to generate germline-competent chimeric mouse [57].
Consistent with the findings, a separate study using mouse mesenchymal cell lines STO and
NIH3T3 stably expressed with ECad as feeder-cell showed higher level of stem cell marker
expression with standard colony-forming phenotype compare to the cells cultured on normal
MEF-feeder-cell layer [58]. A number of feeder-free culture methods for ESCs have been
reported where ESCs grow with their standard tightly-bound colony phenotype
[4,11,13,22,24,56,59]. This type of tight colony formation generates heterogeneous cell popu‐
lation within a colony, which potentially affects homogenous accessibility of cytokines to these
cells as well as creates heterogeneous niches. As a result stem cells in a colony differentiate
heterogeneously and produce various kinds of cells as contamination with the desired type of
cells, a major drawback that regenerative medicine has to overcome. In this respect, ECad-Fc
matrix drives murine stem cells out of the colony to form a normal monolayer of cells, where
stem cell resides as single cell condition [55]. This is a ground breaking technology that
provides an exciting solution for overcoming the inherent colony forming phenotype-linked
cellular heterogeneity. Biochemical analyses revealed that these cells bear all the signatures of
pluripotent stem cells, and can form all three germ layers in a teratoma forming assay, and as
mentioned earlier can generate germline-competent chimeric mouse. Additionally, they
require lower amounts of LIF for maintenance of pluripotency, reducing costs related to ESCs
culture. The monolayer-type single cell ESCs was also associated with higher proliferation
ability and greater transfection efficiency compared to the colony-forming cells cultured on
other substratum. Such improved proliferation ability could be extremely helpful for quick
amplification of iPSCs on ECad-Fc substratum, which could mean shorter waiting periods for
patients to receive cell therapy. The higher transfection efficiency of stem cells on ECad-Fc
cooking plate could be exploited for targeted delivery of desired extracellular cargo for
example, transgene products or drug molecules, into these cells for better outcomes.
This type of cooking-plate technology, where ECad-Fc provides basal support to the cells, and
other immobilized factors for example, LIF-Fc [57] which satisfy specific needs, can be very
advantageous for (1) ensuring undifferentiated state of stem cell in culture, (2) cost reduction
associated with cytokines, and (3) hassle-free working condition without the necessity of
regular media change, which is a standard time-consuming practice for stem cell culture.
The single-cell phenotype seen for ESCs was also observed for other stem cells for example,
mouse embryonal carcinoma cells F9 and P19 but not for differentiated cells for example,
NMuMG mouse mammary gland cells, MDCK kidney epithelial cells and isolated mouse
primary hepatocytes [60]. This result indicated that ECad-Fc-mediated cellular migratory
behaviors are most likely specific for embryonic stem cells. Reportable that ECad-facilitated
cell-cell adhesion is often rearranged during initial stages of embryogenesis to control cell
migration, cell sorting, and tissue function, which is suggesting a close cooperativity of stem
cell maintenance, proliferation, and differentiation with ECad [39,48,49,61,62]. However, there
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to address this issue; after a decade, it has been proven to be a suitable material for stem cell
technology and regenerative medicine.
4. ECad-Fc as a cell-recognizable biomaterial
As a biomaterial, ECad-Fc was first applied as plate-coating materials for hepatocyte differ‐
entiation experiments [50]. It was observed that differentiated hepatocytes can efficiently
adhere with the cell culture plate coated with ECad-Fc. The adhered cells demonstrated
comparable molecular characteristics e.g., low DNA synthesizing activity and maintenance of
tryptophan oxygenase (TO) expression like those of spheroid-form hepatocytes. As well, the
hepatocyte cultured on ECad-Fc-coated plate supported the differentiation of hepatocytes in
culture. These results suggested important roles of ECad-Fc matrix for the maintenance of
differentiating hepatocytes. This was the first report of ECad-mediated matrix dependability,
as a biomaterial, for any cell type in regenerative medicine. After a while, Nagaoka et al.
published the landmark report regarding the application of ECad-Fc cell-cooking plate (since
target cell can be obtained on such type of biomaterial-coated plate without additional cell
purification method therefore named so) as a defined matrix for successful maintenance of
murine stem cells without any feeder layer in 2006 [55]. This report signified the alluring
potential of ECad-Fc as a biomaterial for practical application in stem cell technology and
regenerative medicine.
Xenogeneic-agent free stem cell culture method is extremely critical if the objective of the
relevant protocol is to apply the relevant products in regenerative medicine. Since MEF secrets
many unidentified molecules, which are potential xenogeneic elements for human subject
therefore feeder-cell-based early methodologies are not considerable for applying in regener‐
ative medicine. Matrigel is also produced from mouse carcinoma tissue and ill-defined
therefore causing serious known and unknown hazards of xenogeneic contamination in
experimentations. An immunogenic sialic acid (NeuGc) has been identified in a co-culture
experiment for human ESCs applying MEF and animal derivatives as serum replacement
[24,56]. This is specifically worrying as such kind of non-human sialic acid can initiate
immunogenic processes in human triggering complete graft rejection and consequential
complexities. Non-human animal-derived products also can be a possible cause for myco‐
plasma contamination, which can directly infect the cells in culture and either damage them
totally or can change their properties, and thereby directly or indirectly initiate complicacies
for regenerative medicine protocols. Human feeder-cells and serum have been recommended
for culturing human ESCs to evade xenogeneic compound in experimental system for
regenerative medicine. However, this is associated with a high risk of microbial contamination,
for example retroviral components, and hence are not as suitable for in vivo application.
Therefore it is a prime importance to establish completely defined human stem cell culture
system for safe application of relevant products in regenerative medicine.
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5. ECad-Fc is a unique defined matrix for ESC and MSC
The study of Nagaoka et al. [55] revealed that murine ESCs can maintain their pluripotency on
ECad-Fc-coated surface for extended culture periods (Fig. 2). Cells cultured on such type of
substratum were later successfully used to generate germline-competent chimeric mouse [57].
Consistent with the findings, a separate study using mouse mesenchymal cell lines STO and
NIH3T3 stably expressed with ECad as feeder-cell showed higher level of stem cell marker
expression with standard colony-forming phenotype compare to the cells cultured on normal
MEF-feeder-cell layer [58]. A number of feeder-free culture methods for ESCs have been
reported where ESCs grow with their standard tightly-bound colony phenotype
[4,11,13,22,24,56,59]. This type of tight colony formation generates heterogeneous cell popu‐
lation within a colony, which potentially affects homogenous accessibility of cytokines to these
cells as well as creates heterogeneous niches. As a result stem cells in a colony differentiate
heterogeneously and produce various kinds of cells as contamination with the desired type of
cells, a major drawback that regenerative medicine has to overcome. In this respect, ECad-Fc
matrix drives murine stem cells out of the colony to form a normal monolayer of cells, where
stem cell resides as single cell condition [55]. This is a ground breaking technology that
provides an exciting solution for overcoming the inherent colony forming phenotype-linked
cellular heterogeneity. Biochemical analyses revealed that these cells bear all the signatures of
pluripotent stem cells, and can form all three germ layers in a teratoma forming assay, and as
mentioned earlier can generate germline-competent chimeric mouse. Additionally, they
require lower amounts of LIF for maintenance of pluripotency, reducing costs related to ESCs
culture. The monolayer-type single cell ESCs was also associated with higher proliferation
ability and greater transfection efficiency compared to the colony-forming cells cultured on
other substratum. Such improved proliferation ability could be extremely helpful for quick
amplification of iPSCs on ECad-Fc substratum, which could mean shorter waiting periods for
patients to receive cell therapy. The higher transfection efficiency of stem cells on ECad-Fc
cooking plate could be exploited for targeted delivery of desired extracellular cargo for
example, transgene products or drug molecules, into these cells for better outcomes.
This type of cooking-plate technology, where ECad-Fc provides basal support to the cells, and
other immobilized factors for example, LIF-Fc [57] which satisfy specific needs, can be very
advantageous for (1) ensuring undifferentiated state of stem cell in culture, (2) cost reduction
associated with cytokines, and (3) hassle-free working condition without the necessity of
regular media change, which is a standard time-consuming practice for stem cell culture.
The single-cell phenotype seen for ESCs was also observed for other stem cells for example,
mouse embryonal carcinoma cells F9 and P19 but not for differentiated cells for example,
NMuMG mouse mammary gland cells, MDCK kidney epithelial cells and isolated mouse
primary hepatocytes [60]. This result indicated that ECad-Fc-mediated cellular migratory
behaviors are most likely specific for embryonic stem cells. Reportable that ECad-facilitated
cell-cell adhesion is often rearranged during initial stages of embryogenesis to control cell
migration, cell sorting, and tissue function, which is suggesting a close cooperativity of stem
cell maintenance, proliferation, and differentiation with ECad [39,48,49,61,62]. However, there
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is no such suitable system to explore the necessary signaling pathways to address these
questions. Nevertheless, since ESC does not form colony on ECad-Fc cell-cooking plate
therefore this can be a perfect tool for obtaining single cell model system of stem cells to
investigate relevant signaling pathways necessary for stem cell maintenance, proliferation,
and differentiation. Our recent study successfully exploited this single-cell phenotype for
monitoring cell cycle properties of stem cells on cell-cooking plate (unpublished), indicating
the importance of this system for cell biology experiments designed to reveal their individual
characteristics. The findings could be invaluable for regulating stem cells for desired applica‐
tion in regenerative medicine.
Most of the stem cell innovations, comprising generation of ESCs and iPSCs, were primarily
established in mouse model, and then applied in human models. Similarly, ECad-Fc cell-
cooking plate technology was first developed and established for murine stem cells [55,57].
Thereafter, ECad-Fc cooking-plate was successfully applied for human ESC culture following
similar methodologies with additional consideration for mild enzymatic treatment during the
cell dissociation and seeding steps [56]. A strong protease cocktail Accutase (Millipore) was
used for murine ESC culture; however, Accutase treatment was found detrimental to human
ESCs, which was recuperated by using enzyme-free proprietary preparation named, Cell
Dissociation Buffer (Life Technologies). It is reportable that the human ESCs were cultured on
Figure 2. ECad-Fc is a defined matrix for culturing monolayer of iPS cells. Mouse EB3 cells were successfully cultured
on ECad-Fc-coated surface that showed monolayer phenotype (C and D) compare with compact colony phenotype (A
and B) for general protocol, which was significantly advantageous for faster growth (E), and higher transfection efi‐
ciency (F).
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ECad-Fc cooking plate with a completely defined media named mTeSR1 (Stemcell Technolo‐
gies), and that made the culture method completely defined and xenogeneic-agent free, which
is a significant achievement in regenerative medicine. The stem cells cultured on ECad-Fc
cooking-plate were practically identical to those cultured on Matrigel-coated plate including
cell morphology, proliferation rate, preservation of undifferentiated phenotype, and ability of
differentiation into multiple cell types in embryoid bodies as well as in teratoma assay [56].
Interestingly, contrasting with the single-cell phenotype for mouse ESCs, human ESCs
produced normal colony forming phenotype on ECad-Fc cooking-plate. The mechanism
underlying the difference for this observation was not completely understood though.
Human and mouse ESCs have been shown to demonstrate significant disparities in expression
of cell surface markers, transcription factors, cytokines, and proteins in them. The difference
was evidently recognized by the fact that mouse ESC can be maintained in undifferentiated
state with the addition of LIF devoid of feeder-cell but human ESC cannot [14]. It has been
shown that the inhibition of Rho-ROCK signaling pathway generates cell scattering in human
ESCs suggesting direct connection between cell scattering and signaling pathways [63]. While
both mouse and human ESCs express ECad, however, it appears there are diverse additional
factors involved to define ECad-mediated activities in these cells and additional investigations
are required to reveal the complete molecular circuitry associated to this phenomenon.
MSC is a type of ASCs, and can be collected from donor by satisfying approved ethical issues.
These cells have been considered as potential starting materials for regenerative medicine and
tissue engineering. They must be expanded in vitro before dispensing for specific applications
to accomplish anticipated therapeutic effects. MSCs also need xenogeneic agent-free culture
method for maintaining their differentiation potency over the culture period. ECad-Fc
cooking-plate technology was effectively applied for this reason as well [43]. The cultured
MSCs on human ECad-Fc (hECad-Fc) matrix exhibited superior attachment on culture plate
compare with standard tissue culture plate and gelatin-coated plate. The MSCs cultured on
hECad-Fc showed comparable level of CD 105 and significantly greater level of β-catenin and
ECad expression. It has been reported that β-catenin enhances the activity of Oct-4, which is
one of the principal Yamanaka factors that plays critical function during the regulation of self-
renewal of ESC [45,64], on conjecture it can be suggested that MSCs maintained on ECad-FC
cooking-plate might preserve superior stem-ness compare to the MSCs maintained on tissue
culture-treated plate and gelatin-coated plate, and therefore possess greater applicability for
regenerative medicine.
6. ECad-Fc in directed differentiation and in-situ cell sorting of stem cell
Targeted differentiation of stem cells and enrichment of desired cell for example, hepatocytes,
from the pool of differentiated cells are very important steps towards use of the cells for
regenerative medicine. Functionally matured hepatocytes derived from stem cells can be a
potential remedy for various hepatic diseases. There have been several hepatic differentiation
protocols reported from ESCs using orthodox techniques including embryonic body (EB)
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is no such suitable system to explore the necessary signaling pathways to address these
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monitoring cell cycle properties of stem cells on cell-cooking plate (unpublished), indicating
the importance of this system for cell biology experiments designed to reveal their individual
characteristics. The findings could be invaluable for regulating stem cells for desired applica‐
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cooking plate technology was first developed and established for murine stem cells [55,57].
Thereafter, ECad-Fc cooking-plate was successfully applied for human ESC culture following
similar methodologies with additional consideration for mild enzymatic treatment during the
cell dissociation and seeding steps [56]. A strong protease cocktail Accutase (Millipore) was
used for murine ESC culture; however, Accutase treatment was found detrimental to human
ESCs, which was recuperated by using enzyme-free proprietary preparation named, Cell
Dissociation Buffer (Life Technologies). It is reportable that the human ESCs were cultured on
Figure 2. ECad-Fc is a defined matrix for culturing monolayer of iPS cells. Mouse EB3 cells were successfully cultured
on ECad-Fc-coated surface that showed monolayer phenotype (C and D) compare with compact colony phenotype (A
and B) for general protocol, which was significantly advantageous for faster growth (E), and higher transfection efi‐
ciency (F).
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ECad-Fc cooking plate with a completely defined media named mTeSR1 (Stemcell Technolo‐
gies), and that made the culture method completely defined and xenogeneic-agent free, which
is a significant achievement in regenerative medicine. The stem cells cultured on ECad-Fc
cooking-plate were practically identical to those cultured on Matrigel-coated plate including
cell morphology, proliferation rate, preservation of undifferentiated phenotype, and ability of
differentiation into multiple cell types in embryoid bodies as well as in teratoma assay [56].
Interestingly, contrasting with the single-cell phenotype for mouse ESCs, human ESCs
produced normal colony forming phenotype on ECad-Fc cooking-plate. The mechanism
underlying the difference for this observation was not completely understood though.
Human and mouse ESCs have been shown to demonstrate significant disparities in expression
of cell surface markers, transcription factors, cytokines, and proteins in them. The difference
was evidently recognized by the fact that mouse ESC can be maintained in undifferentiated
state with the addition of LIF devoid of feeder-cell but human ESC cannot [14]. It has been
shown that the inhibition of Rho-ROCK signaling pathway generates cell scattering in human
ESCs suggesting direct connection between cell scattering and signaling pathways [63]. While
both mouse and human ESCs express ECad, however, it appears there are diverse additional
factors involved to define ECad-mediated activities in these cells and additional investigations
are required to reveal the complete molecular circuitry associated to this phenomenon.
MSC is a type of ASCs, and can be collected from donor by satisfying approved ethical issues.
These cells have been considered as potential starting materials for regenerative medicine and
tissue engineering. They must be expanded in vitro before dispensing for specific applications
to accomplish anticipated therapeutic effects. MSCs also need xenogeneic agent-free culture
method for maintaining their differentiation potency over the culture period. ECad-Fc
cooking-plate technology was effectively applied for this reason as well [43]. The cultured
MSCs on human ECad-Fc (hECad-Fc) matrix exhibited superior attachment on culture plate
compare with standard tissue culture plate and gelatin-coated plate. The MSCs cultured on
hECad-Fc showed comparable level of CD 105 and significantly greater level of β-catenin and
ECad expression. It has been reported that β-catenin enhances the activity of Oct-4, which is
one of the principal Yamanaka factors that plays critical function during the regulation of self-
renewal of ESC [45,64], on conjecture it can be suggested that MSCs maintained on ECad-FC
cooking-plate might preserve superior stem-ness compare to the MSCs maintained on tissue
culture-treated plate and gelatin-coated plate, and therefore possess greater applicability for
regenerative medicine.
6. ECad-Fc in directed differentiation and in-situ cell sorting of stem cell
Targeted differentiation of stem cells and enrichment of desired cell for example, hepatocytes,
from the pool of differentiated cells are very important steps towards use of the cells for
regenerative medicine. Functionally matured hepatocytes derived from stem cells can be a
potential remedy for various hepatic diseases. There have been several hepatic differentiation
protocols reported from ESCs using orthodox techniques including embryonic body (EB)
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formation, and clustered colony formation on gelatin- or feeder-cell-coated plates [52,54].
However, these protocols come with many drawbacks, for example, heterogeneous cell
population, spontaneous differentiation, xenogeneic contamination, inefficient conversion to
hepatocytes, requirement for enrichment of target cell population etc. Our group has effec‐
tively applied ECad-Fc as a cell-recognizable plate-coating materials that facilitated good
quality mouse ESCs in culture with superior proliferative activities and single-cell phenotype.
Similarly, the cell-recognition property of such Cadherin-Fc chimeric protein was exploited
for the possibility of facilitated differentiation of ESCs to specific cells for example, hepatocytes
and neural cells [29,30,50,65]. Remarkably, ECad-Fc substratum favored progressive differen‐
tiation of ESCs to cells with features of definitive endoderm, hepatic progenitor cells, and
finally phenotypical as well as functional hepatocytes-like cells [30,50]. The ECad-Fc-coated
substratum stimulated selective hepatocyte differentiation in association with ectopic hepa‐
tocyte-producing cocktail resulting around 55% hepatic endoderm cells devoid of neuroecto‐
derm and mesoderm markers [30]. High level of (approximately 98%) ECad and developing-
hepatocyte marker α-fetoprotein (FTP) were co-expressed in these cells. Since these
differentiating hepatocytes express high level of ECad on the plasma membrane therefore
ECad-Fc was employed for on-site one-step enrichment of de novo hepatocyte-like cells.
Practically, 92% albumin expressing cells were successfully harvested on ECad-Fc cooking-
plate without any harsh enzymatic treatment or mechanical cell sorting, which are usually
detrimental for cells [30]. Therefore the technology can be successfully applied for quick and
stress-free cell purification, which will be useful in regenerative medicine.
The enhanced differentiation and cell-recognizable properties were also observed with ECad-
Fc and NCad-Fc-based mixed biomaterial cooking-plate for neural cells [65], and is discussed
in detail under NCad-Fc section. Such kind of ECad-Fc and NCad-Fc hybrid cooking-plate can
be applied for either generation of large number of homogeneous cell population, which can
be applied for therapeutic evaluation, or for analyzing the signaling pathways related to nerve
generation at a single cell level.
7. ECad-Fc is a superior matrix for iPSC
iPSCs are commonly derived from somatic cells by ectopic and forced expression of common
transcription factors Oct4, Sox2, and Nanog along with protocol-dependent treatments with
cocktails of some other transcription factors, and even miRNA or small molecules
[10,66,67,68,69,70,71,72,73]. Despite the existence of many protocols for generating iPSCs, the
required time and efficiency of iPSC generation is still not practical for application of the
technology to a mass scale. As per recent published information, depending on protocol, it
may take somewhere between 2~4 weeks to get a 1% conversion of cells to iPSCs. During the
reprograming process, starting cells experience mesenchymal-to-epithelial transitions (METs)
as a natural requirement [74]. This fact was further proved by the findings that MET happens
during the initial stage of reprograming process [71,74,75]. Recent evidence further suggested
significant functional roles of ECad and other cell adhesion molecules in METs.
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ECad interacts with cytoskeletal components via various intracellular molecules for example,
α-catenin, β-catenin, and p-120 [38]. ECad-mediated signaling was found associated with
cytoskeletal remodeling processes through Rho activation [41,63,76]. ECad has been estab‐
lished as an essential factor for maintaining typical colony-forming phenotype of ESCs and
iPSCs. Recent studies, remarkably, revealed that forced expression of ECad can significantly
enhance the effectiveness of relevant iPSCs-generation protocol [45]. A separate study revealed
that ECad expression was enhanced upon treatment with small molecules resulting in
enhanced efficiency for the relevant iPSC-generation protocol [77]. This enhanced productivity
for iPSCs was successfully reproduced by the application of N terminal extracellular domains
of ECad, which suggested that the phenomenon is mainly mediated by the extracellular
functional domains of this protein [77]. Most importantly, ECad was sufficient to generate
iPSCs with only three Yamanaka factors –KLF4, SOX2, and c-MYC from murine fibroblasts
without OCT4 [45]. This study indicated that the spatial and mechanical input exerted by ECad
has a critical role in driving cell fate. However, it is not clearly understood how ECad can
compensate for OCT4. Since many studies showed that where it was possible to skip other
factors of Yamanaka-cocktail for reprograming of somatic cells to iPSCs but OCT4 was hardly
indispensable [10,70,78], further studies are warranted to determine the underlying mecha‐
nism. One potential explanation might be that ECad and KLF4 together initiated an early MET
process of the experimental cells, and then SOX2 and KLF4 operated co-operatively to propel
pluripotency genes to induce initiation of reprogramming [74]. The hypothesis is favored by
the fact that cells those already express ECad, for example keratinocytes, can be reprogrammed
more effectively and quicker because the MET process is not required [71]. Since the extracel‐
lular domain of ECad is adequate to produce ECad-mediated influences related to the
reprogramming of somatic cells to iPSCs we have therefore assumed that ECad-Fc could
significantly enhance the reprogramming efficiency. Our preliminary observation suggested
that indeed co-transfection of ECad-Fc-expressing plasmid with Yamanaka factors enhanced
reprograming efficiency of mouse fibroblast (unpublished). Enhanced reprogramming
efficiency was further witnessed while the Yamanaka-cocktail-transfected starting cells were
cultured on ECad-Fc-coated plate compare to gelatin-coated plate. However, further experi‐
ments are necessary for providing detail quantitative and qualitative information for these
observations. Nonetheless this finding is highly promising regarding enhanced and efficient
generation of iPSCs using a biomaterial as substratum.
The protocols for generating ESCs or iPSCs as well as differentiation to target cells from these
cells require cell isolation step either by mechanical process or in combination with enzymatic
treatment [79]. These types of methodologies require skilled labor, specialized instrumenta‐
tion, additional time and cost, and distinct morphologic and phenotypic features. Several
protocols have been described recently for enzyme-selective passage of specific cells; however,
they are not globally applicable and very often appeared with unwanted cells. Enzymatic
treatment also caused karyotypic anomalies compared with manual passaging [66,80]. FACS
protocol has been applied for cell sorting based on surface marker recognition. However,
relevant protocols need enzymatic treatment, application of foreign molecules, and mechanical
processes involving severe stress on experimental cells [81,82], which are highly unfavorable
for cells. ECad-Fc cooking-plate, advantageously, neither needs any kind of mechanical sorting
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formation, and clustered colony formation on gelatin- or feeder-cell-coated plates [52,54].
However, these protocols come with many drawbacks, for example, heterogeneous cell
population, spontaneous differentiation, xenogeneic contamination, inefficient conversion to
hepatocytes, requirement for enrichment of target cell population etc. Our group has effec‐
tively applied ECad-Fc as a cell-recognizable plate-coating materials that facilitated good
quality mouse ESCs in culture with superior proliferative activities and single-cell phenotype.
Similarly, the cell-recognition property of such Cadherin-Fc chimeric protein was exploited
for the possibility of facilitated differentiation of ESCs to specific cells for example, hepatocytes
and neural cells [29,30,50,65]. Remarkably, ECad-Fc substratum favored progressive differen‐
tiation of ESCs to cells with features of definitive endoderm, hepatic progenitor cells, and
finally phenotypical as well as functional hepatocytes-like cells [30,50]. The ECad-Fc-coated
substratum stimulated selective hepatocyte differentiation in association with ectopic hepa‐
tocyte-producing cocktail resulting around 55% hepatic endoderm cells devoid of neuroecto‐
derm and mesoderm markers [30]. High level of (approximately 98%) ECad and developing-
hepatocyte marker α-fetoprotein (FTP) were co-expressed in these cells. Since these
differentiating hepatocytes express high level of ECad on the plasma membrane therefore
ECad-Fc was employed for on-site one-step enrichment of de novo hepatocyte-like cells.
Practically, 92% albumin expressing cells were successfully harvested on ECad-Fc cooking-
plate without any harsh enzymatic treatment or mechanical cell sorting, which are usually
detrimental for cells [30]. Therefore the technology can be successfully applied for quick and
stress-free cell purification, which will be useful in regenerative medicine.
The enhanced differentiation and cell-recognizable properties were also observed with ECad-
Fc and NCad-Fc-based mixed biomaterial cooking-plate for neural cells [65], and is discussed
in detail under NCad-Fc section. Such kind of ECad-Fc and NCad-Fc hybrid cooking-plate can
be applied for either generation of large number of homogeneous cell population, which can
be applied for therapeutic evaluation, or for analyzing the signaling pathways related to nerve
generation at a single cell level.
7. ECad-Fc is a superior matrix for iPSC
iPSCs are commonly derived from somatic cells by ectopic and forced expression of common
transcription factors Oct4, Sox2, and Nanog along with protocol-dependent treatments with
cocktails of some other transcription factors, and even miRNA or small molecules
[10,66,67,68,69,70,71,72,73]. Despite the existence of many protocols for generating iPSCs, the
required time and efficiency of iPSC generation is still not practical for application of the
technology to a mass scale. As per recent published information, depending on protocol, it
may take somewhere between 2~4 weeks to get a 1% conversion of cells to iPSCs. During the
reprograming process, starting cells experience mesenchymal-to-epithelial transitions (METs)
as a natural requirement [74]. This fact was further proved by the findings that MET happens
during the initial stage of reprograming process [71,74,75]. Recent evidence further suggested
significant functional roles of ECad and other cell adhesion molecules in METs.
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ECad interacts with cytoskeletal components via various intracellular molecules for example,
α-catenin, β-catenin, and p-120 [38]. ECad-mediated signaling was found associated with
cytoskeletal remodeling processes through Rho activation [41,63,76]. ECad has been estab‐
lished as an essential factor for maintaining typical colony-forming phenotype of ESCs and
iPSCs. Recent studies, remarkably, revealed that forced expression of ECad can significantly
enhance the effectiveness of relevant iPSCs-generation protocol [45]. A separate study revealed
that ECad expression was enhanced upon treatment with small molecules resulting in
enhanced efficiency for the relevant iPSC-generation protocol [77]. This enhanced productivity
for iPSCs was successfully reproduced by the application of N terminal extracellular domains
of ECad, which suggested that the phenomenon is mainly mediated by the extracellular
functional domains of this protein [77]. Most importantly, ECad was sufficient to generate
iPSCs with only three Yamanaka factors –KLF4, SOX2, and c-MYC from murine fibroblasts
without OCT4 [45]. This study indicated that the spatial and mechanical input exerted by ECad
has a critical role in driving cell fate. However, it is not clearly understood how ECad can
compensate for OCT4. Since many studies showed that where it was possible to skip other
factors of Yamanaka-cocktail for reprograming of somatic cells to iPSCs but OCT4 was hardly
indispensable [10,70,78], further studies are warranted to determine the underlying mecha‐
nism. One potential explanation might be that ECad and KLF4 together initiated an early MET
process of the experimental cells, and then SOX2 and KLF4 operated co-operatively to propel
pluripotency genes to induce initiation of reprogramming [74]. The hypothesis is favored by
the fact that cells those already express ECad, for example keratinocytes, can be reprogrammed
more effectively and quicker because the MET process is not required [71]. Since the extracel‐
lular domain of ECad is adequate to produce ECad-mediated influences related to the
reprogramming of somatic cells to iPSCs we have therefore assumed that ECad-Fc could
significantly enhance the reprogramming efficiency. Our preliminary observation suggested
that indeed co-transfection of ECad-Fc-expressing plasmid with Yamanaka factors enhanced
reprograming efficiency of mouse fibroblast (unpublished). Enhanced reprogramming
efficiency was further witnessed while the Yamanaka-cocktail-transfected starting cells were
cultured on ECad-Fc-coated plate compare to gelatin-coated plate. However, further experi‐
ments are necessary for providing detail quantitative and qualitative information for these
observations. Nonetheless this finding is highly promising regarding enhanced and efficient
generation of iPSCs using a biomaterial as substratum.
The protocols for generating ESCs or iPSCs as well as differentiation to target cells from these
cells require cell isolation step either by mechanical process or in combination with enzymatic
treatment [79]. These types of methodologies require skilled labor, specialized instrumenta‐
tion, additional time and cost, and distinct morphologic and phenotypic features. Several
protocols have been described recently for enzyme-selective passage of specific cells; however,
they are not globally applicable and very often appeared with unwanted cells. Enzymatic
treatment also caused karyotypic anomalies compared with manual passaging [66,80]. FACS
protocol has been applied for cell sorting based on surface marker recognition. However,
relevant protocols need enzymatic treatment, application of foreign molecules, and mechanical
processes involving severe stress on experimental cells [81,82], which are highly unfavorable
for cells. ECad-Fc cooking-plate, advantageously, neither needs any kind of mechanical sorting
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nor any harsh chemical or enzymatic treatment. The experimental cells can selectively and
strongly make homophilic binding with ECad-Fc matrix in a Ca+2-dependent manner subjected
to the differential expression pattern of ECad in them during the transformation process. The
cells with no or low level expression of ECad cannot and does not firmly bind with ECad-Fc
substratum and can be washed off with suitable buffer thus offering a unique, robust, and
stress-free cell enrichment system. Such a protocol ensures quicker, cheaper and convenient
cell enrichment system for in vitro culture without risk of additional contamination and cellular
alteration, and therefore, is highly advantageous for application in regenerative medicine and
tissue engineering to achieve desired therapeutic effect with minimal adverse consequences.
8. NCad in cell biology
N-cadherin (NCad) or neural cadherin is also known as Cadherin-2, which is encoded in
human by CADH2 gene [83,84]. Like ECad, it is also a cell-cell adhesion molecule composed
of five extracellular cadherin domains, a transmembrane domain and a highly conserved
cytoplasmic region. NCad can exist either as strand dimers or in an alternate monomeric form
[85]. NCad typically forms homotypic homophilic interactions between two neighbouring cells
for example, Sertoli cells and spermatides, and also heterotypic homophilic and heterophilic
interactions, such as interaction between N- and R-cadherin in transfected L cells [86]; such
interactions are Ca+2 dependent [87], and can be reversed by withdrawing Ca+2 from the system.
During embryogenesis cells undergo an epithelial-mesenchymal transition (EMT) initiating
upregulation of NCad and the downregulation of ECad in the mesoderm [88]. It has been
suggested that NCad expression is essential for morphogenesis of the mesodermal germ layer
during gastrulation [89]. NCad expression pattern has been found complementary to that of
ECad in epidermal ectoderm [88,90,91]. NCad expression has been detected in mesoderm and
notochord in the early phase of embryonic development, which is later also evident in neural
tissue, lens placode [92], some epithelial tissues, myocardium of heart [93], epiblast of skeletal
muscle [94], endothelial cells, osteoblasts, mesothelium, limb cartilage, and primordial germ
cells [95,96].
NCad is found to be present in the early hematopoietic progenitor CD34+CD19+ cells, and it
was proposed that NCad plays critical role for the hematopoietic cell differentiation as well as
the early retention of this subpopulation in bone marrow [97]. During skeletal muscle forma‐
tion mesodermal precursors exit from the cell cycle, and differentiate into myoblasts that
terminally differentiates into multinucleate myofibers [98]. Cell cycle arrest and the expression
of skeletal muscle–specific genes are the critical checkpoints for this developmental process
[99]. All the epiblast cells undergoing skeletal myogenesis express the skeletal muscle-specific
transcription factor MyoD, among them only the cells expressing NCad but not ECad can
differentiate into skeletal muscle [94]. NCad function-perturbing antibodies showed that it
plays a significant role in interaction between myoblasts in myotube formation and in
myofibrillogenesis [100,101,102]. NCad is also found to be involved in myoblast migration in
limb bud [103].
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Cartilage is formed from the vertebrate embryonic limb by a highly synchronized and
systematic event of cell commitment, condensation and chondrogenic differentiation of
mesenchymal cells to chondrogens, and by the production of cartilaginous matrix. SOX9, an
essential transcription factor for chondrocyte differentiation and cartilage formation, binds to
the SOX9-binding motif in NCad promoter [104] that facilitates expressing of NCad gene
products to play necessary roles in cellular condensation [105]. Prolonged expression of NCad
due to the missexpression of wnt7a stabilizes NCad-mediated cell-cell adhesion resulting
inhibition of chondrogenesis from mesenchymal chondrogenic culture [106]. The level of
NCad mRNA was found increases during osteoblast differentiation and decreased during
adipogenic differentiation thus suggesting their involvement in relevant differentiation
processes [107]. NCad expression is increased in osteoblasts by BMP-2, FGF-2 and phorbol
ester (e.g., PMA) in PKC-dependent manner, whereas factors like TNFα and IL-1 reduce the
expression of NCad [108].
Migratory cell populations, also known as neural crest cells, are pluripotent cells those
originate from dorsal part of neural tube and play important roles in embryonic development
and pathophysiological conditions. These cells express NCad when they are associated with
neural tube; however, NCad expression is down-regulated after EMT process and the relevant
cells started to migrate over long distance, and finally transform into different types of tissues
and cell populations, such as peripheral nervous system, cartilage, bone and melanocytes. Slug
plays here important roles in down-regulating NCad that leads to a loss of cell-cell adhesion
and allowing the cells to migrate. The dorso-ventral migratory cells re-express NCad during
dorsal root and sympathetic ganglia developmental steps and promotes cell aggregation;
thereafter, only dermal melanocytes express NCad [109,110]. This observation is suggesting
critical involvement of NCad in the development of relevant tissues.
Several proteins can interact with NCad via intracellular and extracellular domains and
influence subsequent signaling pathways. The functions of NCad in controlling neurite
outgrowth, synaptic plasticity and guidance in synapse formation have been proposed [111].
These functions may involve interaction with other membrane bound molecules, such as
fibroblast growth factor receptor (FGFR), which was confirmed by blocking the FGFR by
pharmacological inhibitor [112]. NCad directly interacts with FGFR via HAV epitope of FGFR
with IDPVNGQ epitope of EC4 of NCad [112], and this interaction between NCad and FGFR
can be of both ligand dependent and independent [113] suggesting wider cooperative
functional significance of this duo in relevant development and physiology.
EMT of squamous epithelial cells ectopically expressed specific amino acid sequences of EC4
of NCad induces motility. The cell motility behavior and adhesion is independent to each other,
as antibody against the aforementioned relevant amino acid sequence of NCad inhibits cell
motility but the cell-cell adhesion phenomena was uninterrupted [114]. The influence of NCad
mediated cell migration is cell type specific, as it was found that NCad can inhibit LM8 mouse
osteosarcoma cell migration but it did not have any significant effect on the movement of
MDA-MB-435 cells [115]. The cytoplasmic domain of NCad form complexes with various types
of molecules, such as p120, β-catenin, α-catenin and GAP-43, and regulate various cytoskeletal
dynamics. All of these interactions are critically involved in tissue-to-animal development,
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cytoplasmic region. NCad can exist either as strand dimers or in an alternate monomeric form
[85]. NCad typically forms homotypic homophilic interactions between two neighbouring cells
for example, Sertoli cells and spermatides, and also heterotypic homophilic and heterophilic
interactions, such as interaction between N- and R-cadherin in transfected L cells [86]; such
interactions are Ca+2 dependent [87], and can be reversed by withdrawing Ca+2 from the system.
During embryogenesis cells undergo an epithelial-mesenchymal transition (EMT) initiating
upregulation of NCad and the downregulation of ECad in the mesoderm [88]. It has been
suggested that NCad expression is essential for morphogenesis of the mesodermal germ layer
during gastrulation [89]. NCad expression pattern has been found complementary to that of
ECad in epidermal ectoderm [88,90,91]. NCad expression has been detected in mesoderm and
notochord in the early phase of embryonic development, which is later also evident in neural
tissue, lens placode [92], some epithelial tissues, myocardium of heart [93], epiblast of skeletal
muscle [94], endothelial cells, osteoblasts, mesothelium, limb cartilage, and primordial germ
cells [95,96].
NCad is found to be present in the early hematopoietic progenitor CD34+CD19+ cells, and it
was proposed that NCad plays critical role for the hematopoietic cell differentiation as well as
the early retention of this subpopulation in bone marrow [97]. During skeletal muscle forma‐
tion mesodermal precursors exit from the cell cycle, and differentiate into myoblasts that
terminally differentiates into multinucleate myofibers [98]. Cell cycle arrest and the expression
of skeletal muscle–specific genes are the critical checkpoints for this developmental process
[99]. All the epiblast cells undergoing skeletal myogenesis express the skeletal muscle-specific
transcription factor MyoD, among them only the cells expressing NCad but not ECad can
differentiate into skeletal muscle [94]. NCad function-perturbing antibodies showed that it
plays a significant role in interaction between myoblasts in myotube formation and in
myofibrillogenesis [100,101,102]. NCad is also found to be involved in myoblast migration in
limb bud [103].
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ester (e.g., PMA) in PKC-dependent manner, whereas factors like TNFα and IL-1 reduce the
expression of NCad [108].
Migratory cell populations, also known as neural crest cells, are pluripotent cells those
originate from dorsal part of neural tube and play important roles in embryonic development
and pathophysiological conditions. These cells express NCad when they are associated with
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with IDPVNGQ epitope of EC4 of NCad [112], and this interaction between NCad and FGFR
can be of both ligand dependent and independent [113] suggesting wider cooperative
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of NCad induces motility. The cell motility behavior and adhesion is independent to each other,
as antibody against the aforementioned relevant amino acid sequence of NCad inhibits cell
motility but the cell-cell adhesion phenomena was uninterrupted [114]. The influence of NCad
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morphogenesis and maturation, and is suggesting the possibility of exploiting this gene
product for regenerative medicine.
9. NCad-Fc as biomaterial in regenerative medicine
NCad-Fc was introduced by Lambert et al. in 2000, and the study revealed that NCad-Fc not
only induced the recruitment of NCad on the plasma membrane but also other components
of the cadherin/catenin complex. This work for the first time demonstrated that NCad-Fc can
mimic natural cell-cell contact formation and signal transduction [116]. Pioneering work from
our lab has introduced NCad-Fc as cell-coating biomaterials for stem cell culture. NCad-Fc
protein was collected from ‘pRC-NCFC’ plasmid, which was constructed by inserting the N
terminal extracellular domain of mouse NCad into pRC/CMV (Invitrogen) plasmid [29]. The
expression and purification methodologies of NCad-Fc are similar like ECad-Fc and have been
described in details in relevant publications [50,55,117]. Over recent years our laboratory work
revealed significant advantages of NCad-Fc in neural differentiation from stem cells. Early
work was performed with mouse embryonic carcinoma cell P19 and neural stem cell MEB5
because of their easy management over the ESCs. It was observed that culturing these cell lines
on NCad-Fc substratum can maintain the undifferentiated state and scattering morphology
compare with other control substratum such as gelatin, fibronectin, laminin or poly-L-
ornithine. P19 and MEB5 cells were differentiated effectively to neural lineage on this defined
matrix in presence of retinoic acid supplemented with insulin-transferrin-selenium commer‐
cial preparation (ITS, Invitrogen). Interestingly, P19 cells showed higher level of Neurog1
expression on NCad-Fc-coated surface compare with gelatin-coated surface. Additionally,
MEB5 differentiated on NCad-Fc matrix, compared to fibronectin-coated surface, showed
complete neuronal differentiation phenomena and significantly higher expression levels of
neural markers, such as Neurog1 and MAP2. These results clearly suggested the superiority of
NCad-Fc substratum over the other experimental substratum for neuronal differentiation
process.
Later, the findings were extrapolated to MEF-dependent mouse embryonic stem cell ST1 and
mouse iPSCs to evaluate whether the effect is restricted to specific pre-committed cell lines or
it is globally applicable [65]. Since during EMT conversion ECad is downregulated and NCad
is upregulated therefore a hybrid matrix of ECad-Fc and N-Cad-Fc was designed to exploit
the stage-specific cadherin switching phenomenon. The concept was that, initially the ESCs
and iPSCs would bind to ECad-Fc through cell-resident ECad, however, during and after
neuroectoderm formation cadherin switching will cater for cellular NCad in place of ECad that
would bind to NCad-Fc. The cadherin switching was experimentally confirmed in house
during neural differentiation protocol (Fig. 3A), where Dkk-1, a Wnt signaling pathway
antagonist, and LeftyA, a Nodal signaling pathway antagonist were used for triggering neural
differentiation. Specific markers for primitive ectoderm, primitive neural stem cells, neural
stem and progenitor cells were checked. Along with, promisingly, the efficiency of neural
progenitor differentiation from mouse ESCs on cadherin-Fc chimeric matrix was significantly
higher compare to the cells cultured on other standard substratum as evaluated by the higher
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level of expression of neural progenitor marker Nestin gene products. Furthermore, the
differentiated cells exhibited greater levels expression of βIII-tubulin (Tuj1) (Fig. 3B), micro‐
tubule associated protein 2 (MAP2), Pax6, and tyrosine hydroxylase but not GFAP, which is a
marker of glial cell, signifying the presence of a lineage confined to neural cells.
Figure 3. NCad-Fc, and ECad-Fc promote directed differentiation of target lineage from iPSCs. (A) Western blot data
revealed ECad to NCad switching occurs during neuronal differentiation. The expression level was normalized using
house-keeping gene, β-actin. (B) βIII-tubulin expression was significantly higher on E/NCad-Fc matrix compared to gel‐
atin.
Culturing of ESCs and iPSCs on ECad-Fc and NCad-Fc hybrid substratum not only developed
scattered cell morphology as reported for ECad-Fc substratum but higher cell proliferation
rate and enhanced differentiation efficiency were also noted. Along with these phenomena
significant higher degree of homogeneity and enhanced differentiation efficiency were also
observed, which is a remarkable advantage for harvesting target neuronal cells from in vitro
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system that can later be applied for regenerative medicine protocol. Although EB-based
protocols are being relatively well-practiced for neural differentiation, however, the inconsis‐
tency of the embryoid body (EB) size and shape, and the asynchronous distribution of growth
factors throughout the EBs give rise to heterogeneous products. Besides, monitoring cell
morphology during differentiation process for EB-based differentiation protocols is incon‐
venient. Culturing ESCs or iPSCs in scattered single cell condition, on the contrary, can
effectively overcome these issues. Interestingly, this blend of Cadherin-Fc matrices maintained
a complete homogeneous cell population for murine ESCs and iPSCs for several passages.
Highly homogeneous population of primitive ectoderm and neural progenitor cells were
routinely generated on such a hybrid-type cooking-plate [65]. Enriched population of neuro‐
ectoderm progenitor cells can be obtained within 4 to 6 days by using E/NCad-Fc based
monolayer-forming ESCs and iPSCs culture protocol and standard neurogenic cocktail
treatment, which is a great advantage for quick generation of the target cells for application in
regenerative medicine.
Some cells release 90 kDa fragment of soluble NCad (sNCad), and NCad-Fc was used to mimic
sNCad response on neurite development [118]. Application of NCad-Fc by Doherty et al. with
cerebral neurons showed that NCad-Fc initiated neurite outgrowth in a FGF receptor depend‐
ed manner [111,119] suggesting that NCad-Fc can be utilized for controlling FGF receptor
signaling pathway to facilitate relevant neuronal development events. Using mouse E12.5
ventral spinal cord explants as a convenient model Marthiens et al. showed that the axons
formed contacts along the axon-shaft by long filopodia-like processes on NCad-Fc matrix [120].
They further showed that growth cones preferentially interact with cad-11 or NCad-Fc when
progressing on this substratum whereas it differs on laminin. This study proved direct
involvement of cadherin-11 and NCad in peripheral nervous system establishment from
embryonic tissues [120].
Not only for neuronal population related regenerative medicine, NCad-Fc also showed
potentials for application in other tissues as well, for example myogenesis related issues.
Charrasse et al. used NCad-Fc to mimic NCad binding effect for myogenic differentiation [121].
They showed that NCad-Fc based NCad–dependent cell–cell adhesion triggers RhoA GTPase
activity, which is essential for myogenic differentiation. Activity and expression of SRF, a
transcription factor that binds to the promoter regions of muscle-specific genes [122,123] and
controls the expression of MyoD, is controlled by RhoA. In turn, MyoD binds to the promoter
region of skeletal muscle activating genes in mesenchymal cells and convert them to skeletal
myoblasts [124,125,126]. These findings demonstrated that N-cadherin–dependent adhesion
event that regulates the RhoA/SRF pathway to trigger myogenesis can be harnessed by NCad-
Fc matrix and therefore such technology is holding great promises for using in relevant
regenerative medicine protocols.
10. Conclusion
To design an efficient biomaterial capable of maintaining and stewarding specific cell pheno‐
types critical for the development, homeostasis, differentiation, and regeneration of tissues,
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the material must have a high degree of selective recognition property to the desired cells. As
well, such a biomaterial should be devoid of unexpected stimulation characteristics to the cells
that can be hazardous to them or to the desired results of the protocols. Being the intrinsic
component of cellular milieu, proteins are highly desirable molecules to be used in regenera‐
tive medicine and tissue engineering technology. Their 3D conformation made them perfectly
fit in the cell-biology and ensuring that only specific function to the experimental cells has been
achieved. The natural homeostasis properties of cells can adequately remove these proteins
once they are used up without exerting any unnatural effect or stress to the cells. Expressing
and purifying large protein with proper 3D conformation is extremely challenging therefore
mimetic peptide technology has been becoming popular. These small peptide sequences
represent small functional domain of the relevant proteins, albeit not with the native 3D
structure of the parent protein molecule. While most cases they are being generated using
artificial synthetic technology in test tubes, however, their purity, reproducibility and yield
are major concerns for their confident application in stem cell technology. Additional limita‐
tions for mimetic peptides are (1) the restricted size of desired peptides, and (2) inability to
provide native post-translational modifications, most of which are critical for proper bio-
functionality of the relevant molecule. Therefore mimetic peptides cannot and do not behave
identically as their natural parent protein. On the contrary, Fc-chimeric proteins can be
generated with high degree of reproducibility with identical molecular properties using the
natural cellular readout process from the DNA template. The additional stability of the target
protein instigated by the presence of Fc domain is significantly advantageous for higher yield
of the tailored chimeric protein. The intrinsic property of Fc domain to form homodimer is
beneficial to keep the target chimeric protein in soluble form. On the other hand, the natural
affinity of Fc domain to bind with Protein A or Protein G is a technical boon for convenient
purification of the target protein without fusion of any secondary bait to the amino acid
sequence, which often create complex situation for getting rid of them at the later stage of the
processing to harvest only the desired designed protein. Directional binding of Fc domain with
the polystyrene or hydrophobic surface and catering the functional protein outwards is also
an intrinsic benefit for using this class of chimeric proteins for obtaining higher functional
efficacy of the applied biomaterials. Since the specific homophilic interactions between
cadherins mediate cell attachment therefore specific cadherin isoform-expressing cells can be
purified by using the relevant cadherin-Fc biomaterial as surface-coating materials. For
example, iPS cells express high level of ECad and neuronal cells express NCad therefore, by
employing these matrices in different time points of differentiation protocol, the target cells
can be purified in situ without the necessity of any harsh enzymatic or mechanical treatments.
Some of these chimeric proteins are commercially available for application and some are in
pipeline, which can be obtained from our laboratory under proper regulatory affairs. Collec‐
tively, Fc-chimeric protein-based biomaterials provide distinct advantages for overcoming
many existing challenges in stem cell technology and significantly advancing the regenerative
medicine and tissue engineering field towards practical application.
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system that can later be applied for regenerative medicine protocol. Although EB-based
protocols are being relatively well-practiced for neural differentiation, however, the inconsis‐
tency of the embryoid body (EB) size and shape, and the asynchronous distribution of growth
factors throughout the EBs give rise to heterogeneous products. Besides, monitoring cell
morphology during differentiation process for EB-based differentiation protocols is incon‐
venient. Culturing ESCs or iPSCs in scattered single cell condition, on the contrary, can
effectively overcome these issues. Interestingly, this blend of Cadherin-Fc matrices maintained
a complete homogeneous cell population for murine ESCs and iPSCs for several passages.
Highly homogeneous population of primitive ectoderm and neural progenitor cells were
routinely generated on such a hybrid-type cooking-plate [65]. Enriched population of neuro‐
ectoderm progenitor cells can be obtained within 4 to 6 days by using E/NCad-Fc based
monolayer-forming ESCs and iPSCs culture protocol and standard neurogenic cocktail
treatment, which is a great advantage for quick generation of the target cells for application in
regenerative medicine.
Some cells release 90 kDa fragment of soluble NCad (sNCad), and NCad-Fc was used to mimic
sNCad response on neurite development [118]. Application of NCad-Fc by Doherty et al. with
cerebral neurons showed that NCad-Fc initiated neurite outgrowth in a FGF receptor depend‐
ed manner [111,119] suggesting that NCad-Fc can be utilized for controlling FGF receptor
signaling pathway to facilitate relevant neuronal development events. Using mouse E12.5
ventral spinal cord explants as a convenient model Marthiens et al. showed that the axons
formed contacts along the axon-shaft by long filopodia-like processes on NCad-Fc matrix [120].
They further showed that growth cones preferentially interact with cad-11 or NCad-Fc when
progressing on this substratum whereas it differs on laminin. This study proved direct
involvement of cadherin-11 and NCad in peripheral nervous system establishment from
embryonic tissues [120].
Not only for neuronal population related regenerative medicine, NCad-Fc also showed
potentials for application in other tissues as well, for example myogenesis related issues.
Charrasse et al. used NCad-Fc to mimic NCad binding effect for myogenic differentiation [121].
They showed that NCad-Fc based NCad–dependent cell–cell adhesion triggers RhoA GTPase
activity, which is essential for myogenic differentiation. Activity and expression of SRF, a
transcription factor that binds to the promoter regions of muscle-specific genes [122,123] and
controls the expression of MyoD, is controlled by RhoA. In turn, MyoD binds to the promoter
region of skeletal muscle activating genes in mesenchymal cells and convert them to skeletal
myoblasts [124,125,126]. These findings demonstrated that N-cadherin–dependent adhesion
event that regulates the RhoA/SRF pathway to trigger myogenesis can be harnessed by NCad-
Fc matrix and therefore such technology is holding great promises for using in relevant
regenerative medicine protocols.
10. Conclusion
To design an efficient biomaterial capable of maintaining and stewarding specific cell pheno‐
types critical for the development, homeostasis, differentiation, and regeneration of tissues,
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the material must have a high degree of selective recognition property to the desired cells. As
well, such a biomaterial should be devoid of unexpected stimulation characteristics to the cells
that can be hazardous to them or to the desired results of the protocols. Being the intrinsic
component of cellular milieu, proteins are highly desirable molecules to be used in regenera‐
tive medicine and tissue engineering technology. Their 3D conformation made them perfectly
fit in the cell-biology and ensuring that only specific function to the experimental cells has been
achieved. The natural homeostasis properties of cells can adequately remove these proteins
once they are used up without exerting any unnatural effect or stress to the cells. Expressing
and purifying large protein with proper 3D conformation is extremely challenging therefore
mimetic peptide technology has been becoming popular. These small peptide sequences
represent small functional domain of the relevant proteins, albeit not with the native 3D
structure of the parent protein molecule. While most cases they are being generated using
artificial synthetic technology in test tubes, however, their purity, reproducibility and yield
are major concerns for their confident application in stem cell technology. Additional limita‐
tions for mimetic peptides are (1) the restricted size of desired peptides, and (2) inability to
provide native post-translational modifications, most of which are critical for proper bio-
functionality of the relevant molecule. Therefore mimetic peptides cannot and do not behave
identically as their natural parent protein. On the contrary, Fc-chimeric proteins can be
generated with high degree of reproducibility with identical molecular properties using the
natural cellular readout process from the DNA template. The additional stability of the target
protein instigated by the presence of Fc domain is significantly advantageous for higher yield
of the tailored chimeric protein. The intrinsic property of Fc domain to form homodimer is
beneficial to keep the target chimeric protein in soluble form. On the other hand, the natural
affinity of Fc domain to bind with Protein A or Protein G is a technical boon for convenient
purification of the target protein without fusion of any secondary bait to the amino acid
sequence, which often create complex situation for getting rid of them at the later stage of the
processing to harvest only the desired designed protein. Directional binding of Fc domain with
the polystyrene or hydrophobic surface and catering the functional protein outwards is also
an intrinsic benefit for using this class of chimeric proteins for obtaining higher functional
efficacy of the applied biomaterials. Since the specific homophilic interactions between
cadherins mediate cell attachment therefore specific cadherin isoform-expressing cells can be
purified by using the relevant cadherin-Fc biomaterial as surface-coating materials. For
example, iPS cells express high level of ECad and neuronal cells express NCad therefore, by
employing these matrices in different time points of differentiation protocol, the target cells
can be purified in situ without the necessity of any harsh enzymatic or mechanical treatments.
Some of these chimeric proteins are commercially available for application and some are in
pipeline, which can be obtained from our laboratory under proper regulatory affairs. Collec‐
tively, Fc-chimeric protein-based biomaterials provide distinct advantages for overcoming
many existing challenges in stem cell technology and significantly advancing the regenerative
medicine and tissue engineering field towards practical application.
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1. Introduction
Embryonic stem (ES) cells have the potential to differentiate to hepatocytes [1]. However, the
use of ES cells may pose ethical problems because they are derived from human embryos. The
use of human induced pluripotent stem (hiPS) cells that have been generated from adult
somatic cells [2], on the other hand, does not create ethical controversies. HiPS cells are useful
tools in drug discovery and regenerative medicine because they can differentiate into func‐
tional somatic cells [3]. If hiPS cells could be differentiated into hepatocytes, they would be
useful for transplantation into patients suffering from hepatic failure [4]. Complications such
as graft-versus-host disease as well as ethical issues could be avoided because patient-specific
somatic cells could be generated from hiPS cells isolated from the patient.
The ES and hiPS cells that survive among the differentiated hepatocytes and are transplanted
to patients may be tumorigenic [5]. Therefore, methods need to be developed to eliminate ES
and iPS cells from the population of differentiated cells used for transplantation. To overcome
these problems, a new medium, called “hepatocyte selection medium” (HSM), has been
developed and will be discussed in this chapter [6].
First, pluripotency and tumorigenicity of ES and iPS cells will be discussed [7]. Next, current
methods of eliminating pluripotent cells will be outlined [8, 9]. All the cells, including human
iPS cells, require glucose and arginine to live [10, 11]. They will die without glucose or arginine.
Hepatocytes have enzymes to produce glucose from galactose and arginine from ornithine.
The unique features of hepatocytes compared with other cells will next be discussed. It was
expected that hepatocytes would survive in a medium without glucose or arginine, and
supplemented with galactose and ornithine [12] [13]. After this introduction, the formulation
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of HSM will be described [14]. Finally, the application of HSM for the selection of cells
differentiated from mouse ES and human iPS cells will be presented.
2. Pluripotency and tumorigenicity
The link between pluripotency and tumorigenicity was reported in 1960 based on a study of
teratocarcinoma [15]. ES and iPS cells are pluripotent and are capable of self-renewal as well
as differentiation into a variety of cell types. Pluripotent cells can, however, be tumorigenic
because they proliferate rapidly and exhibit telomerase activity [7]. Therefore, one of the
problems faced while using ES and iPS cell-derived cells for transplantation into patients is
the risk of tumorigenicity [5]. For example, transplantation of mouse hepatocytes differenti‐
ated from ES cells into liver resulted in the formation of teratoma [16]. Tumorigenicity was
initially attributed to genomic integration of the viral vectors used for the induction of
pluripotency [17]. The Sendai virus was also used to generate iPS cells because it posed no risk
of altering the host genome [18]. To reduce this risk, plasmid vectors have been used to
introduce reprogramming factors such as Oct3/4, Sox2, Klf4, and c-Myc [19]. In addition, the
ES cell-specific microRNA, miR-302, has been used to reduce the iPS cells tumorigenicity by
suppressing cyclin E-CDK2 and cyclin D-CDK4/6 [20]. Furthermore, Yakubov et al. introduced
RNA synthesized from the cDNA of the four reprogramming transcription factors [21]. Several
combinations of reprogramming factors have also been investigated. Nakagawa et al. omitted
c-Myc to generate iPS cells, thereby reducing the tumorigenicity because c-Myc is a well-
known oncogene [22]. Despite these efforts, the risk of tumorigenicity has not yet been
eliminated. The process of pluripotency and tumorigenicity involve self-renewal, prolifera‐
tion, and active telomerase mechanisms [7]. It is, therefore, necessary to develop methods for
the efficient eradication of iPS cells that survive among differentiated somatic cells.
3. Methods of eliminating iPS cells
Flow cytometry, which is commonly used to isolate target cells, was used by Yamamoto et al.
to isolate hepatocytes differentiated from the mouse ES cells [8]. These workers generated ES
cells expressing green fluorescent protein driven by an albumin promoter/enhancer. However,
since albumin is expressed in endodermal cells as well [23], this approach led to isolation of
cells other than hepatocytes, such as endodermal cells. Therefore, a different strategy was
required to improve hepatocyte isolation. Flow cytometry has also been used to analyze
surface antigens specific for hepatocytes. For example, delta-like 1 homolog (DLK1) has been
used for isolation of hepatoblasts [9]. The issue with DLK1, however, is that this surface antigen
is not expressed in the human adult liver [24]. Therefore, it may not be possible to isolate mature
hepatocytes differentiated from hiPS cells using DLK-1 as a marker. In our research we focused
on other methods to eliminate iPS or ES cells from heptocytes. Sub-lethal heat shock was shown
to induce apoptosis in human ES cells [25], but it might also damage differentiated cells
intended for transplantation. Cheng et al. reported the same strategy using suicide genes [26].
They introduced a thymidine kinase gene driven by the Nanog promoter into hiPS cells, which
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were subsequently ablated by ganciclovir treatment. This method may be ideal for differenti‐
ated hepatocytes, which do not express Nanog, but the toxicity of ganciclovir may be a
potential issue. Conesa et al. screened a library of 1120 small chemicals to identify molecules
that caused mouse ES cells to undergo apoptosis [27], and found that benzethonium chloride
and methylbenzethonium induced apoptosis in hiPS and mouse ES cells but not in human
fibroblasts or mouse embryonic fibroblasts. Both reagents are quaternary ammonium salts
used as antimicrobial agents; they are also used in cancer therapy and may have damaging
effects on hepatocytes. N-oleoyl serinol (S18), which is a ceramide analogue, eliminated
residual pluripotent cells in embryoid bodies [28]. Interestingly, S18 also promoted neural
differentiation of embryoid body-derived cells. This strategy is promising because the reagent
not only eradicates undifferentiated cells but also promotes their differentiation into the target
cell types.
4. Arginine and urea cycle
Among all the amino acids, the deficiency in arginine is the least tolerated by the cells cultured
in vitro [29]. Arginine is produced through the urea cycle, which is exclusive to hepatocytes.
Indeed, an arginine-deficient medium was the first one used for the hepatocyte selection [10].
Tyrosine also is produced by hepatocytes, and H4 II E, a hepatoma cell line adapted to growth
in serum-, arginine-, and tyrosine-free medium, has been established [30]. This cell line
expresses ornithine transcarbamylase (OTC) involved in the urea cycle, and phenylalanine
hydroxylase (PAH), which catalyzes the synthesis of tyrosine in the liver and kidney [31].
The major role of urea synthesis is the excretion of ammonium ions generated in the process
of protein degradation. Urea synthesis is a cyclic process as shown in Figure 1. Ornithine plays
the key role in urea synthesis, and OTC mediates the formation of L-citrulline from L-ornithine
and carbamoylphosphate. Importantly, this process occurs in liver mitochondria (area
bounded with green line in Figure 1). The OTC deficiency, linked to X-chromosome is the cause
of hyperammonemia type 2 [32]. The elevated ammonium levels lead to infantile death or
mental retardation later in life.
Consequently, it could be expected that hepatocytes can be selected from ES cells in a medium
deficient in arginine and tyrosine.
5. Glucose and gluconeogenesis
Glucose is an important source of energy for a majority of cells. Glucose deprivation aids in
the hepatocyte selection process because hepatocytes are capable of synthesizing glucose [10].
Pyruvate is the final product of glycolysis, which then enters the tricarboxylic acid cycle. It
was shown that pyruvate and glucose deficiency led to neural cell death [11]. Galactose enters
glycolysis as a substrate for galactokinase, which is expressed in the liver and kidney [33, 34].
Therefore, it is expected that hepatocytes can survive in a medium deprived of glucose or
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Galactose is produced from lactose by hydrolysis in the gastrointestinal tract and is converted
to glucose in the liver (Figure 2). Galactokinase catalyzes ATP-dependent phosphorylation of
galactose to galactose 1-phosphate which then reacts with uridine diphosphate(UDP)-glucose
to produce UDP-galactose converted to UDP-glucose by uridine diposphogalactose 4-
epimerase. UDP-glucose is used by glycogen synthase to synthesize glycogen, which is stored
in the liver and used as a source of glucose.
Deficiency in the enzymes such as galactokinase, galactose-1-phosphate uridyltransferase, or
uridine diphosphogalactose 4-epimerase causes galactosemia. Galactose is then reduced to
galactitol, which accumulates in the eye lenses causing cataracts. Deficiency in galactose-1-
phosphate uridyltransferase results in accumulation of galactose-1-phosphate and depletion
of inorganic phosphate in the liver causing liver failure. This is the reason why children
suffering from galactosemia are kept on a galactose-free diet.
6. Hepatocyte selection medium
The hepatocyte selection medium (HSM) was made from powdered amino acids following
the formulation of Leibovits-15 medium (Life Technologies, Grand Island, NY). HSM did not
contain arginine, tyrosine, glucose, and sodium pyruvate, but was supplemented with
galactose (900 mg/L), ornithine (1 mM), glycerol (5 mM), and proline (260 mM) (all from Wako
Figure 1. Urea cycle.
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Pure Chemicals, Osaka, Japan); proline (30 mg/L) was added as a component necessary for
DNA synthesis [35]. Aspartic acid as a nonessential amino acid was not included because it
can be synthesized from ornithine and arginine. Fetal calf serum (FCS, Life Technologies) at a
final concentration of 10% was used to culture mouse ES cells. For human iPS cells, 10%
knockout serum replacement (KSR) (Life Technologies) was used instead of FCS to establish
xeno-free conditions. Depending on the experiment, FCS and KSR were dialyzed against
phosphate buffered saline (PBS) to remove amino acids and glucose.
7. Embryoid bodies in HSM
EB5, a mouse ES cell line provided by Dr. H. Niwa (Center for Developmental Biology, Riken,
Kobe, Japan) was maintained in the undifferentiated state in gelatin-coated dishes without
feeder cells, in Glasgow minimum essential medium (GMEM) (Sigma Aldrich Japan K.K.,
Tokyo, Japan) supplemented with 10% FCS (Roche Diagnostics K.K., Tokyo, Japan), 1×
nonessential amino acids (NEAA), sodium pyruvate (1 mM), leukemia inhibitory factor (LIF)
(1000 U/ml) (Invitrogen Japan, Tokyo, Japan), and 2-mercaptoethanol (0.1 mM) (Wako) [36].
Dissociated ES cells were cultured in hanging drops at a density of 1 × 103 cells per 30 µµl of
media without LIF (ESM) to form embryoid bodies. After four days in hanging drop culture,
the resulting embryoid bodies were plated onto plastic dishes (Iwaki-Asahi Techno Glass,
Tokyo, Japan) precoated with gelatin (Sigma Aldrich). Seven days after their formation, the
embryoid bodies transferred to HSM appeared slightly smaller than those in ESM. The cells
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comprising the embryoid bodies in ESM differentiated to various cell types 28 days after the
formation of embryoid bodies.
Figure 3. Mouse embryonic stem cells in HSM. Scale bar, 250 μm.
28 days after the formation of embryoid bodies, sizes of colonies in HSM reduced, and the
surviving cells appeared cuboidal (Figure 3). Some of these cells were binuclear, which is
characteristic of hepatocytes; it was also previously shown that HSM was selective for
hepatoblast-like cells [14]. These results suggest that HSM eliminated undifferentiated cells
and enriched the population of hepatoblast-like cells.
8. Expression levels of GALK1, GALK2, and OTC
Human fetal and adult hepatocytes express galactokinase and OTC, and would survive in
HSM containing galactose and ornithine. If hiPS cells express similar levels of these enzymes,
HSM could not be applied for selection of differentiated hepatocytes. Therefore, we compared
the expression levels of galactokinase and OTC in hiPS cells with those in human fetal and
adult livers. The hiPS cell line 201B7 (RIKEN Cell Bank, Tsukuba, Japan) was cultured feeder-
free in ReproFF medium (Reprocell, Yokohama, Japan) in dishes coated with a thin layer of
Matrigel (Becton Dickinson, Franklin Lakes, NJ). Two galactokinase isoforms, GALK1
(GenBank: NM_000154) and GALK2 (BC107153), have been identified in humans. The
expression levels of GALK1, GALK2, and OTC in the 201B7 cells and fetal and adult livers
were compared [6]. The expression levels of these enzymes in the 201B7 cells constituted 22.2%
± 5.0%, 14.2% ± 1.1%, and 1.2% ± 0.2% (mean ± standard deviation) of those in the adult liver,
respectively, and the OTC expression was also significantly lower in the 201B7 cells than in
the fetal liver. We then cultured 201B7 cells in HSM to assess their survival rates.
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9. Human iPS cells in HSM
The 201B7 cells were cultured in 6-well plates coated with Matrigel in the ReproFF medium,
which was then changed to HSM (Figure 4). The 201B7 cells started to die and were completely
eliminated in three days. Nuclear condensation and fragmentation was observed after staining
with hematoxylin and eosin [6]. These nuclei also tested positive by terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling (TUNEL). Some of the 201B7 cells that
survived in HSM one day after medium change to HSM were immunostained with antibodies
against Nanog, SSEA4, and TRA-1-60. The results suggested that the death of undifferentiated
201B7 cells in HSM was caused by apoptosis.
Figure 4. Human iPS cells cultured in HSM. Scale bar, 50 μm. Medium was changed to HSM for human iPS cells in
feeder-free culture. All the human iPS cells died on day 3.
10. Primary human hepatocytes
Several protocols for the differentiation of iPS cells to hepatocytes have been reported [3, 37],
which describe the differentiation of iPS cells into hepatocyte-like cells which are different
from primary human hepatocytes. Recently, a method to generate three-dimensional vascu‐
larized liver from iPS cells has been reported [38]. The authors induced hepatic differentiation
of human iPS cells by following the protocol described by Si-Tayeb et al [37]. They mixed the
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mouse brain. This method is sophisticated and promising, but xenograft rejection may be a
problem when the generated liver is transplanted to patients with liver failure. Practical
methods for the differentiation of human iPS cell to functional hepatocytes are not available.
It is therefore necessary to use primary human hepatoctyes as a model of hepatocytes fully
differentiated from iPS cells. Hepatocytes were isolated from a fragment of resected donor
liver by using 2-step collagenase perfusion [39].
11. Co-culture of human iPS cells and primary human hepatocytes
Methods have not been established regarding hepatocye differentiation from human iPS cells.
It is impossible to select hepatocytes differentiated from human iPS cells from the mixture of
human iPS cells. Primary human hepatocytes were used as a model of hepatocytes differen‐
tiated from human iPS cells. It was expected that human iPS cells and hepatocytes differenti‐
ated from them were mixed. Therefore, co-culure of primary human hepatocytes and human
iPS cells was used as a model of the mixtures. Primary human hepatocytes were purchased
from Lonza (Walkersville, MD) and cultured as per the manufacturer’s instructions. Briefly,
hepatocytes were thawed and spread at a density of 1.5 × 105 cells/cm2 onto CellBIND 24-well
plates coated with type I collagen from the bovine dermis (Koken Co., Ltd., Tokyo, Japan) and
cultured in the hepatocyte culture medium (HCM, Lonza).
The 201B7 cells and human primary hepatocytes were co-cultured as follows: human primary
hepatoctyes were cultured in HCM for 24 h as described above. The 201B7 cells were added
to the wells at a density of 3 × 104 cells/well. After 24 h of culture in the ReproFF medium, it
was changed to HSM. Human primary hepatocytes survived in HSM, while the human 201B7
cells did not (Figure 5).
12. Potential application of HSM
The HSM that we developed can be safely used for the elimination of hiPS cells because it does
not contain hazardous reagents or introduce genetic material. Our results show that hiPS cells
die after three days of culture in HSM. Prior to performing the experiments, we compared the
hiPS cell viability in media containing crude or dialyzed KSR or combination of insulin (10
µM), dexamethasone (10 µM) and aprotitin (5000 U/ml) (IDA) Unexpectedly, the KSR dialysis
and IDA had no effect on hiPS cell survival. As expected, primary human hepatocytes survived
in HSM as well as in HCM, which is the recommended medium for their culture.
HSM can be used in clinical practices in situations when hepatocytes differentiated from
human iPS cells are transplanted to patients suffering from liver failure.
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Figure 5. Human iPS cells co-cultured with primary human hepatocytes in HSM. Scale bar, 50 μm; arrow, hepatocytes;
arrowhead, 201B7 cells.
13. Conclusion
HSM can be successfully used for the selection of hepatoblast-like cells derived from mouse
ES cells. HSM is an ideal medium for the elimination of hiPS cells and the isolation of differ‐
entiated hepatocytes without causing any damage. In the future, methods will be established
to produce hepatocytes from human iPS cells. Residual human iPS cells are a potential hazard
when the hepatocytes will be transplanted for patients with liver insufficiency because the
undifferentiated cell harbor tumorigenicity. At that stage, HSM will be an indispensable
medium to select hepatocytes differentiated from residual human iPS cells.
Acknowledgements
This work was supported in part by a Research Grant-in-Aid for Scientific Research (C) (Grant




mouse brain. This method is sophisticated and promising, but xenograft rejection may be a
problem when the generated liver is transplanted to patients with liver failure. Practical
methods for the differentiation of human iPS cell to functional hepatocytes are not available.
It is therefore necessary to use primary human hepatoctyes as a model of hepatocytes fully
differentiated from iPS cells. Hepatocytes were isolated from a fragment of resected donor
liver by using 2-step collagenase perfusion [39].
11. Co-culture of human iPS cells and primary human hepatocytes
Methods have not been established regarding hepatocye differentiation from human iPS cells.
It is impossible to select hepatocytes differentiated from human iPS cells from the mixture of
human iPS cells. Primary human hepatocytes were used as a model of hepatocytes differen‐
tiated from human iPS cells. It was expected that human iPS cells and hepatocytes differenti‐
ated from them were mixed. Therefore, co-culure of primary human hepatocytes and human
iPS cells was used as a model of the mixtures. Primary human hepatocytes were purchased
from Lonza (Walkersville, MD) and cultured as per the manufacturer’s instructions. Briefly,
hepatocytes were thawed and spread at a density of 1.5 × 105 cells/cm2 onto CellBIND 24-well
plates coated with type I collagen from the bovine dermis (Koken Co., Ltd., Tokyo, Japan) and
cultured in the hepatocyte culture medium (HCM, Lonza).
The 201B7 cells and human primary hepatocytes were co-cultured as follows: human primary
hepatoctyes were cultured in HCM for 24 h as described above. The 201B7 cells were added
to the wells at a density of 3 × 104 cells/well. After 24 h of culture in the ReproFF medium, it
was changed to HSM. Human primary hepatocytes survived in HSM, while the human 201B7
cells did not (Figure 5).
12. Potential application of HSM
The HSM that we developed can be safely used for the elimination of hiPS cells because it does
not contain hazardous reagents or introduce genetic material. Our results show that hiPS cells
die after three days of culture in HSM. Prior to performing the experiments, we compared the
hiPS cell viability in media containing crude or dialyzed KSR or combination of insulin (10
µM), dexamethasone (10 µM) and aprotitin (5000 U/ml) (IDA) Unexpectedly, the KSR dialysis
and IDA had no effect on hiPS cell survival. As expected, primary human hepatocytes survived
in HSM as well as in HCM, which is the recommended medium for their culture.
HSM can be used in clinical practices in situations when hepatocytes differentiated from
human iPS cells are transplanted to patients suffering from liver failure.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models172
Figure 5. Human iPS cells co-cultured with primary human hepatocytes in HSM. Scale bar, 50 μm; arrow, hepatocytes;
arrowhead, 201B7 cells.
13. Conclusion
HSM can be successfully used for the selection of hepatoblast-like cells derived from mouse
ES cells. HSM is an ideal medium for the elimination of hiPS cells and the isolation of differ‐
entiated hepatocytes without causing any damage. In the future, methods will be established
to produce hepatocytes from human iPS cells. Residual human iPS cells are a potential hazard
when the hepatocytes will be transplanted for patients with liver insufficiency because the
undifferentiated cell harbor tumorigenicity. At that stage, HSM will be an indispensable
medium to select hepatocytes differentiated from residual human iPS cells.
Acknowledgements
This work was supported in part by a Research Grant-in-Aid for Scientific Research (C) (Grant





Minoru Tomizawa1*, Fuminobu Shinozaki2, Yasufumi Motoyoshi3, Takao Sugiyama4,
Shigenori Yamamoto5 and Makoto Sueishi4
*Address all correspondence to: nihminor-cib@umin.ac.jp
1 Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
2 Department of Radiology, National Hospital Organization Shimoshizu Hospital, Yotsukaido
City, Japan
3 Department of Neurology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
4 Department of Rheumatology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
5 Department of Pediatrics, National Hospital Organization Shimoshizu Hospital, Yotsukaido
City, Japan
References
[1] Greenhough S, Bradburn H, Gardner J, Hay DC. Development of an embryoid body-
based screening strategy for assessing the hepatocyte differentiation potential of hu‐
man embryonic stem cells following single-cell dissociation. Cell Reprogram
2013;15(1):9-14.
[2] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Cell 2007;131(5):861-72.
[3] Takayama K, Inamura M, Kawabata K, Sugawara M, Kikuchi K, Higuchi M, Naga‐
moto Y, Watanabe H, Tashiro K, Sakurai F, Hayakawa T, Furue MK, Mizuguchi H.
Generation of metabolically functioning hepatocytes from human pluripotent stem
cells by FOXA2 and HNF1alpha transduction. J Hepatol 2012.
[4] am Esch JS, 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, Piechaczek
C, Burchardt ER, Feifel N, Stoldt V, Stockschlader M, Stoecklein N, Tustas RY, Eisen‐
berger CF, Peiper M, Haussinger D, Hosch SB. Portal application of autologous
CD133+bone marrow cells to the liver: a novel concept to support hepatic regenera‐
tion. Stem Cells 2005;23(4):463-70.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models174
[5] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluri‐
potent stem cells. Nature 2007;448(7151):313-7.
[6] Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Survival
of primary human hepatocytes and death of induced pluripotent stem cells in media
lacking glucose and arginine. PLoS One 2013;8(8):e71897.
[7] Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights
from molecular imaging. J R Soc Interface 2010;7 Suppl 6(S753-63.
[8] Yamamoto H, Quinn G, Asari A, Yamanokuchi H, Teratani T, Terada M, Ochiya T.
Differentiation of embryonic stem cells into hepatocytes: biological functions and
therapeutic application. Hepatology 2003;37(5):983-93.
[9] Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A. Mouse
hepatoblasts at distinct developmental stages are characterized by expression of Ep‐
CAM and DLK1: drastic change of EpCAM expression during liver development.
Mech Dev 2009;126(8-9):665-76.
[10] Leffert HL, Paul D. Studies on primary cultures of differentiated fetal liver cells. J
Cell Biol 1972;52(3):559-68.
[11] Matsumoto K, Yamada K, Kohmura E, Kinoshita A, Hayakawa T. Role of pyruvate
in ischaemia-like conditions on cultured neurons. Neurol Res 1994;16(6):460-4.
[12] Phillips JW, Jones ME, Berry MN. Implications of the simultaneous occurrence of
hepatic glycolysis from glucose and gluconeogenesis from glycerol. Eur J Biochem
2002;269(3):792-7.
[13] Sumida KD, Crandall SC, Chadha PL, Qureshi T. Hepatic gluconeogenic capacity
from various precursors in young versus old rats. Metabolism 2002;51(7):876-80.
[14] Tomizawa M, Toyama Y, Ito C, Toshimori K, Iwase K, Takiguchi M, Saisho H, Yoko‐
suka O. Hepatoblast-like cells enriched from mouse embryonic stem cells in medium
without glucose, pyruvate, arginine, and tyrosine. Cell Tissue Res 2008;333(1):17-27.
[15] Pierce GB, Jr., Dixon FJ, Jr., Verney EL. Teratocarcinogenic and tissue-forming poten‐
tials of the cell types comprising neoplastic embryoid bodies. Lab Invest
1960;9(583-602.
[16] Teramoto K, Hara Y, Kumashiro Y, Chinzei R, Tanaka Y, Shimizu-Saito K, Asahina
K, Teraoka H, Arii S. Teratoma formation and hepatocyte differentiation in mouse
liver transplanted with mouse embryonic stem cell-derived embryoid bodies. Trans‐
plant Proc 2005;37(1):285-6.
[17] Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi
M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the
safety of induced pluripotent stem cell lines. Nat Biotechnol 2009;27(8):743-5.
[18] Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of trans‐





Minoru Tomizawa1*, Fuminobu Shinozaki2, Yasufumi Motoyoshi3, Takao Sugiyama4,
Shigenori Yamamoto5 and Makoto Sueishi4
*Address all correspondence to: nihminor-cib@umin.ac.jp
1 Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
2 Department of Radiology, National Hospital Organization Shimoshizu Hospital, Yotsukaido
City, Japan
3 Department of Neurology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
4 Department of Rheumatology, National Hospital Organization Shimoshizu Hospital,
Yotsukaido City, Japan
5 Department of Pediatrics, National Hospital Organization Shimoshizu Hospital, Yotsukaido
City, Japan
References
[1] Greenhough S, Bradburn H, Gardner J, Hay DC. Development of an embryoid body-
based screening strategy for assessing the hepatocyte differentiation potential of hu‐
man embryonic stem cells following single-cell dissociation. Cell Reprogram
2013;15(1):9-14.
[2] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Cell 2007;131(5):861-72.
[3] Takayama K, Inamura M, Kawabata K, Sugawara M, Kikuchi K, Higuchi M, Naga‐
moto Y, Watanabe H, Tashiro K, Sakurai F, Hayakawa T, Furue MK, Mizuguchi H.
Generation of metabolically functioning hepatocytes from human pluripotent stem
cells by FOXA2 and HNF1alpha transduction. J Hepatol 2012.
[4] am Esch JS, 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, Piechaczek
C, Burchardt ER, Feifel N, Stoldt V, Stockschlader M, Stoecklein N, Tustas RY, Eisen‐
berger CF, Peiper M, Haussinger D, Hosch SB. Portal application of autologous
CD133+bone marrow cells to the liver: a novel concept to support hepatic regenera‐
tion. Stem Cells 2005;23(4):463-70.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models174
[5] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluri‐
potent stem cells. Nature 2007;448(7151):313-7.
[6] Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Survival
of primary human hepatocytes and death of induced pluripotent stem cells in media
lacking glucose and arginine. PLoS One 2013;8(8):e71897.
[7] Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights
from molecular imaging. J R Soc Interface 2010;7 Suppl 6(S753-63.
[8] Yamamoto H, Quinn G, Asari A, Yamanokuchi H, Teratani T, Terada M, Ochiya T.
Differentiation of embryonic stem cells into hepatocytes: biological functions and
therapeutic application. Hepatology 2003;37(5):983-93.
[9] Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A. Mouse
hepatoblasts at distinct developmental stages are characterized by expression of Ep‐
CAM and DLK1: drastic change of EpCAM expression during liver development.
Mech Dev 2009;126(8-9):665-76.
[10] Leffert HL, Paul D. Studies on primary cultures of differentiated fetal liver cells. J
Cell Biol 1972;52(3):559-68.
[11] Matsumoto K, Yamada K, Kohmura E, Kinoshita A, Hayakawa T. Role of pyruvate
in ischaemia-like conditions on cultured neurons. Neurol Res 1994;16(6):460-4.
[12] Phillips JW, Jones ME, Berry MN. Implications of the simultaneous occurrence of
hepatic glycolysis from glucose and gluconeogenesis from glycerol. Eur J Biochem
2002;269(3):792-7.
[13] Sumida KD, Crandall SC, Chadha PL, Qureshi T. Hepatic gluconeogenic capacity
from various precursors in young versus old rats. Metabolism 2002;51(7):876-80.
[14] Tomizawa M, Toyama Y, Ito C, Toshimori K, Iwase K, Takiguchi M, Saisho H, Yoko‐
suka O. Hepatoblast-like cells enriched from mouse embryonic stem cells in medium
without glucose, pyruvate, arginine, and tyrosine. Cell Tissue Res 2008;333(1):17-27.
[15] Pierce GB, Jr., Dixon FJ, Jr., Verney EL. Teratocarcinogenic and tissue-forming poten‐
tials of the cell types comprising neoplastic embryoid bodies. Lab Invest
1960;9(583-602.
[16] Teramoto K, Hara Y, Kumashiro Y, Chinzei R, Tanaka Y, Shimizu-Saito K, Asahina
K, Teraoka H, Arii S. Teratoma formation and hepatocyte differentiation in mouse
liver transplanted with mouse embryonic stem cell-derived embryoid bodies. Trans‐
plant Proc 2005;37(1):285-6.
[17] Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi
M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the
safety of induced pluripotent stem cell lines. Nat Biotechnol 2009;27(8):743-5.
[18] Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of trans‐




RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys
Biol Sci 2009;85(8):348-62.
[19] Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse
induced pluripotent stem cells without viral vectors. Science 2008;322(5903):949-53.
[20] Lin SL, Ying SY. Mechanism and method for generating tumor-free iPS cells using
intronic microRNA miR-302 induction. Methods Mol Biol 2013;936(295-312.
[21] Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts
to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys
Res Commun 2010;394(1):189-93.
[22] Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mo‐
chiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells
without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26(1):101-6.
[23] Abe K, Niwa H, Iwase K, Takiguchi M, Mori M, Abe SI, Abe K, Yamamura KI. Endo‐
derm-specific gene expression in embryonic stem cells differentiated to embryoid
bodies. Exp Cell Res 1996;229(1):27-34.
[24] Yanai H, Nakamura K, Hijioka S, Kamei A, Ikari T, Ishikawa Y, Shinozaki E, Mizu‐
numa N, Hatake K, Miyajima A. Dlk-1, a cell surface antigen on foetal hepatic stem/
progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcino‐
mas at a high frequency. J Biochem 2010;148(1):85-92.
[25] Alekseenko LL, Zemelko VI, Zenin VV, Pugovkina NA, Kozhukharova IV, Kovaleva
ZV, Grinchuk TM, Fridlyanskaya, II, Nikolsky NN. Heat shock induces apoptosis in
human embryonic stem cells but a premature senescence phenotype in their differen‐
tiated progeny. Cell Cycle 2012;11(17):3260-9.
[26] Cheng F, Ke Q, Chen F, Cai B, Gao Y, Ye C, Wang D, Zhang L, Lahn BT, Li W, Xiang
AP. Protecting against wayward human induced pluripotent stem cells with a sui‐
cide gene. Biomaterials 2012;33(11):3195-204.
[27] Conesa C, Doss MX, Antzelevitch C, Sachinidis A, Sancho J, Carrodeguas JA. Identi‐
fication of specific pluripotent stem cell death--inducing small molecules by chemical
screening. Stem Cell Rev 2012;8(1):116-27.
[28] Bieberich E, Silva J, Wang G, Krishnamurthy K, Condie BG. Selective apoptosis of
pluripotent mouse and human stem cells by novel ceramide analogues prevents tera‐
toma formation and enriches for neural precursors in ES cell-derived neural trans‐
plants. J Cell Biol 2004;167(4):723-34.
[29] Wheatley DN, Scott L, Lamb J, Smith S. Single amino acid (arginine) restriction:
growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Bio‐
chem 2000;10(1-2):37-55.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models176
[30] Niwa A, Yamamoto K, Sorimachi K, Yasumura Y. Continuous culture of Reuber hep‐
atoma cells in serum-free arginine-, glutamine-and tyrosine-deprived chemically de‐
fined medium. In Vitro 1980;16(11):987-93.
[31] McGee MM, Greengard O, Knox WE. The quantitative determination of phenylala‐
nine hydroxylase in rat tissues. Its developmental formation in liver. Biochem J
1972;127(4):669-74.
[32] Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, Matsuo M, Yoshino M,
Shigematsu Y, Yorifuji T, Kasahara M, Horikawa R, Endo F. Long-term outcome and
intervention of urea cycle disorders in Japan. J Inherit Metab Dis 2012;35(5):777-85.
[33] Ohira RH, Dipple KM, Zhang YH, McCabe ER. Human and murine glycerol kinase:
influence of exon 18 alternative splicing on function. Biochem Biophys Res Commun
2005;331(1):239-46.
[34] Ai Y, Jenkins NA, Copeland NG, Gilbert DH, Bergsma DJ, Stambolian D. Mouse gal‐
actokinase: isolation, characterization, and location on chromosome 11. Genome Res
1995;5(1):53-9.
[35] Nakamura T, Teramoto H, Tomita Y, Ichihara A. L-proline is an essential amino acid
for hepatocyte growth in culture. Biochem Biophys Res Commun 1984;122(3):884-91.
[36] Niwa H, Masui S, Chambers I, Smith AG, Miyazaki J. Phenotypic complementation
establishes requirements for specific POU domain and generic transactivation func‐
tion of Oct-3/4 in embryonic stem cells. Mol Cell Biol 2002;22(5):1526-36.
[37] Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Dun‐
can SA. Highly efficient generation of human hepatocyte-like cells from induced plu‐
ripotent stem cells. Hepatology 2010;51(1):297-305.
[38] Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y,
Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional
human liver from an iPSC-derived organ bud transplant. Nature 2013;499(7459):
481-4.
[39] Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of hu‐




RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys
Biol Sci 2009;85(8):348-62.
[19] Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse
induced pluripotent stem cells without viral vectors. Science 2008;322(5903):949-53.
[20] Lin SL, Ying SY. Mechanism and method for generating tumor-free iPS cells using
intronic microRNA miR-302 induction. Methods Mol Biol 2013;936(295-312.
[21] Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts
to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys
Res Commun 2010;394(1):189-93.
[22] Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mo‐
chiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells
without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26(1):101-6.
[23] Abe K, Niwa H, Iwase K, Takiguchi M, Mori M, Abe SI, Abe K, Yamamura KI. Endo‐
derm-specific gene expression in embryonic stem cells differentiated to embryoid
bodies. Exp Cell Res 1996;229(1):27-34.
[24] Yanai H, Nakamura K, Hijioka S, Kamei A, Ikari T, Ishikawa Y, Shinozaki E, Mizu‐
numa N, Hatake K, Miyajima A. Dlk-1, a cell surface antigen on foetal hepatic stem/
progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcino‐
mas at a high frequency. J Biochem 2010;148(1):85-92.
[25] Alekseenko LL, Zemelko VI, Zenin VV, Pugovkina NA, Kozhukharova IV, Kovaleva
ZV, Grinchuk TM, Fridlyanskaya, II, Nikolsky NN. Heat shock induces apoptosis in
human embryonic stem cells but a premature senescence phenotype in their differen‐
tiated progeny. Cell Cycle 2012;11(17):3260-9.
[26] Cheng F, Ke Q, Chen F, Cai B, Gao Y, Ye C, Wang D, Zhang L, Lahn BT, Li W, Xiang
AP. Protecting against wayward human induced pluripotent stem cells with a sui‐
cide gene. Biomaterials 2012;33(11):3195-204.
[27] Conesa C, Doss MX, Antzelevitch C, Sachinidis A, Sancho J, Carrodeguas JA. Identi‐
fication of specific pluripotent stem cell death--inducing small molecules by chemical
screening. Stem Cell Rev 2012;8(1):116-27.
[28] Bieberich E, Silva J, Wang G, Krishnamurthy K, Condie BG. Selective apoptosis of
pluripotent mouse and human stem cells by novel ceramide analogues prevents tera‐
toma formation and enriches for neural precursors in ES cell-derived neural trans‐
plants. J Cell Biol 2004;167(4):723-34.
[29] Wheatley DN, Scott L, Lamb J, Smith S. Single amino acid (arginine) restriction:
growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Bio‐
chem 2000;10(1-2):37-55.
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models176
[30] Niwa A, Yamamoto K, Sorimachi K, Yasumura Y. Continuous culture of Reuber hep‐
atoma cells in serum-free arginine-, glutamine-and tyrosine-deprived chemically de‐
fined medium. In Vitro 1980;16(11):987-93.
[31] McGee MM, Greengard O, Knox WE. The quantitative determination of phenylala‐
nine hydroxylase in rat tissues. Its developmental formation in liver. Biochem J
1972;127(4):669-74.
[32] Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, Matsuo M, Yoshino M,
Shigematsu Y, Yorifuji T, Kasahara M, Horikawa R, Endo F. Long-term outcome and
intervention of urea cycle disorders in Japan. J Inherit Metab Dis 2012;35(5):777-85.
[33] Ohira RH, Dipple KM, Zhang YH, McCabe ER. Human and murine glycerol kinase:
influence of exon 18 alternative splicing on function. Biochem Biophys Res Commun
2005;331(1):239-46.
[34] Ai Y, Jenkins NA, Copeland NG, Gilbert DH, Bergsma DJ, Stambolian D. Mouse gal‐
actokinase: isolation, characterization, and location on chromosome 11. Genome Res
1995;5(1):53-9.
[35] Nakamura T, Teramoto H, Tomita Y, Ichihara A. L-proline is an essential amino acid
for hepatocyte growth in culture. Biochem Biophys Res Commun 1984;122(3):884-91.
[36] Niwa H, Masui S, Chambers I, Smith AG, Miyazaki J. Phenotypic complementation
establishes requirements for specific POU domain and generic transactivation func‐
tion of Oct-3/4 in embryonic stem cells. Mol Cell Biol 2002;22(5):1526-36.
[37] Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Dun‐
can SA. Highly efficient generation of human hepatocyte-like cells from induced plu‐
ripotent stem cells. Hepatology 2010;51(1):297-305.
[38] Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y,
Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional
human liver from an iPSC-derived organ bud transplant. Nature 2013;499(7459):
481-4.
[39] Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of hu‐





New Stem Cell Models
Section 4
New Stem Cell Models
Chapter 8
Human Pluripotent Stem Cell Applications in Drug
Discovery and Toxicology – An overview
Shiva Prasad Potta, Tomo Šarić, Michael Heke,
Harinath Bahudhanapati and Jürgen Hescheler
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/58485
1. Introduction
Various drugs are being introduced into market for generating beneficial therapeutic effects
in humans. The pharmaceutical industry invests about $1.5 billion over the time period of 10-15
years to take a candidate drug from primary screen to market. Unfortunately, many drugs are
withdrawn due to side effects associated with off-and on-target toxicity [1]. For example, as
many as nine out of ten promising candidates beginning clinical phase I will not achieve
marketing approval [2] and only 20% of agents that show efficacy against cardiovascular
diseases in preclinical development are licensed after demonstrating sufficient efficacy in
phase III testing [3]. The success rate in anticancer drug development process is with 5% of
licensed agents even lower. Off-target cardiac toxicity is the most common cause of regulatory
delay in approval and market withdrawal of newly developed pharmaceuticals [4, 5]. Drug-
induced sudden cardiac death and ventricular arrhythmia caused the withdrawal of more
drugs in recent years than any other adverse drug reaction. Moreover, over 100 non-cardiac
drugs are suspected to be of high-risk and carry cardiovascular-related black box warnings [6].
Similar considerations are raised concerning arrhythmia and toxicity induced by environ‐
mental factors, including industrial chemicals, food additives, cosmetics, and others, as
outlined in the European REACH initiative (Registration, Evaluation, Authorization and
Restriction of Chemical substances).
Current drug safety evaluation processes that are required for regulatory purposes mostly rely
on animal studies and immortalized cell-based assays due to lack of suitable human in vitro
cell systems. In Europe, almost 10 million vertebrate animals are used annually for research.
Although highly predictive assays involving whole heart or slice preparations and in vivo
animal testing remain the standard for preclinical safety pharmacology, this extensive use of
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animals and their tissues does not eliminate high attrition rates of novel drugs. One of the
major reasons for this is limited predictability of existing preclinical animal (and cellular)
models for assessment of drug safety and efficacy. Animal models do not always predict the
toxicity in humans with sufficient accuracy because of inter-species differences [7]. For
example, murine and human hearts greatly differ in some aspects of electrophysiological
properties [8]. In addition, inbred animals that are frequently used in these analyses do not
mimic the genetic diversity of human population required for accurate prediction of drug
responses [9]. Therefore, identification of reliable and robust human cell systems for toxicity
assessment has become a driving interest for pharmaceutical industries.
In cardiac area different types of tests are already playing an important role in reducing costs
and drug attrition rates. These strategies involve a tiered system which starts with in vitro
single cell analyses followed by tests with ex vivo tissues and organs and progresses to in vivo
animal models and, finally, clinical trials [10]. The most important in vitro test consists of
automated patch-clamp recordings of Chinese hamster ovary (CHO) cells expressing human
Ether-à-go-go-Related Gene (hERG) channel. This test is being used to identify compounds
that block hERG channel and prolong cardiac action potential (AP) duration (i.e. the QT
interval) predisposing to Torsade de pointes tachycardia and sudden cardiac death [11]. The
assessment of the torsadogenic potential of each compound in the drug discovery process also
includes determination of drug’s ability to prolong the AP in isolated, arterially perfused rabbit
ventricular wedge preparations or canine Purkinje fibers and monitoring of heart rates and
occurrence of arrhythmia in animals. Each of these endpoints has it’s own specificity and
sensitivity [12]. For example, hERG-expressing CHO cells lack the complexity of native CMs
and cannot accurately predict the organ toxicity or lethal and arrhythmogenic side effects of
compounds that block other channels or signaling pathways. Therefore, additional in vitro
assays that better recapitulate human pathophysiology and diversity are needed to better
predict all potential on-and off-target toxicities, reduce drug attrition rates and avoid use of
animals for testing drugs that would never reach clinical application.
Pluripotent stem cells (PSCs) have unrestricted proliferation capacity, are able to differentiate
into any differentiated cell type thus offering a cost-effective unlimited and invaluable source
of organotypic differentiated cells relevant to assess human long-term organ toxicity. The
ethical issues associated with human embryonic stem cells (ESCs) were a major concern in
their application in toxicity studies. However, the Nobel prize-winning discovery that
transient expression of a few transcription factors can stably convert an adult somatic cell into
an early embryonic stage, i.e. into so called induced pluripotent stem cells (iPSCs) [13], has
opened new possibilities in drug discovery circumventing ethical issues and problematic
accessibility.
Repeated dose toxicity (RDT) occurs after repeated exposure to a substance over certain period
of time. In the context of cosmetics, which are generally used for months and years, long-term
RDT testing is of particular importance and forms the integral part of the quantitative risk
assessment. The prediction of endpoints and hazard identification of both newly developed
and existing cosmetic ingredients in humans is mainly based on the animal systems as they
allow simultaneous evaluation of multiple organ systems. However, there is a great demand
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and need for the development of multidisciplinary integrated approaches consisting of human
in vitro models for risk assessment as an alternative to animal models as they better mimic the
human in vivo system [14].
In this chapter, we will summarize the latest developments in applications of PSCs and their
tissue-specific derivatives for toxicity testing. We will outline the recent developments in
toxicogenomic technologies which are employed to develop and investigate human biomark‐
ers for toxicity in PSC based models accelerating drug development process. We mainly focus
on the application of PSCs in RDT testing.
2. Human pluripotent stem cells for repeated dose toxicity assessment
Human pluripotent stem cells (PSC) offer with their ability to recapitulate the most essential
steps of embryonic development and give rise to different mature cell types in vitro an optimal
human cellular model, which could help in increasing the safety and predictability of RDT
testing leading to low late stage attrition of compounds. Combined with this cell model,
toxicogenomic technologies would help predict biomarkers in an evidence-based approach.
So far, the safety assessment for novel drug candidates includes in vivo RDT tests in rodent
and non-rodent models. The drawbacks of RDT studies include false negative results and
unexpected humans toxicity of compounds that were judged to be safe in preclinical studies
[15, 16]. Such unexpected toxicity is one of the major reasons for the withdrawal of a drug from
the market. The heart and liver are often target organs in toxicology. Novel in vitro screening
methods are, thus, required to classify toxic compounds earlier in development, which would
lead to safer drugs, more efficient drug discovery process, lower costs and reduced laboratory
animal use [17]. There is an increasing interest from biopharmaceutical industry to develop
such test systems by using derivatives of human ESCs or iPSCs.
The iPSCs have a clear advantage over ESCs as they do not involve ethical issues. The
generation of iPSCs involves reorganization of condensed chromatin to open state chromatin,
which is aided by histone acetylation. Epigenetic factors are crucial for iPSC generation and
maintenance of their pluripotent state. Although the epigenetic state of iPSCs largely resembles
that of ESCs, iPSCs also have a unique DNA methylation patterns they retain epigenetic
memory of the respective somatic tissue of origin which might influence their differentiation
potential and affect the quality and quantity of cells for RDT [18]. On the other side, it is also
well known that different agents, so called epimutagens, can cause DNA methylation and
histone modification changes leading to disease [19]. These epigenetic modifications directly
affect transcription factors and other chromatin binding proteins that regulate cell type-specific
gene expression. The detection of biomarkers related to epigenetic modifications in RDT would
be of great importance, but until now there are no systematic studies conducted in this
direction. In addition, employing of iPSCs and their derivatives for this purpose poses a great
challenge because genetic and epigenetic variations in iPSCs associated with reprogramming
and in vitro manipulation may compromise their utility for downstream applications [20]. The
lesser the variation in epigenetic changes in iPSCs the greater will be the specificity in in vitro
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RDT testing is of particular importance and forms the integral part of the quantitative risk
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and existing cosmetic ingredients in humans is mainly based on the animal systems as they
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well known that different agents, so called epimutagens, can cause DNA methylation and
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toxicological studies. Recently, Planello and coworkers demonstrated that the choice of
reprogramming factors greatly influences the DNA methylation abnormalities in iPSCs. Even
highly selected iPSC lines have been shown to retain epigenetic signature of donor cell [21].
Gupta et al have shown that global transcriptional profiles of human iPSCs and ESCs are very
similar and that this similarity also exists between the corresponding beating clusters derived
from them [22]. They have also shown that some fibroblasts-specific mRNA expression
partners were retained in the iPSCs derived from them. Significant proportion of these genes
were also shown to be expressed at the same level in iPSC-derived but not in ESC-derived
beating clusters indicating the retention of epigenetic memory even in the differentiated and
highly enriched iPSC derivatives. Likewise, several microRNA expression profiling studies
have shown the subtle differences between iPSC derivatives [23]. Hence, the iPSCs may not
represent an ideal platform for RDT testing. With the current pace of iPSC research it may be
possible to create iPSCs with little or no epigenetic anomalies. Polo and coworkers have shown
that this retained epigenetic memory of iPSCs in early passages can be erased using extensive
continued passage [24]. By using chromatin-modifying compounds like HDAC inhibitors it
may be possible to stabilize the epigenetic state of iPSCs and their derivatives and decrease
the frequency of heterogeneity within iPSCs. However, using the PSC-derivatives to predict
RDT in human toxicological endpoints is still challenging.
3. PSC-derived cardiomyocytes for toxicity testing
Human Stringent cosmetics legislation amending directives especially within the European
Union (EU) related to complete replacement of animal models in cosmetic industry safety
testing by alternative methods has emphasized an urgent need for the development of
reduction, refinement and replacement (3R) of the existing animal studies [25]. In order to fill
gaps in non-animal alternative methods and to focus on complex RDT a research initiative
called "Safety Evaluation Ultimately Replacing Animal Testing 1 (SEURAT-1)" composed of
six complimentary research projects was launched in 2011 and jointly funded by the European
Commission’s FP7 HEALTH Programme and Cosmetics Europe (http://www.seurat-1.eu/).
Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS) is a European
Union's Seventh Framework Programme (FP7), which focuses on developing a human ESC
based novel toxicity test platforms to accelerate drug development. Human ESC based in vitro
reproductive toxicity, neurotoxicity, toxicogenomics, proteomics and kinetics were tested for
their predictive value in the identification of toxicity endpoints (http://www.esnats.eu). The
RDT delivers the No Observable Adverse Effect (NOAEL), which is used in calculation of the
substance safety parameters [25]. PSC-derived models hold a great potential for refinement of
current models of cardiotoxicity. For many toxicology applications, a homogeneous defined
population of specific cell types is required which stem cells can provide.
Validity of human PSC-derived cardiomyocytes (CM) for toxicity testing and safety pharma‐
cology has been investigated in several studies [26-28]. The susceptibility of disease-specific
human iPSC-CMs to toxicity compared to healthy human PSC-CMs was evaluated recently
by Joseph Wu laboratory [29]. This group showed that disease-specific human iPSC-CM are
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more accurate predictors of drug-induced cardiotoxicity than standard hERG-expressing
HEK293 cells. This observation suggests that human iPSC-CM may represent a suitable model
for evaluation of drug safety and efficacy. However, there is still a need to examine how well
the alternative systems can replace the animal models for RDT testing. The traditional
repeated-dose toxicological endpoints that relate to cardiotoxicity include histopathological
examinations of the heart and electrocardiographic recordings in the non-rodent species [30].
The current regulatory framework guidelines for cardiotoxicity testing include blood pressure,
heart rate and electrocardiogram (ECG) parameters as well as repolarization and conductance
abnormalities, cardiac output, ventricular contractility and vascular resistance. The limitations
of RDT testing in vivo clearly encouraged the scientific community to identify and develop
alternative in vitro methodologies to thoroughly estimate the integrated and complex re‐
sponses in the endpoints that are taken into consideration.
Drugs exerting toxic effects on cardiovascular system have shown to affect the heart function
in a way that includes changes in the contractility, cardiac rhythm, blood pressure and ischemia
[31]. Such toxic effects have led these drugs to be withdrawn, requiring expansion of rules on
cardiotoxicity testing. A new application for CMs derived from human ESCs and iPSCs has
surfaced because of the lack of availability of human primary material for cardiotoxicity testing
and their ability to overcome species variability. In vitro cardiotoxicity testing applications
using human PSC-CMs is very advantageous and complimentary to the existing RDT appli‐
cations. Endpoints such as action potential parameters, metabolic activity, membrane leakage,
energy content and intracellular calcium handling can be monitored for assessing cardiotox‐
icity. As mentioned above, the effect of new drugs on cardiac electrophysiology (i.e. changes
in ventricular repolarization) is a focus for tight control. The balanced concerted activity of
several cardiac ion channels is important for proper ventricular repolarization and alterations
may lead to ventricular arrhythmias. Therefore, electrophysiological assessment of the
proarrhythmic potential of drugs is very relevant in cardiotoxicity assays and human PSC-
derived CMs are suitable for such assays because they exhibit calcium handling properties,
ion channel activity and regulatory protein expression important for the development of a
mature repolarization phenotype in CMs [12].
Recently, several studies evaluated the potential of human iPSC-CMs for pharmacological
screening-assays and drug discovery applications [32-34]. However, the utility of iPSC-CMs
to accurately predict toxicity in humans may be limited by their immature character [35].
Current differentiation protocols give rise to heterogeneous phenotypes of spontaneously
beating human PSC-CMs with structural proteins, Ca2+release units, ion channels, action
potentials, and hormonal response being similar to that of native fetal CMs. However, the
electrophysiological and structural properties of PSC-CMs do not fully resemble those of adult
CMs. Therefore, the model based on human PSC-CMs must be improved before it can
represent an ideal platform for cardiac RDT. The mentioned issues can be solved by following
measures: a) by modulating cellular signaling pathways it is possible to get a homogeneous
CM population [36] b) with the application of tissue engineering it is possible to create a 3D
tissue constructs which provide microenvironment similar to native heart thus helping in
structural maturation of CMs [37] and c) prolonged culturing of iPSC-CMs can increase the
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may lead to ventricular arrhythmias. Therefore, electrophysiological assessment of the
proarrhythmic potential of drugs is very relevant in cardiotoxicity assays and human PSC-
derived CMs are suitable for such assays because they exhibit calcium handling properties,
ion channel activity and regulatory protein expression important for the development of a
mature repolarization phenotype in CMs [12].
Recently, several studies evaluated the potential of human iPSC-CMs for pharmacological
screening-assays and drug discovery applications [32-34]. However, the utility of iPSC-CMs
to accurately predict toxicity in humans may be limited by their immature character [35].
Current differentiation protocols give rise to heterogeneous phenotypes of spontaneously
beating human PSC-CMs with structural proteins, Ca2+release units, ion channels, action
potentials, and hormonal response being similar to that of native fetal CMs. However, the
electrophysiological and structural properties of PSC-CMs do not fully resemble those of adult
CMs. Therefore, the model based on human PSC-CMs must be improved before it can
represent an ideal platform for cardiac RDT. The mentioned issues can be solved by following
measures: a) by modulating cellular signaling pathways it is possible to get a homogeneous
CM population [36] b) with the application of tissue engineering it is possible to create a 3D
tissue constructs which provide microenvironment similar to native heart thus helping in
structural maturation of CMs [37] and c) prolonged culturing of iPSC-CMs can increase the
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maturation of Ca2+handling [38]. Further improvements of differentiation methods will enable
generation of more homogeneous and mature CM populations thus increasing their validity
for RDT testing. The overall predictability of drug efficacy and toxicity using iPSC-CMs and
disease specific iPSC-CMs has been recently reported by several groups [29, 39-41]. An absolute
requirement for CMs to be used for RDT is to be able to stably maintain the beating cardiac
phenotype for a prolonged period of time under defined conditions. Both hiPSC-CMs and
hESC-CMs display beat rate variability similar to that of a human heart sinoatrial node [42].
However, recently, variability in action potentials and sodium currents in response to lidocaine
and tetrodotoxin was shown in late stage in vitro differentiated human iPSC-CMs [32], thus
warranting some caution and further analyses.
Bioanalytics is a very promising tool in the application of in vitro cardiotoxicty assays. Novel
bioanalytical tools for discovery of biomarkers of cardiotoxicity include the field potential QT
scanning, using cellular oxygen uptake for monitoring the metabolic state of CMs, using
surface plasmon resonance (SPR) biosensing for key CM biomarkers, and also exploiting real-
time multi-wavelength fluorimetry [12]. Novel imaging technologies and physiological
analyses such as impedance measurements [43] and microelectrode arrays (MEAs) [44] give
an insight into major in vitro cellular events such as migration, proliferation, cell morphology,
cell–cell interactions and colony formation, relevant to biomarker discovery.
4. Stem cell-derived hepatocytes for toxicity testing
So far, hepatotoxicity is evaluated on day 28 or 90 in in vivo RDT tests by analysis of clinical
parameters, hematology, and histopathology. RDT tests evaluate chronic effects on organ
toxicity to establish a NOAEL which is used in calculation of the substance safety parameters
[25]. The extrapolation of the quantitative risk assessment for cosmetic ingredients using data
derived from animal studies to in vitro systems could be done by considering a margin of
safety (MoS) value of at least 100 for intra-species and inter-species variation [25]. Human PSCs
represent a promising human cellular model which could help in increasing the safety and
predictability of RDT testing. Combined with this cell model, toxicogenomic technologies
would help predict biomarkers in an evidence-based approach. During these RDT tests, the
animals are observed for indications of toxicity. Afterwards, necropsy, blood analysis and
histopathology of the organs of the animals are performed [17]. However, these parameters
can turn out to be insensitive and potentially generate false negative results [15, 16]. Unex‐
pected hepatotoxicity may be seen in the clinical trials or even when the product is already on
the market because careful examinations of idiosyncratic (person specific) or non-idiosyncratic
inter-drug interactions are either ignored or overseen [45]. This is also probably because of
dose-dependent reactions and other unknown peculiar drug interactions. There is need for
novel screening methods that can address these hepato-toxicological hazards early in the
development [46]. Most studies relied on the use of liver slices as an in vitro model for toxicity
testing due to limited availability of tissue samples. However, the human PSC-derived
hepatocytes have the potential to replace these in vitro models and be applied for toxicity
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assessment. The suitability of hepatocyte-like cells derived from human PSCs for toxicity
testing and drug discovery were systematically studied by several groups [47-49].
5. Omics strategies to develop biomarkers for RDT
5.1. Toxicogenomics
Proteomics, genomics and metabonomics, either alone or in combination have the potential
for developing biomarkers in applied toxicology. Toxicogenomics refers to the areas men‐
tioned above and is a thorough-mean for hi-throughput discovery of biomarkers using latest
technologies [50]. Transcriptomics measures the levels of both coding and non-coding RNAs
using hi-throughput technology such as microarrays. This whole genome gene expression
analysis can measure the levels of expression of a gene at any stage, in any tissue and in any
vitro model. Examples of toxicogenomics applications include prediction of genotoxicity or
carcinogenicity, target organ toxicity and endocrine disruption. Expression profiling of any
selected cellular systems exposed to new test substances is compared against controls to
identify, classify and validate toxic compound and its effects. Bioinformatic analyses of the
data sets obtained from above can be used to predict the patterns and signatures of a toxin
(e.g. biological processes or signaling pathways affected by a toxin). Furthermore, the data sets
can be matched up against existing databases for predicting and carving out a mode-of-action
for the toxin. The main disadvantage of this approach is limited reproducibility and also it is
semi quantitative and detects only changes in gene expression. Therefore, mRNA expression
profiling cannot be used as a standalone method in identifying potential biomarkers of RDT.
EU FP7 project Predict-IV is evaluating the integration of ‘omics’ technologies, biomarkers and
high content imaging for the early prediction of toxicity of pharmaceuticals in vitro. The aim
is to identify general molecular response pathways that result from toxic drug effects that are
independent of the cell/tissue type [51]. Detection of endpoints and biomarkers of RDT using
in vitro systems (DETECTIVE) is a unique large scale SEURAT-1 cluster project aimed at
establishing screening pipeline of high content, high throughput as well as classical functional
and “-omics” technologies to detect human biomarkers for RDT in in vitro test system (http://
www.detect-iv-e.eu/). Other-omics technologies such as microRNA analysis and epigenetics
also play a vital role.
5.2. Proteomics
Drug induced toxicity can also exhibit various effects at the proteome level. Classification of
such endpoints is difficult using traditional RDT methods. Proteomics improves the classifi‐
cation by identifying individual proteins or such protein panels that reflect the specific toxic
pathway mechanisms. Proteomics-based in vitro toxicity assays measure drug-induced
changes by comparing in vitro to in vivo effects thus validating the suitability of in vitro
models. There is an absolute need for integration of standard RDT tests with the ‘omics’
applications. Current proteomic technologies include gel-based (1-DE or 2-DE) and gel-free
(LC-MS/MS) techniques [17]. Recently thalidomide-specific proteomics signatures during
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maturation of Ca2+handling [38]. Further improvements of differentiation methods will enable
generation of more homogeneous and mature CM populations thus increasing their validity
for RDT testing. The overall predictability of drug efficacy and toxicity using iPSC-CMs and
disease specific iPSC-CMs has been recently reported by several groups [29, 39-41]. An absolute
requirement for CMs to be used for RDT is to be able to stably maintain the beating cardiac
phenotype for a prolonged period of time under defined conditions. Both hiPSC-CMs and
hESC-CMs display beat rate variability similar to that of a human heart sinoatrial node [42].
However, recently, variability in action potentials and sodium currents in response to lidocaine
and tetrodotoxin was shown in late stage in vitro differentiated human iPSC-CMs [32], thus
warranting some caution and further analyses.
Bioanalytics is a very promising tool in the application of in vitro cardiotoxicty assays. Novel
bioanalytical tools for discovery of biomarkers of cardiotoxicity include the field potential QT
scanning, using cellular oxygen uptake for monitoring the metabolic state of CMs, using
surface plasmon resonance (SPR) biosensing for key CM biomarkers, and also exploiting real-
time multi-wavelength fluorimetry [12]. Novel imaging technologies and physiological
analyses such as impedance measurements [43] and microelectrode arrays (MEAs) [44] give
an insight into major in vitro cellular events such as migration, proliferation, cell morphology,
cell–cell interactions and colony formation, relevant to biomarker discovery.
4. Stem cell-derived hepatocytes for toxicity testing
So far, hepatotoxicity is evaluated on day 28 or 90 in in vivo RDT tests by analysis of clinical
parameters, hematology, and histopathology. RDT tests evaluate chronic effects on organ
toxicity to establish a NOAEL which is used in calculation of the substance safety parameters
[25]. The extrapolation of the quantitative risk assessment for cosmetic ingredients using data
derived from animal studies to in vitro systems could be done by considering a margin of
safety (MoS) value of at least 100 for intra-species and inter-species variation [25]. Human PSCs
represent a promising human cellular model which could help in increasing the safety and
predictability of RDT testing. Combined with this cell model, toxicogenomic technologies
would help predict biomarkers in an evidence-based approach. During these RDT tests, the
animals are observed for indications of toxicity. Afterwards, necropsy, blood analysis and
histopathology of the organs of the animals are performed [17]. However, these parameters
can turn out to be insensitive and potentially generate false negative results [15, 16]. Unex‐
pected hepatotoxicity may be seen in the clinical trials or even when the product is already on
the market because careful examinations of idiosyncratic (person specific) or non-idiosyncratic
inter-drug interactions are either ignored or overseen [45]. This is also probably because of
dose-dependent reactions and other unknown peculiar drug interactions. There is need for
novel screening methods that can address these hepato-toxicological hazards early in the
development [46]. Most studies relied on the use of liver slices as an in vitro model for toxicity
testing due to limited availability of tissue samples. However, the human PSC-derived
hepatocytes have the potential to replace these in vitro models and be applied for toxicity
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assessment. The suitability of hepatocyte-like cells derived from human PSCs for toxicity
testing and drug discovery were systematically studied by several groups [47-49].
5. Omics strategies to develop biomarkers for RDT
5.1. Toxicogenomics
Proteomics, genomics and metabonomics, either alone or in combination have the potential
for developing biomarkers in applied toxicology. Toxicogenomics refers to the areas men‐
tioned above and is a thorough-mean for hi-throughput discovery of biomarkers using latest
technologies [50]. Transcriptomics measures the levels of both coding and non-coding RNAs
using hi-throughput technology such as microarrays. This whole genome gene expression
analysis can measure the levels of expression of a gene at any stage, in any tissue and in any
vitro model. Examples of toxicogenomics applications include prediction of genotoxicity or
carcinogenicity, target organ toxicity and endocrine disruption. Expression profiling of any
selected cellular systems exposed to new test substances is compared against controls to
identify, classify and validate toxic compound and its effects. Bioinformatic analyses of the
data sets obtained from above can be used to predict the patterns and signatures of a toxin
(e.g. biological processes or signaling pathways affected by a toxin). Furthermore, the data sets
can be matched up against existing databases for predicting and carving out a mode-of-action
for the toxin. The main disadvantage of this approach is limited reproducibility and also it is
semi quantitative and detects only changes in gene expression. Therefore, mRNA expression
profiling cannot be used as a standalone method in identifying potential biomarkers of RDT.
EU FP7 project Predict-IV is evaluating the integration of ‘omics’ technologies, biomarkers and
high content imaging for the early prediction of toxicity of pharmaceuticals in vitro. The aim
is to identify general molecular response pathways that result from toxic drug effects that are
independent of the cell/tissue type [51]. Detection of endpoints and biomarkers of RDT using
in vitro systems (DETECTIVE) is a unique large scale SEURAT-1 cluster project aimed at
establishing screening pipeline of high content, high throughput as well as classical functional
and “-omics” technologies to detect human biomarkers for RDT in in vitro test system (http://
www.detect-iv-e.eu/). Other-omics technologies such as microRNA analysis and epigenetics
also play a vital role.
5.2. Proteomics
Drug induced toxicity can also exhibit various effects at the proteome level. Classification of
such endpoints is difficult using traditional RDT methods. Proteomics improves the classifi‐
cation by identifying individual proteins or such protein panels that reflect the specific toxic
pathway mechanisms. Proteomics-based in vitro toxicity assays measure drug-induced
changes by comparing in vitro to in vivo effects thus validating the suitability of in vitro
models. There is an absolute need for integration of standard RDT tests with the ‘omics’
applications. Current proteomic technologies include gel-based (1-DE or 2-DE) and gel-free
(LC-MS/MS) techniques [17]. Recently thalidomide-specific proteomics signatures during
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human ESCs differentiation were identified using two-dimensional electrophoresis coupled
with Tandem Mass spectrometry [52]. Proteomic studies are quantitative, sensitive and are
more accurate and powerful in detecting protein biomarkers of RDT. Main pitfalls include
posttranslational changes and limited protein detection capacity.
5.3. Metabonomics
Human PSCs offer a potential alternative test system for the identification of developmen‐
tal toxicants [53]. Metabonomics refers to profiling of diverse metabolic complement of a
biofluid  or  tissue  using  analytical  tools  such  as  high-field  NMR  together  with  mass
spectrometry [54]. Subsequent statistical modeling and analysis of a multivariate spectral
profiles obtained using NMR [55] in combination with LC-MS and UPLC helps to distin‐
guish the phenotypes and metabolites of interest. These metabolites might represent new
biomarkers for toxicity. Previously, some of metabolites were identified to be biomarkers
for a variety of pathological diseases [56]. Metabonomics-based approaches have proved to
be  highly  successful  in  furthering  our  understanding  of  research  in  the  field  of  drug
metabolism, drug pathways and toxicology [54, 55]. In addition, metabonomics provides a
useful  link between ‘omics'  platforms such as genomics,  transcriptomics and proteomics
and end-stage histopathological analyses [54].
The Consortium for Metabonomic Toxicology (COMET) project (a collaboration between five
pharmaceutical companies and Imperial College London) focused on pre-clinical toxicological
research and resulted in the generation of an extensive 1H NMR biofluid spectral database
which was used for screening of toxins and also to build an expert system for prediction of
target organ toxicity [57]. A follow-up project, COMET-2, is currently investigating the detailed
biochemical mechanisms of toxicity, and seeks a better understanding of inter-subject variation
in metabonomics analyses [55]. Several groups have developed Metabonomics-based robust
human ESC in vitro test systems for predicting human developmental toxicity biomarkers and
pathways [58, 59]. Metabonomics is the most relevant and robust omics platform to study both
in vivo and in vitro toxicology. It is possible to detect metabolites with accuracy but it is limited
by its high costs and complex metabolite isolation procedures.
6. Bioinformatic and statistical analysis of candidate biomarkers
Since the omics methods are extensively data-intensive and bulk, there is a definite need for
bioinformatics and statistical analysis for organizing the data in conveniently accessible
databases, which integrate huge number of data sets, and therefore need quality database
manager software such as SQL for centralized storage and flexible web based access to the
bulk data.
Noncommercial databases available on the web such as CEBS (chemical effects in biological
systems, (http://cebs.niehs.nih.gov), PhenoGen (http://phenogen.uchsc.edu), along with and
commercial databases like ArrayTrack and ArrayExpress (http://www.ebi.ac.uk/arrayexpress)
help to generate large data sets. These are complemented by metabonomics databases (http://
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www.hmdb.ca). PrestOMIC is proteome-specific open-source that is a user-friendly database,
where researchers can upload and share data with the scientific community using a custom‐
izable browser [60]. Such a database helps researchers to increase the exposure and impact of
their data by enabling extensive data set comparisons.
Another open-source systems biology application called SysBio-OM, integrates information
from the CEBS database with other open source projects, including MAGE-OM (micro-array
gene expression object model) and PEDRo (proteomics experiment data repository), to model
profiling of protein, and metabolite expression and protein-protein interactions following
insult [61]. SysTox-OM is a more specific application that performs expression profiling of
genome, proteome, and metabolome, after the introduction of a toxicant. Different omics
approaches and some of the crucial data bases are summarized in Table.1. While incorporating
toxicological endpoints such as – clinical chemistry, hematology, observations and histopa‐
thology, it profiles the phenotype [62]. With this application, one can identify a single toxic
phenotype, classify, and compare gene and protein expression profiles in an organ after
administration of each drug. It is also possible to predict a common toxicologic pathway,
mechanism or a biomarker. ToxBank is an EU FP7 project aimed at establishing a dedicated
web-based warehouse for toxicity data management and modeling along with establishing a




























































Table 1. Summary of different Omics approaches and corresponding databases
Human Pluripotent Stem Cell Applications in Drug Discovery and Toxicology – An overview
http://dx.doi.org/10.5772/58485
189
human ESCs differentiation were identified using two-dimensional electrophoresis coupled
with Tandem Mass spectrometry [52]. Proteomic studies are quantitative, sensitive and are
more accurate and powerful in detecting protein biomarkers of RDT. Main pitfalls include
posttranslational changes and limited protein detection capacity.
5.3. Metabonomics
Human PSCs offer a potential alternative test system for the identification of developmen‐
tal toxicants [53]. Metabonomics refers to profiling of diverse metabolic complement of a
biofluid  or  tissue  using  analytical  tools  such  as  high-field  NMR  together  with  mass
spectrometry [54]. Subsequent statistical modeling and analysis of a multivariate spectral
profiles obtained using NMR [55] in combination with LC-MS and UPLC helps to distin‐
guish the phenotypes and metabolites of interest. These metabolites might represent new
biomarkers for toxicity. Previously, some of metabolites were identified to be biomarkers
for a variety of pathological diseases [56]. Metabonomics-based approaches have proved to
be  highly  successful  in  furthering  our  understanding  of  research  in  the  field  of  drug
metabolism, drug pathways and toxicology [54, 55]. In addition, metabonomics provides a
useful  link between ‘omics'  platforms such as genomics,  transcriptomics and proteomics
and end-stage histopathological analyses [54].
The Consortium for Metabonomic Toxicology (COMET) project (a collaboration between five
pharmaceutical companies and Imperial College London) focused on pre-clinical toxicological
research and resulted in the generation of an extensive 1H NMR biofluid spectral database
which was used for screening of toxins and also to build an expert system for prediction of
target organ toxicity [57]. A follow-up project, COMET-2, is currently investigating the detailed
biochemical mechanisms of toxicity, and seeks a better understanding of inter-subject variation
in metabonomics analyses [55]. Several groups have developed Metabonomics-based robust
human ESC in vitro test systems for predicting human developmental toxicity biomarkers and
pathways [58, 59]. Metabonomics is the most relevant and robust omics platform to study both
in vivo and in vitro toxicology. It is possible to detect metabolites with accuracy but it is limited
by its high costs and complex metabolite isolation procedures.
6. Bioinformatic and statistical analysis of candidate biomarkers
Since the omics methods are extensively data-intensive and bulk, there is a definite need for
bioinformatics and statistical analysis for organizing the data in conveniently accessible
databases, which integrate huge number of data sets, and therefore need quality database
manager software such as SQL for centralized storage and flexible web based access to the
bulk data.
Noncommercial databases available on the web such as CEBS (chemical effects in biological
systems, (http://cebs.niehs.nih.gov), PhenoGen (http://phenogen.uchsc.edu), along with and
commercial databases like ArrayTrack and ArrayExpress (http://www.ebi.ac.uk/arrayexpress)
help to generate large data sets. These are complemented by metabonomics databases (http://
Pluripotent Stem Cell Biology - Advances in Mechanisms, Methods and Models188
www.hmdb.ca). PrestOMIC is proteome-specific open-source that is a user-friendly database,
where researchers can upload and share data with the scientific community using a custom‐
izable browser [60]. Such a database helps researchers to increase the exposure and impact of
their data by enabling extensive data set comparisons.
Another open-source systems biology application called SysBio-OM, integrates information
from the CEBS database with other open source projects, including MAGE-OM (micro-array
gene expression object model) and PEDRo (proteomics experiment data repository), to model
profiling of protein, and metabolite expression and protein-protein interactions following
insult [61]. SysTox-OM is a more specific application that performs expression profiling of
genome, proteome, and metabolome, after the introduction of a toxicant. Different omics
approaches and some of the crucial data bases are summarized in Table.1. While incorporating
toxicological endpoints such as – clinical chemistry, hematology, observations and histopa‐
thology, it profiles the phenotype [62]. With this application, one can identify a single toxic
phenotype, classify, and compare gene and protein expression profiles in an organ after
administration of each drug. It is also possible to predict a common toxicologic pathway,
mechanism or a biomarker. ToxBank is an EU FP7 project aimed at establishing a dedicated
web-based warehouse for toxicity data management and modeling along with establishing a
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7. Conclusion and future perspective
Improved toxicity testing methods complementing advanced in vitro assays are very crucial
in reducing the rate of attrition in final stages of product development. To avoid failures and
withdrawals, there is an absolute need for integration of all available technologies to minimize
cumbersome process of trials and expenses and eventually reduce the increasing costs of
bringing a new drug into market. Supplementing toxicology evaluation methods, such as
histopathology, physiology and clinical chemistry with transcriptomics, proteomics and
metabonomics could provide new insights into the mechanisms underlying toxicological
pathologies. Integration of in vitro toxicology technologies, with systems biology methods
resulted in ‘systems toxicology’. Expansion of open source databases and analytical platforms
is critical to the discovery of novel biomarkers of toxicity. So far, the available approaches for
discovery of biomarkers included toxicogenomics, toxicoproteomics, metabonomics and
bioinformatics analyses (systems biology approach) while the technologies available for
quantification include ELISA, solid phase ELISA, Luminex technology and patterned paper
technology [50]. Individual technologies have limited usefulness unless the data generated
from these assay platforms and ‘-omics’ discovery technologies are integrated. The discovery
of DNA microarrays and protein chips has made information exchanges extraordinarily easy,
convenient and quick. Integration of information from these powerful sources using analytical
computing software products, noncommercial databases, and advances in hi-throughput
technology is the future of the next phase in the identification, selection and qualification of
novel biomarkers of toxicity.
Future of toxicogenomics lies in developing a more refined understanding of molecular
mechanisms related to specific toxicologies, to elucidate molecular signatures associated with
the prediction of biomarkers or panels of biomarkers with support from the field of transcrip‐
tomics, metabolomics, and proteomics. These analytical tools applied to the emerging human
PSC-based in vitro platforms utilizing their organ-specific differentiated derivatives, such as
CMs, hepatocytes and neurons, have a great potential to revolutionize the field of toxicology.
However, the full potential of these human in vitro cell-based platforms in predicting toxicity
of compounds in humans will be realized only with further improvements in derivation of
highly standardized, well-defined and homogeneous cell populations that functionally and
structurally strongly resemble their adult counterparts and development of sensitive and
robust methods for accurate detection of toxicity.
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1. Introduction
The establishment of pluripotent mouse embryonic stem cells (ESCs), which have the capacity
to differentiate into all cell types in the mammalian body, was first described by Evans and
Kaufman in 1981. Seventeen years later, in 1998, the first report of human ESCs, with similar
differentiation characteristics was published by James Thompson. In 2006, Takahashi and
Yamanaka discovered that the genome of a differentiated somatic cell could be epigenetically
reprogrammed to pluripotency by inducing the expression of pluripotency transcription
factors, resulting in the production of pluripotent stem cells (iPSCs). This research has
accelerated the study of regenerative medicine.
In 2009, the US Food and Drug Administration approved the first Phase I clinical trials of
human ESC-derived cells for the treatment of spinal cord injuries. However, previous reports
had revealed that stem cell-based therapies increase the risk of tumor development. Therefore,
further basic research is needed before stem cell-based therapies can be applied in the clinic.
The development of stem cell tools can be critically evaluated using animal models that express
human disease genes.
Research on the stem cell biology of the minipig is developing rapidly. Although research on
mouse and human stem cells currently predominates over that in other species, data from these
well-studied species have provided a good foundation for current and future porcine stem cell
research. In addition, the increasing popularity of alternative-species models for the study of
human diseases and disease mechanisms has further spurred porcine stem cell research. As a
model system for pluripotent embryonic stem cell research, however, the pig presents several
challenges as compared with mice and humans. Nonetheless, porcine minipig embryonic germ
cells have recently been produced, and may prove particularly useful for in vitro and in vivo
differentiation studies, gene targeting, and the creation of transgenic animals. In addition,
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Yamanaka discovered that the genome of a differentiated somatic cell could be epigenetically
reprogrammed to pluripotency by inducing the expression of pluripotency transcription
factors, resulting in the production of pluripotent stem cells (iPSCs). This research has
accelerated the study of regenerative medicine.
In 2009, the US Food and Drug Administration approved the first Phase I clinical trials of
human ESC-derived cells for the treatment of spinal cord injuries. However, previous reports
had revealed that stem cell-based therapies increase the risk of tumor development. Therefore,
further basic research is needed before stem cell-based therapies can be applied in the clinic.
The development of stem cell tools can be critically evaluated using animal models that express
human disease genes.
Research on the stem cell biology of the minipig is developing rapidly. Although research on
mouse and human stem cells currently predominates over that in other species, data from these
well-studied species have provided a good foundation for current and future porcine stem cell
research. In addition, the increasing popularity of alternative-species models for the study of
human diseases and disease mechanisms has further spurred porcine stem cell research. As a
model system for pluripotent embryonic stem cell research, however, the pig presents several
challenges as compared with mice and humans. Nonetheless, porcine minipig embryonic germ
cells have recently been produced, and may prove particularly useful for in vitro and in vivo
differentiation studies, gene targeting, and the creation of transgenic animals. In addition,
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studies involving the transplantation of somatic mesenchymal stem cells into porcine heart,
cartilage, and bone have yielded very promising results. Lastly, minipig induced pluripotent
stem cells have been established by using Sendai viruses to introduce pluripotency transcrip‐
tion factors into the cells.
Thus, despite the challenges of developing porcine pluripotent stem cells, recent successes in
the fields of both induced pluripotent stem cells and somatic stem cells suggest that the future
of research using minipig stem cells is quite promising.
2. Embryonic stem cells
Most porcine embryonic stem cell research has been performed in large domestic pig breeds
rather than minipigs. Therefore, this discussion will focus on studies performed on the large
domestic breeds, yet with attention paid to outcomes observed in the minipig. Research in the
domestic species is highly transferrable to the minipig.
Although researchers have sought to establish ESCs in the pig, the characterization of ESCs in
this animal falls short, due to a lack of both in vivo and long-term culture studies as compared
to ESCs of mouse or human origin. The first reports on ESC production in the pig were in 1990
[1] [2] [3] [4]. However, those attempts produced only putative ESCs or embryonic stem-like
cells.
A number of standard techniques are typically employed to verify the identity of true ESCs.
Several in vitro techniques are generally performed to determine the expression profile of the
ESCs, including gene-expression and protein analyses. The transcription factors expressed in
both mouse and human ESCs include OCT4, NANOG, and SOX2. In addition, stage-specific
embryonic antigen 1 (SSEA1) is expressed in mouse but not human ESCs, and SSEA3 and
SSEA4 are detected in human but not mouse ESCs [5].
While the efforts to establish porcine ESCs have been well reviewed in the scientific literature
[6] [7], a general overview of the research suggests that true porcine ESCs have not yet been
produced. The production of porcine epiblast stem cells (EpiSCs) was recently reported [8].
These cells are thought to be derived from the epiblast, rather than the inner cell mass, of the
developing embryo. Evidence suggests that mouse ESCs are of inner cell mass origin, while
human ESCs originate from epiblasts [9]. The porcine epiblast stem cells could be cultured for
22 passages, and could differentiate in vitro into cell types representative of the three embryonic
germ lineages as well as germ precursor cells and trophectoderm. However, it is not known
whether these cells also demonstrate pluripotency.
To date, two research groups have attempted to produce porcine ESCs from the minipig [10,
11]. Li and colleagues reported that outgrowth cultures could be obtained after isolating the
inner cell mass from Chinese minipig blastocysts, although sustained culture was difficult to
achieve, and only a preliminary characterization of these cells was performed [10]. Long-term
cultures of porcine ESC-like cells were reported by Kim and colleagues [11]. In this study,
porcine ESC-like cells were derived from cloned blastocysts. These embryos were produced
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by somatic cell nuclear transfer, using minipig fetal or neonatal fibroblasts as the donor and
prepubertal gilt oocytes, followed by culture in vitro to the blastocyst stage of development.
Two cells lines could be cultured for more than 48 passages, and expressed alkaline phospha‐
tase (AP), SSEA1 and SSEA3, OCT4, TRA-1-60, and TRA-1-81. The only method used to
characterize their differentiation ability was the observation of spontaneous differentiation
into embryoid bodies (EBs), which are spheres of cells that contain cell types of all three germ
layers. These EBs were assessed solely by gene analysis, thus further characterization would
be necessary before they could be verified as true ESCs.
Only two reports to date describe the production of chimeras from porcine ESC-like cells: one
in 1999, from Chen and colleagues [12], and a more recent publication in 2010 [13]. The first
report claimed that somatic chimeric piglets could be produced, although clear analyses of
these chimeric animals was lacking. The second report indicated that porcine ESC-like cells
from an early passage could form chimeric piglets. The chimeric contribution was low,
however; only 4 chimeric piglets were born after the transfer of hundreds of embryos. Only 2
of the 4 chimeric piglets showed coat chimerism, and this contribution was low and restricted
to a single spot near the tail. Such a chimeric contribution is much lower than what would be
expected from mouse ESCs, indicating that improvements to the cell culture conditions may
be required to improve the plasticity of these cells.
There are several possible reasons for the difficulty in producing porcine ESCs. The lack of
defined culture conditions may be one reason. Pluripotency appears to be controlled by more
than one cell-signaling pathway, and these pathways are different in mouse and human ESC
lines. The origin of the cells, that is, the inner cell mass (mouse) versus the epiblasts (human)
may contribute to this diversity of regulatory pathways. This idea is supported by a recent
publication showing that even mouse EpiSCs regulate pluripotency slightly differently from
human ESCs [14]. The cell signaling that governs pluripotency in the pig remains largely
unknown, although the details are beginning to be investigated [15]. For example, it was
reported that fibroblast growth factor (FGF) signaling may be active in porcine epiblasts, and
that the JAK/STAT pathway is inactive. The Activin/Nodal pathway also appears to be active
in porcine epiblasts [8]. Culturing porcine epiblasts in medium containing basic FGF (bFGF)
cannot prevent their differentiation, indicating that other factors are apparently necessary to
help maintain cellular pluripotency.
Differences occurring during early embryonic development in the domestic pig, as compared
with mouse and human, could also account for the observed difficulties in producing porcine
ESCs. The early development of the porcine embryo prior to implantation takes longer and is
less advanced than in the other species. The inner cell mass differentiates into the hypoblast
and epiblast at a later time point than in the mouse and human, and the porcine epiblast
expands and develops over a period of several days. The cell signaling controlling this
development in the pig could differ markedly from that in the mouse or human, and should
be investigated to ascertain which stage of development is optional for isolating the pluripotent
cells. It is possible that the later epiblast is already predetermined at the cell-signaling level to
undergo gastrulation, or that the inner cell mass cells have not yet acquired the necessary cell
signaling machinery to support proliferation.
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We have yet to observe bona fide ESCs produced from the pig. Nevertheless, continued research
toward this goal is important, as the pig is a particularly useful biomedical model for studying
human disease, and ESCs are a unique cell type that is especially useful for studying human
disease.
3. Embryonic germ cells
Embryonic germ cells (EGCs) are pluripotent cells derived in vitro from primordial germ cells
(PGCs). They were first derived in the mouse by Matsui et al. [16] and Resnick et al. [17]. Mouse
EGCs are morphologically similar to mouse ESCs, and express similar pluripotency markers
such as AP, SSEA1, Oct4, Sox2, and Nanog. The differentiation potential of these cells is also
similar to that of mouse ESCs, as evidenced by their ability to differentiate in vitro into different
tissues from the three primary germ layers [18], as well as to re-enter the germline when
injected into blastocyst embryos [19]. Mouse EGCs may thus be considered equivalent to ESCs.
Similar to the conditions required to derive mouse ESCs, mouse EGCs need two important
growth factors in addition to leukemia inhibitory factor (LIF) for their successful derivation
from PGCs. The first is stem cell factor (SCF), a ligand for c-Kit, which supports PGC survival
in vivo and in vitro by suppressing apoptosis [20]. The second is bFGF, which plays a major
role in the reprogramming of mouse PGCs into pluripotent cells in vitro [21]. Although the
mechanism of this reprogramming is still poorly understood, bFGF is known to downregulate
the expression of basic lymphocyte maturation protein 1 (Blimp1) in vitro, which in turn causes
the upregulation of c-Myc and Klf4 [21]. Because mouse PGCs also express Oct4 and Sox2, a
similar mechanism may be involved in their reprogramming to ESCs.
Porcine EGCs were first derived by Shim et al. [22], who used embryos from domestic breeds
on day 25 of gestation under conditions similar to those used to culture mouse EGCs. The
established cell lines had an ESC-like morphology, expressed AP, and were able to differentiate
into different cell types in vitro and in vivo. Other groups have derived porcine EGC lines using
day 25-28 embryos from domestic breeds [23] [24] [25] [26] [27], and from the Chinese minipig
[28]. Recently, putative porcine EGC lines derived from the PGCs of day 20-24 embryos from
Danish Landrace crosses and Yucatan minipigs were reported [29]. Notably, these findings
suggest that EGC lines can be established from any porcine breed, unlike mouse ESCs, which
are restricted to certain strains.
Immunocytochemical analysis of pluripotency marker expression showed that, in addition to
AP activity, EGCs express Oct4, SSEA1, SSEA3, and SSEA4 at variable levels. Analysis of the
porcine EGC gene expression suggested that they are similar to human EGCs in expressing
AP, Oct4, SSEA1, and SSEA4 [30]. The pig EGCs typically have long cell cycles, and proliferate
slowly over many passages.
The tissue culture conditions used by all groups for the derivation and propagation of porcine
EGCs are similar to those used for human and mouse ESCs. The cells are grown on feeder
layers of mitotically inactivated embryonic mouse fibroblasts, most often on immortalized
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mouse fibroblast cells from a cell line known as STO. The initial establishment of cell lines is
hampered by the fact that large numbers of porcine PGCs undergo apoptosis and die in culture
within 6 hours of their incubation [25]. However, by using protease inhibitors and antioxidants
to reduce the level of PGC apoptosis in vitro, Lee et al. were able to increase the number of EGC
colonies in the primary culture. In addition, alpha 2-macroglobulin together with N-acetyl‐
cystein and butylated hydroxyanisole (both antioxidants) increased the number of AP-positive
colonies in primary cultures at least twofold. Another approach is to use growth factors and
various feeder cells to increase the survival and prevent the differentiation of PGCs in long-
term culture. Lee et al. [26] showed that supplementing the culture medium with three growth
factors (LIF, SCF, and bFGF) increased the number of colonies obtained in primary culture,
and improved the quality of the colonies in subsequent passages compared to cells treated
with only two of these growth factors. The use of feeder layers other than STO cells did not
have a significant effect on PGC survival or on the quality of the derived EGCs. In another
study, membrane-bound SCF and soluble LIF were sufficient to increase the number of
surviving PGCs on days 3 and 5 of primary culture, while adding bFGF did not affect the
results significantly [23]. It is possible that the membrane-bound form of SCF is more potent
than the soluble form, which could explain these differing results. However, it has also been
reported that established PGCs are capable of generating chimeras without added growth
factors, while adding LIF to the culture does not improve the efficiency of establishing EGC
lines [22]. Thus, further study is needed to elucidate the effects of these supplements in culture.
Pluripotent stem cells are able to form EBs, spherical aggregates containing differentiated
cells, when cultured in suspension. Porcine EGCs cultured in “hanging drops” can also form
simple EBs, consisting of large epithelial-like cells on the periphery surrounding mesenchy‐
mal-like cells in the center. When allowed to attach to gelatin-treated plastic dishes, the EB
cells proliferate and spread on the surface of the dish, giving rise to several different types
of cells [27].
Pluripotent cells can proliferate and differentiate in vivo, forming tumors containing differen‐
tiated tissues called teratomas, when injected into immunodeficient mice. To date, only one
group has reported teratoma testing for porcine EGCs, using cell lines derived from the
Chinese minipig [28]. The authors reported that the teratomas contained cells from the three
primary germ layers: epithelial, neuroepithelial, and adipose tissue. In contrast to these results,
two studies showed that the injection of human EGCs into immunodeficient mice failed to
generate teratomas. [31] [32]. However, more recently, the formation of teratomas from human
EGCs cultured under serum-free conditions was reported [33].
Another way of testing the differentiation potential of pluripotent cells in vivo is by chimera
formation, in which the cells injected into early embryos contribute to the three germ layers
and potentially to the germline. Unlike mouse ESCs and EGCs, which have been shown to re-
enter the germline of chimeras, pig EGC chimeras have not displayed a proven germline
contribution; furthermore, the somatic tissues of these porcine chimeras contained only a low
percentage of donor-derived cells [22] [34] [24]. Other researchers demonstrated a similarly
low chimeric contribution after the injection of somatic cells into sheep blastocysts and 8-cell
mouse embryos [35, 36]. This is troubling because germline contribution is considered to be
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percentage of donor-derived cells [22] [34] [24]. Other researchers demonstrated a similarly
low chimeric contribution after the injection of somatic cells into sheep blastocysts and 8-cell
mouse embryos [35, 36]. This is troubling because germline contribution is considered to be
The Minipig — A New Tool in Stem Cell Research
http://dx.doi.org/10.5772/57603
201
the ultimate proof of pluripotency, and has been demonstrated only in the mouse and chicken
to date. Human ESCs are presumed to be true stem cells as well, even though their germline
potential has not been tested for ethical reasons. Caution is needed when interpreting chimera
experimental results. Proper controls are necessary to distinguish the “true” stem cells from
somatic cells that can be integrated into the embryos after partial reprogramming by the
surrounding embryonic cells.
The reasons for the limited pluripotency of the porcine EGCs are currently unclear. It is possible
that the tissue culture conditions are not sufficient for maintaining the pluripotency of the
PGCs in vitro, similar to the problems that exist in the cultures of inner cell mass and epiblast
cells. Another possibility is that the pig PGCs do not undergo full epigenetic reprogramming
into pluripotency like the mouse PGCs do. One indication that there might be differences in
the biology of PGCs between the pig and mouse is that porcine PGCs survive and proliferate
in vitro in the absence of externally added growth factors, regardless of whether they are
cultured in serum-supplemented or serum-free conditions, while mouse PGCs fail to survive
in the absence of any of the three growth factors LIF, SCF, or bFGF. In addition, mouse PGCs
have not been shown to form chimeras, whereas porcine PGCs can contribute to somatic tissues
after their injection into early blastocysts [24]. Thus, some of the molecular mechanisms that
are important for reprogramming mouse PGCs to pluripotent EGCs in culture may be different
in the pig.
4. Induced pluripotent stem cells
Takahashi and Yamanaka [37] discovered that the genome of a differentiated somatic cell can
be epigenetically reprogrammed to pluripotency by the induced expression of pluripotency
transcription factors, resulting in the generation of pluripotent stem cells [induced Pluripotent
Stem Cells (iPSCs)]. These authors initially expressed 24 pluripotency genes in fetal fibroblasts
to reprogram them into pluripotent cells, and subsequently found that the expression of only
4 of these genes, namely Oct4, Sox2, c-myc, and Klf4, was sufficient to achieve the same results.
Nanog was dispensable for the cellular reprogramming. In addition, a year later, Okita et al.
[38] produced germline-competent mouse iPSCs using the same growth factors, but by
selecting the reprogrammed cells by Nanog expression.
The production of human iPSCs started shortly after the publication of the first report of mouse
iPSC derivation. Thus, it was not surprising that the establishment of the first human iPSCs
was reported by two groups simultaneously. The laboratory that produced the first mouse
iPSCs successfully generated iPSCs from adult human fibroblasts by using the same 4
transcription factors employed in the initial experiment [39]. The other group, from the
laboratory of human ESC pioneer James Thompson, was able to reprogram human fibroblasts
by expressing OCT4, SOX2, NANOG, and LIN28 [40].
Predictably, these studies sparked significant interest among researchers working in the area
of porcine pluripotent cells. Within two years after the publication of the first papers describing
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human and mouse iPSCs, three different groups reported the establishment of iPSCs in the
pig. One of these groups generated porcine iPSCs using fetal fibroblasts from Danish Landrace
pigs, by the lentiviral transduction of six human transcription factors (OCT4, SOX2, c-Myc,
KLF4, LIN28, and NANOG) under the control of a doxycycline-inducible promoter [41].
Simultaneously, another Chinese group reported the derivation of iPSCs from fibroblasts from
the Tibetan minipig, using constitutively expressed lentiviral vectors carrying the mouse
cDNA sequences of Oct4, Sox2, c-myc, and Klf4 [42]. The third report published shortly
thereafter by Ezashi et al. [43] also described the production of porcine iPSCs through the use
of 4 human transcription factors (OCT4, SOX2, c-Myc, and KLF4). In addition, these researchers
claimed that the porcine iPSCs were positive for SSEA-1 but negative for SSEA3 and SSEA-4,
indicating that they were more similar to mouse than human iPSCs.
Transcriptional profiling of the cell line by Affymetrix microarray confirmed that the cells were
indeed reprogrammed, and expressed a variety of ESC markers endogenously. However, the
continued expression of the exogenous transcription factors was detected in the iPSCs
generated by all three groups. This problem is not unique to the pig, as it has been reported in
other species as well [39]. In any case, the continued expression of pluripotency genes did not
pose any problems for the differentiation of the cells, since all three laboratories demonstrated
that their cell lines were able to differentiate in vitro (including EB formation) and in vivo by
forming teratomas containing cells of all three germ layers. More recently, it was demonstrated
that porcine iPSCs can form chimeras with high efficiency (85.3%), and contribute to all three
germ layers [44]. Because germline chimerism was not confirmed in this study, it remains to
be determined whether the porcine iPSCs are fully equivalent to mouse iPSCs.
One of the major advantages iPSCs may offer in the future is the potential for custom derivation
of pluripotent cells from individual patients to use for regenerative therapies without the risk
of immune rejection. However, since the epigenetic reprogramming necessary to produce
them requires prolonged expression of the transgenes (2-3 weeks), most of the iPSCs described
to date have been generated with the use of lentiviral vectors that integrate known oncogenes
(such as c-myc and Klf4) into the cell genome. The dangers of using these genes became evident
in a study in which mouse chimeras generated with iPSCs developed tumors following
reactivation of the initially silenced transgene c-myc [38]. In the only report to date in which
porcine chimeras were produced from iPSCs [44], no tumor formation was reported in the
newborn piglets. However, because long-term testing and monitoring were not conducted
prior to the publication of these results, at present there is no guarantee that these iPSCs would
be safe for clinical applications.
To avoid problems associated with viral integration and the use of oncogenes, many groups
have developed strategies for iPSC production in which the disadvantages discussed above
have been minimized. For example, it has been shown that reprogramming can be achieved
in both human and mouse cells without the use of c-myc, albeit at the expense of efficiency [45].
In addition, the use of certain transcription factors can be omitted when using cell types already
expressing them; for example, neural progenitor cells, which already express endogenous Sox2
and c-myc were reprogrammed using only the induced expression of OCT4 and Klf4 [46] [47].
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the ultimate proof of pluripotency, and has been demonstrated only in the mouse and chicken
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cells. Another possibility is that the pig PGCs do not undergo full epigenetic reprogramming
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Furthermore, some transcription factors can be replaced by small molecules that have similar
effects on somatic cell reprogramming [48]. Viral integration, which carries risks of insertional
mutagenesis, can be avoided by using nonintegrating adenoviral vectors [49] [50]. Our
laboratory has established porcine iPSCs derived from pig skin fibroblasts using Sendai virus
vectors to introduce 4 human transcription factors (OCT4, SOX2, c-Myc, and KLF4) (data not
shown). Another attractive alternative to the use of viral vectors are transposon vectors, which
combine high transfection efficiency with enhanced safety, and can be removed from the cell
genomes following reprogramming. For example, piggyBac is a DNA transposon that,
following insertion, can be removed from the reprogrammed genome without leaving a trace.
This transposon has already been used successfully to produce iPSCs [51, 52]. Finally, Zhou
[53] produced iPSCs by providing the transcription factors in the form of recombinant proteins.
With regard to future research in porcine iPSC production, the choice of cell type and strategy
will undoubtedly play an important role in the reprogramming efficiency. It should be noted,
however, that the same problems existing in porcine ESC culture are likely to affect the long-
term maintenance of the newly generated pig iPSC lines. For example, the culture conditions
supporting the pluripotency and self-renewal of the porcine iPSCs apparently require further
optimization, given that, in all the published reports to date, the reprogrammed cell lines could
be maintained only with the continued expression of exogenous pluripotency genes. In one
study, for example, instead of using growth factors or other supplements, the pig iPSCs were
maintained with doxycycline-induced expression of the pluripotency transgenes, until the
authors chose to differentiate the cells [41].
Despite these challenges, we can without doubt look forward to an exciting future in which
iPSCs will add another dimension to pluripotent stem cell research in the pig.
5. Epiblast stem cells
Epiblast stem cells are pluripotent stem cells derived from the epiblast layer of post-implan‐
tation mouse embryos [54]. Epiblast stem cells are distinct from ES cells, which are derived
from the inner cell mass of blastocysts. Both ES cells and epiblast stem cells can differentiate
into mesoderm, endoderm, and ectoderm. However, epiblast stem cells do not have germ-line
transmission.
Rodent pluripotent stem cells are considered to have two distinct states: naïve and primed.
Naïve pluripotent stem cell lines are distinguished from primed cells in their response to LIF
signaling and MEK/GSK3 inhibition (LIF/2i conditions) and X chromosome activation. Human
ES and iPS cells both resemble rodent primed epiblast stem cells more closely than rodent
naïve ES cells. In addition, iPS cells derived from pigs can obtain the properties of primed
epiblast stem cells. iPS cells derived from human, monkey, rabbit, and rat, but not mouse, can
also obtain the properties of primed epiblast stem cells [55].
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6. Conclusions
Stem cell biology research of the minipig is developing rapidly. Although studies on mouse
and human stem cells currently outnumber those of other species, data from these well-studied
species provide a good foundation for current and future porcine stem cell research. Despite
the challenges associated with developing porcine pluripotent stem cells, recent successes in
the fields of induced pluripotent stem cells and somatic stem cells suggest that minipig stem
cell research has a promising future.
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1. Introduction
It is estimated that 2.1 million married couples or 5 million people in the United States are
affected by infertility.[1] Infertility is defined as failure to get pregnant after one year of
unprotected intercourse. About 40% of infertility cases are due to a female factor and 40% due
to a male factor. The remaining 20% are the result of a combination of male and female factors,
or are of unknown causes. [2] Issues of human infertility are extremely complex physiologi‐
cally, psychologically, financially, legally and ethically. It is estimated that 85-90% of infertile
couples will receive conventional treatment and 10-15% may become candidates for various
forms of Assisted Reproductive Technologies (ARTs) to assist them in having their own
biological children. In-vitro fertilization (IVF) is one of the most utilized reproductive proce‐
dures that has allowed couples to have their own biological children. IVF accounts for 99% of
ART. This procedure has been effective but it is still inefficient and expensive. One aspect of
the inefficiency is that numerous embryos have been frozen through a process called cryopre‐
servation. It has been estimated that there are 400,000 embryos frozen and stored since the late
1970s. [3] In reality, the actual number of frozen embryos is probably closer to 500,000 with an
additional 20,000 embryos added yearly. [4] Freezing these embryos has allowed for a
limitation on the number of embryos transferred to a woman’s uterus which has decreased
the number of multiple gestations. It also allows couples to use the frozen embryos in the future
if the initial cycles are unsuccessful. This is not only more effective but also lowers the cost.
The issue is now what to do with the 400,000 to 500,000 frozen embryos that remain as “spares.”
Various alternatives have been suggested. The embryos could be thawed and then destroyed,
continued to be cryopreserved indefinitely, used for research, or offered for donation/
adoption. All of these options present problems medically, legally and ethically.
Medically, the lifespan of a cryopreserved embryo is unknown. The effect of the freezing
process is also unknown on the quality of the embryo if brought to term. “Studies have found
that babies created through IVF are twice as likely to be born underweight and with major
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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birth defects.” [5] With the unknown effects of cryopreservation on embryo development the
medical issues become even more complex. Legally, only 2% of frozen embryos are specifically
designated for donation/adoption and 5% are specifically designated for destruction or
research. [6] The legal issues focus on the applicability of contract law versus family law
because frozen embryos are technically considered “property” not “persons.” Presently, the
applicability of contract law or family law remains unclear. In addition, to date only three states
—Florida, Louisiana and New Hampshire—have adopted legislation concerning the disposi‐
tion or disposal of embryos. Legally and legislatively the issue of embryo donation/adoption
is ambiguous at best. Ethically, depending on one’s view of when personhood begins, frozen
embryos may be considered human persons, which deserve dignity and respect, or they may
have less than human status with no particular ethical rights. From an ethical perspective that
views personhood beginning at fertilization, one could argue that the “rescue” of these
embryos would not only be ethically acceptable but morally mandatory. To determine if frozen
embryos should be donated/adopted all of these issues will have to be examined.
This article will focus on embryo donation/adoption as a viable option to address the 400,000
to 500,000 frozen embryos in the United States. The intended purpose of this article is fourfold:
first, to examine the medical issues surrounding the cryopreservation of frozen embryos;
second, to examine the legal issues that focus on the applicability of contract law and family
law; third, to give an ethical analysis of the arguments for and against embryo donation/
adoption; and fourth, to give recommendations on how to avoid the continuation of this
problem in the future.
2. Medical aspects
Infertility is a major problem for many couples in the United States. “About one married couple
in 12 cannot conceive a child after two years of trying. Infertility stems from many factors,
including a woman’s age at the first attempt to conceive, damage from pelvic inflammatory
disease, previous abortions, uterine abnormalities, and a man’s low sperm count or low sperm
motility.” [7] Individually, male and female factors each account for about 40% of infertility in
the United States. Numerous technologies are available to couples from artificial insemination
by a husband or a donor, to gamete intrafallopian transfer (GIFT), to zygote intrafallopian
transfer (ZIFT), to in-vitro fertilization. Of these reproductive technologies IVF has become the
ART of choice for many infertile couples. IVF is an assisted reproductive technology which
had its first success in 1978 when Drs. Edwards and Steptoe in Oldham, England created the
first “test tube baby” named Louise Brown. Since that first success, IVF technology has been
refined and over 3 million babies have been born worldwide. [8]
There are five basic steps to IVF. 1) Harvesting the eggs from the woman’s ovaries. The woman’s
ovaries are hyperstimulated using fertility drugs that produce numerous eggs. During this
period the woman will have regular transvaginal ultrasounds to examine the ovaries and blood
tests to check hormone levels. 2) Egg retrieval. The eggs are removed from the woman’s body
using follicular aspiration. Using ultrasound images as a guide the physician inserts a thin
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needle through the vagina and into the ovary and sacs containing the eggs. The needle is
connected to a suction device, which pulls the eggs and fluid out of each follicle, one at a time.
In rare cases, a pelvic laparoscopy may be used to remove the eggs. 3) Insemination and
Fertilization. The man’s sperm is placed with the best quality eggs in a petri dish and stored in
an environmentally controlled chamber. The mixing of the sperm and egg is called insemina‐
tion. The sperm usually enters an egg a few hours after insemination. If there is a low chance
for fertilization, one single sperm can be injected into an egg in a procedure called Intracyto‐
plasmic Sperm Injection (ICSI). 4) Embryo culture. The fertilized eggs remain in the petri dish
for 48 to 72 hours to verify that the embryo is not defective and growing properly. If a couple
is at high-risk for passing on genetic (hereditary) disorders to a child they may consider using
Pre-implantation Genetic Diagnosis (PGD). The procedure is performed 3-4 days after
fertilization. A single cell is removed from each embryo to screen it for specific genetic
disorders. Those embryos with the genetic disorder are usually destroyed. 5) Embryo trans‐
fer. Anywhere from 1-4 embryos are placed in the woman’s womb 3 to 4 days after fertilization.
The physician inserts a thin catheter containing the embryos into the woman’s vagina, through
the cervix, and up into the womb. If the embryo implants in the woman’s uterine wall
pregnancy will result. [9]
The implantation rate is estimated at 10-25%. [10] The overall birth rate varies from 11%
(women over 40) to about 35% (women under 35). [11] This clearly shows that a number of
embryos transferred fail to survive, which is why multiple embryos are transferred per cycle
and why numerous cycles are required. On average, 2.7 embryos per cycle are transferred in
women under 35, with an average of 3 in older women. Depending on the embryo quality, up
to 5-6 embryos can be transferred. [12] The average cost of IVF is $12,000-17,000 per cycle. It
is estimated that 75% of couples who have tried IVF and who spent from $10,000-100,000 still
go home without a baby. [13] Risks include the possibility of ovarian hyperstimulation
syndrome (OHSS), risks in the egg retrieval stage which include reactions to anesthesia,
bleeding, infection and damage to structures surrounding the ovaries including the bowel and
bladder, and finally there are the risks associated with multiple pregnancies. Since 1980 the
rate of twins has climbed 70% to 3.2% of births in 2004. Multiple gestations raise the risk of
preterm births; low-birth-weight babies, with the possibility of death in very premature
infants; long-term health problems; and pregnancy complications, which include pre-eclamp‐
sia, gestational diabetes, and Caesarean section. Studies have shown that 56% of IVF twins
born in 2004 weighed less than 5.5 pounds, and 65% were born prematurely, before 37 weeks
of gestation. [14] Embryos not transferred in a fresh IVF cycle are usually cryopreserved.
Freezing these embryos offers individuals the possibility of transferring the frozen embryos
for later IVF cycles if the previous cycle does not result in a pregnancy. It is also cost effective
and eliminates the need to undergo the steps needed for a fresh IVF cycle. In most cases the
best quality embryos are transferred in the fresh cycle and those of a lesser quality are frozen
for later transfer. It should be noted that some clinics have individual freezing and thawing to
achieve the exact number of embryos desired for transfer. This procedure avoids embryo
wastage.
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The process of cryopreservation has become an integral part of the IVF procedure. “Cryopre‐
servation is a process of freezing biological tissues for storage, while minimizing cellular
damage from freezing and thawing.” [15] This technique entails freezing the embryo while
simultaneously removing the intracellular water and replacing it with a cryoprotectant
solution which help to protect the embryo during the freezing process. The embryos are then
placed into cryopreservation straws or vials, which are labeled with the patient’s name, the
patient’s IVF number, and the date of the freeze. Once the process is complete, the embryos
are placed in a computer controlled freezing unit. After the freezing run is complete, the straws
are stored in a special tank filled with liquid nitrogen at a temperature of minus 196 degrees
centigrade. [16] Many storage facilities use a back-up system to minimize the risk of interrup‐
tion in the freezing process. Liquid nitrogen containers are armed with an automatic alarm
system to monitor nitrogen levels and prevent premature thawing. [17] These embryos are
looked upon as being in a state of “suspended animation.” Cellular activity has ceased, but
each embryo is still alive. When the remaining embryos are needed a procedure utilizing rapid
thawing and removal of the cryopreservative solution with simultaneous rehydration is used.
The embryos are first warmed in a 98.6 F degree solution and the cryoprotectant chemicals are
removed. [18]
The embryo thawing process is quite complex. “Embryo survival is based on the number
of viable cells in an embryo after thawing. An embryo has ‘survived’ if >50% of the cells
are viable. An embryo is considered to ‘partially survive’ if <50% of its cells are viable and
to be ‘atretic’ if all the cells are dead at thaw. Approximately, 65-70% of embryos survive
thaw, 10% partially survive and 20-25% are atretic. Data suggests that embryos with 100%
cell survival are almost as good as embryos never frozen but only about 30-35% survive
this fashion. Embryos that are 2, 4 or 8 cells when frozen have about a 5-10% greater survival
than embryos with an odd number of cells. Donor egg embryos have a 2-5% greater survival
rate than embryos from infertile women when compared by morphology score” [19] The
cost of cryopreservation is approximately $600-700 a year. The success rate or pregnancy
rate  depends  on  numerous  factors:  the  number  of  surviving  embryos  transferred,  the
number  of  100%  surviving  embryos  transferred,  and  the  morphology  scores  of  the
transferred embryos. The delivered pregnancy rates range from 5% (a single poor quality
embryo) to 36% (4 high quality embryos) when the cycles from 1987 to 2001 were com‐
bined. It is estimated that embryo cryopreservation adds about 10-30% more pregnancies
per retrieval cycle and the outcomes of the children are normal.  [20] The reason for the
wide range of costs and success rates is because the Assisted Reproductive Technologies
industry in the United States is  unregulated.  The success rates and costs can vary from
clinic to clinic and there is no government oversight examining the widespread differences.
The RAND/SART survey in 2003 found that of the 400,000 frozen spare embryos 88.2% were
designated for family building and 2.8% (11,000) were designated for research. Those embryos
designated for research could produce as many as 275 stem cell lines (cell cultures suitable for
further development). However, the number would in reality be much lower. Of the remaining
embryos, it is estimated that 2.3% (10,000) are awaiting donation, 2.2% are designated to be
discarded, and 4.5% are held in storage for other reasons, including lost contact with a patient,
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patient death, abandonment, and divorce. [21] There are numerous issues concerning the
“spare” frozen embryos. The ART clinics transfer the highest quality embryos (those that grow
at a normal rate) to the patient during treatment cycles. The remaining embryos are usually
designated as not of the highest quality. In addition, some of the frozen embryos have been in
storage for many years, and when these embryos were created the laboratory cultures were
not as conducive to preserving embryos as they are today. Some embryos would also die in
the freeze-thaw process. Considering all these issues, the question is how many embryos
actually are available for research and donation/adoption? The RAND/SART team estimated
that 65% of the approximately 11,000 embryos designated for research would survive the
freeze-thaw process, resulting in 7,334 embryos. Of those, about 25% (1,834 embryos) would
likely be able to survive the initial stages of development to the blastocyst stage (a balstocyst
is an embryo that has developed for at least 5 days). Even fewer could be converted into
embryonic stem cell lines. Their estimate is about 275 embryonic stem cell lines could be
converted from the total number of embryos designated for research. The RAND/SART team
also estimates that 2.3% of the 400,000 frozen “spare” embryos designated for donation/
adoption, only 23,000-100,000 embryos could be adopted, thawed and successfully born. [22]
Having this many children potentially available for adoption would help meet the need of
couples seeking adoption in the United States. The problem is that the adoption process for
frozen embryos is quite ambiguous and very complex.
3. Legal aspects
There are approximately 200,000 couples actively seeking to adopt in the United States.
Having  the  potential  of  23,000-100,000  embryos  available  to  be  adopted,  thawed  and
successfully born would offer great hope to these couples.  Organizations like Nightlight
Christian Adoptions, licensed in California since 1959, arrange both domestic and interna‐
tional adoptions. Their Snowflake Embryo Adoption Program, which began in 1997, matches
couples who have spare frozen embryos with other infertile couples trying to have babies.
Their philosophy is that every embryo is a person from the minute it exists in a petri dish.
Nightlight  Christian  Adoptions  approached  embryo  adoption  differently  from  other
agencies.  “Snowflake  goes  beyond the  embryo donation  provided by  fertility  clinics  by
offering  safeguards  and  education  available  in  traditional  adoption.  A  home  study  is
prepared on the adopting family that includes screening and education. The donating family
is responsible for selecting a family to raise their genetic child (as opposed to a doctor in
a clinic making the selection for the family), and they will know if the child (children) is
born from the adopted embryos. Our program recognizes the importance of counseling all
parties  involved.  Most  importantly,  at  Nightlight  we  recognize  the  personhood  of  em‐
bryos and we treat them as precious preborn children.” [23] There are no agency or program
fees for the genetic parents who place their embryos for adoption. Any costs during the
adoption process for medical records, blood work, etc., will be paid by the adopting parents.
Fees differ for in-state California residents and out-of-state residents. If you live outside of
California the Program Fee is $8000; fee for the agency performing the home study ranges
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tional adoptions. Their Snowflake Embryo Adoption Program, which began in 1997, matches
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Their philosophy is that every embryo is a person from the minute it exists in a petri dish.
Nightlight  Christian  Adoptions  approached  embryo  adoption  differently  from  other
agencies.  “Snowflake  goes  beyond the  embryo donation  provided by  fertility  clinics  by
offering  safeguards  and  education  available  in  traditional  adoption.  A  home  study  is
prepared on the adopting family that includes screening and education. The donating family
is responsible for selecting a family to raise their genetic child (as opposed to a doctor in
a clinic making the selection for the family), and they will know if the child (children) is
born from the adopted embryos. Our program recognizes the importance of counseling all
parties  involved.  Most  importantly,  at  Nightlight  we  recognize  the  personhood  of  em‐
bryos and we treat them as precious preborn children.” [23] There are no agency or program
fees for the genetic parents who place their embryos for adoption. Any costs during the
adoption process for medical records, blood work, etc., will be paid by the adopting parents.
Fees differ for in-state California residents and out-of-state residents. If you live outside of
California the Program Fee is $8000; fee for the agency performing the home study ranges
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from $1000-3000; and the Fertility Clinic’s Fee for a Frozen Embryo Transfer (FET) ranges
from $2000-7500. In-state residents pay a Program Fee of $10,600. A $2600 credit is applied
if you already completed a home study with another agency. The Fertility Clinic’s Fee for
FET  ranges  from  $2000-7500.  [24]  By  contrast,  the  National  Embryo  Donation  Center
estimates the cost of embryo adoption to be $4,560-5,360. That includes the Application Fee
$200  (international  application  fee  is  $300);  Program  Fee  (to  proceed  to  assessment  for
embryo transfer) $800; Embryo Transfer $650; Embryology Laboratory Fee $565; Monitor‐
ing Fee $250; Facility Fee $700; Home Study $1000-2000; Initial Consult Fee $200; and Trial
Transfer  Fee  $85.  The  National  Average  for  IVF  is  $7500-9000/  cycle  and  the  National
Average for  IVF with Donor Egg is  $22,127.  [25]  It  is  clear  that  the price  differential  is
considerable. Recent statistics show that Snowflake has matched 289 placing families (with
approximately 2,092 embryos) with 192 adopting families. 139 babies have been born and
14 adopting families are currently expecting 15 babies. [26]
The legal issues focus on the terminology surrounding adoption and donation. The term
“adoption” raises opposition with abortion-rights groups because it encourages people to
view the frozen “spare” embryos as equivalent to children. These groups would prefer the
term “embryo donation,” or in more neutral, reductive terms, a term such as “transfer of
genetic  material”  from  one  party  to  another.  [27]  The  distinction  between  “embryo
adoption” and “embryo donation” may seem trivial to many but from a legal perspective
it raises numerous issues. The Supreme Court of Tennessee in Davis v. Davis  recognized
that, “semantical distinctions are significant in this context because language defines legal
status and can limit legal rights.” [28] The court in Davis v.Davis also concluded that pre-
embryos  are  not,  strictly  speaking,  either  persons  or  property,  but  occupy  an  interim
category that entitles them to special respect because of their potential for human life. [29]
The  American  Society  of  Reproductive  Medicine  has  echoed  this  conclusion:  “The  em‐
bryo  deserves  respect  greater  than  that  accorded  to  human  tissue  but  not  the  respect
accorded to actual persons. The embryo is due greater respect than human tissue because
of its  potential  to become a person and because of its  symbolic meaning for many peo‐
ple. Yet, it should not be treated as a person, because it has not yet developed the features
of personhood, is not yet established as developmentally individual, and may never realize
its biological potential.” [30] The conclusion seems to indicate that neither contract law nor
family  law  can  directly  interpret  embryo  donation/adoption  agreements.  Contract  law
governs  the  transfer  of  property,  while  family  law governs  lives  of  persons  in  familial
relationships. If embryos are neither property nor persons, but an interim category, it follows
that a hybrid approach must be considered. [31]
Parties involved with embryo donation/adoption need certainty concerning their contractual
rights and obligations. “Unlike traditional adoption, which has multiple procedural require‐
ments, embryo donation is largely unregulated. Some commentators warn that calling an
embryo donation an “embryo adoption” may give the recipient parents a false sense of security
regarding their parental rights and responsibilities since most states do not extend traditional
adoption laws to the adoption of an embryo. Additionally, both state laws and the Uniform
Adoption Act consistently state that children cannot be adopted until after they are born.” [32]
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Because the law is so ambiguous on this topic it would appear that the state legislatures or the
federal government would be the appropriate forum to address these issues. As one court
noted:
We must call on the Legislature to sort out the parental rights and responsibilities of those involved in artificial
reproduction. No matter what one thinks of artificial insemination, traditional and gestational surrogacy (in all its
permutations), and—as now appears in the not-too-distant future, cloning and even gene splicing—courts are still going
to be faced with the problem of determining lawful parentage. A child cannot be ignored. [33]
A few states have begun to enact legislation regarding embryo donation/adoption, but in
reality most states lack appropriate statutes. In Florida, a donated embryo is presumed to be
a child of the intended parents if both the donor couple and the intended parents consent in
writing. The statute effectively requires the donor couple to relinquish their parental rights,
but the statute does not specify how this is to be accomplished. [34] In Oklahoma the statute
requires that both the donor and the intended parents must be married and the physician
performing the transfer must obtain written consent from both the donor and the intended
parents. This consent form must be signed by both the physician and the judge of a court with
adoption jurisdiction. The original consent form is then filed with the court by the physician.
Any child resulting from the embryo donation is considered to be the child of the donee couple
and the donee couple is relieved of all parental responsibilities. [35] Worldwide embryo
adoption is performed in at least 19 countries (Canada, UK, France, Spain, Italy, Australia,
Belgium, India, Greece, Singapore, Argentine, Colombia, Japan, Holland, Uruguay, Romania,
Portugal, Venezuela and Finland). Embryo Adoption is illegal in 14 countries (Austria, China,
Denmark, Germany, Israel, Italy, Latvia, Norway, Slovenia, Sweden, Switzerland, Taiwan,
Tunisia and Turkey). In the United States all 50 states and the District of Columbia permit
living embryo adoption and implantation. [36] The problem is that there is real uncertainty in
the law and some might even say it is chaotic. It appears that legislation is needed to protect
the rights of these embryos, their biological parents and their adopted parents. Issues con‐
cerning legislation range from disagreement about whether this legislation should be initiated
from the states or from the federal government to ambiguities concerning personhood and
how this will impact on current legal statutes. Legislation appears to be the only route available
to overcome the ambiguity in the law. However, legislators are looking for guidance and one
area that might offer such assistance is the realm of ethics.
4. Ethical aspects
Ethically,  embryo donation/adoption focuses on the issue of personhood. If  embryos are
persons then it would be a moral imperative to “rescue” these embryos from their current
status of being in “frozen animation.” Numerous ethicists, embryologists, legal professio‐
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nals  and  specifically,  the  Roman  Catholic  Church,  argue  that  personhood  begins  at
conception or  what  is  known as  fertilization.  Prior  to  fertilization  we have  two human
gametes—sperm and egg, that are living but are not a living organism. When fertilization
occurs, something human and living “in a different sense comes into being.” [37] Embryol‐
ogists argue that “human development begins at fertilization when a male gamete or sperm
(spermatozoon)  unites  with  a  female  gamete  or  oocyte  (ovum)  to  form  a  single  cell—
zygote.  This  highly specialized,  totipotent  cell  marked the beginning of  each of  us  as  a
unique individual.” [38] The Catholic Church teaches that “human life must be absolutely
respected and protected from the moment of conception.” [39] “Right from fertilization is
begun the adventure of a human life, and each of its great capacities requires time...to find
its  place and to be in a  position to act.  This  teaching remains valid and is  further con‐
firmed, if confirmation were needed, by recent findings of human biological science which
recognize that  in  the zygote  resulting from fertilization the biological  identity  of  a  new
human individual is already constituted.” [40] The Church argues that at fertilization there
is a new genetic individual in its own right, one who is whole, bodily, self-organizing, and
genetically distinct from his or her mother and father. [41] Those who argue that person‐
hood begins at fertilization would also argue that there is a moral imperative to give these
frozen embryos the opportunity to be born and to develop because they are persons. Ethicist
Therese Lysaught believes that embryo donation/adoption is an act that can properly be
described as “rescuing a child orphaned before birth.” [42] Ethicists arguing for the “rescue”
of these children would encourage women to implant these embryos in their  wombs in
order to bring them to term. Some would permit not only married women to do this but
also single women and even lesbian couples. The moral principle of sanctity of human life
would overcome any other moral considerations.  However,  not all,  even in the Catholic
Church,  would agree to this  ethical  analysis.  Opponents  of  this  position argue that  this
would  amount  to  material  cooperation  in  an  objective  immoral  action.  Not  only  is  the
process of IVF considered an intrinsic moral evil by the Magisterium of the Catholic Church,
but  allowing  for  the  adoption  of  these  embryos  might  condone  the  objective  immoral
procedure and may even encourage the creation of additional embryos through the IVF
process.  Even though the Catholic  Church has not  taken an official  position on embryo
donation/adoption, one could argue that from previous teaching, it  is the only means of
survival for these persons. “In consequence of the fact that they have been produced in
vitro, those embryos which are not transferred into the body of the mother and are called
‘spares’ are exposed to an absurd fate, with no possibility of their being offered safe means
of survival which can be licitly pursued.” [43] Embryo donation/adoption is the only safe
means  of  survival  for  these  persons  so  thus  it  would be  ethical.  This  statement  by  the
Magisterium was directed toward embryo experimentation but it could also be applicable
to embryo donation/adoption. To determine if embryo donation/adoption is ethical and to
address the ambiguities and unresolved issues surrounding this controversy, the tradition‐
al ethical principle of the lesser of two evils will be applied to this situation.
Society, in general, has always recognized that in our complex world there is the possibility
that we may be faced with conflict situations that leave us with two options both of which are
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nonmoral evils. [44] The time-honored ethical principle that has been applied to these situa‐
tions is called the principle of the lesser of the two evils. When one is faced with two options,
both of which involve unavoidable (nonmoral) evil, one ought to choose the lesser evil. [45]
Bioethicist Richard McCormick, S.J., argues that
The concomitant of either course of action is harm of some sort. Now in situations of this kind, the rule of Christian reason,
if we are governed by the ordo bonorum, is to choose the lesser evil. This general statement is, it would seem, beyond
debate; for the only alternative is that in conflict situations we should choose the greater evil, which is patently absurd.
This means that all concrete rules and distinctions are subsidiary to this and hence valid to the extent that they actually
convey to us what is factually the lesser evil... Now, if in a conflict situation one does what is, in balanced Christian
judgment (and in this sense objectively), the lesser evil, his intentionality must be said to be integral. It is in this larger
sense that I would attempt to read Thomas Aquinas’s statement that moral acts recipiunt speciem secundum id quod
intenditur. Thus the basic category for conflict situations is the lesser evil, or avoidable/unavoidable evil, or proportionate
reason. [46]
Therefore, in a conflict situation, an individual may directly choose to do a nonmoral evil
(violating the person’s autonomy, privacy, etc.) as a means to a truly proportionate good end
(preservation and protection of human life). [47]
The principle of the lesser of two evils is applicable to the issue of embryo donation/adoption
because one is faced with two options, both of which involve unavoidable nonmoral evils. On
the one hand, failure to thaw, transfer and allow these embryos to be born would result in the
death of thousands of persons. On the other hand, if the frozen embryos are not donated/
adopted they will be discarded, destroyed for research purposes, abandoned, or left in
“suspended animation” indefinitely, which would continue to jeopardize their life.
The direct intention of embryo donation/adoption is to protect and preserve human life by
saving the lives of vulnerable at-risk embryos. It would also lessen significant hardship
associated with ova harvesting, reduce the cost of infertility treatments, and would overcome
the objections of couples who resist traditional adoption by allowing the mothers to bond with
the child in pregnancy. [48] However, in the process of protecting and preserving human life
and acting in the best interest of the frozen embryo, the autonomy of parents might be violated
in that some may wish to discard the embryos, allow them to be destroyed to obtain embryonic
stem cells, abandon them or allow them to stay in indefinite “suspended animation.” The hope
is that couples would voluntarily agree to embryo donation/adoption, but studies have shown
that only 2% of couples with frozen embryos wish to allow them to be donated or adopted.
About 5% are designated for destruction or research which leaves about 87% that are unde‐
cided about disposition of their remaining frozen embryos. [49] The linchpin for resolving
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nonmoral evils. [44] The time-honored ethical principle that has been applied to these situa‐
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reason. [46]
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because one is faced with two options, both of which involve unavoidable nonmoral evils. On
the one hand, failure to thaw, transfer and allow these embryos to be born would result in the
death of thousands of persons. On the other hand, if the frozen embryos are not donated/
adopted they will be discarded, destroyed for research purposes, abandoned, or left in
“suspended animation” indefinitely, which would continue to jeopardize their life.
The direct intention of embryo donation/adoption is to protect and preserve human life by
saving the lives of vulnerable at-risk embryos. It would also lessen significant hardship
associated with ova harvesting, reduce the cost of infertility treatments, and would overcome
the objections of couples who resist traditional adoption by allowing the mothers to bond with
the child in pregnancy. [48] However, in the process of protecting and preserving human life
and acting in the best interest of the frozen embryo, the autonomy of parents might be violated
in that some may wish to discard the embryos, allow them to be destroyed to obtain embryonic
stem cells, abandon them or allow them to stay in indefinite “suspended animation.” The hope
is that couples would voluntarily agree to embryo donation/adoption, but studies have shown
that only 2% of couples with frozen embryos wish to allow them to be donated or adopted.
About 5% are designated for destruction or research which leaves about 87% that are unde‐
cided about disposition of their remaining frozen embryos. [49] The linchpin for resolving
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which option is the lesser of two evils rests on whether or not there is a proportionate reason
for allowing embryo donation/adoption.
Proportionate reason refers to a specific value and its relation to all elements (including
nonmoral evils) in the action. [50] The specific value in allowing for embryo donation/adoption
is to protect and preserve human life. The nonmoral evil, which is the result of trying to achieve
this value, is the violation of the couple’s right to privacy and autonomy to allow the frozen
embryos to be discarded, destroyed for research, abandoned, or left in “suspended animation”
indefinitely. The ethical question is whether the value of protecting and preserving human life
outweighs the nonmoral evil of violating a couple’s right to privacy and autonomy? To
determine if a proper relationship exists between the specific value and the other elements of
the act, ethicist Richard McCormick, S.J. proposes three criteria for the establishment of
proportionate reason:
1. The means used will not cause more harm than necessary to achieve the value.
2. No less harmful way exists to protect the value.
3. The means used to achieve the value will not undermine it. [51]
The application of McCormick’s criteria to embryo donation/adoption supports the argument
that there is a proportionate reason for allowing these embryos to be thawed, transferred and
brought to term. The bottom line is that these embryos already exist and therefore, the
preservation of their lives takes moral precedence over any other consideration. First, it is
estimated that the average couple who undergoes IVF has seven embryos in storage; the
average storage period is four years; and 87% of IVF couples are ‘undecided’ as to the
disposition of their remaining frozen embryos. It is estimated that 23,000 to 100,000 children
could be adopted, thawed and successfully born from the 400,000 to 500,000 live human
embryos stored at present. [52] Some opponents argue that these embryos are vital to embry‐
onic stem cell research. Allowing for donation/adoption will have an adverse effect on our
embryonic stem cell research program. The RAND/SART researches calculated that about 275
embryonic stem cell lines could be created from the total number of embryos available for
research. However, they argue that even this number is probably an overestimate because it
assumes that all the embryos designated for research in the United States would be used to
create stem cell lines, which is highly unlikely. [53] Considering the new methods being
proposed to obtain embryonic stem cells such as modified therapeutic cloning, reprogramming
of skin cells to their embryonic stage, etc., and the condition of the frozen embryos after
thawing, it appears that using these frozen embryos for research purposes would not be in the
best interest of the scientific community. There are approximately 200,000 couples seeking to
adopt children in the United States. The cost of infertility treatments place ART out of reach
for many of these couples. Traditional adoption is also quite expensive and denies couples the
chance to experience pregnancy, bonding and breastfreeding that makes the experience
“theirs.” Embryo donation/adoption allows couples or single women to preserve the lives of
already existing embryos which is acting in their best interest. This means gestation by a couple
or a single woman who will assume full parental authority for the child. Clearly, this will bring
about more good than harm, and will cause less harm than necessary to protect and save lives.
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Second, at present, there does not appear to be an alternative that is as effective as embryo
donation/adoption to protect and preserve the value of the human lives that are presently in
“suspended animation.” There are three alternatives to embryo donation/adoption: discarding
of the embryos, destruction of the embryos for research purposes and allowing the embryos
to stay in “suspended animation” indefinitely. None of these alternatives will protect and
preserve the value of the life of the embryo. There is a concern that the length of time embryos
are kept in frozen storage may have a detrimental effect on the outcome of embryo transfer
and possibly increase fetal abnormalities. To date, no long-term studies have been carried out
since the age of the oldest child born as a result of frozen embryo transfer 14 years ago. [54] In
addition, according the Genetics and IVF Institute, “Approximately 65-70% of embryos survive
thaw, 10% partially survive and 20-25% are atretic.” [55] Subjecting embryos to the freeze-thaw
process is placing them at significant risk of harm and possibly death. Intentionally or
unintentionally, frozen embryos have the potential to be damaged and destroyed. Being in the
category of having a special status, embryos deserve not to be harmed or killed. Embryo
donation/adoption is the only alternative that protects and preserves the life of the already
existing embryo. In the United States there seems to be a consensus that these embryos deserve
special respect. This led the Ethics Committee of the American Fertility Society to conclude:
We find a widespread consensus that the pre-embryo is not a person but is to be treated with special respect because it
is a genetically unique, living human entity that might become a person. In cases in which the transfer to a uterus is
possible, special respect is necessary to protect the welfare of the potential offspring. In that case, the pre-embryo deserves
respect because it might come into existence as a person. This viewpoint imposes the traditional duty of reasonable
prenatal care when actions risk harm to prospective offspring. Research on or intervention with a pre-embryo, followed
by transfer, thus creates obligations not to hurt or injure the offspring who might be born after transfer. [56]
Whether one believes the frozen embryo is a person or a potential person, it seems clear that
this human entity deserves dignity and respect. The only option that would allow for this
dignity and respect is to allow for the protection and preservation of the human embryo
through embryo donation/adoption.
Third, embryo donation/adoption does not undermine the value of human life. One can argue
convincingly that the intention of embryo donation/adoption is to protect and preserve the
lives of already existing embryos that are currently in the state of “suspended animation.”
Those who adopt these embryos have the best interest of the embryos as their primary concern,
because they wish to allow the embryos to resume their natural development and growth. The
couples and individuals who bring these embryos to term are also willing to adopt these
children and take full responsibility for their upbringing in the future. In many situations,
couples allow for cryopreservation of embryos because it saves both time and money in the
event that the previous cycle of IVF is unsuccessful. This undermines the basic value of human
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2. No less harmful way exists to protect the value.
3. The means used to achieve the value will not undermine it. [51]
The application of McCormick’s criteria to embryo donation/adoption supports the argument
that there is a proportionate reason for allowing these embryos to be thawed, transferred and
brought to term. The bottom line is that these embryos already exist and therefore, the
preservation of their lives takes moral precedence over any other consideration. First, it is
estimated that the average couple who undergoes IVF has seven embryos in storage; the
average storage period is four years; and 87% of IVF couples are ‘undecided’ as to the
disposition of their remaining frozen embryos. It is estimated that 23,000 to 100,000 children
could be adopted, thawed and successfully born from the 400,000 to 500,000 live human
embryos stored at present. [52] Some opponents argue that these embryos are vital to embry‐
onic stem cell research. Allowing for donation/adoption will have an adverse effect on our
embryonic stem cell research program. The RAND/SART researches calculated that about 275
embryonic stem cell lines could be created from the total number of embryos available for
research. However, they argue that even this number is probably an overestimate because it
assumes that all the embryos designated for research in the United States would be used to
create stem cell lines, which is highly unlikely. [53] Considering the new methods being
proposed to obtain embryonic stem cells such as modified therapeutic cloning, reprogramming
of skin cells to their embryonic stage, etc., and the condition of the frozen embryos after
thawing, it appears that using these frozen embryos for research purposes would not be in the
best interest of the scientific community. There are approximately 200,000 couples seeking to
adopt children in the United States. The cost of infertility treatments place ART out of reach
for many of these couples. Traditional adoption is also quite expensive and denies couples the
chance to experience pregnancy, bonding and breastfreeding that makes the experience
“theirs.” Embryo donation/adoption allows couples or single women to preserve the lives of
already existing embryos which is acting in their best interest. This means gestation by a couple
or a single woman who will assume full parental authority for the child. Clearly, this will bring
about more good than harm, and will cause less harm than necessary to protect and save lives.
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to stay in “suspended animation” indefinitely. None of these alternatives will protect and
preserve the value of the life of the embryo. There is a concern that the length of time embryos
are kept in frozen storage may have a detrimental effect on the outcome of embryo transfer
and possibly increase fetal abnormalities. To date, no long-term studies have been carried out
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addition, according the Genetics and IVF Institute, “Approximately 65-70% of embryos survive
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process is placing them at significant risk of harm and possibly death. Intentionally or
unintentionally, frozen embryos have the potential to be damaged and destroyed. Being in the
category of having a special status, embryos deserve not to be harmed or killed. Embryo
donation/adoption is the only alternative that protects and preserves the life of the already
existing embryo. In the United States there seems to be a consensus that these embryos deserve
special respect. This led the Ethics Committee of the American Fertility Society to conclude:
We find a widespread consensus that the pre-embryo is not a person but is to be treated with special respect because it
is a genetically unique, living human entity that might become a person. In cases in which the transfer to a uterus is
possible, special respect is necessary to protect the welfare of the potential offspring. In that case, the pre-embryo deserves
respect because it might come into existence as a person. This viewpoint imposes the traditional duty of reasonable
prenatal care when actions risk harm to prospective offspring. Research on or intervention with a pre-embryo, followed
by transfer, thus creates obligations not to hurt or injure the offspring who might be born after transfer. [56]
Whether one believes the frozen embryo is a person or a potential person, it seems clear that
this human entity deserves dignity and respect. The only option that would allow for this
dignity and respect is to allow for the protection and preservation of the human embryo
through embryo donation/adoption.
Third, embryo donation/adoption does not undermine the value of human life. One can argue
convincingly that the intention of embryo donation/adoption is to protect and preserve the
lives of already existing embryos that are currently in the state of “suspended animation.”
Those who adopt these embryos have the best interest of the embryos as their primary concern,
because they wish to allow the embryos to resume their natural development and growth. The
couples and individuals who bring these embryos to term are also willing to adopt these
children and take full responsibility for their upbringing in the future. In many situations,
couples allow for cryopreservation of embryos because it saves both time and money in the
event that the previous cycle of IVF is unsuccessful. This undermines the basic value of human
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life, because it commodifies, objectifies and exploits these embryos. Allowing the frozen
embryos to be discarded, destroyed for research purposes, abandoned or left in the state of
“suspended animation” undermines the value of human life. The only possible consequence
of this action is the potential destruction of human life.
The intention of embryo donation/adoption is to save lives and it has been proven through
organizations such as the National Embryo Donation Center and Nightlight Christian
Adoptions to be effective. This is a critical issue that must be addressed immediately because
innocent lives are hanging in the balance. It seems clear that there is a proportionate reason
for allowing embryo donation/adoption. It is estimated that 23,000-100,000 children could
potentially be born as a result of embryo donation/adoption. Couples who are unable to afford
ART would have a viable option of having a child that is within their financial means. Finally,
safeguards could be put in place that would eliminate creating “spare” embryos in the future.
Therefore, it is ethically justified under the principle of proportionate reason for allowing
embryo donation/adoption. Embryo donation/adoption is the lesser of two evils because the
greater good is promoted in spite of the potential for evil consequences.
5. Conclusion & safeguards
Embryo donation/adoption is a complex issue that has medical, legal and ethical dimensions.
Allowing for embryo donation/adoption is the only viable option that protects and preserves
their human life. The other viable options: being discarded, destroyed for research, abandoned
or kept in “suspended animation” indefinitely, are unacceptable because they have the
potential of harming or intentionally killing these embryos that deserve special respect.
To make sure that this situation does not continue in the future, the following recommenda‐
tions and safeguards are proposed:
1. Only the number of eggs to be placed in the uterus of the mother will be fertilized. Embryos
must not be subjected to an intentional interruption of their natural growth and develop‐
ment. There will no longer be “spare” embryos subjected to cryopreservation. Only
cryopreservation of gametes would be acceptable.
2. Nationally, laws and legislation must be enacted at the federal level that begins to regulate
Assisted Reproductive Technologies. Having each state governed by differing sets of
legislation could cause potential complications associated with the practice of donation/
adoption. How each state defines jurisdiction and how each state interprets at what stage
jurisdiction would begin (conception, transfer, or birth) could become highly complex.
Specifically, guidelines and safeguards must be put in place that protects donors, parents,
providers, and children born of ART.
3. Nationally, laws and legislation must be enacted that regulates the creation, destruction
and exploitation of human embryos. Example would be the following: a) legislation
established in New Mexico stating that human embryos can only be disposed of through
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implantation, not intentional destruction or through destructive human embryo research.
b) Embryos must not be subjected to non-therapeutic experimentation.
4. Internationally, due to the globalization of medical research, it would be imperative for
the United Nations (UN) of the World Health Organization (WHO) to establish a forum
to study these issues and to formulate a comprehensive policy to regulate the creation of
spare embryos and other pertinent issues related to this issue. Both the UN and the WHO
have agencies that could bring about legislative mandates.
5. Infertile couples and individuals willing to take full responsibility for the upbringing of
these children should be encouraged to consider adoption of the presently existing frozen
embryos.
6. Children who are adopted from frozen embryos have the right to know their genetic make-
up. They should be given full access to documentation about their biological mothers and
fathers so that if this information is needed in the future it is available. This does not mean
they have the right to know the names of their biological parents. The right of privacy of
the biological parents should be respected.
If we as a nation truly believe that human life deserves dignity and respect, then our failure
to bring these embryos to term would be medically irresponsible and ethically objectionable.
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Pluripotent stem cells have the potential to revolutionize treatment options for a range of 
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